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  II 
Abstract 
Peptides and proteins made from the 20 canonical amino acids are responsible for 
many processes necessary for organisms to function. Beside their composition, 
proteins obtain their activity and unique selectivity through an ability to display 
functionalities accurately in the three-dimensional space. These properties are highly 
sought after in pharmaceutical agents, where the interest in this class of compounds is 
increasing. However, due to susceptibility to proteolytic degradation in cellular 
environments and often poor cell-penetrating properties, this class of compounds has 
traditionally been considered unsuitable for drug discovery. Circumventing the 
inherent stability problems, non-natural peptide analogues have shown significant 
potential for the development of new materials and pharmacologically active ligands.  
Mimics of natural amino acids have received considerable attention, for their ability 
to mimic the structural elements seen in proteins. Two prominent peptidomimetics are 
β-peptides and α-peptoids (N-alkylglycines), which have been shown to fold into 
helical and sheet-like arrangements. To expand the chemical space available for 
mimicking protein structure their features have been combined to give the β-peptoids, 
which has found use in biologically active compounds but has been sparsely studied 
with respect to folding propensity. Thus, an aim of this Ph.D. project has been to 
investigate the effect of structural variations, including side chain substitution, 
introduction of thioamides, and trifluoroacetylation, on the cis−trans amide bond 
rotamer equilibria in monomer model systems. The latter systems revealed an 
increase in the preference for cis-amides as compared to their parent compounds and 
thus provide novel strategies for affecting the folding of peptoid constructs. Using 
NMR spectroscopy, X-ray crystallographic analysis, and density functional theory 
(DFT) calculations, we found evidence for the presence of thioamide–aromatic 
interactions through Csp2−H···Samide hydrogen bonding. Based on these studies we 
designed a β-peptoid oligomer from residues prone to fit a helical arrangement found 
by DFT calculations. The designed oligomer indeed proved the existence of a β-
peptoid helical conformation by X-ray. Further studies of these compounds indicated 
a structured display in solution. These helices thus definitively show that the β-
peptoids should be considered a valid addition to the already existing ensemble of 
foldamer designs. 
Sequences of alternating α-peptides and β-peptoids, containing basic α-amino acid 
residues have been shown to possess antimicrobial activity. Using X-ray surface 
scattering techniques the interaction of two oligomers, containing different basic 
moieties, and model lipid membranes of Gram-positive and Gram-negative bacteria, 
respectively, were investigated. We also synthesized fluorophore labeled analogues of 
the hybrid oligomers, which during a preliminary biological screening, showed cases 
of enhanced antimicrobial activity. The X-ray scattering studies confirmed earlier 
findings, showing that the guanidino-group binds more deeply into the membranes of 
Gram-positive bacteria, and that the nitrobenzoxadiazole-fluorophore enhanced this 
interaction.  
  III 
Resume 
Peptider og proteiner, bestående af de 20 naturligt forekommende aminosyrer, udfører 
mange processer, som er nødvendige for organismers funktioner. Udover deres 
sammensætning opnår proteiner deres aktivitet og unikke selektivitet ved at være i 
stand til at placere deres funktionaliteter præcist i rummet. Disse egenskaber er 
eftertragtede i forbindelse med udviklingen af nye typer medicin, hvor interessen for 
denne type stoffer er stigende. Desværre bliver disse forbindelser nedbrudt af 
proteaser, og er ofte dårlige til at trænge ind i celler, hvorfor man har anset denne type 
stoffer som uegnede til udvikling af nye lægemidler. Unaturlige analoger af peptider 
har vist sig at være proteasestabile, og besidde egenskaber som gør dem interessante i 
forbindelse med udvikling af nye materialer og lægemidler. Især analoger af de 
naturlige aminosyrer har tiltrukket sig særlig meget opmærksomhed da de er i stand til 
at efterligne stukturelementer fra proteiner. To af de mest prominente analoger er β-
peptider og α-peptoider (N-alkylglyciner), som har vist sig at kunne danne både 
heliske og β-sheet-lignende strukturer. For at udvide mængden af stoffer som kan 
danne analoger af proteinstrukturer, har man kombineret egenskaberne for β-peptider 
og peptoider og derved udviklet β-peptoider. Forbindelserne er blevet brugt i 
biologisk aktive systemer, men kun undersøgt for foldnings egenskaber i et begrænset 
omfang.  Det har således det været et mål for dette Ph.D. project, at undersøge 
hvordan cis–trans ligevægten for amidbindingen påvirkes i monomere modelsystemer 
efter hhv. ændring af sidekæder, introduktion af thioamider, samt trifluoracetylering 
af N-terminalen. De sidst nævnte systemer udviste en øget præference for cis-
konformationen, sammenlignet med de oprindelige forbindelser, hvilket giver nye 
muligheder for at påvirke foldningen i peptoid systemer. Ved at anvende NMR-
spektroskopi, røntgenkrystallografisk analyse samt “density functional theory” 
(DFT)-beregninger, fandt vi frem til en vekselvirkning mellem et thioamid og et 
aromatisk system gennem en Csp2−H···Samid hydrogenbinding. Ud fra vores studier 
designede vi en oligomer indeholdende enheder, med stor tilbøjelighed til at antage en 
konformation, som ifølge DFT beregningerne skulle føre til en helisk struktur. Ved 
røntgenkrystallografi udviste denne oligomer en helisk struktur. Yderligere studier af 
denne helix indikerede tilstedeværelsen af en ordnet struktur i opløsning. Med denne 
heliske struktur kan man definitivt tilføje β-peptoiderne til de allerede eksisterende 
foldamer designs. 
Sekvenser bestående af skiftevis α-peptid- og β-peptoid enheder, indeholdende 
basiske α-aminosyrer har udvist antimikrobielle egenskaber. Ved at bruge teknikker 
baseret på røntgenstrålers spredning ved refleksion fra overflader, har vi undersøgt 
vekselvirkningen mellem to hybrid oligomerer og modelmembraner af Gram positive 
og Gram negative bakterier. Vi har også syntetiseret fluorophor-mærkede analoger af 
hybrid oligomererne, som ved en indledende biologisk screening viste øget aktivitet. 
De førnævnte røntgenstudier bekræftede de tidligere resultater, og viste at guanidino-
grupper binder dybere i membraner fra Gram positive bakterier, samt at 
nitrobenzoxadiazol-fluorophoren forstærker denne vekselvirkning. 
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 3 
1 Introduction 
Proteins and peptides constitute a major class of biological polymers, which Nature 
rely on to carry out a broad variety of sophisticated chemical operations, such as 
catalysis, tight and specific binding, transport and storage of nutrients and metabolites 
and signaling. These biomolecules are polymers built from a single type of monomer, 
namely the 20 canonical amino acids, which are connected by amide linkages (peptide 
bonds), allowing for great variation of the sequence. The diversity of the polymer 
arises from variations in the chain length and identity of the side chain of each residue 
along the sequence.1 For most proteins the specific function arises from the ability to 
obtain a well-defined three-dimensional structure, which is encoded by the sequence 
of amino acids. These structures are governed by a series of non-covalent interactions 
such as hydrogen bonding, hydrophobic interactions, van der Waals- and electrostatic 
interactions and covalently by disulfide bonds.2 A vast amount of research has been 
performed to obtain a fundamental understanding of the relationship between amino 
acid sequence, folding, and functions of proteins.3 Traditionally this class of 
compounds has not been considered suitable for drug design due to the high cost of 
production, susceptibility to proteolytic degradation in cellular environments, and 
often poor cell-penetrating properties.4 Nevertheless, the interest in this type of 
compounds has been increasing in the pharmaceutical industry after the development 
and marketing of recombinant protein therapeutics.5 For this reason, research in 
unnatural oligomers capable of mimicking the folding patterns of proteins have 
received considerable attention.6,7 In these efforts a number of backbone constructs 
have been identified that adopt rather stable secondary structures. Unnatural 
analogues of peptides that contain the same functionality, with a similar or 
complementing three-dimensional display might retain the interactions with an 
intended target.7-9 Given their unnatural origin, peptidomimetics are thought to exhibit 
improved stability towards enzymatic degradation and hence have improved 
bioavailability. The field of research in unnatural compounds displaying the ability to 
fold in a similar manner to peptides and proteins were coined ”foldamers” by Gellman 
in the late 1990’s.10 This field of research contains two important goals, one is 
exploring the properties of folding behavior in unnatural backbones which also helps 
the understanding of the sequence–folding relationship of natural oligomers. Second, 
this field of research holds the possibility to provide protein-like functions in 
synthetic compounds that overcome the limitations of the natural oligomers as 
therapeutic agents. Recently numerous accounts of foldameric compounds capable of 
interrupting protein-protein interactions have been reported, showing this class of 
compounds to be promising candidates for drug-development.7,9 The research in 
foldameric compounds has also resulted in a number of oligomeric compounds 
capable of adopting stable structures. These compounds can be divided into two 
classes, foldamers closely resembling peptides (peptidomimetic foldamers), and 
compounds having none or very little similarity to peptides (non-peptidomimetic 
foldamers). Though the latter class may not share much similarity with the natural 
peptides, members have shown the ability to display similar folding patterns. 
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Compounds of this type have provided a basic understanding of factors that dictate 
the folding propensities of oligomers of a given residue type, extending the ensemble 
of methods for obtaining folded structures. The peptidomimetic foldamers are built on 
backbones resembling that of the natural peptides, to which minor alterations are 
made. Through the development of such molecules it has been shown that even minor 
alterations may greatly affect the folding propensity and bioactivity of the compound.  
 
 
Figure 1.1. Generic structure for peptides and peptidomimetic backbones. 
 
The aim of this project has been to obtain fundamental understanding of the folding 
propensities of β-peptoids, a combination of two well-studied peptidomimetic 
foldamers, the β-peptides and peptoids (Figure 1.1). β-Peptoids have been combined 
with α-amino acids, giving hybrid oligomers that display some interesting bioactive 
properties, but thus far studies of their folding propensity have been sparse.11-13  
The following chapter will provide a brief overview of the fundamental research in 
understanding the folding propensity of peptides and their synthesis. A discussion of 
foldamers will provide examples of how folding has been obtained in both 
peptidomimetic and non-peptidomimetic oligomers. Being the parent compounds of 
β-peptoids, a special focus will be given to β-peptides and peptoids. Also oligomers 
based on combinations of these residues will be discussed, as they have proved to be 
valuable additions.  
 
1.1 Peptide folding 
Proteins are macromolecules build up from the 20 canonical amino acids, which are 
connected by amide linkages, or peptide bonds. By varying the positioning and 
number of residues, these 20 building blocks allow for an almost infinite variation of 
the sequence (primary structure). However, proteins realize their high potential and 
diversity by folding the backbone into well-defined arrangements, displaying the 
functionalities appropriately in the three dimensional space (secondary structure). The 
patterns in which the protein display its functionalities give rise to active sites, in 
which residues spaced far apart in the backbone sequence can be placed in close 
proximity.  These displays are achieved using a relatively small number of secondary 
structure elements, predominantly helices, β-sheets (strands), and turns (Figure 1.2). 
These elements will also have very well defined orientations in the globular protein 
(tertiary structure). 
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Figure 1.2. Cartoon representations of secondary structure types.14 
 
The specific folding of a given sequence of α-amino acid residues is stabilized by a 
series of weak non-covalent interactions, such as hydrophobic interactions, hydrogen 
bonding, van der Waals- and electrostatic interaction and covalently by disulfide 
bonds.2 By disrupting these interactions the protein loses its secondary structure and 
thereby its activity.15,16 In the beginning of the 20th century it was realized that the 
unfolding of a protein is a reversible process, and that the refolding of some proteins 
can take place in vitro, in the absence of the cellular machinery.17 This also makes it 
possible to design and synthesize folded proteins in the laboratory which, given their 
complexity, is an extremely challenging task. To achieve this goal the propensity of 
smaller fragments, or peptides, to form discrete folds have been studied intensely.1 
 
1.1.1 Helices 
The existence of both the helix and β-sheet were discovered by Pauling and Corey in 
1951.18,19 Helices are the most abundant type of secondary structure, it is estimated 
that a third of all residues in proteins participate in a helical motif.20 Helices are 
stabilized by hydrogen bonding, and it is the bonding partners that determine the 
identity of the helix (Figure 1.3). The identity of a helix is defined by the number of 
residues and atoms needed to complete a full turn.  
 
 
Figure 1.3. Hydrogen bonding pattern for various peptide helices. 
 
Amongst the helices the most common is known as the α-helix, which has a hydrogen 
bond between the carbonyl oxygen of the ith residue and the amide hydrogen of the 
(i+4th) residue. This gives a helix with 3.6 residues per turn, and a pitch of 5.4 Å. 
When the α-helix is the most abundant helix it is because this geometry places the 
backbone and side chains in such a way that steric interactions are avoided (Figure 
1.4). As indicated in figure 1.3 other helices are possible, the 310 helix is slightly 
involved in sheet format ion and stability.34 These
model systems, a consensus zinc-finger pept ide,35 and
the B1 domain of st reptococca l protein G36-38 u t ilize
host-guest methods as previously applied to helica l
systems4,39,40 and help construct a hierarchy of !-sheet
‘propensit ies’ for the 20 na tura lly occur r ing amino
acids.35-38 Again , the observa t ion tha t the energy
difference between the best and least !-sheet-forming
residues var ies with the exper imenta l system41 re-
itera tes the fact tha t simple ‘residue propensit ies’
cannot be used in the design of !-st rands in !-ha ir -
pins. In addit ion , invest iga t ions of side cha in-side
cha in in teract ions in the context of !-sheet forma-
t ion42-44 and ana lysis of cross-st rand residue pa irs
in ant ipara llel sheets do not revea l any st rong
preference.33,45 Such studies imply tha t design of
!-ha irpins does not benefit grea t ly from the kind of
residue pat terning adopted in the design of R-helices.
While !-branched residues, such Thr or Ile, and
aromat ic residues such as Phe can be viewed as ‘!-
sheet formers’, the problem of !-ha irpin format ion is
easier solved by the design of stable !-tu rns, whose
conformat ion serves to form the fir st hydrogen bond
of the !-hairpin and helps st itch together subsequent
residues that register in hydrogen-bonding posit ions.
We, therefore, tu rn to an a lterna te approach to fold
control, namely, conformat ional control, which ar ises
from the observa t ion tha t cer ta in protein , unna tura l
and synthet ica lly designed amino acids have re-
st r icted conformat iona l freedom.
B. Conformational Control
The diversity of polypept ide cha in folds ar ises
because of the mult iple conformat ions tha t a re en-
erget ica lly accessible at each amino acid residue. The
two degrees of conformat ional freedom N-CR (φ) and
CR-CO (ψ), ava ilable a t every residue, resu lt in
approximately 9 (32) stable loca l conformat ions. For
Figure 1. Var ious levels of st ructura l organiza t ion observed in protein st ructures.
Design of Folded Peptides Chemical Reviews, 2001, Vol. 101, No. 10 3133
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narrower and rises with a pitch of 6.0 Å, which places the side chains to experience 
some steric interactions.21  
 
 
Figure 1.4. Left: The α-helix, and the building block constituting one turn (α-turn). right: The 310 helix 
and the sequence of one turn (type III β-turn).22 
 
The π-helix is rarely observed, probably due to its wider and more flat conformation 
as compared to the two mentioned helices. This allows for an axial hole inside the 
helix, which is too narrow to fit a water molecule yet too wide to allow for van der 
Waals association across the axis which greatly reduces stability.23  
 
1.1.2 β-Sheets 
β-sheets consist of extended segments of a peptide chain (strands) that are 
interconnected by hydrogen bonds. When the β-sheet was first proposed, by Pauling 
and Corey, they where thought to be flat.19 Since then X-ray crystallography has 
shown a number of different variations in the structure of β-sheets.24 These variations 
are caused by the fact that the chain is composed from chiral L-amino acids. The 
chiral subunits tend to assume minimum energy conformations that twist the sheet 
away from planarity.25 Twisting of the strands results in the introduction of 
energetically unfavorable distortions to the interchain hydrogen bonds. The final 
conformation is hence a result of an energetic compromise of optimizing 
conformational energy of the strand while preserving the interchain hydrogen bonds. 
 
Figure 1.5. The hydrogen bonding pattern of antiparallel (A) and parallel (B) β-sheets. 
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ing the related peptide groups nearer the axis). The
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As the β-sheet motif is composed from two segments of the chain, they do not 
necessarily have the same directionality. β-sheets are either parallel or antiparallel, 
meaning that the interconnected strands have the same N- to C-terminus direction or 
the opposite, respectively (Figure 1.5). Whether the β-sheet is parallel or antiparallel 
results in a slightly different overall conformation. 
 
1.1.3 Turns  
The direction of a peptide sequence can be changed, and if this happens in a well 
defined manner through hydrogen bonding this motif is known as a turn.26 Turns are 
characterized according to the number of residues in the hydrogen bonded ring: γ-
turns (three residues), β-turns (four residues), α-turns (five residues), and π-turns (six 
residues).27 Turns, unlike helices and β-sheets, do not represent a certain set of torsion 
angles, which allows for some variation within each class of turn (Figure 1.6). These 
variations are referred to as the type of a specific turn-class, for instance eight types of 
β-turns have been identified.26  
 
 
Figure 1.6. Turn-structure with hydrogen bond between position i and i + 3 (β-turn). The arrows 
indicate flexible torsion angles. 
 
As shown in figure 1.4 these motifs make up the individual turns of helices, e.g. the 
torsion angles of a type III β-turn are the same as those of an α-helix. 
 
1.2 Peptide synthesis 
The synthesis of peptides is a valuable tool in biology, drug discovery, and many 
other areas. As peptides are oligomers of amino acids, even the synthesis of relatively 
short peptide chains require a large number of operations, many of which are 
purifications, when using conventional synthetic methodologies. To efficiently 
produce peptides and proteins different technologies are available e.g. extraction from 
natural sources, production by recombinant DNA technology or by chemical 
synthesis.28 The size of the desired peptide determines which of the technologies are 
best suited for production. For large peptides recombinant DNA technology has 
proven useful, as illustrated by the production of insulin and hormones.28 
Macromolecules that, due to their size and complexity, have only been obtained by 
natural means are referred to as biologics. Given the advantages in synthetic methods, 
such as solid-phase synthesis (SPS)29 and chemical ligation,30 the amount of biologics 
is decreasing. However, many molecules relevant to research regarding structure, 
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function or activity are of a substantially smaller size and of less complexity, and 
since the introduction of SPS this has been the method of choice for peptide 
production in research laboratories. This method deviates from conventional synthesis 
by growing the peptide on an insoluble polymer material. In this manner many 
purification steps can be avoided by simply washing the solid-bound product. As we 
have applied this method to the synthesis of foldameric compounds, a brief 
introduction to the principle and factors involved in SPS will be given. 
 
1.2.1 Solid-phase synthesis 
The basic principle of SPS is to grow oligomeric compounds on an insoluble support 
(Figure 1.7). This is achieved by adding the first residue to the support through the C-
terminal, while the N-terminus remains protected. After attaching the residue, excess 
reagents and solvent can be removed by filtration, leaving only the coupled compound 
and the solid support. In the next step the N-terminal protecting group is removed, and 
the next residue attached, resulting in elongation of the oligomer. This procedure is 
then repeated until an oligomer of the desired length is achieved, at which time it can 
be cleaved from the support. 
 
 
 
Figure 1.7. Illustration of the principle of solid-phase peptide synthesis. 
 
By being able to simply filter of any excess reagents, and wash the compound on the 
resin, vast amounts of time can be saved using SPS compared to conventional 
solution-phase chemistry. This method also has its limitations, given that incomplete 
reactions will lead to by-products which are highly similar to the desired product, and 
are hence difficult to remove.  
For a successful solid supported synthesis a number of factors are in play. Starting 
with the choice of solid support, the handle attaching the oligomer is to the support, 
the activating agent, the protecting groups and finally the cleaving conditions.  
 
1.2.2 Solid supports 
A variety of solid supports are in existence, and in the process of selecting one that 
fits the conditions and reactants of the synthesis is important.31 When solid-phase 
peptide synthesis was first described by Merrifield, beads of polystyrene with 2% 
cross-linked divinylbenzene was employed as solid support (Figure 1.8 A).29 This 
resin is still widely used today, however, a serious drawback of this type of resins are 
their incompatibility with polar solvents. If exposed to polar solvents the apolar nature 
of the resin will make the beads contract leaving the reactive sites inaccessible for the 
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incoming reagents. To improve the properties of this resin Albericio and co-workers 
developed a resin combining polystyrene and polyethylene glycol (PEG), an example 
of this type of resin is PEG-polystyrene (Figure 1.8B).32 This combination enhanced 
the swelling properties of the solid support in both polar and non-polar solvents. Also 
a pure PEG resin has been designed by cote, named ChemMatrix (Figure 1.8C).33 The 
cross-linked PEG makes the resin amphiphilic, providing good swelling properties in 
most solvents. This resin has been shown to be better than polystyrene-based resins 
for the synthesis of complicated and highly basic peptide sequences.34 
 
 
 
Figure 1.8. Structures of selected solid supports. 
 
1.2.3 Handles/linkers 
As can be seen from figure 1.8 most of the resins have amino functionalities to which 
compounds can be attached. If a peptide was directly attached to the resin through a 
peptide bond it would be impossible to cleave it from the resin without breaking any 
further peptide bonds. Therefore linkers, or handles, have been developed to enable 
cleavage of the synthesized compounds without degradation. Also for this class of 
compounds a broad variety of alternatives exist, depending on the desired C-terminal 
functionality and desired cleaving conditions.  
One of the most used type of handles for making peptide acids is based on trityl (1).35 
The trityl group is also known as a side chain rotecting group, thus, it allows for 
simultaneous cleavage from the resin and deprotection. Since it is a very acid labile 
handle it is also possible to cleave the peptide from the resin without deprotecting the 
side chains.36 It has been showed that substitutions at the 2-postion of the trityl group 
can enhance the sensitivity to acids.35 A peptide linked to trityl (1, X = H) can be 
cleaved using pure acetic acid, when using 2-chlorotrityl (1, X = Cl) 20% acetic acid 
in CH2Cl2 is sufficient. This also serves as an example of how small changes to the 
structure of handles have a large effect on their properties.  
Cl
Cl
Merrifields polystyrene resin
Ph
Ph
N
H
H
N N
H
O O
H
N NH2
O
HN
O
n
N
H
O O
H
N NH2
O
O
n
PEG-polystyrene resin
A B
H2N O
O O NH2
O OH2N
O O O NH2H2N
NH2
n
n
n
Aminomethyl-ChemMatrix
C
 10 
 
 
Figure 1.9. Structure of two linkers commonly used in solid-phase chemistry. 
 
Another widely used family of handles are based on a benzhydryl-skeleton, and 
results in C-terminal amides upon cleavage using trifluoroacetic acid (TFA). One of 
the most prominent members of this group is the rink amide handle (2).37 The linkers 
mentioned here are both acid-labile and compatible with Fmoc-solid-phase chemistry, 
which will be discussed below. Linkers displaying base-lability38 or photo-lability39 
are also available. Furthermore, linkers connecting the backbone to the resin have 
been developed.40 
 
1.2.4 Coupling reagents 
When creating peptides the ability to form amide bonds, by linking a carboxylic acid 
of one amino acid and the amine of another, is crucial. This reaction does not occur 
spontaneously, but requires heating to >200 °C41 or some other kind of activation42.  
Heating to these temperatures is seldom optimal for the substrates, and activation by 
coupling reagents is used instead. These reagents are used to convert the acid OH into 
a better leaving group (LG), before the amino substrate is added (Figure 1.10). 
 
 
Scheme 1.1. Principle of the activation process for amide-bond formation. 
 
One of the first, and still widely used, types of coupling reagents are carbodiimides. 
Within this class one of the first coupling reagents to be used in synthesis was 
dicyclohexylcarbodiimide (DCC), which was first used in 1955 (Figure 1.10).43 The 
reactivity of the carbodiimides can be tuned by variation of the end-groups. This has 
yielded in a large variety of this kind of coupling reagents. One of the best known 
members of this family is diisopropylcarbodiimid (DIC). The activating mechanism 
of this class of coupling reagents is shown in scheme 1.2. 
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Scheme 1.2. Coupling using carbodiimid-based activating agents. 
 
As can be seen from scheme 1.2 the first step of the activation is coupling of the acid 
to the carbodiimide forming an O-acylurea. From here the reaction can follow three 
different pathways, where only two leads to the desired product. The first is direct 
addition of the amine to the formed O-acylurea yielding the desired amide. The next 
path is a rearrangement forming an N-acylurea by-product. Finally, adding another 
acid resulting in an anhydride, which can subsequently be attacked by an amine, also 
giving the desired amide. One problem that can occur when using carbodiimides is 
the possible formation of oxazolone-compounds from the O-acylurea, which leads to 
epimerization of the amino acid.44 To reduce epimerization additives have been 
introduced.45 These additives react with the O-acylurea forming an intermediate, 
termed activated ester, which has an enhanced reactivity towards amines. The lower 
degree of epimerization and the better reactivity of the activated esters are most likely 
coursed by hydrogen-bonding between the OXt ester and the amine.42 The most 
common additives are 1-hydroxy-1H-benzotriazol (HOBt) and 1-hydroxy-7-
azabenzotriazol (HOAt) (Scheme 1.3).  
 
 
Scheme 1.3. Coupling using OXt additives. HOBt = 1-hydroxy-1H-benzotriazol, HOAt = 1-hydroxy-
7-azabenzotriazol 
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The 1H-benzotriazol additive has also been used to develop another class of coupling 
reagents. This class consists of salts of 1H-benzotriazoles associated with 
uronium/aminium, phosphonium or immonium and a counter ion. 
 
 
Figure 1.10. Examples of coupling reagents. DIC = diisopropylcarbodiimid, DCC = 
dicyclohexylcarbodiimid, HATU = 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] 
pyridinium 3-oxid hexafluorophosphate, HBTU = N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-
yl)uronium hexafluorophosphate, PyBOP = (Benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate. 
 
 
Figure 1.10 shows a small selection of the many variants of these salts available. Also 
the counterion can be varied, however, no effect on reactivity has been observed. 
These compounds react directly with the carboxylic acid, forming an activated ester, 
which will subsequently react with the amine (Scheme 1.4). When using uronium or 
aminium salts the timing of addition of the different species is crucial. If the amine is 
added before the activated ester is formed, it can react with the coupling reagent 
yielding guanidinium by-products.46 To avoid the formation of guanidinium by-
products, phosphonium salts can be used instead. Another important consideration 
when using these salts is that base is added to deprotonate the amino acid prior to 
activation. This puts some restraints on the protecting groups that can be used during 
synthesis.  
 
 
 
Scheme 1.4. Coupling using ammonium/uranium type coupling reagents. 
 
Also a broad variety of coupling reagents involving different reaction pathways exist. 
What is described here are some of the most common classes, which can be applied 
on a large selection of substrates.42 
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1.2.5 Protecting group strategies 
When synthesizing peptides two main strategies exist: the Fmoc strategy47,48 and the 
Boc-strategy49. Both these strategies rely on the orthogonal removal of the N-terminal 
protecting group over the side chain protecting group, allowing for the addition of the 
next residue. The Boc protecting group is removed using TFA, whereas the Fmoc 
group is removed upon treatment with 20% piperidine or 2% 1,8-diazabicycloundec-
7-ene (DBU) in dimethyl formamide (DMF).  Therefore, stability towards the chosen 
conditions will be crucial for the side chain protecting groups. When the peptide is 
connected to the solid support by a handle, the protecting groups must either be stable 
to the cleaving procedure or designed for removal upon cleavage. If one wishes to 
modify the side chain while the peptide is bound to the solid support, three degrees of 
orthogonality is required. That is, the side chain protecting group can be cleaved 
without cleaving the peptide from the support or removing the terminal nor any other 
protecting group in the peptide. As the amino acids have different side chain 
functionalities, they need different protecting groups, figure 1.11 shows a few of the 
commonly used.50 
 
 
Figure 1.11. Selection of some commonly used protecting groups. Fmoc = 9-Fluorenyl 
methoxycarbonyl, Boc = tert-butoxycarbonyl, Alloc = Allyloxycarbonyl, Cbz = Carboxybenzyl. 
 
1.3 Foldamers 
The ability of oligomers to display an ordered arrangement of sub-units is not 
exclusive to the proteins and peptides. Various chemotypes capable of adopting 
stabilized three-dimensional structures have been identified and been named 
“foldamers”.10 The term has been further specified by Moore, who defined foldamers 
as “Oligomers that fold into a conformationally ordered state in solution, the 
structures of which are stabilized by a collection of non-covalent interactions between 
nonadjacent monomer units".8 Within this class of compounds a wide variety of un-
natural backbones have been developed and studied.7,8,51 However, these definitions 
also holds limitations as it is not sufficient to display a stable structure, the molecule 
must also be in equilibrium with an unfolded state. Compounds that adopts helical 
structures, but are locked by covalent constraints predetermining the backbone 
conformation are hence excluded from this category (Figure 1.12).8 
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Figure 1.12. Examples of molecules not classified as foldamers: Helicenes (3),52 
Polyoxapolyspiroalkanones (4),53 and “geländer” helices (5).54 
As peptides are themselves foldamers, it is not surprising that many of the interactions 
utilized in the stabilization of these natural compounds are also prevalent in the 
unnatural systems. However, as the ensemble of backbones and side chains are much 
broader, other types of interactions can play a key role in structure determination.51 
 
1.3.1 Non-peptidomimetic foldamers 
Any stabilized structure can be described by the torsion angles of the backbone, or 
from a design point of view, any structure can be achieved through control over these 
angles. This implies that the difficulties designing a molecule that adopt a predictable 
fold are increasing with the amount of rotatable bonds in each residue. An effective 
way to restrict rotation around single bonds is by introduction of π-conjugation, as 
this will favor the two sp2-hybridized systems to be co-planar, which gives only two 
favorable conformations. The structures of these molecules can be further affected by 
the introduction of non-covalent bonding partners, which can only interact in one of 
the two conformations (Figure 1.13).  
 
Figure 1.13. Examples of monomers on which local conformational control is exerted. Attractive 
interactions are marked as hashed lines and repulsive as arrows. 
By connecting units of the type shown in figure 1.13 a variety of folded structures can 
be obtained (Figure 1.14).55-58 Depending on the substitution pattern of the aromatic 
system, and the preferred interactions both helical (6 and 7), Straight (8), and curved 
(9) structures can be obtained. As most of these monomer molecules are flat, the 
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number of possible secondary structure motifs of a specific oligomer is limited, and 
the prediction of their folding is much easier than for the natural peptides. 
 
Figure 1.14. Examples of secondary structures from arylamide type building blocks. 
The examples shown in figure 1.14 all use secondary amide bonds to connect the 
aromatic residues, and hydrogen bonds to control the rotation. Another way to control 
the rotation around an amide bond is the introduction of a tertiary amide, between an 
aromatic acid and an aromatic amine, in which case the two aryl groups are projected 
to the same side (trans amide bond) (Scheme 1.5).59 
 
Scheme 1.5. cis–trans equilibrium for aromatic amides 
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a ! 16.116(3) Å, b ! 9.253(2) Å, c ! 35.630(7) Å, ! ! 90°, " !
92.275(10)°, # ! 90°. Compound 9: space group P1, a !
11.4923(3) Å, b ! 11.6685(3) Å, c ! 20.4178(6) Å, ! !
76.607(1)°, " ! 87.084(1)°, # ! 71.170(1)°.
Results and Discussion
Symmetrical nonamers 2a and 2b were designed to simplify their
synthesis, which can be carried out based on a convergent route
by combining two amino tetramer fragments with a diacid
residue. Nonamers 2a (more soluble) and 2b (less soluble) were
synthesized by coupling the corresponding isophthalic acids with
the amino tetramers 4a and 4b. The resulting symmetry is readily
apparent in one-dimensional (1D) 1H NMR—i.e., the spectrum
of 2a contains nearly the same number of peaks as that of 3,
whose structure is roughly half of 2a (1D and 2D NMR spectra,
distance calculation, and other details are published as support-
ing information on the PNAS web site, www.pnas.org).
Ab initio calculations (22) indicate that isophthalamide 5a adopts
a flat conformation that is rigidified by the two three-center
hydrogen bonds. Alternative conformations of 5a resulted from
interrupting the hydrogen bonds are mostly much less stable. The
ab initio results are confirmed by the crystal structure f 5b, whose
backbone shows a flat conformation enforced by the presence of
the two three-center hydrogen bonds (Fig. 1a). Thus, the isoph-
thalamide unit rigidified by three-center hydrogen bonds maintains
a conformation inwhich the two amide carbonyl groups point to the
same side. The crystal structure of tetramer 4cwas also determined
and shows awell-defined crescent backbonewith theOatoms of the
amide and nitro groups pointing inward (Fig. 1b). Combining the
isophthalamide unit with two rigid tetramer units may lead to
9-mers 2 with an overall rigidified curved backbone yielding a
helical conformation.
Evidence for a helical conformation was provided by the
crystal structure of 9-mer 2b. As shown in Fig. 2, the molecule
folds into a helical conformation in the solid state, with the
amide O atoms pointing toward the center of a nearly 10-Å
cavity. All of the amide protons and the alkoxy O atoms are
involved in forming three-center hydrogen bonds. The side
chains point radially away from the center of the molecule. There
are about seven benzene rings per turn. If all of the backbone
atoms had the planar trigonal 120° symmetry typical of sp2
centers, a helix with exactly six benzene rings per turn, thus a
smaller interior cavity, would result. However, the crystal struc-
tures of 2b, 4c, 5b, and, as shown in Fig. 4, 8 and 9, and two other
short oligomers previously reported by us (12) revealed that the
two amide bond angles, ! (aryl–N–C(O)) and " (N–C(O)–aryl),
deviate from 120° (! " 127°, " " 117°), resulting in the curving
of the amide linkages toward the NH side. Such slightly curved
amide linkages appear to be responsible for the ‘‘opening up’’ of
the backbone of 2b. In contrast, in two previously described
Fig. 1. (a) The crystal structure of 5b in which the three amide-linked
benzene rings lie on the same plane. (b) The crystal structure of tetramer 4c.
The octyl groups are replaced with dummy atoms (green) for clarity of view.
Fig. 2. Crystal structure of 2b: cylindrical bond (a), and Corey–Pauling–
Koltun (CPK) (b) representations. For cylindrical bond representations, only
amide hydrogens are shown for clarity of view.
Fig. 3. (a–d) End-to-endNOEs in 2a as revealed byNOESY (500MHz) in CDCl3
(2 mM, 263 K, mixing time 500 ms) (a), DMSO-d6!CDCl3 [1!1 (vol!vol), 2 mM
283 K,mixing time 500ms] (b), or DMSO-d6!CDCl3 [1!1 (vol!vol), 2mM, 283 K,
mixing time 100 ms] (c). (d) The corresponding NOEs are not observed in the
reference compound 3 (CDCl3, 4 mM, 263 K, mixing time 500 ms). (e) The
helical conformation of 2a and the corresponding end-to-end NOEs (arrows),
along with the crescent conformation of 3
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reacted with 14 in refluxing chloroform to produce 4b in
65% yield. As expected, compound 4b is highly soluble in
nonpolar solvents such as chloroform and dichloromethane.
The 7-mer compound 5 was then prepared, as shown in
Scheme 3. Diacid 17 first reacted with benzyl bromide in
DMF with sodium hydride as base to produce 19 in 63%
yield. Acid 19 was then converted to 20 with hot thionyl
chloride. The reaction of 20 with amine 216a also in hot
chloroform afforded 22 in 70% yield. Subsequent deprotec-
tion of the carboxylic acid group by Pd-catalyzed hydrogena-
tion gave 23 in 75% yield. DCC-mediated coupling reaction
of 23 with 6 in dichloromethane with HOBt as catalyst was
then car ied out to produce 24 in 56% yield. Finally, 24
reacted with 18 in hot chloroform with NEt3 as base to afford
5 in 85% yield.
Single crystals of 1-3 were grown by slow evaporation
of the chloroform solution at room temperature. Figure 1a
shows the crystal structure of 1. As expected, two six-
membered ring hydrogen bonds (NH‚‚‚O distance ) 1.81
Å) between the adjacent amide NH and ester CdO groups
are formed, which lead to a perfectly planar conformation.
Evidence for the straight and planar features of the linear
molecules are provided by the X-ray structures of 3-mer 2
and 3. As shown in Figure 1b,c, both 2 and 3 possess four
six-membered-ring hydrogen bonds (NH‚‚‚O distances )
1.81 and 1.82 Å). All three benzene units and the amide
groups in both compounds share one plane due to the
presence of these strong three-center intramolecular hydrogen
bonds (see the packing diagrams of 2 and 3 in the Supporting
Information), whereas all the side methyl and ethyl groups
point away from the central aromatic skeleton. Since the
longer oligomers 4 and 5 also possess the identical repeated
structural feature, it is reasonable to consider that these longer
oligomers should also adopt similar planar and straight
conformations. A CPK model of planar 7-mer 5, with a
length of 4.30 m, is shown in Figure 2.
The amide NH signals of the 1H NMR spectra of all
compounds 1-5 in chloroform-d appeared at downfield
positions (Table 1). The results provide strong evidence to
support that strong six-membered ring hydrogen bonds are(12) Itami, K.; Palmgren, A.; Thorarensen, A.; Ba¨ckvall, J.-E. J. Org.Chem. 1998, 63, 6466.
Scheme 3
Figure 1. Crystal structures of 1 (a), 2 (b), and 3 (c). All the
molecules adopt perfectly flat conformations, and both 2 and 3
possess straight pi-extended skeletons, due to the strong six-
membered ring hydrogen bonds.
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respect ively. Under simila r condit ions, t rea tment of 10
with 2.2 equiv of 6 produced 2 in 85% yield.
For the synthesis of 7-mer 3, compound 12 was fir st
produced in 70% yield from the react ion of 5 and 6 in
dich loro ethane (Scheme 2). Under simila r condit ions,
compoun 12 reacted with 13 to fford 14 in 75% yield.
The la t ter was then hydrolyze with lith ium hydroxide
in hot THF and methanol to afford acid 15 quantita t ively.
Compound 15 was coupled with 11 in dich loromethane
in the presence of DCC to produce 7-mer 3 in 30% yield.
Under similar react ion condit ions, 9-mer 4 was produced
in 40% yield from the react ion of 9 and 11. Simila r ly,
t rea tment of diamine 5 with 2.2 equiv of 15 afforded 3
in 16% yield.
Single crystals of 3-mer 1 were grown by slow evapora-
t ion of the ethyl aceta te solu t ion a t room tempera ture.
F igure 1a shows the crysta l st ructure of 1. As expected,
the NH bonds are involved in both five-membered (N-
H ‚‚‚O distance ) 2.23 Å) and six-membered (N-H ‚‚‚O
distance ) 1.83 Å) r ing hydrogen bond, leading to a
planar conformat ion . Evidence for the planar and zig-
zagged conformat ion of the oligoamides is provided by
the X-ray st ructure of 5-mer 2. The crysta ls of 2 were
grown by slow evapora t ion of the chloroform solu t ion a t
room tempera ture. As shown in Figure 1b, compound 2
possesses three sets of three-center hydrogen bonds. The
N-H ‚‚‚O distances of the per iphera l and cent ra l six-
membered r ing hydrogen bonds are 1.82 and 1.83 Å,
respect ively, while the N-H ‚‚‚O distances of the cor re-
sponding two five-membered r ing hydrogen bonds are
2.22 and 2.24 Å, respect ively. These values are very close
to tha t revea led in the solid sta te of 1, suggest ing a
similar ity in the backbone of the compounds. In addit ion,
a ll five benzene units and the amide groups in compound
2 a lso share one plane due to the presence of the st rong
in t ramolecula r three-center hydrogen bonds. The back-
bone formed by the five benzene unit s a lso clear ly
displays a r igid zigzagged secondary st ructure. Since the
longer 7-mer 3 and 9-mer 4 possess the ident ica l st ruc-
tura l subunit , it is reasonable to consider tha t these
oligomers or even longer polymers of the same skeleton
should a lso adopt simila r planar and zigzagged confor -
mat ions. A space filling model of planar 9-mer 4, with a
length of 4.60 nm, is shown in Figure 2, which revea ls
tha t the long oligomer takes up a slight ly curved confor-
mat ion due to the presence of the in t ramolecular hydro-
gen bonding. This result is consistent with the solid-sta te
st ructure of 5-mer 2, a s shown in Figure 1b.
The solu t ion conformat ions of the oligoamides were
invest iga ted by 1H NMR in chloroform-d . The selected
chemica l sh ift s of oligomers 1-4 and in termedia tes 10
and 14 are collected in Table 1. The signa ls have been
assigned based on the NOESY experiments. The 1H NMR
result s show severa l fea tures to suppor t the r igid planar
structures. In part icular , large downfield shifts (∆δ 2.03-
2.66 ppm) of the NH resonances were displayed for a ll
the compounds, compared to tha t of 4-methoxy-N -(4-
methoxyphenyl)benzamide (7.64 ppm).5d The H-2 reso-
nances (PhHa and PhHc in Table 1) of the isophthalamide
unit s of a ll the oligomers were a lso grea t ly downfield
sh ifted due to the st rong shielding effect of the two
adjacent carbonyl groups, which are well consistent with
the r igid planar conformat ion .5e,6b Adding 20% DMSO-
d 6 to the solu t ion of 1 in ch loroform-d caused only a
SCHEME 2
FIGURE 1. Crysta l st ructures of 3-mer 1 (a ) and 5-mer 2 (b).
Both molecules adopt preorganized conformat ions due to the
st rong three-center hydrogen bonding.
FIGURE 2. CPK mod l of 9-mer 4, produced with AccuModel
2.1.
S ynthesis of a Metallocyclophane
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Although no clear preference for the rotation around the aryl–NCO or aryl–CON 
bonds are defined, it is affected by sterics and weak electrostatic interactions between 
the aryl groups. Especially when molecules carrying this motif is dissolved in protic 
solvents the interactions of the aryl groups are reinforced by a solvophobic effect. 
This pattern has been used to furnish foldameric oligomers of e.g. guanidines and 
ureas connecting aromatic rings (Figure 1.15).60,61 When interconnecting two aromatic 
moieties in this way they can be arranged to allow for an almost perfect face-to-face 
stacking interaction. 
 
Figure 1.15. Examples of secondary structure of aromatic urea and guanidine-compounds. 
The tertiary amide is also known from the naturally occurring amino acid proline. 
Despite an inability to form hydrogen bonds, polyprolines have been shown to adopt 
helices of all cis- or trans-amide bonds, referred to as polyproline helix type I and II, 
respectively (Figure 1.16).22 
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Fig. 2 ORTEP Stereoview of 3 (a), and 4 (b). The counteranions and 2 molecules of H20 were omitted in the structure of 4. 
means of sequential condensations and functional group transformations using standard methods. Compound 
4 was expected to be hydrophilic properties in layered aromatics, and was confirmed to be freely soluble in 
water. 
The crystal structures of 3 (mp, 179.5-182.5 °C) and 4 (rap, 242-245 °C, dec.) are shown in Fig. 2. 9 Both 
compounds have multi-layered aromatic structures with large dihedral angles (65 - 80 °) between the benzene 
ring planes and the planes of the - N - C ( = X ) - N -  groups (all-cis-conformations). Each pair of face-to-face 
aromatic rings is tilted; this should be at least partly due to repulsive interactions of  their x electrons by 
analogy with the splayed-out structures of the conformationally restricted 1,8-diarylnaphthalenes. 1° The 
stable conformations of the simple benzene dimer have also been calculated to be T-shaped or displaced 
parallel rather than parallel sandwich structure. H It is interesting to form the multi-layered aromatics with 
displaced parallel conformation linked by flexible urea or guanidine bonds in 3 and 4. The dihedral angles 
between two neighboring benzene in a molecule ring planes are 30 - 40 °, similar to those in the simple 
compounds 1 (35 °) and 2 (31°), while the alternate benzene rings are nearly parallel (10 - 18 °) in both 
compounds. Similarly, the planes of the alternate linking groups [ - N - C ( = X ) - N -  planes] in a molecule are 
nearly parallel; for example, the dihedral angles are 8.6 ° and 3.5 ° in the case of the guanidinium groups in 4. 
The orderly helical structures in both compounds arise from the same-directional conformations of the 
two substituents on the benzene rings. For example, the structure of 3 (Fig. 2a) has all-R (or all-S) chirality 
along the axes.~2 Although the oligomeric compounds 3 and 4 have no fixed chirality, well-ordered structures 
would be favored rather than diastereomeric broken helical conformations (R- and S-mixed conformations in 
a molecule) for steric reasons. 
The crystals are racemic (space group, 3: P2/c, 4: P2Jc),  both enantiomeric helices existing in 1 : 1 ratio 
in the unit cell (Z = 2 and 4 for 3 and 4, respectively). Interesting packing structures are seen in the crystals 
(Fig. 3). The helical molecules in 3 are ordered in the same direction with an alternate arrangement of all-R 
and all-S conformers in the crystal. The terminal phenyl groups of one molecule lie in parallel to those of 
neighboring molecules with the opposite helicity, the distance between two planes being 4.1 /k (Fig. 3c). 
Similarly, all of the urea bonds are arranged in a face-to-face parallel manner with respect to those of  the 
opposite helical molecules with a 3.5 ~ C---O distance (Fig. 3d). Unlike 3, compound 4 formed double 
zigzag chains consisting of molecules arranged alternately in the reverse direction, each chain being composed 
of molecules with one helicity. In this case, the terminal phenyl groups of two neighboring molecules in one 
chain form tilted T-structures with a 4.9 ,~ C---C distance (Fig. 3e), like the stable conformer of benzene 
dimer deduced from calculation, u The difference in crystal packing may be caused by the electronic nature 
of the linking groups including counter anions of 4. Both arrangements of aromatic layered helix are of 
( 
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Figure 1.16. The two types of helices formed by polyproline. a) type I (all cis) b) Type II (all trans).22 
The examples of this section have utilized the control over the conformation of a 
relatively small number of bonds, and in these efforts exploited local interactions of a 
single residue or by non-covalent interactions with a neighboring residue to construct 
folded molecules. Most of these monomer building blocks have little resemblance to 
the naturally folded amino acid sequences found in nature, although they use some of 
the same interactions to stabilize secondary structure. One of the major differences 
from the natural oligomers to those of this section is the ability to engage in 
interactions with more distant residues than the neighbors.  
 
1.3.2 Peptidomimetic foldamers 
In traditional medicinal chemistry, peptidic compounds have not been considered 
suitable for drug development. This is due to their susceptibility to proteolytic 
degradation in cellular environments and often poor cell penetrating properties. To 
circumvent the inherent stability issues, extensive research in mimicking peptide 
structure and function has been undertaken. Compounds able to mimic or complement 
the three-dimensional folding of peptides and proteins have been further classified as 
peptidomimetic foldamers. Most strategies for the preparation of molecules that fold 
like oligomers of α-amino acids contain only minor modifications to the natural 
amino acids.8 Concerning foldamers, alterations to the backbone, e.g. positioning of 
the side chains or the addition of fragments, are the most studied. If a methylene unit 
is added to the backbone of an α-amino acid, the corresponding β-amino acid is 
formed, if yet another methylene is added the product is a γ-amino acid and so forth. 
Even though these molecules have more rotatable bonds than the natural α-amino 
acids, their oligomers have been shown to form stable helices, resembling those of α-
peptides (Figure 1.17).62,63 
 18 
 
Figure 1.17. Structures of the helices from α-, β- and γ-peptides.62 
Given their close relation to the α-amino acids, it is not surprising that the β-amino 
acids have received considerably more attention than further elongated analogues.  As 
can be seen from figure 1.17, when the backbone is elongated additional carbons 
capable of carrying a side chain are present. This is a major difference from natural 
peptides, and a major factor in the determination of which secondary structures can be 
formed by these molecules (Section 1.4). The introduction of additional backbone 
carbon atoms has also made substitution of individual backbone atoms possible, while 
retaining the side chain on a carbon. This kind of substitution is also possible for α-
amino acids where the Cα has been substituted with a nitrogen to give azapeptides64 
and azatides65 (Figure 1.18A). The conformation of azapeptides is rigidified due to the 
planarity of the urea, and repulsion between the lone pairs of the two covalently 
linked nitrogens. This gives azapeptides a tendency to adopt torsion angles 
corresponding to those of a peptide turn, which has been shown both in solution66 and 
by X-ray crystallography67. A β-peptide analogue of the azatides has also been made, 
termed an aza-β-peptide.68 For this family the aza-β3-peptides have been shown to 
form an eight membered turn called a hydrazino-turn.69  This turn structure is 
stabilized by hydrogen bonds from “amide” hydrogen to both the hydrazine-group 
and the carbonyl oxygen of the adjacent residue (12). This motif has also been 
demonstrated in the solid state for a hexamer compound, consisting of three such 
turns (13).70 
 19 
 
Figure 1.18. A) Structures of aza-β- and aza-peptides. B) Crystal structure of an azapeptide turn.67 C) 
Crystal structure of a hexameric aza-β3-peptide.70 
As shown in figure 1.15 aryl-ureas have been used to furnish create foldamers from 
aromatic residues, but also aliphatic ureas have shown foldameric properties. Being 
aza-analogues of γ4-peptides, they form well-defined helical structures, stabilized by 
three-centered hydrogen bonds (Figure 1.19).71 
 
 
Figure 1.19. Right) Top view of an oligourea-helix. Left) Stabilizing three-centered hydrogen bond.71 
Versions of the aza-β-peptides carrying an oxygen rather than a nitrogen in the 
backbone have also been proposed as foldamers and are called α-aminoxy peptides.72 
 
the Z geometry. The value of the torsional angle φ, which
approaches+120° or-120°, corresponds to an orthogonal
arrangement between the lone pairs of electrons of the
two adjacent nitrogen atoms (referred to as N! and NR
according to the literature), which minimizes electron
repulsion (Figure 5a). The values taken by θ (around
-75° or +75°) corresponds to a (-)-synclinal or (+)-
synclinal conformation that makes H-bonding between
with the hydrazidic NH and the CO possible and further
places the R substituent in a free zone of space (Figure
5b). H-bonding between NHi and NRi-1 restricts the
rotation around the corresponding bond and forces ψ to
adopt a low value (Figure 5c).
The structural features, which determine the set of
angles ω, φ, θ, and ψ, clarifies why the hydrazinoturn
conformation is so strongly favored. In fact, this particu-
lar turn allows the simultaneous minimizing of both
steric crowding and electronic repulsion, while satisfying
most H-bond donors and H-bond acceptors present in the
oligomers.
The values of the torsional angles revealed by our solid-
state analysis are very close to the values of the H8 (1.758)
helix postulated by Gu¨nther and Hofmann to be one
of the most stable conformation of hydrazino peptides.
This prediction is in good agreement with our observa-
tions.
Wu and Yang calculated that pseudopeptides formed
by R-aminoxy acids (oxa-peptides) should develop the
same secondary structure with a cooperative effect for
the formation of adjacent C8 structures.12 It is not
surprising that aza-!3-peptides behave similarly, since
the structures of the NR-substituted hydrazino acetic
fragment and the R-aminoxy acid fragment are closely
related by the presence of the two adjacent heteroatoms
(respectively, N-N and N-O), which both induces lone-
pair electron repulsion and allows comparable H-bonding.
Wu and Yang also predicted that homo-(S)-oxa-peptides
(12) Wu Y-D.; Wang, D.-P.; Chan, K. W. K.; Yang, Dan. J. Am.
Chem. Soc. 1999, 121, 11189.
FIGURE 4. (a) Crystal structure of 1. H-bonds as dotted lines. (b) Crystal structure of 2 H-bonds as dotted lines. Side chains are
ommited for clarity. (c) Crystal structure of 3. H-bonds as dotted lines. Side chains ommited for clarity. (d) Sructural features of
a hydrazinoturn.
TABLE 1. Average Torsional Angles (deg) of a R and a
S-Hydrazinoturn
torsional angle
ω φ θ ψ
R-hydrazinoturn 180 +120 -75 -15
S-hydrazinoturn 180 -120 +75 +15
FIGURE 5. Schematic Newman projections showing the
structural features of a R-hydrazinoturn in relation to the
angles φ, θ, and ψ.
J. Org. Chem, Vol. 70, No. 16, 2005 6501
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A 
FIGURE 3 
Stereoviews of the &folded crystal molecular structures of Z-AzAsn( Me)-Pro-NHiPr, 2 (a). Z-AzAsp(0Et)-Pro-NHiPr, 3 (b )  and Boc- 
AzAla-Pro-NHiPr, 4 (c). The intramolecular hydrogen bonds are indicated by broken lines. 
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NMR spectroscopy studies of oligoureas in solution.[23–25]
Octamer 3, which has one single conformation in the crystal,
has a nearly perfect repeat of 2.5 residues per turn (Figure 1a)
and a rise per turn of 5.1!. The average backbone torsion
angles f, q1, and q2[34] are !1038, + 578, and + 808, and are
characterized by relatively low RMSD values (118, 58, 78).
Such a regular fold is allowed, as all possible intramolecular
12- and 14-membered H-bonded rings (i.e. 14) are present in
the crystal structure of 3 (Figure 1). Distances between O(i)
and H-bonded N’(i!2) and N(i!3) are very similar, and range
from 2.78 to 2.99 ! and 2.82 to 3.00!, respectively. The O(i)-
H-N’(i!2) and O(i)-H-N(i!3) angles are comparable with an
average value of 1398 (RMSD of 98 and 118 respectively).
Overlay of the X-ray structure of octamer 3 and the
optimized structure of a related nona-urea determined by
NMR spectroscopy[31] provides precise insight into the
behavior of this helical fold in solution (Figure 1c). First,
the helix in solution is clearly distorted at both ends, which is a
direct consequence of an incomplete H-bond network.
Indeed, the carbonyl group of the residue 9 in the nonamer
only establishes an H-bond with the amide proton of the
residue 6. Compared to the crystal structure, the absence of
H-bonding between O(9) and HN’(7) modifies the orienta-
tion of the residue 9 urea plane and thus slightly distorts the
helix axis. The same feature is found for the residue 4, which is
not H-bonded to the HN" amide of residue 2 but only to HN
of residue 1. As no H-bond occurs for the preceding residues,
the corresponding tail appears much more flexible than in the
solid sta e structure. T e detailed conformations of residues 4
and 9 highlight the weaker H-bond character of the HN"
amide compared to the HN amide. Such an observation is also
made for central residues of the helix, for which slightly
greater distances accompanied with smaller O-H-N angles are
found between O(i) and N’(i!2) than for O(i) and N(i!3).
This structural feature is in very good agreement with
experimental data recorded on oligoureas in pyridine, for
which temperature coefficients of well-structured regions
were all found to be greater for the HN amide (between !2.0
and !3.5 ppbK!1) than for HN’ (between !4.4 and
!5.6 ppbK!1),[25] but differs from the crystal structure of 3,
in which both H-bonds are equivalent. Torsion angles f, q1,
and q2 obtained over the 20 best NMR spectroscopically
determined structures for the well-defined segments are
!1008, 438, and 968, with RMSD values of 18, 68, and 78 ;
these values are comparable to those measured in the crystal
structure of 3. The difference of about 158 for q1 and q2 could
be related to the significant planarity deviations found for the
urea motifs in the crystal structure. Indeed, C-N’-C’-O
dihedral angles range from 58 to 188 and C-N-C’-O angles
from !238 to !68. As a consequence, whereas C-N’-N-C
dihedral angles are between 0 and 58 for all the calculated
structures determined from NMR spectroscopy, they range
between !238 and 188 in the X-ray structure. This result
shows that the double-bond character of the amide bond is
significantly reduced within urea motifs. Overall, slight
differences in H-bonding in NMR and X-ray structures and
in the distortion of urea planes observed in the crystal
structure account for the 2.5! root-mean-square deviation
obtained when aligning solution and crystal structures
(Figure 1c).
Shorter oligoureas 1, 2, and 4 crystallized with two (1 and
2) or four (4) independent molecules in the asymmetric unit
(Figure 2a; Supporting Information, Figure S1). In all three
cases, the conformations of independent molecules differ
perceptibly, with the largest differences being localized at
both ends (Figure 2). These distortions, which are presumably
caused by packing effects and/or H-bonded interaction with
solvent molecules (H2O, MeOH), reflect conformational
plasticity of shorter helices. For example, in the crystal of
tetra-urea 1, the O!N distance between O(3) and NH(Me)
increases from 2.91! (molecule A) to 3.67! (molecule B)
owing to the insertion of a bridging water molecule (Fig-
Figure 1. Crystal structure of 3. a) View along helical axis. b) Detail of
the three-centered H-bonding. O(7)···HN(4) and O(7)···HN’(5) distan-
ces in !. c) Overlay with the 20 best NMR structures (in gray) of a
related nona-urea.[31] Side chains are omitted for clarity.
Figure 2. X-ray crystal structures of 1 and 4. a) Overlay of independent
molecules (blue and orange) in 1 (left) and 4 (right). Side chains in 1
have been removed for clarity. b) H-bond network at upper and lower
extremities of the helix in 4 (top) and 1 (bottom), showing conforma-
tional differences between independent molecules (carbon atoms in
blue and orange). D···A distances in !.
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In a similar way to the N–N bond, the repulsion of lone pairs in the N–O bond are 
thought to rigidify the backbone. The foldameric properties of these molecules have 
been shown in both solution and in the solid state, where it was shown that monomer 
model systems formed turn like structures. These structures are stabilized through 
hydrogen bonding interactions from the amide hydrogen to the carbonyl oxygen of 
the adjacent residue (Figure 1.20A).73,74 Oligomers as short as dimers of these 
compounds have been shown to fold into helical arrangements (Figure 1.20B).75 
Analogues of the α-aminoxy peptides carrying one (β-aminoxy) or two additional 
methylenes (γ-aminoxy) in the backbone have also been prepared, and exhibits the 
same tendency to form turns between adjacent residues and helices in oligomers 
based on the same interactions.75 In addition to this the β-aminoxy residues have been 
shown to engage in three-centered hydrogen bonding pattern including the amide 
hydrogen and the adjacent carbonyl carbon, but also the backbone oxygen (Figure 
1.20C).76 This structure can be further stabilized by the introduction of a cyclic 
constraint in the backbone (17). 
 
Figure 1.20. X-ray crystal structures of A) α-Aminooxy N-O turn.74 B) Helix of an α-aminoxy dimer.75 
C) β-Aminoxy N-O turn of cyclically constrained monomer.76 
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1.4 β-Peptides 
Like the α-peptides described above, the β-peptides consist of amino acid building 
blocks. The amino acids of β-peptides represent a minimal step away from the α-
amino acid backbone, by the introduction of an additional methylene. Hence, these 
compounds are especially appealing for investigations into the field of folded non-
biological polymers. β-amino acids are found in nature, displaying far greater 
diversity than the proteinogenic amino acids.63 Amongst the most common β-amino 
acids are β-alanine, an essential component of pantotheic acid (vitamin B5), which is a 
part of coenzyme A (Figure 1.21).77  
 
 
Figure 1.21. Structure of coenzyme A. 
 
Although being present in natural compounds, no pure β-peptidic sequences from 
natural sources are known.63 Early investigations of polymeric β-peptides indicated 
that they are capable of adopting stable helical structures, although the precise 
geometries of their secondary structure was challenging to determine.78,79,80,81 Even 
though adding a single methylene unit to each residue in the backbone may seem as a 
small alteration, it introduces a cascade of conformational and chemoselective 
possibilities.  
 
1.4.1 Conformational properties of β-peptides 
The conformations of β-amino acids, as monomer building blocks or in a peptide 
strand are described by the torsion angles, ω, φ, θ, ψ of the backbone (Figure 1.22).82 
 
Figure 1.22. A) Definition of torsion angles in β-peptides. B) Rotamers of β-alanine regarding the 
θ angle. 
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the α-peptides, the torsion angles providing the lowest energy conformation of a β-
peptide falls within a certain region.82 Compared to the α-amino acids, a few 
additional components such as the number of side chains, and their stereo- and 
regiochemistry, determines which set of torsion angles will provide the most stable 
conformation.83 The conformational preference of β-amino acids can be described by 
the rotation around the C2–C3 bond, also given as the torsion angle θ (Figure 1.22B). 
If no substituents are present in the backbone the residue will have a high degree of 
flexibility. In both cases of having a single substituent at either C2 (β2-amino acid) or 
C3 (β3-amino acid) a gauche conformation is favored (Figure 1.23).84 If a β-amino 
acid has substituents on both backbone methylenes (β2,3amino acid), it is the 
stereochemical relationship between the side chains that determines the most stable 
backbone conformation. If the two substituents have the same stereochemistry the 
residue will strongly favor a gauche configuration, and if they have the opposite 
stereochemistry the anti conformation will be strongly favored.84  
 
 
Figure 1.23. Preferred conformation of substituted β-amino acids. 
 
In the case of β2,3 residues the side chains can be connected, this type of compounds 
show an even greater preference for the gauche conformation.85 The torsion angles for 
the cyclically constrained residues can be fine-tuned by changing the size of the 
ring.86  The prefered conformation of the β-amino acids in a sequence determines what 
secondary structures can be adopted. Helical and turn-like structures require gauche 
conformations, whereas an anti conformation will lead to extended structures.87,88,89  
 
1.4.2 Helices of β-peptides 
Oligomers of β-amino acids that are most stable in a gauche conformation are known 
to adopt helical conformations.79,85,90 As for the α-peptides, β-peptides can also adopt 
a number of different helical structures.83,91 The helical structure displayed by an 
oligomer is determined by the precise θ angles of the oligomer. Referring to a β-
amino acid having a gauche conformation does not refer to an exact θ value, but 
merely the directionality of the side chains. The factors described in the last paragraph 
can be used to manipulate the dihedral angles more precisely. It is the exact torsion 
angles that will further define what kind of helix is the most stable.  
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Figure 1.24. Possible helices of β-peptides. 
 
This far five distinct helices have been identified for oligomeric β-peptides: a 
14,84,92,93,94 a 12-,95 a 10-,96,97 an 8-98 and a mixed 10/12-helix87 (Figure 1.24). These 
helices are named according to the number of bonds in their hydrogen bonded rings 
making up a full turn of the helix.85  
 
1.4.3 The 14-helix  
The most studied secondary structure motif amongst β-peptides is the 14-helix.91 The 
14 membered ring that makes up one full turn of the helix consist of three residues, 
connected by a hydrogen bond between an N–H (i) and C=O (i + 2) (Figure 1.25). 
Somewhat surprising, these helices are quite stable compared to α-helical displays of 
α-peptides.83 The stability of this helix type is affected by the substitution pattern of 
the backbone, as it has been shown that β2-oligomers form less stable helical displays 
as compared to β3-oligomers, with the same side chains.84 Further, the helices of β3-
peptides display right handed helices, whereas the helices of β2–residues are left-
handed.91 Also, as the C=O bonds of both the α-helix and the 14-helix is directed 
along the helical axis a macro-dipole is created, which in the natural α-helix runs in 
the N- to C-terminal direction, but in the 14-helix is reversed. 
 
 
Figure 1.25. NMR structure of a β2,3-hexapeptide in MeOD.84 
 
It should also be noted that in the patterns formed, two kinds of positions are available 
for substitution, the axial and the lateral, and for any other substituents than fluorine 
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and hydroxide, the substituents must occupy lateral positions in order to form helical 
displays.99  
 
Figure 1.26. Structure of 14-helix with axial substituents.99 
 
The formation of helices in α-peptides require 10-12 residues whereas the 14-helix 
can be formed from six residues.90 To further stabilize helical displays, a cyclic 
constraint has been introduced into the backbone of β-peptides. As few as four of 
these residues have been shown to display a helical conformation.100 
 
 
Figure 1.27. Structure of trans-2-aminocyclohexanecarboxylic acid. 
 
If a trans-cyclohexane is used as constraint, the θ torsion angle will be near 55°, 
which specifically stabilizes the 14-helix (Figure 1.27).85 Oligomers of trans-2-
aminocyclohexanecarboxylic acid, has been shown to adopt very stable 14-helices by 
NMR and X-ray crystallography (Figure 1.29).85,101 
The collection of side chains allowed in the 14-helix has been shown to posses great 
diversity.84,90,93,102,103 However, initial studies of the 14-helix found it difficult to 
achieve both helix stabilization and great diversity of side chains within the same 
molecule.101 The most stabilizing residues found were the cyclically constrained, but 
these were found hard to further functionalize.104 To overcome these issues Gellman 
and co-workers synthesized a sequence of combined β3- and cyclically constrained β-
amino acid residues (21).93 This β-peptide was a further development of two β-
peptides designed by Seebach and co-workers (19)105 and DeGrado and co-workers 
(20)106, respectively, to deal with the generally low propensity to form helical 
structures in water.107 The two latter mentioned β-peptides were designed to allow 
ionic interactions of the side chains, which stabilizes the helical display near neutral 
pH, but unfolding occurs at either basic or acidic conditions.  
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Figure 1.28. Sequences designed to increase helix stability in water, and to improve the diversity of 
side chains within a helix. 
 
The sequence designed by Gellman contained a lower percentage of preorganized 
residues, as well as residues not able to engage in ionic interactions, but still the 
circular dichroism-spectre showed retention of the helical conformation, even at 
extreme pH conditions (pH 2 and 12).93 It was hence concluded that the introduction 
of les than 50% pre-organized residues were sufficient to stabilize the formation of 
14-helical displays. 
1.4.4 The 12-helix 
When the size of the cyclic backbone constrain is decreased to a trans substituted 
pentane ring, the dihedral angles are restricted in a way that does not allow the 14-
helix. For the trans-2-cyclopentane carboxylic acid residues the θ torsion angle is 
found to be above 85°, and oligomers composed from these residues fold into 12-
helices (Figure 1.29).95 The secondary structure is stabilized by hydrogen bonds 
between N–H (i) and C=O (i + 3), which gives approximately 2.5 residues per turn. 
 
Figure 1.29. Crystal structures of: Left) The 14-helix of β-peptides containing the cyclohexyl 
backbone constraint.85 Right) The 12-helix of cyclopenthyl-constrained β-peptides86. 
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primary sequence. Nevertheless, high-resolution structures of
sheets formed by b-peptides [26,27] and a/b-peptides [28,29]
have been reported. Appropriately designed a-peptoid
sequences have also been shown to be capable of forming
two-dimensional sheets of uniform thickness [30].
2.3 Toward protein-like complexity: tertiary and
quaternary structures
With the impressive strides made in the development of fol-
damer secondary structure in the ~ 10 years after the first
reports on folding in unnatural backbones, attention has
turned recently toward tertiary and quaternary structures.
The quest for higher-order folding serves as a crucible for fol-
damer design strategies, because success in such endeavors
requires effective control over both local backbone conforma-
tion and long-range interactions between elements of second-
ary structure in a single oligomer chain (tertiary structure) or
multiple chains (quaternary structure). These are the same
challenges faced in the design of foldamers that bind with
high affinity to biological receptors, so an examination of
the design strategies employed is informative with respect to
efforts toward the functional foldamers detailed below.
The structure-based modification of the known b-
peptide 14-helix has led to helix-bundle quaternary assemblies
that form readily in aqueous solution (Figure 2D) [31,32]. The
enhanced understanding of b-peptide folding that came
from these and related studies has led to extensive use of the
14-helix in the development of inhibitors of protein--protein
binding interactions. A conceptually different design strategy
used to construct foldamer quaternary structure is the
sequence-based modification of natural proteins to produce
unnatural-backbone analogs that fold like the parent
sequence. In these studies, it has been shown that the
helix-bundle quaternary structure encoded in an a-peptide
sequence will still manifest itself when the natural sequence
of side chains is displayed on various a/b-peptide backbones
(Figure 2E) [33,34]. This concept has also found significant util-
ity in the development of bioactive foldamers. In a-peptoids,
self-association [35] as well as unimolecular folding [36] to form
putative helix-bundles has been reported; however, high-
resolution structural characterization has remained elusive.
The recent report of supramolecular sheet formation in
a-peptoids is an example of a non-helical quaternary structure
available to these oligomers [30].
3. Biomedical applications from
amphiphilicity
In many bioactive a-peptides, global amphiphilicity (i.e., spa-
tial separation of charged and hydrophobic functional groups)
in the folded state is sufficient for biological efficacy. Inspired
by this observation, many early examples of biological function
in foldamers relied on lessons learned in fundamental studies
toward secondary structure to design sequences that would
adopt amphiphilic helical folds. Although these designs utilize
only a fraction of the structural control that can be exerted over
unnatural backbone scaffolds, amphiphilic foldamers have
shown a variety of interesting biological activities.
1 32
b-peptide
14-helix
b-peptide
12-helix
a-peptoid
helix
a/b-peptide
helix bundle
O
O
O
6
NH OBn O
O
O
6
N
H
OBn O
NH2
N
H
5
b-peptide
helix bundle
A. B. C. D.
E.
Figure 2. A -- C. Examples of helical secondary structures formed by b-peptides (A, [7]; B, [9]) and a-peptoids (C, [18]). Atoms are
colored by element (C, N, O from lightest to darkest); some atoms in each structure are omitted for clarity. D -- E. Helix-
bundle quaternary structures formed by a b-peptide (D, [32]) and an a/b-peptide (E, PDB 2OXK, [33]).
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The ability to switch between two different helix-types by making relatively modest 
modifications, reveals a significant difference to the α-peptides. Using β-amino acid 
building blocks a far greater control over the secondary structure can be exerted than 
for the α-amino acids. β-peptides made from these residues tend to be poorly soluble 
in water, therefore an analogue carrying a pyrrolidine-constraint in an alternating 
fashion was designed (Figure 1.30). These positively charged oligomers were shown 
to retain the 12-helical display of the parent oligomer.108  
 
 
Figure 1.30. Pyrrolidinyl containing oligomer. 
 
The amino functionality of the pyrrolidine-constraint has also been used to 
incorporate side chains.109 This was achieved through sulfonylation of the amine, 
incorporating a selection of proteinogenic side chains e.g. 23 and 24. 
 
 
Figure 1.31. Structure of sulfonylated cyclically constrained residues. 
 
It was also noted that upon incorporation of these residues, into sequences otherwise 
consisting of purely cyclopentane- or pyrrolidine constrained residues, the oligomers 
retained both their solubility and structural display. 
 
1.4.5 The 10-helix 
Only a few examples of this helix type have been reported, one of which is the 
terminally unprotected tetramer of trans-2-cyclohexane carboxylic acid.96 In this case 
both the penta- and hexamer were found to adopt the 14-helix, like the protected  
tetra-, penta-, and hexamer. Oligomers of β-amino acids containing an oxetane ring 
have also been shown to adopt this conformation (25).97  
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Figure 1.31. Structure of oxetane oligomer. 
 
Interestingly, in this case the amino group and carboxylic acid are cis on the four 
membered ring, as opposed to the trans configuration of cyclopentane- and 
cyclohexane-constrained residues discussed above. 
 
1.4.6 The 8-helix 
This kind of helix has never been observed experimentally. However, crystal 
structures of short oligomers of 1-(aminomethyl) cyclopropanecarboxylic acid 
residues revealed a propensity to form eight-membered ring hydrogen bonds.98 
 
1.4.7 The 10/12-helix 
When a β-peptide sequence consist of alternating β2- and β3 residues, the resulting 
helix has a mix of 10- and 12 membered rings.87 In this helix amides surrounded by 
methylenes interact with one another (i, i + 2) forming 10 membered rings, while the 
12 membered rings are formed by amides surrounded by side chains (i, i + 3). 
 
 
Figure 1.33. Hydrogen bonding in 10/12-helices. 
 
In contrast to the uniform alignment of the C=O bonds of the 12- and 14-helices, the 
carbonyls in the 10/12-helix are oriented differently. The amide bonds of the 10-ring 
has the C=O bond perpendicular to the helical axis, whereas the C=O bonds of the 12-
ring are directed along the helical axis. 
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Figure 1.34. NMR-solution structure of a 10/12-helix in MeOH.91 
 
This helical type is special as no naturally occurring peptides consist of two different 
types of turns. This strengthen the ability to manipulate the display of side chains 
further, again by relatively modest means. 
 
1.4.8 Sheets 
Sheets of β-peptides can, in principle, be assembled in two ways, one with an anti 
configuration of the C2-C3 bond, and one with a gauche conformation.89 Sheets 
formed by anti-configured β-amino acids will display a net dipole, as all the carbonyl 
oxygens are oriented in the same direction, and the amide protons opposite. In 
contrast, the α-peptidic β-sheet display no dipole, due to the alternating direction of 
the carbonyls. Backbones of gauche-type β-amino acids would lack a dipole for the 
same reason. 
 
Figure 1.35. Hydrogen bonding pattern in sheet-structures of β-peptides. 
 
From the studies of helices it was shown that β-peptides containing (2R,3S)-β2-3 
amino acids could not possibly fold into a helical conformation, as this substitution 
pattern puts both substituents in the “forbidden” axial position (Figure 1.35).63 These 
hydroxy-3-aminocarboxylic acid moieties with Val,
Ala, and Leu side chains.37 MD simulations, how-
ever, suggested a preference for this b-peptide to
form 12-membered H-bonded rings: it was pointed
out61 that the measured NMR data are equally com-
patible with a (P)-2.512-helix structure (Figure 6C).
3-Aza-62,63 and 3-oxa-b-amino-acid64,65 oligomers
have also been found to fold to 8-helices.63,64
(b3hPro)n: A helix without intramolecular hydrogen
bonds? Polyproline [Poly(Pro)n] and polyhydroxypro-
line [Poly(Hyp)n], where Hyp is 4-hydroxyproline]
play an important role in nature. They fold to helices
and triple helices (collagen) without backbone stabili-
zation by intramolecular hydrogen bonding. Oligomers
of homologated proline (b3hPro or (S)-pyrrolidin-2-yl
acetic acid and b2hPro or (R)-piperidin-3-carboxylic
FIGURE 4 The (P)-2.712/10-helix of b3/b2-mixed peptides. (A) NMR structure in MeOH solu-
tion of the b-nona-peptide Boc-b3hVal-b2hAla-b3hLeu-b2hVal-b3hAla-b2hLeu-b3hVal-b2hAla-
b3hLeu-OBn. (B) Schematic presentation of the 12- and 10-membered hydrogen-bonded rings. (C)
View along the axis of the R-b2hVal-b3hAla-b2hLeu-b3hVal-b2hAla-b3hLeu-OR0 helix (NMR
structure in MeOH). (D) Newman projection along the Cb–Ca bond. For nomenclature see also
Figure 3 and Seebach et al.6
b- and g-Peptide Secondary Structures 27
Biopolymers (Peptide Science) DOI 10.1002/bip
N
H
N
H
N
H
N
H
O O O O
N
H
N
H
N
H
N
H
O O O O
H
N N
H
H
N N
HO
O
O
O
N
H
H
NN
H
H
N
O
O
O
O
Gauche
Anti
 29 
residues form fully extended conformations, with all carbonyl oxygens pointing in 
one direction, the amide protons in the opposite, and the side chains oriented 
approximately perpendicular to the amide planes, which is ideal for sheets. Sheets of 
this type was demonstrated by Seebach and co-workers (26).110 This study also 
showed that by incorporating a flexible residue into the strand a turn could be 
introduced (27). 
 
 
Figure 1.36. A) X-ray crystal structure of a β-peptide trimer packing in a β-sheet like arrangement. B) 
NMR-structure of a β-peptide hexamer displaying a turn motif.110 
 
1.4.9 Non-hydrogen bonded structures 
Different analogues of the α-amino acid proline have been prepared.111,112 It has been 
shown that although unable to form hydrogen bonds, oligomers of these residues form 
secondary structures in solution. From the crystal structure of (β3hPro)2,3-derivatives a 
higher oligomer was modeled, which pointed to a helical conformation.112 
 
1.5 Bioactivity of β-peptides 
Compounds exhibiting bioactivity consisting of either pure β-peptides, or peptidic 
compounds with a single or several mimetic residues have been synthesized. From the 
structural control that can be exerted on foldamers a number of useful compounds 
have been made. The simple separation of cationic and lipophilic side chains has been 
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used to furnish potent antimicrobials,113,114 cell penetrating compounds115-117 and the 
ability to form further helical displays have furnished compounds capable of 
biomolecular recognition.118  
After having established that β-peptides are stable to proteases in vitro, a number of in 
vivo tests were performed to determine how this type of compound would be 
distributed.119-121 It was found that only half the amount of a nonapeptide consisting of 
three (β3-hAla–β3hLys–β3Phe) repeats was degraded during 7 days from injection into 
rats.121 A second β-peptide of four residues, were tested in a similar manner, and 
showed to be distributed to different organs from the nonamer.120 It was shown to 
cross the blood-brain barrier, intervene in the regulation of a number of genes and 
displayed no inflammatory effect, while retaining the same metabolic stability of the 
nonamer. This enhanced proteolytic stability presents a great advantage over the 
natural proteins and peptides with regard to designing a successful drug. 
 
1.5.1 β-peptide inhibitors of protein interactions 
The interaction of proteins control many cellular processes, and is therefore an 
emerging target for the development of a range of therapeutics. Proteins usually 
interact by making intermolecular contacts over a large binding domain, which is 
often a non-polar cleft. Designing synthetic molecules with a high affinity for one 
domain over another is challenging. As the domains are often large and do not differ 
much, they are nearly impossible to target selectively using conventional “small-
molecule”-drugs. In the endeavor to create more selective therapeutic compounds the 
foldamers offer many attractive scaffolds. 
Seebach and co-workers designed an amphiphilic β-peptide with a 14-helical 
structure (28), mimicking the α-helices of human apolipoproteins, which are involved 
in lipid uptake and transport.118 Since amphipathic α-helical peptides are able to 
inhibit the lipid uptake process it was thought that β-peptides with an appropriate 
display of side chains might also be potent inhibitors. It was indeed shown that 
amphipathic β-peptides inhibited the process, while a series of unstructured β-
peptides could not. It is also noteworthy that these compounds are only half the size 
of the natural peptides of which they are analogues.  
 
 
Figure 1.37. β-Peptide shown to inhibit fat uptake. 
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The fusion of enveloped HIV virion with a host cell is mediated by the viral protein 
gp41.122 α-Peptides derived from gp41 (e.g. 29) can act as potent anti HIV agents by 
binding to pre-fusion states of gp41, thereby disrupting the fusion mechanism, 
involving the formation of a six-helix bundle. Schepartz and co-workers reported a 
decamer β-peptide designed to inhibit cell-fusion, by the same mechanism.123 The 
design was based on the observation that three residues, two tryptophans and an 
isoleucine, of the natural sequence contributed especially to the binding.124 In a later 
paper the same group showed that the distribution of these residues could be 
optimized giving a potency in cell-fusion assays in the low-micromolar range (30).125 
It was later suggested that the sites responsible for the high binding affinity in the 
fusion process of gp41 were more spatially delocalized.126 Gellman and co-workers 
have designed extended sequences of mixed α- and β-residues, arranged in repeats of 
βαααβαα, forming a helix that binds more efficiently to the surface of the central 
trimeric coiled coil of gp41.127 The longer α/β-peptide analogue 31 exhibited low 
nanomolar potency protection against infection by primary HIV-isolates in a cell-
based assay. From this study it is worth noting that the foldamers are equipotent to the 
parent α-peptides in cell-fusion inhibition assays and in inhibition of HIV-1 
infectivity. Even though the sequence only contained two β-peptide residues it 
showed a highly improved proteolytic stability. Crystallographic data confirmed a six-
helix bundle of three helices of 31 and the gp41 fragment (Figure 1.38).126 This 
strategy is attractive as six-helix bundle fusion mechanism is common to many vira 
and thus represents an important target for drug development. 
 
 32 
 
Figure 1.38. A) Sequence of gp41 derived peptide and foldamer mimics. B) 29 bound to gp41.127 C) 31 
bound to gp41.126 
 
The protein p53 is a transcription factor controlling the survival of cells, by 
upregulating the expression of gene products that promote cell-cycle arrest or induce 
apoptosis.128 The human oncogene protein product double minute 2 (hDM2) 
negatively regulates p53 by binding to the p53 transcription domain and targeting the 
protein for degradation by the proteasome. In many cancers hDM2 is overexpressed, 
why inhibitors of the p53/hDM2 interaction holds potential as chemotherapeutic 
agents.129 The binding interaction of p53 and hDM2 has been localized to a short α-
helical domain in p53 (32), that binds to a hydrophobic cleft on the surface of 
hDM2.130 Based on this sequence Schepartz and co-workers developed a β-peptide 
analogue (33) mimicking the p53 activation domain, displaying three key 
hydrophobic residues, found in p53 binding-studies, on the same face of a 14-helix.131  
Through combinatorial screenings132 and docking studies in silico133 the sequence was 
optimized yielding 34 which exhibits a low nanomolar affinity for hDM2. The 
interaction of p53 and hDM2 happens inside cells, making cell penetration an 
important factor. The Schepartz group reported on two strategies to improve on the 
A 
 
29: Ac-TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL-NH2 
 
30: H-β3O-β3V-β3I-β3E-β3V-β3W-β3O-β3V-β3W-β3E-OH 
 
31: Ac-β3T-TWE-β3X-WD-β3Z-AIA-β3E-YA-β3X-RIE-β3X-LI-β3Z-AAQ-β3E-
QQ-β3E-KNE-β3X-AL-β3Z-EL-NH2  
 
 
 
 
 
 
 
 
                        B                                       C  
recently, DeGrado has reported designed b-peptide
that binds specifically to the transmembrane domain of the
integrin aIIb [128]. The design, based on a 12-helical scaffold,
led to a compound that activates an intact aIIbb3 integrin
in vitro.
4.6 Peptoid ligands from high-throughput screening
Most of the examples of bioactive folda ers presented above
were generated by rational design strategies, either structure-
or sequence-based. A conceptually different approach has also
proven useful: the screening of large libraries of random sequen-
ces in unnatural oligomers. Unbiased by assumptions as to the
target bioactive conformation or pharmacophore, this approach
can generate ligands in systems where minimal structural infor-
mation about the protein-binding partner is available. Among
foldamers, a-peptoids are exceptionally well suited to use in
such a discovery regime because they can be prepared on solid
phase using a so-called submonomer approach that is amenable
to diversification by combinatorial methods [129]. Indeed, in the
first report of peptoids, Simon emphasized this feature, charac-
terizing the scaffold as a ‘modular approach to drug
discovery’ [130]. Recent efforts from Harbury have yielded tech-
nology that allows peptoid libraries to be subjected to in vitro
selection and amplification through a combination of DNA-
programmed combinatorial chemistry and molecular biology
techniques [131]. High-throughput solid-phase synthesis
coupled with efficient assays to screen for protein binding has
led to the discovery of a-peptoids with affinity for diverse
protein targets.
The biomedical importance of p53 in cancer was discussed
above. Kodadek reported an a-peptoid identified from a
library of ~ 80,000 sequences that was capable of binding to
hDM2 without inhibiting its interaction with p53 [132].
Designed compounds capable of modulating proteasome
activity have potential utility as therapeutics as well as probes
for understanding proteasome function in cells. Kodadek
applied a similar combinatorial approach as described above
for hDM2 to identify n a-peptoid that binds proteasome
particles; this oligomer was found to inhibit proteasome-
mediated protein degradation by engaging a ring ATPase
found the in the 19S regulatory particle [133,134]. Because of
their role in angiogenesis that supports tumor growth, the
interactions between vascular endothelial growth factor
(VEGF) and its receptors (VEGFR1, VEGFR2) are actively
targeted for the development of new therapeutics [135].
Kodadek and coworkers reported an a-peptoid from a
combinatorial library that inhibits VEGFR2-mediated signal-
ing [136,137]. Interestingly, the oligomer does not engage
the VEGF binding site on the receptor [138]; this highlights
the utility of a library-based approach for finding modes of
activity that are not obvious from a structure-based analysis
of a particular protein--protein interaction.
gp41 CHR a-peptide 
and foldamer mimics
a-peptide 14
bound to gp41 NHR
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Figure 5. A. An HIV gp41 C-heptad repeat (CHR) domain a-peptide along with foldamer mimics. B -- D Crystal structures of a-
peptide 14 (B, PDB 3F4Y, [123]), a/b-peptide 16 (C, PDB 3O42, [124]) and a/b-peptide 17 (D, PDB 3O43, [122]) bound to protein
models of the native gp41 receptor.
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in vitro.
4.6 Peptoid ligands from high-throughput creening
Most of the examples of bioactive foldamers pr ented above
were generated by rational design strategies, either structure-
or sequence-based. A conceptually different approach has also
proven useful: the screening of large libraries of random sequen-
ces in unnatural oligomers. Unbiased by assumptions as to the
target bioactive conformation or pharmacoph re, this approach
can generate ligands in systems wher minimal structural infor-
mation about the protein-binding p rtner is available. Amo
foldamers, a-peptoids are exceptionally well suited to use in
such a discovery regime because they can be prepar d on solid
phase using a so-called submonomer approach that i amenable
to diversification by combina rial methods [129]. Indeed, in the
first report of peptoids, Simon emphasized this feature, charac-
terizing the scaffold as a ‘modular approach to drug
discovery’ [130]. Recent efforts from Harbury hav yi lded tech-
nology that allows peptoid libraries o be subject d to in vit o
selection and amplification through a combination f DNA-
programmed combinatorial chemistry and olecula biology
techniques [131]. High-throughput solid-phase synthesis
coupled with efficient assay to scree for protei binding has
led to the discovery of a-p ptoids with affinity for diverse
protein targets.
The biomedical importance of p53 in cancer was discussed
above. Kodadek reported n a-peptoid identified from a
library of ~ 80,000 sequences that was capable of binding to
hDM2 without inhibiting its interacti n with p53 [132].
Designed compounds capable of modulating proteasome
ctivity hav potential utility as therapeutics as well as probes
o understanding proteasome function in cells. Kodadek
applied a similar combinatorial approach s described above
for hDM2 to identify an a-peptoid that binds prote some
particles; this oligomer was found to inhibit proteasome-
ediated protein degradation by engaging a ring ATPase
found the in the 19S regulatory particle [133, 34]. Because of
their role in angiogenesis that supports tum r growth, he
interactions between vascular endothelial growth factor
(VEGF) and its r ceptors (VEGFR1, VEGFR2) are actively
targeted for the development of new therapeutics [135].
Ko adek nd coworkers reported an a-peptoid from a
combinatorial library that inhibits VEGFR2-mediated signal-
ing [136,137]. Interestingly, the oligomer does ot engage
th VEGF binding site on receptor [138]; th s highlights
the utility f a library-based approach for f nding mo es of
activity that are n t obvious from a structure-based analysis
of a particular pro ein--protein inte a tion.
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 33 
cellular uptake; the modifications of the sequence to promote cell uptake134 and by the 
introduction of alkene side chain cross links to stabilize the folding135. These studies 
showed that attachment of cationic residues did indeed promote cellular uptake, but at 
the same time diminished the affinity for hDM2.134 On the other hand, the 
introduction of a hydrocarbon bridge stabilized the secondary structure and thereby 
the affinity, but had a decreasing effect on the cellular uptake.135 
 
 
Figure 1.39. A) Residues 15–29 of the α-helical binding domain of p53, the residues responsible for 
the binding interaction are marked in red. B) Structures of two β3-peptide mimics of peptide 32.  
 
B-cell lymphoma protein 2 (Bcl-2) family of proteins also play a crucial role in the 
life and death of cells. This balance is controlled by a complex network of binding 
interactions between pro-survival and pro-apoptotic Bcl-2 family members, the 
misregulation of this balance is implicated in many cancers.136 Despite the complexity 
of signaling, the structural features of the binding interaction are very well conserved 
within this family. It has been shown that an α-helical BH3 domain from a pro-
apoptotic member binds into a hydrophobic cleft of a pro-survival counterpart.137 
Hence mimics of the proapoptotic BH3 domains of Bcl-2 would be useful in cancer 
treatment. Gellman and co-workers designed a series of mimics that binds tightly to 
the BH3 recognition site of pro-survival Bcl-2 family members.138,139 The designs 
were based on a BH3 peptide from the protein Bak (35). After screening ~300 
sequences, of β- or α/β- known to adopt helical structures, a lead compound 
consisting of an alternating 1:1 mixture of α- and β-residues were found (36), which 
displayed low micromolar binding affinity for Bcl-xL. A modification to this sequence 
having a foldamer N-terminal region and an α-peptidic C-terminal region (37) 
increased the binding affinity by 1000-fold.140 However, despite extensive efforts  
improvement of the proteolytic stability has been unsuccessful.141,142 In a later study 
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with mimics composed of different mixtures of α- and β-residues carrying identical 
side chains to the natural BH3 domain of the protein Puma (38), a sequence with low 
nanomolar binding affinity for Bcl-xL was identified (39).143 Using a similar 
distribution of α- and β-residues to the HIV-inhibiting β-peptides (ααβαααβ), 
sequences of both high binding affinity and improved proteolysis resistance have been 
furnished. Further, it was shown that the bound state of a helix, formed by a related 
α/β-peptide mimic (40), is almost identical to the α-peptidic prototype (Figure 
1.40D).144 
 
 
Figure 1.40. A) Sequences natural peptides and their mimics. B) NMR structure of peptide #1 bound 
to Bcl-xL.137 C) Crystal structure of hybrid #3 bound to Bcl-xL.140 D) Crystal structure of hybrid #6 
bound to Bcl-xL.144 
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35 H-GQVGRQLAIIGDDINR-NH2 
 
36 Ac-βZ-A-βX-R-βX-L-βX-K-β3B-A-β3D-A-β3F-A-βZ-ΝΗ 
 
37 Ac-βZ-A-βX-R-βX-L-βX-K-β3L-GDAFNR-NH2   
38 Ac-EEQWAREIGAQLRRMADDLNAQYERR-NH2 
 
39 Ac-EEQ-β3W-AR-β3E-IGAβ3Q-LR-β3R-MAD-β3D-LN-β3AQYEβ3R-R-NH2  
40 Ac -EEQ-β3W-AR-β3E -IGAβ3Q-LR-β3R-MAD-β3D-LN- β3A QYE−NH2 
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that showed micromolar activity in cell-based fusion assays
that model the HIV-cell fusion process [120]. The design
was based on the observation in earlier studies that a
Trp-Trp-Ile motif found in a localized region of the gp41
CHR domain contributed disproportionately to the binding
of CHR-derived peptides to the NHR domain [118]. Subse-
quent side-chain mutagenesis in the b-peptide produced ana-
logs with potency in cell-based assays in the low-micromolar
range [121].
It has been suggested recently that the high binding affinity
between NHR and CHR domains of gp41 may be more
spatially delocalized than was previously appreciated [122].
The sequence-based modification of longer peptides derived
from the gp41 CHR domain produced a/b-peptide analogs
(e.g., 17, Figure 5A) with low-nanomolar potency protection
against infection by primary HIV isolates in cell-based
assays [123]. Several high-resolution crystal structures of the
gp41-derived a/b-peptides bound to soluble forms of the
gp41 receptor were reported in the course of this work
(Figure 5C, D) [122-124]. The a/b-peptide foldamer helices pre-
pared by sequence-based design were highly homologous to
the natural a-helix they were intended to mimic. In contrast
to the case for BH3 domain mimicry, rigidification of
the a/b-peptide CHR helix by the use of b-residues with
five-membered ring constraint was essential for achieving
good biological potency (e.g., compound 16 was much less
active than analog 17).
The molecular mechanism by which herpes viruses, such as
human cytomegalovirus (HCMV), enter host cells is less
structurally characterized than the entry pathway of HIV;
however, a-peptides based on regions predicted to be
involved in the fusion of the virus and host-cell membranes
can block infection [125]. Gellman and Compton reported
the structure-based design of a 12-helical b-peptide analog
of a known a-peptide fusion inhibitor that blocks the cell
entry of HCMV [126].
4.5 Ligands that target transmembrane protein
domains
Although some of the proteins discussed above are membrane-
bound (e.g., gp41), each of the domains successfully targeted
by a foldamer ligand is either soluble or far removed
from the membrane environment. Integrins are a class of
cell-surface receptors involved in diverse cellular processes,
including adhesion and migration [127]. Integrins are
heterodimeric membrane proteins, and their activation
requires dissociation of the membrane-spanning a-helical
domains of the a and b subunits that constitute the dimer.
Thus, an inhibitor of the association of these transmembrane
helices is useful as an activator of integrin signaling. Very
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Figure 4. A. NMR structure of a pro-apoptotic Bak BH3 domain a-peptide (8) bound to pro-survival Bcl-xL (PDB 1BXL, [109]).
B. Natural BH3 domain a-peptides from Bak (8) and Puma (11) along with foldamer mimics. C. Crystal structure of (a/b+a)-
peptide 10 bound to Bcl-xL (PDB 3FDM, [112]). D. Crystal structure of a/b-peptide 13 bound to Bcl-xL (PDB 2YJ1, [116]).
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that showed micromolar activity in cell-based fusion assays
that model the HIV-cell fusion process [120]. The design
was based on the observation in earlier studies that a
Trp-Trp-Ile motif found in a localized region of the gp41
CHR domain contributed disproportionately to the binding
of CHR-derived peptides to the NHR domain [118]. Subse-
quent side-chain mutagenesis in the b-peptide produced ana-
logs with potency in cell-based assays in the low-micromolar
range [121].
It has been suggested recently that the high binding affinity
between NHR and CHR omains of gp41 may be more
spatially delocalized than was previously appreciated [122].
The sequence-based modification of longer peptides derived
f om the gp41 CHR omain produced a/b-peptide analogs
(e.g., 17, Figure 5A) with low-nanomolar pot ncy protection
against infection by primary HIV isolates in cell-based
assays [123]. Several high-resolution crystal structures of the
gp41-derived a/b-peptides bound to soluble forms of th
gp41 receptor were reported in the cours of this work
(Figure 5C, D) [122-124]. The a/b-peptide foldamer helices pre-
pared by eque ce-based design we e highly h mologous to
the natural a-helix they were intended to mimic. In contrast
to the case for BH3 omain mimicry, rigidification of
the a/b-peptide CHR helix by the use of b-residues with
five-membered ring constraint was essential for achieving
good biological pot ncy (e.g., compound 16 was much less
active than analog 17).
The molecular mechanism by which herpes viruses, such as
human cytomegalovirus (HCMV), enter host cells is less
structurally characterized than the entry pathway of HIV;
however, a-peptides based on regions predicted to be
involved in the fusion of the virus and host-cell membranes
can block infection [125]. Gellman and Compton reported
the structure-based design of a 12-helical b-peptide analog
of a known a peptide fusion inhibitor that blocks the cell
entry of HCMV [126].
4.5 Ligands that target transmembrane protein
domains
Although some of the proteins discussed above are membrane-
bound (e.g., gp41), each of the domains successfully targeted
by a foldamer ligand is either soluble or far removed
from the membrane envir nment. Integrins are a class of
cell-surface receptors involved in diverse cellular processes,
including adhesion and migration [127]. Integrins are
heterodimeric membrane pr teins, and their activation
requires dissoci tion of the membrane-spanning a-helical
domains of the a and b subunits that constitute the dimer.
Thus, an inhibitor of the association of these transmembrane
helices is useful as an activator of integrin signaling. Very
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that showed micromolar activity in cell-based fusion assays
that model the HIV-cell fusion process [120]. The design
was based on the observation in earlier studies that a
Trp-Trp-Ile motif found in a localized region of the gp41
CHR domain contributed disproportionately to the binding
of CHR-derived peptides to the NHR domain [118]. Subse-
quent side-chain mutagenesis in the b-peptide produced ana-
logs with potency in cell-based assays in the low-micromolar
range [121].
It has been suggested recently that the high binding affinity
between NHR and CHR domains of gp41 may be more
spatially delocalized than was previously appreciated [122].
The sequence-based modification of longer peptides derived
from the gp41 CHR domain produced a/b-peptide analogs
(e.g., 17, Figure 5A) with low-nanomolar potency protection
against infection by primary HIV isolates in cell-based
assays [123]. Several high-resolution crystal structures of the
gp41-derived a/b-peptides bound to soluble forms of the
gp41 receptor were reported in the course of this work
(Figure 5C, D) [122-124]. The a/b-peptide foldamer helices pre-
pared by sequence-based design were highly homologous to
the natural a-helix they were intended to mimic. In contrast
to the case for BH3 domain mimicry, rigidification of
the a/b-peptide CHR helix by the use of b-residues with
five-membered ring constraint was essential for achieving
good biological potency (e.g., compound 16 was much less
active than analog 17).
The molecular mechanism by which herpes viruses, such as
human cytomegalovirus (HCMV), enter host cells is less
structurally characterized than the entry pathway of HIV;
however, a-peptides based on regions predicted to be
involved in the fusion of the virus and host-cell membranes
can block infection [125]. Gellman and Compton reported
the structure-based design of a 12-helical b-peptide analog
of a known a-peptide fusion inhibitor that blocks the cell
entry of HCMV [126].
4.5 Ligands that target transmembrane protein
domains
Although some of the proteins discussed above are membrane-
bound (e.g., gp41), each of the domains successfully targeted
by a foldamer ligand is either soluble or far removed
from the membrane environment. Integrins are a class of
cell-surface receptors involved in diverse cellular processes,
including adhesion and migration [127]. Integrins are
heterodimeric membrane proteins, and their activation
requires dissociation of the me brane-spanning a-helical
domains of the a and b subunits that constitute the dimer.
Thus, an inhibitor of the association of these transmembrane
helices is useful as an activator of integrin signaling. Very
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B. Natural BH3 domain a-peptides from Bak (8) and Puma (11) along with foldamer mimics. C. Crystal structure of (a/b+a)-
peptide 10 bound to Bcl-xL (PDB 3FDM, [112]). D. Crystal structure of a/b-peptide 13 bound to Bcl-xL (PDB 2YJ1, [116]).
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1.5.2 Antimicrobial activity of β-peptides 
Helicity and amphipathicity are prevalent amongst natural antimicrobial peptides, 
which are important components of the innate immune system and toxins of a variety 
of different vertebrate and invertebrate species, including human.145 These peptides 
are assumed to have more than one possible mechanism of action in killing bacterial 
cells. The nature of antimicrobial peptides, their mechanism of action and cell 
selectivity will be elaborated upon in chapter 4. A common feature of all mechanisms 
is the ability of the peptide to interact with bacterial cell surfaces, which are distinct 
from mammalian cell surfaces as they are charged.146,147 Mimicry of the amphipathic 
α-helicity of these peptides has led to a large number of potent antimicrobial β-
peptidic compounds, designed as both 14-114 (28 and 41–43) and 12-helices (44),148 
which show low IC50 values as well as selectivity towards bacterial cells rather than 
mammalian.  
 
 
Figure 1.41. Antimicrobial β-peptides designed to display 14-helicity (28 and 41–43) and 12-helicity 
(44). 
 
1.5.3 Cell-penetrating β-peptides 
Peptides and proteins usually have rather poor cell penetrating properties, an 
exception being the naturally occurring cell-penetrating peptides. An example is the 
transcription-transactivating (Tat)-protein of human immunodeficiency virus.149 The 
cell-penetrating properties of Tat, and related proteins, have been ascribed to short 
10–20 residue sequences. These peptide fragments are highly cationic, and often rich 
in arginine. The attachment of these fragments to other cargo molecules have been 
shown to impart cell-penetrating properties in species otherwise incapable of crossing 
membranes.150 Such abilities make this class of compounds useful as drug delivery 
vehicles, and have motivated efforts towards protease stable foldamer analogues. 
Raines and Gellman synthesized an analogue of Tat in which each α-amino acid 
residue was substituted for a β3-residue, the resulting β-peptide was capable of 
crossing human cell membranes with an efficiency resembling that of the natural 
analogue.116 The ability of amphipathic versus unordered polycationic sequences to 
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cross membranes has been studied by Seebach and Co-workers, who showed that a 
seven-residue β3-homoarginine was the most efficient.117 These two classes of 
compounds, ordered and unordered, have been shown to exhibit different cell 
penetrating mechanisms, 151,152 and later studies have shown that the efficiency and 
mechanism of penetration are dependent on the folding behavior of the β-
peptide.153,154 
 
 
Figure 1.42. β3-Peptide derived from the naturally occurring Tat peptide (residues 47–57). 
 
1.6 Peptoids 
Oligomers of N-subtituted glycines, called peptoids (or α-peptoids), were initially 
investigated as lead compounds for drug development.155 Peptoids are described as 
peptide mimics where the side chain has been shifted to the nitrogen rather than the 
α-carbon. Oligomers of this kind present an attractive scaffold as they can be 
generated using a straight forward sub-monomer based synthesis, that allows for the 
incorporation of  a broad variety of side chain functionalities (Figure 1.43).156,157  
 
 
Figure 1.43. Illustration of the principle of sub-monomer peptoid synthesis. 
 
The submonomer synthesis involves the addition of a primary amine to an α-bromo 
acetylated compound, in this way all primary amines can potentially be utilized in the 
synthesis of peptoids. The ease of synthesis and diversity of sequence, makes this 
class of compounds highly amenable for high throughput screening.158,159 Peptoids are 
believed to hold great value as therapeutics due to their enhanced proteolytic 
stability160 and increased cell-penetrating properties, as compared to α-peptides.161 
The early peptoid research was mostly based on the generation of large oligomer 
libraries, which could be screened for novel functions. However, biologically active 
peptoids have also been discovered through rational design.162,163 The use of peptoids 
as drug delivery agents has also been explored, by conjugation of known bioactive 
agents to peptoid oligomers.164,165 Many applications of peptoids require a certain well 
defined display of functionalities. Therefore the propensity of peptoids to adopt 
specific secondary structures has been studied intensively. 
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1.6.1 Peptoid structure 
By moving the side chain from the α-carbon to the nitrogen the backbone chirality 
and the ability to form hydrogen bonds are lost. The tertiary amide nitrogens of 
peptoids yield a lower energy barrier of rotation, around the amide bond, than the 
secondary amides of peptides. The greater stability of trans peptide bonds in α-amino 
acids is assumed to solely arise from steric effects of C-α substituents in the cis 
conformation.166 Hence the isomerization between cis and trans conformations 
happens far more readily in peptoids than in the secondary amides of α-peptides 
(Figure 1.44).  
 
 
Figure 1.44. Equilibrium of cis- and trans-amides. 
 
The lack of hydrogen bonding capabilities present a challenge in stabilizing secondary 
structures, as the amide bond rotation becomes a major stabilizing factor. These 
characteristics make peptoid oligomers highly flexible, which also complicates the de 
novo design of well defined structures. However, early research in peptoid secondary 
structure revealed that peptoids had a propensity to form helical structures analogous 
to the polyproline I helix in solution, which consist of all cis amides.167 This structure 
was later confirmed in the solid state (Figure 1.45).168 It was shown that helix 
formation was promoted if the sequence consisted of at least 50% N-α-chiral side 
chains, or if every third residue (i, i+3 positions) is α-chiral and aromatic and the C-
terminus has an α-chiral side chain.169,170 Circular dichroism-investigations of the 
length dependence of helix formation also revealed that at the nonamer length the 
signal was inconsistent with helicity otherwise observed for sequences up to 20 
residues.169  
 
 
Figure 1.45. X-ray crystal structure of a peptoid oligomer. 
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primary sequence. Nevertheless, high-resolution structures of
sheets formed by b-peptides [26,27] and a/b-peptides [28,29]
have been reported. Appropriately designed a-peptoid
sequences have also been shown to be capable of forming
two-dimensional sheets of uniform thickness [30].
2.3 Toward protein-like complexity: tertiary and
quaternary structures
With the impressive strides made in the development of fol-
damer secondary structure in the ~ 10 years after the first
reports on folding in unnatural backbones, attention has
turned recently toward tertiary and quaternary structures.
The quest for higher-order folding serves as a crucible for fol-
damer design strategies, because success in such endeavors
requires effective control over both local backbone conforma-
tion and long-range interactions between elements of second-
ary structure in a single oligomer chain (tertiary structure) or
multiple chains (quaternary structure). These are the same
challenges faced in the design of foldamers that bind with
high affinity to biological receptors, so an examination of
the design strategies employed is informative with respect to
efforts toward the functional foldamers detailed below.
The structure-based modification of the known b-
peptide 14-helix has led to helix-bundle quaternary assemblies
that form readily in aqueous solution (Figure 2D) [31,32]. The
enhanced understanding of b-peptide folding that came
from these and related studies has led to extensive use of the
14-helix in the development of inhibitors of protein--protein
binding interactions. A conceptually different design strategy
used to construct foldamer quaternary structure is the
sequence-based modification of natural proteins to produce
unnatural-backbone analogs that fold like the parent
sequence. In these studies, it has been shown that the
helix-bundle quaternary structure encoded in an a-peptide
sequence will still manifest itself when the natural sequence
of side chains is displayed on various a/b-peptide backbones
(Figure 2E) [33,34]. This concept has also found significant util-
ity in the development of bioactive foldamers. In a-peptoids,
self-association [35] as well as unimolecular folding [36] to form
putative helix-bundles has been reported; however, high-
resolution structural characterization has remained elusive.
The recent report of supramolecular sheet formation in
a-peptoids is an example of a non-helical quaternary structure
available to these oligomers [30].
3. Biomedical applications from
amphiphilicity
In many bioactive a-peptides, global amphiphilicity (i.e., spa-
tial separation of charged and hydrophobic functional groups)
in the folded state is sufficient for biological efficacy. Inspired
by this observation, many early examples of biological function
in foldamers relied on lessons learned in fundamental studies
toward secondary structure to design sequences that would
adopt amphiphilic helical folds. Although these designs utilize
only a fraction of the structural control that can be exerted over
unnatural backbone scaffolds, amphiphilic foldamers have
shown a variety of interesting biological activities.
1 32
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Figure 2. A -- C. Examples of helical secondary structures formed by b-peptides (A, [7]; B, [9]) and a-peptoids (C, [18]). Atoms are
colored by element (C, N, O from lightest to darkest); some atoms in each structure are omitted for clarity. D -- E. Helix-
bundle quaternary structures formed by a b-peptide (D, [32]) and an a/b-peptide (E, PDB 2OXK, [33]).
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It was found that at exactly this length the C- and N-terminal was connected by 
hydrogen bonding, creating a loop conformation consisting of both cis and trans 
amides.171 
In an effort to obtain high-resolution structures of peptoids, covalent constraints have 
been introduced. Head-to-tail cyclizations of peptoids have resulted in a number of 
crystal structures, giving information on the distribution of cis and trans isomers in 
turn-like displays.172 Similar approaches of covalently connecting two side chains to 
stabilize helical displays have been reported (Figure 1.46).173,174  
 
 
Figure 1.46. Examples of side chain constrained peptoids.  
 
These efforts showed that upon introduction of side chain “bridges” the amount of α-
chiral aromatic side chains could be reduced to 33% in organic solvents and 50% in 
water. 
  
The investigations of peptoid oligomers have indeed shown that peptoids are capable 
of forming secondary structures, and that control over the isomerization of the amide 
bond is important for the rational design of folded peptoids. As peptoid compounds 
are devoid of hydrogen bonding capabilities, a number of other non-covalent 
interactions have been proposed to stabilize the secondary structure of peptoids. To 
gain insight into the factors governing the conformational preferences a series of 
monomer model-systems have been investigated.175,176 Determination of the amide 
bond cis/trans ratio, by NMR, upon changing the size and electronic properties of the 
side chains, revealed that the conformational preference at a local residue can be 
tuned (Table 1.1).177 In general, it was shown that branched and unbranched alkanes 
(48a) gave rise to a preference for the trans conformation.176 However, it was shown 
that by attaching a secondary carbon to the backbone (48b) the trans conformation 
became less favored. A later report has shown that by going from a secondary carbon 
to a tert-butyl group (48c) the amides exclusively populate the cis-conformation.178 
This implies that the sterics around the amide can be used to manipulate the 
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population distrubituion of cis- and trans-conformations.  When incorporating 
benzylic side chains (48d) the preference was comparable to that of an unbranched 
alkane.176 Further, it was shown that incorporation of both α-chirality and aromaticity 
(48e) gave a slight preference for the cis-conformation in polar solvents, and a 
slightly higher Kcis/trans in apolar solvents as compared to the achiral aromatic side 
chain. It was also shown that by using electron poor aromatic systems (48f and 48g) 
the preference for the cis-conformation was further enhanced, and was exclusively 
populated when using triazolium-type side chains (48h).176,179 Also the incorporation 
of a naphthyl group in combination with α-chirality gave a strong preference for the 
cis-conformation, however, as the naphthyl group had to be installed through the 1-
position (48i) this effect has been argued to arise from steric effects, as a naphthyl 
group attached through the 2-position (48j) behaves like the phenylethyl-peptoid 
(48e). 
 
 
Table 1.1. cis–trans equilibrium constants of different peptoids, determined by NMR. a From ref 176. 
b From ref 178. c From ref 179. 
 
CD3OD CD3CN CDCl3
 Comp.  Side chain  K cis / trans  K cis / trans  K cis / trans
48a a et 0.5 0.7 0.2
48ba ip 0.6 1.1 0.4
48cb tBu >19.0 >19.0 >19.0
48da bn 0.6 1.2 0.2
48ea pe 1.3 2 0.7
48fa np 1.8 3.4 1.5
48ga fe 2.5 3.8 1.6
48hc bte 11.1 11.8 >19.0
48ia 2npe 1.6 2.2 0.9
46ja 1npe 4.6 6.3 2.6
N
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N N
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These findings suggest that the lone pair (n) of the amide oxygen can interact with the 
aromatic moiety attached to the α-carbon of the side chain. This kind of interaction 
has been observed in other systems, and is referred to as n → π*Ar interactions.180,181 
This sort of interaction is known from the literature, through both calculations and 
experimental data.181,182 The data from table 1.1, suggest that the population of the cis-
conformation is increased upon introduction of electron poor aromatic rings, which 
correlates with this kind of interaction.176,177 Contrary, when using aniline type side 
chains trans is the only conformation found.175 This preference was investigated prior 
to their use as peptoids, in N-methyl acetanilide, where it was argued that the electron 
rich center of the aromatic ring would repel the amide oxygen in the cis-
conformation.183 It was also found that when changing the C-terminal from an ester to 
an amide the trans became more populated, indicating that the electronic properties of 
the termini has some importance. It was thus postulated that the N-terminal amide 
oxygen might interact with the C-terminal carbonyl carbon. This kind of interaction 
has also been investigated in proline-systems and helices of collagen-like peptides, 
which led to the suggestion of an interaction similar to a hydrogen bond, but rather 
than delocalizing the oxygen lone pair (n) to a σ* orbital of a hydrogen, it is 
delocalized to an empty π* orbital of a carbonyl carbon (n → π*C=O).184,185 Due to the 
positioning of the π* orbitals, the strength of the interaction is optimized when the 
incoming lone pair “attacks” along the Burgi-Dunitz trajectory,186 similar to a 
nucleophilic attack.187 The requirements for this kind of interaction are met by the 
backbones of peptoids, where this interaction have been proposed as a stabilizing 
factor.177 Further, it has been shown that the interaction can be used to manipulate the 
cis–trans isomeric distribution of proline systems upon changing the electronic 
properties of the involved donor-acceptor system (Scheme 1.6).187 It was shown that 
by substituting a carbonyl oxygen for sulfur, which increases the nucleophilicity of 
the donor, the conformation allowing the n → π* overlap was more favored. If the n 
→ π*C=O effect is present in peptoids or β-peptoids, it should be possible to change or 
enhance the preferred conformations by altering the electronic properties of the 
backbone. 
 
 
Scheme 1.6. Proline system used to explore n → π* interactions. 
 
Recently a paper, by Gorske and co-workers, describing another mode of n → π*aryl 
was published. Herein it is argued that the direct interaction between the lone pair and 
the aromatic moiety is only present when the aromatic system is severely electron 
deficient.188 In electron rich, neutral and slightly electron deficient systems a 
“bridged” interaction was proposed (bridged n → π*). In this interaction the transfer 
of electron density is facilitated by an intermediary N-α-C-H σ* orbital (Figure 1.47).  
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Figure 1.47. Representation of an n → π* (left), and a “bridged” n → π* interaction (right). 
 
The understanding of how these factors dictate the conformations of the individual 
peptoids has been crucial in understanding the fundamental folding propensities of 
peptoids.189 The understanding of peptoid folding was tested by solving the structures 
of two linear trimers and a cyclic nonamer by X-ray crystallography, and 
simultaneously doing a blind prediction in silico.190 The predicted structures from this 
study were in close agreement with the experimentally determined X-ray structure 
(Figure 1.47).  
 
 
Figure 1.47. Comparison of structures found by X-ray crystallography (gray) and by molecular 
modeling (green).190 
 
By taking some of the most uniform residues, it has been possible to rationally design 
certain motifs. A homo-oligomer composed of (S)-N-(1-naphthylethyl)glycine has 
been shown to fold into a rather robust helix, with approximately three residues per 
turn and a helical pitch of 6.0 Å (Figure 1.48).191 The use of alternating cis and trans 
promoting residues has also provided compounds with a well-defined secondary 
structure. In these cases either tert-butyl178 or naphthylethyl192 was used as cis-
promoters, whereas N-aryl was used as trans-promoting side chains in both accounts.  
 
 
Figure 1.48. X-ray crystal structure of a peptoid helix with (S)-1-(1-naphthyl)ethyl side chains.191 
N
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crystal structure and pick1 shows the two flipped φ angles result in
one side chain residue rotating relative to the plane of the macro-
cycle ring. Other than this local inversion, the rest of the back-
bone atoms match closely, with a 1.0 Å backbone rmsd to the
crystal structure, and 0.47 Å rmsd if the flipped backbone atoms
are omitted from the comparison.
Free energies for backbone torsional states computed from the
REMD simulations of the cyclic nonamer show a “foldable” land-
scape dominated by a handful of lowest free energy conformations.
Only approximately 5% of accessible states are found within
approximately 3 kcal∕mol or less of the ground state. The sub-
mitted pick1 state (cccctccct, +−++−+++−) is predicted by
REMD to be among the five lowest-free energy states (approxi-
mately 1.22 kcal∕mol above the ground state), while the experi-
mental crystal state (cccctccct, +−++−+−−−) is predicted to
be among the 30 lowest-free energy conformations (approximately
3.08 kcal∕mol) (SI Appendix, Fig. S9). Because the state corre-
sponding to the experimental structure had a relatively high free
energy, conformations from this basin were not selected for QM
refinement. This finding indicates that our selection criteria, which
were based on the cis/transstate alone, were too coarse.
We believe that improved agreement between prediction and
experiment (beyond the intrinsic accuracy of DFT) may require a
priori information about the crystal-packing environment and the
solvent present during crystallization (in this case, ethanol). To
support this idea, we performed computational studies compar-
ing our top predicted structure to the experimental structure (full
results described in the SI Appendix). Without the ethanol, the
two DFT functionals considered here disagree as to whether the
experimental or predicted structure is more favorable. Further-
more, when a bound ethanol is added to the predicted structure,
DFT predictions unambiguously show a preference for the crystal
conformation (see SI Appendix for details). These results suggest
that it is important for high-resolution structure predictions to
model crystal packing and potential solvent interactions (at least
for small foldamers in which crystal and solvent contacts may
outnumber intramolecular contacts). Computational studies of
cyclo-ðsarcosineÞ9 analogs show similar backbone conformational
preferences, suggesting that the bulky N-1-phenylethyl side
chains do not play a significant role in determining overall back-
bone geometries.
Discussion
Our blind prediction results suggest that a combined MD-QM
computational approach can produce accurate ab initio peptoid
structure predictions. This work is a tangible milestone on the
path to reliable and efficient computational peptoid design.
We can provide some context regarding the significance of
these results by comparing to similar advances in protein struc-
ture prediction. The cyclic peptoid nonamer contains 36 bonds
that have at least two rotameric possibilities, while the N-aryl
and N-alkyl peptoid trimers have 11 and 14 rotatable bonds, re-
spectively. The nonamer search problem is similarly complex to
chignolin (35) (10 residues, 29 bonds) or the C-terminal hairpin
of protein G (36) (16 residues, 53 bonds), and the trimers similar
to met-enkephalin (37) (5 residues, 15 bonds), all model peptide
systems that were the subject of state-of the-art folding simula-
tions a decade ago.
Continued progress in computational peptoid structure predic-
tion and design will require further advances in forcefield devel-
opment and sampling. One encouraging finding here is that
currently available automated tools to provide transferrable for-
cefield parameters for arbitrary organic molecules can be used to
predict folded peptoid structures accurately. This finding is a pro-
mising development for computational peptoid design, although
further forcefield validation studies are required. We hope that
the increasing number of high-resolution peptoid crystal struc-
tures (including those reported here) and solution-phase data
can be used to develop and test even more accurate molecular
models, as well as coarse-grained potentials that can model
the thermodynamic driving forces responsible for the assembly
of peptoid nanostructured materials (12, 38–40). As our compu-
tational work demonstrates, we can now accurately predict local
Fig. 4. Experimental and predicted structures of cyclic peptoid nonamer 3, composed of (S)-N-(1-phenylethyl) glycine units. The amide bonds in the crystal
structure were found to exhibit a cis/transpattern of cccctccct, with several significant deviations from amide planarity (see Table 1). (A) Shown superimposed
are the backbone conformation of the compound 3 crystal structure (gray) and the top-ranked blind prediction (green), with a backbone-rmsd of pproxi-
mately 1.0 Å. (B) The crystal structure shows the side chains oriented toward alternating faces of the macrocycle, with five side chain groups forming a “mo-
lecular basket” encompassing a single bound ethanol ( rrow). (C) The predicted structure, which was m deled in the absence of ethan l, shows instead a
peptoid side chain “filling” this basket (arrow), resulting in the rotation of two backbone ψ angles, compared to the crystal structure backbone.
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on peptoid secondary structure.32 They found that these α-chiral
aromatic side-chain-containing peptoids adopted largely helical
structures in acetonitrile (with few exceptions), and that the
degree of helicity became length-independent after 12 residues.
In order to compare to this past work, we chose to synthesize a
series of peptoid Ns1npe homo-oligomers with lengths varying
from 1 to 13 residues (Table 1). We hypothesized that these
peptoids would also adopt helical conformations in acetonitrile,
and that their CD signatures would display a similar length-
dependent increase. Moreover, we reasoned that the Ns1npe
peptoids would exhibit significantly higher overall amide Kcis/trans
values relative toNrpe systems, based on our previously reported
Kcis/trans values for anNs1npe monomer (6.3), homodimer (7.0),
and homotrimer (9.7).35
Synthesis of Peptoid Oligomers. Peptoid oligomers are
typically synthesized on solid-phase resins using the highly
efficient submonomer approach.22 Using this method for the
synthesis ofNs1npe peptoids, however, resulted in low yields and
purities of the desired peptoid oligomers after the trimer stage,
presumably due to the increased steric congestion of the s1npe
side chain. We therefore utilized solution-phase synthetic tech-
niques to generate the peptoid oligomers, and used methods that
were similar to previously reported peptoid syntheses (see
Supporting Information for details).34,40 Because such synthetic
routes afford the opportunity to install unique functionalities at
the C- and N-termini, we selected C- and N-terminal moieties
that would be compatible with our investigations into peptoid
helix formation and obviate problems of residual functionality
associated with solid-phase synthesis. Most peptoid oligomers
synthesized on solid-phase resins are cleaved from Rink-amide
linkers under TFA-mediated conditions, affording a peptoid with
a primary amide at the C-terminus and an ammonium group at
the N-terminus. Notably, these functional groups can strongly
influence peptoid secondary structure. Hydrogen-bonding inter-
actions between these two termini andmultiple carbonyl oxygens
within the peptoid backbone play a significant role in stabilizing a
competing threaded loop structure at an oligomer length of nine
residues, and thereby disfavoring PPI helix formation.38,41 Ad-
ditionally, hydrogen-bonding interactions from carbonyl oxy-
gens within the peptoid backbone to the C-terminal amide
hydrogens are believed to contribute to conformational hetero-
geneity in peptoid helices by favoring the presence of trans-amide
bonds.30 These problems were avoided by using our solution-
phase synthetic approach. While solution-phase synthesis is
comparatively more labor-intensive than a solid-phase approach,
we were able to reproducibly obtain 50!100 mg of each peptoid
oligomer, which proved especially useful for performing a variety
of structural experiments on each compound.
We synthesized a series of peptoid Ns1npe homo-oligomers
with lengths varying from 1 to 13 residues (1!13, Table 1) with
t-butyl esters at the C-termini and acetyl groups at the N-termini
to mitigate hydrogen-bonding interactions. We found that the
presence of the t-butyl ester moiety was adventitious, as it greatly
facilitated the crystallization of Ns1npe peptoid dimer, trimer,
and tetramer (2!4) relative to their respective C-terminal
primary amide equivalents. Peptoid monomer 1 did not crystal-
lize despite repeated attempts, and we therefore include 10 for
crystallographic analysis purposes. TheNspe pentamer 50, which
contains an acetylated N-terminus and a t-butyl ester at the
C-terminus, was also synthesized as a key control to allow for
spectroscopic comparison to previously reportedNspe peptoids.
X-ray Crystallographic Study of N1npe Oligomers. Pep-
toids 10 and 2!4 readily crystallized, and we analyzed their
solid-state structures byX-ray crystallography (Figure 2). The back-
bone amide bonds in each peptoid all adopted cis-amide con-
formations. Notably, the X-ray crystal structure of tetramer 4
Figure 2. X-ray crystal structures of peptoids 10 and 2!4. (A) View perpen icular to the helical axis. (B) View parallel to t e helical axis. Atom
designations: red = oxygen; blue = nitrogen; gray = carbon. Hydrogen atoms in parts A and B and the t-butyl methyl groups in part B have been re oved
for clarity.
The solution phase and crystal structures were further
analyzed for potential noncovalent int ra tions that may
stabilize the peptoid ribbon conformation, which lacks
a hydrogen b nding network. Int restingly, in all structures,
every other backbone carbonyl was oriented perpendicular to
on other, but the overall dipole was point d t wards the N-
terminus. At the C-terminus of 4a, we detected an n!p*C=O
interaction (Figure 3b).[16] Previous X-ray crystallographic
studies in our laboratory have revealed that C=Oi!1···C’i=O
interactions can exist in peptoid monomers and at the N-
terminus of a peptoid oligomer,[9a,d] yet this is, to our
knowledge, the first report of an C=Oi+ 1···C’i=O interac-
tion in p pt s. We analyzed all sequential backbone
carbonyl groups in the structures of 3, 4a, and 6 i for n!
p*C=O interactions, and although the distances between the
main-chain carbonyl oxyge toms and the carbonyl carbon
atoms of the preceding or subsequent residue were under
3.2! (as is typical for the n!p* interaction[16]), the angle of
approach was outside of 109" 108 window necessary for
sufficient orbital overlap in all but the C-terminal residue of
4a.[17] We therefore surmise that n!p*C=O interactions do not
play a major role in nforcing the ribbon conformation in
these peptoids.
We also evaluated the structures of 4a and 6 i for
intramol cular romatic–aroma ic interactions between side
chains by measuring the angles between the aryl planes, the
distances between the aryl centroids, and the distances
between nearest interr sidue atoms.[18] In the X-ray crystal
structure of 4a, the i and i+ 3 side chains are positioned in an
oblique orientation of a displaced stacking interaction (angle
between aromatic planes= 33.58) with a centroid–centroid
distance of 5.4 ! and nearest interresidue C!C distance of
4.6! (Figure 3c; Supporting Information, Figure S11a). Cor-
respondingly, the ensemble of NMR structures of 6 i also
revealed displaced aromatic stacking interactions between
the i and i+ 3 residues at the beginning and end of each turn
unit (Supporting Information, Figure S11b–d). Elucidating
the contribution, if any, of these aromatic–aromatic inter-
actions to the thermodynamic stability of the peptoid ribbon
is an important avenue for future study, and is the subject of
ongoing investigations in our laboratory.
We next used circular dichroism (CD) spectroscopy to
study the effects of peptoid length, solvent, and temperature
on the ribbon structure. The CD spectra for all of the peptoid
oligomers had nearly identical spectral features in acetoni-
trile, 1:1 acetonitrile/water, and methanol (negative maxima
of ellipticity at 224–226 nm and broad positive peaks of
ellipticity between 197–205 nm; Figure 4), indicating that all
of the peptoids in this series adopted similar secondary
structures in both organic and polar protic solvents (at 30 mm,
20 8C). Additionally, CD data for peptoid 8 at varying
concentrations (7–80 mm) in acetonitrile suggested that inter-
molecular interactions were not affecting the observed CD
signal (Supporting Information, Figure S19). Interestingly,
the CD spectra of the peptoid ribbon most closely resembled
data reported for poly-ld-Pro sequences,[19] which also adopt
an alternating cis/trans amide backbone pattern. Beyond the
dimer chain length, there were no length-dependent changes
in the CD spectral intensities. Instead, in all solvents, we
observed a difference in signal intensity between even and
odd numbered chain lengths. This effect could potentially be
due to the absorption properties of the s1npe side chains,
which are more solvent-exposed in the ribbon as the C-
terminal residue in odd numbered chain lengths.
The CD spectral shape for peptoids 2–8 varied slightly in
the different solvents. In the acetonitrile/water mixture,
shoulders were apparent in all CD traces from 227–230 nm
(Figure 4b), and the shoulders were more pronounced in
methanol (Figure 4c). These observations could indicate
a slight change in overall conformation that is solvent-
dependent, or a change in the UV adsorption properties or
orientations of the aromatic side chains in these solvents.
Lastly, the thermal stability of 8 (30 mm) was examined in
acetonitrile (15–75 8C), 1:1 acetonitrile/water (10–75 8C), and
methanol (10–65 8C) (Supporting Information, Figures S20–
S22). A linear decrease in signal intensity was observed with
increasing temperatures; however, the spectral shape of 8 in
all solvents was maintained throughout the temperature
ranges investigated. This temperature destabilization can be
attributed, in part, to the increase in amide bond isomer-
ization at elevated temperatures that we observed in 1H–13C
HSQC experiments for 8 (see above).
In summary, we report a new peptoid secondary structure
comprised of a regular alternating sequence ofNs1npe andN-
aryl residues, which we term the “peptoid ribbon”. This
structure is a result of our first rational design of discretely
Figure 3. a) X-ray crystal structures of Br-Nph-Ns1npe-dma, 3, and 4a. All of the hydrogen atoms except for the s1npe side-chain methines have
been omitted for clarity. The black dashed line indicates a side-chain–side-chain C···C distance. b) The main-chain atoms of the X-ray crystal
structure of 4a illustrate the reverse turn, and the green arrow dep cts an n!p*C=O interaction. The black dashed line indicates a main chain
Ca···Ca distance. c) A displaced aromatic–aromatic stacking interaction was detected between the side chains of residues 1 and 4 in the X-ray
crystal structure of 4a. Only the side-chain and nitrogen atoms are shown. The black dashed line indicates the centroid to centroid distance
between the two aryl ring .
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1.6.2 Bioactivity of Peptoids 
Like β-peptides, peptoids have shown superior stability towards protease degradation 
as compared to the natural proteins and peptides. Given their foldameric properties, 
these residues have also attracted attention for their potential as pharmaceuticals. As 
peptoids were originally thought as a way to fast and efficiently synthesize large 
libraries from which lead compounds could be found through high throughput 
screenings, many bioactive peptoids have been identified this way. As the focus of 
this thesis is the structure and function of foldameric compounds, the following 
examples of bioactive peptoids have been chosen as they describe efforts to realize 
activity through a structure based design.  
 
1.6.3 Peptoids as antimicrobials and cell penetrating compounds 
Like β-peptides the peptoids are stable to proteolytic enzymes found in cellular 
environments. As for natural peptides, a limiting factor in testing and marketing a β-
peptide drug is the tedious synthesis, which is also associated with high cost of 
production. As the side chains are shifted to the nitrogen in the peptoidic backbones 
the chirality is eliminated making the synthesis of peptoids far more straight forward 
than both α- and β-peptide oligomer synthesis.  
Peptoids have been investigated with regard to many of the same functions as the β-
peptides, since these studies were based on rather simple systems displaying only a 
single type of secondary structure. As one of the first secondary structures found in 
peptoids were helical, an effort to design antimicrobial peptoids were undertaken. 
Some of the first examples of antimicrobial peptoids, made by Goodson and co-
workers, were di- and trimers effective against both Gram positive and Gram negative 
bacteria with minimum inhibitory concentration (MIC) values of 5–40 µM.193 
However, these short peptoids also displayed a modest hemolytic activity at low 
concentrations. Barron and co-workers synthesized analogues of the naturally 
occurring magainin-2,194 which later underwent further scrutiny resulting in some 
general guidelines for the synthesis of peptoid antimicrobials, which are further 
discussed in section 4.5.1.162 
 
Kodadek and co-workers evaluated the ability to cross mammalian cells of peptoids 
versus their corresponding α-peptide sequences (e.g. 49).161 In this study it was found 
that the peptoids displayed a 3- to 30-fold increase in cell-penetrating properties over 
the peptides. The authors suggested that this increase was due to the lack of backbone 
amide hydrogens increasing the overall lipophilicity of the molecule. Following this 
investigation a more thorough study of 350 peptoid- and their corresponding peptide 
tetramers were tested to generate structure–activity relationship.195 It was found that 
generally the cell penetrating ability of peptoids was twice that of the corresponding 
peptides, with the peptoids being slightly more lipophilic given lower polarity of the 
backbone. It was also noted that the peptides and peptoids with the highest cell 
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permeabilities shared common side chain compositions of one-third hydrophobic and 
two-thirds hydrophilic residues. 
 
 
Figure 1.49. Example of a cell-penetrating peptoid.  
 
Like for the β-peptides, the ability of peptoids to cross membranes has led to research 
in their ability to transport cargo. Bräse and co-workers evaluated some simple 
fluorophore conjugated peptoid hexamers, (NLys)6 (50) and (NArg)6 (51), for their 
ability to cross membranes.196  For these peptoids it was concluded that the guanidino-
groups were responsible for a more rapid uptake. The same research group made an 
effort to characterize the secondary structure of a rhodamine-labeled hexa-NLys (52), 
and found it to display a helix-like structure.197  
 
 
Figure 1.50. Cell-penetrating peptoids used to explore transport across membranes. 
 
Bradley and co-workers found that a fluorescein-labeled peptoid nonamer [(NLys)9] 
(53) displayed remarkable delivery properties in being able to label a variety of cell 
lines within minutes.198 Due to the proteolytic stability of these peptoidic fluorescent 
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probes they have recently been utilized to track primary phagocytes over several days 
in vivo.199 
 
1.6.4 Lung surfactant mimics 
Lung surfactant (LS) is a naturally occurring material essential for proper respiration 
in humans. It is composed of lipids and proteins that regulate the surface tension at 
the air-liqiud interface in the lungs.200 A deficiency of functional LS leads to 
respiratory distress syndrome, a leading cause of mortality in premature infants and 
respiratory impairment in adults. Treatment with synthetic LS formulations is less 
effective than the naturally occurring LS, and animal LS have been shown to cause an 
immune response. Barron and co-workers have designed peptoid mimics of the 
helical hydrophobic surfactant protein SP-B.201 The peptoid was designed to mimic 
the N-terminal segment of SP-B (residues 1 to 25) having a hydrophobic insertion 
region (residues 1 to 9) and an amphipathic helix containing arginine and lysine. The 
SP-B mimics had α-chiral (S)-phenylethyl (Nspe) or (S)-sec-butyl (Nsbu) as 
hydrophobic side chains and to promote helicity, and NArg or NLys as cationic 
residues.  
 
 
Figure 1.51. Examples of lung surfactant peptide mimics. 
 
The helicity was examined using CD-spectroscopy, and as expected it was found that 
oligomers with a high content of Nspe displayed more stable helices. When tested for 
their surface activity, it was shown that the aliphatic containing peptoids were better 
at interacting with lipid mixtures. This shows that varying the stability of the 
secondary display is possible and can in some cases be beneficial. The study also 
concluded that the substitution of lysine-like for arginine-like side chains had no 
effect on the surface activity. 
 
1.6.5 Peptoid-peptide interactions 
Appella designed a helical peptoid (56), designed to mimic the binding sequence of 
the protein p53, responsible for binding to the human double minute 2 protein, as 
explained earlier.202 The peptoid was designed to display three key hydrophobic side 
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chains on a helical peptoid. It was found that using a rigid helical peptoid scaffold did 
not lead to effective mimicry of p53. However, when using a less structured peptoid 
lacking helix inducing residues reasonable binding affinities in the low micromolar 
range could be obtained, without loss of cell-penetrating ability. 
 
 
Figure 1.52. Structure of peptoid used to inhibit the interaction of p53 and hDM2, residues important 
for binding are shown in red. 
 
The ability to interact with proteins without well-defined structures has also been used 
as an asset to break fibril formation. Liskamp and co-workers designed a peptoid (57) 
mimicking the core region of amylin (residues 20 to 29), a protein known to aggregate 
and form amyloid fibrils (β-sheets) in insulin producing β-cells.203 It was found that 
peptoids could break up the hydrogen bonding patterns of the β-sheets without 
displaying a well-defined structure, and thereby terminate aggregation. 
 
 
Figure 1.53. β-Sheet breaking peptoid. 
 
Also a number of peptoids have been identified that binds to specific proteins and 
inhibit their function.204 These peptoid oligomers have been identified through library 
synthesis and subsequent high-throughput screening. The positive hits have most 
often been modified to optimize certain capabilities e.g. cell-penetration. As these 
bioactive, and in a therapeutic context highly relevant, compounds have not been 
investigated and optimized with regards to their secondary structure they have not 
been discussed here. 
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2 β-Peptoids 
2.1 Secondary structure of β-peptoids 
β-Peptoids contains the modifications of both the β-peptides and peptoids, an extra 
methylene in the backbone and the side chain attached to the nitrogen.205 As these 
compounds are also devoid of hydrogen bonding capabilities, one must expect that the 
factors governing secondary structure formation for oligomers of β-peptoids are more 
similar to peptoids than β-peptides. The secondary structure of β-peptoids is not as 
well explored as for the two parent compounds. Given the lack of hydrogen bonding 
capability, and the additional backbone methylene, these compounds should be very 
flexible. The first investigation of the secondary structure in β-peptoid oligomers, was 
inspired by the early investigations of peptoid oligomers.206 By looking at CD-spectra 
of growing oligomers, of the type (β-N-(S)-phenylethyl)n-OH (βNspe), it was 
concluded that these compounds did not form any regular structure in MeOH, 
Trifluoroethanol (TFE) or MeCN solution. However, a similar study performed on N-
terminally acetylated oligomers of the type (β-Nspe)n-NH2 showed that the CD-signal 
was both dependent on the length of the oligomer and the temperature of the 
solution.207 These findings suggest that β-peptoids longer than four residues fold into 
some kind of ordered structure. The first high resolution structure of a β-peptoid 
oligomer was determined for a cyclized homo-tetramer with propargyl side chains 
(58).208 This constrained structure displayed all the amide bonds in the cis-
conformation.  
 
 
Figure 2.1. X-ray crystal structure of cyclic tetramer 58.208 
 
To get a better understanding of the folding propensities, and to develop new 
scaffolds for multivalent display, a series of linear and cyclic alternating α/β-peptoids 
were synthesized.209 NMR-spectroscopy of the linear compounds revealed quite 
heterogeneous mixtures of cis- and trans-conformations. The CD spectra, on the other 
hand, indicated that the compounds have at least one ordered conformation, which is 
dependent on the solvent. The cyclically constrained compounds exhibited the same 
CD-spectral shape, but with a more intense trace, implying some stabilization of the 
secondary structure. The octamer was later used to determine the importance of the 
amount of α-chiral side chains and their pattern.210 Here it was shown that increasing 
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ABSTRACT
The first synthesis of functionalized !-peptoid macrocycles is reported. X-ray crystallographic structure of tetramer 9 reveals a C2-symmetrical
derivative with unexpected all-cis-amide bonds and spatial disposition of the appendages toward the two opposite faces of the ring. Quantum
calculations suggest that 9 is locked in this layout. These macrocycles constitute novel promising templates for multimeric ligation of biologically
active ligands. The concept was exemplified by chemical decoration of tetramer 9 via “click” reactions.
The development of oligomers with artificial backbones
carrying diverse side chains, capable of mimicking bioactive
peptides, is an area of intense research activity.1 These so-
called peptidomimetics can be designed for conformational
rigidity of the backbone, their resistance to hydrolytic
peptidases and proteases,2 and their folding properties.3
Oligoureas,4 azapeptides,5 peptoids,6 γ-peptides,7 and "-pep-
tides8 are representative oligomers that belong to this class
of peptidomimetic. Among them, "-peptides have been
particularly studied in this regard as "-peptides can adopt a
large variety of secondary structures from very short
sequences.9 This unique feature makes them not only
interesting oligomers as peptidomimetics but also as fol-
damers for multimeric attachment of biologically active
pharmacophoric groups.10 "-Peptoids represent a new class
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the amount of α-chiral side chains from 50% to 75% did not have a pronounced effect 
of the conformational preference. However, when the pattern of the side chains where 
shifted so that the α-chiral side chains resided on the peptoid residue (60) rather than 
the β-peptoid (59), the NMR-spectrum revealed a more homogeneous distribution of 
the cis- and trans-conformations (Figure 2.2). 
 
 
Figure 2.2. Structures of cyclic α-/β-hybrid peptoids with different side chain distributions, and X-ray 
crystal structure of 60.210  
 
Further, the X-ray crystal structure was solved for this compound revealing four cis-
amides and four trans-amides. These are distributed in pairs, giving rise to a twisted 
rectangular shape of the backbone, with the cis-amide pairs located at the corners. The 
β-peptoid with propargyl side chains has also been used in cyclic scaffolds of mixed 
α− and β-peptoids.211 An X-ray crystal structure of a tetramer, with a sequence of 
alternating α- and β-peptoid residues, revealed all β-peptoids to be in a cis-
conformation while the α-peptoids where in the trans-conformation. 
 
The existing literature on linear oligomers of β-peptoids or β-peptoid-hybrids shows 
ambiguities concerning their foldameric properties. To obtain experimental data 
regarding the folding propensities of β-peptoids, we designed a series of monomers, 
inspired by the studies of peptoids. These monomers were designed to test the 
influence of steric bulk and stereo-electronic effects on the cis–trans ratio. Ultimately 
we hope that knowledge on how the individual residues behave, would result in 
guidelines to rationally design oligomers with defined structures. 
 
2.2 Design and synthesis of monomeric β-peptoid model systems 
First it was decided that all model compounds should be based on acetylated β-
peptoid model. This design was chosen as it was thought to mimic the local 
interactions encountered in an oligomer structure. In this way the effect of the side 
chains can be investigated with regard to steric bulk and stereoelectronic properties. 
Since a study has shown that the capping of these compounds are influencing on the 
CD-spectrum of oligomers, we decided to prepare series of both C-terminal tert-butyl 
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esters and morpholino amides (Figure 2.3).212 The tert-butyl ester was chosen as these 
can also be readily deprotected, which allows for further coupling. The tertiary amide 
of the morpholino compounds were chosen as they are closer to the actual properties 
of the backbone of a β-peptoid oligomer. 
 
 
Figure 2.3. Structure of β-peptoid backbones. 
 
Our preliminary study was designed to investigate a diverse set of N-alkyl side chains 
regarding the steric bulk, α-branching, aromatic vs. saturated substituents and direct 
attachment of aromatic compounds (N-aryl substituents). A set of eight side chains 
(a–i) were installed in monomer model systems (Scheme 2.1). To probe the effects of 
the various side chains on the cis–trans rotamer preference, the monomers were 
acetylated to generate a N-terminal tertiary amide. As the rotation around the amide 
bond is sufficiently slow, the population of the cis- and trans-conformation can be 
determined by integration of the 1H NMR peaks assigned to each rotamer, analogous 
to the studies of α-peptoids.176,177,179  
Syntheses of the β-peptoid monomers were achieved by aza-Michael addition of a 
primary amine to either tert-butyl-acrylat (61) or acryloylmorpholine (62), giving the 
monomer series 63a–i and 64a–i (Scheme 2.1). This reaction was carried out in 
MeOH, which has turned out to be superior to earlier suggested mixtures of 
tetrahydrofurane (THF) and water206 or the originally proposed mimethylsulfoxide 
(DMSO).205 The Michael addition was followed by acetylation to give the desired N-
terminally capped monomers 65a–i and 66a–i for NMR evaluation. 
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Scheme 2.1. A) Acetylated monomers 65a-h and 66a-h. Reagents and conditions: (a) MeOH, 50 °C, 
16h; (b) (i) for esters Ac2O (2 equiv), pyridine (2 equiv), DMF, 0 °C → rt, 4h or (ii) for amides AcCl (2 
equiv), pyridine (2 equiv), CH2Cl2, 0 °C, 1h. B) Abbreviations for N-alkyl side chains used: spe = (S)-
1-phenylethyl, sce = (S)-1-cyclohexylethyl, bn = benzyl, sbu = sec-butyl, s1npe = (S)-1-(1-
naphthyl)ethyl, npm = 1-naphthylmetyl, bnz = benzhydryl, ph = phenyl, rpe = (rac)-1-phenylethyl. 
 
In addition to the N-alkyl side chains and C-terminal capping group, model systems 
designed to probe local n → π* interactions were prepared. The concept of these 
designs was to alter the electronic properties of the backbone, thereby altering the 
strength of the interactions. In case of an n → π* interaction being present, one of the 
conformations should be further stabilized. The N-terminal amides was modified by 
the introduction of a trifluoroacetyl group, which was installed by treating 63a, 63e, 
63f, 64a, 64e and 64f with trifluoroacetic anhydride (Scheme 2.2). Due to the electron 
withdrawing effect of fluorine, this modification was made to enhance the acceptor 
capabilities of the amide carbonyl carbon.  
 
Scheme 2.2. Synthesis of a series of backbone modified monomer models: a) trifluoroacetic anhydride 
(2 equiv), pyridine (2 equiv), CH2Cl2, 0 °C, 1h. 
 
The carbonyl oxygens were also substituted with sulfur, creating minimal peptide 
bond surrogates with altered electronic properties.187 Sulfur has an electronegativity 
close to that of carbon, as a result the C=S bond should be less polarized than a C=O 
bond.213 We reasoned that this substitution would enhance an n → π* delocalization 
as sulfur is a softer base than oxygen, and thus a better electron pair donor. This 
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substitution was done selectively at both amide groups of compounds 66a, e, f using 
Lawesson’s reagent (69).214,215 This reagent is a mild thionating agent for ketones, 
esters and amides, that allows preparation of the thio analogue of the parent 
compound. In solution Lawesson’s reagent is in equilibrium with a more reactive 
dithiophosphonium ylide (70) (Scheme 2.3). This ylide can react with a carbonyl 
group to give a thiooxaphophetane (71) intermediate, which collapses to give the 
thiocabonyl-analogue (72) (Scheme 2.3). The driving force of this reaction is the 
formation of a very stable P=O bond.  
 
Scheme 2.3. Reaction mechanism for thionation using Lawessons reagent. 
Lawessons reagent has been used to replace amide bonds in biologically active 
peptides with thioamides, in an effort to furnish more potent and selective 
compounds. These studies have shown that Lawessons reagent will convert amides to 
thioamides in the presence of esters, without formation of thioesters.216 This 
selectivity can also be used to selectively install the thioamide at either end of the β-
peptoids (Scheme 2.4).  
 
Scheme 2.4. Synthesis of thioamide-containing monomeric model compounds. Reagents and 
conditions: (a) Lawesson's reagent (1.5 equiv), toluene, 110 °C, 3 h; (b) AcCl (2 equiv), i-Pr2NEt (2 
equiv), CH2Cl2, 0 °C, 3 h; (c) Lawesson’s reagent (0.6 equiv), toluene, 110 °C, 1 h; (d) 1M LiOHaq–
DMF 1:1, rt, 16 h; (h) morpholine (2 equiv), HBTU (2 equiv), i-Pr2Net (2 equiv), CH2Cl2, rt, 16 h. 
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By applying Lawessons reagent to 64a, 64e, 64f, the C-terminal thioamide containing 
monomers 73a, 73e and 73f can be obtained. The monomers can subsequently be 
acetylated giving the thionated monomeric model systems 74a, 74e and 74f (Scheme 
2.4A). If Lawessonss reagent is applied to the acetylated monomers 75a, 75e, 75f in 
equimolar amounts, only the N-terminal amides are transformed to thioamides giving 
75a, 75e and 75f. The obtained compounds can then be deprotected and the desired 
C-terminal capping group can be installed by a coupling reaction. For our purpose we 
chose to install morpholine capping groups yielding the N-terminally thionated 
compounds 76a, 76e and 76f (Scheme 2.4B).  
 
2.3 Synthesis of monomeric peptoid model systemsa 
As fluorination and thionation of peptoid backbones of any length had not been 
described prior to our investigation, we decided to prepare peptoid analogues as well. 
For these compounds we chose a single scaffold, which we thought most likely to 
engage in any of the interactions we were investigating. As the peptoids present a 
shorter and less flexible backbone, we thought it relevant to investigate if the 
introduction of these groups would have comparable effects in this system.  
 
 
Figure 2.4. Synthesized peptoid model systems. 
 
The preparation of the monomeric model systems were achieved by applying 
published methods for solution-phase peptoid synthesis209 in combination with the 
protocols described in section 2.3 for β-peptoids, giving compounds 77, 78 and 79 
(Figure 2.4). 
 
2.4 Methods to evaluate monomeric model systems 
Because the isomerization of the tertiary amide bond is slow on the NMR timescale, 
two sets of signals appear. Though most of these signals exist as multiplets and 
overlap with those of the isomer, it was possible for all the systems investigated to 
isolate a pair of corresponding signals. The ratio of the integrals of the signal for each 
isomer gives the Kcis/trans of the amide bond directly. In all model systems containing 
an α-chiral side chain, the methine proton was used to determine the isomeric ratio 
                                                
a The syntheses of the monomeric peptoid model systems were performed by fellow Ph.D student Jens 
Engel-Andreasen. 
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(Figure 2.5). For the systems without chiral side chains the methyl of the acetyl group 
could be used to determine the ratio.   
 
Figure 2.5. 1H NMR-spectrum highlighting the signal utilized for determination of Kcis/trans. 
 
This method has been used in earlier studies where it was determined that the signal 
with the most downfield chemical shift corresponds to the cis conformation.217 To 
assess if our system displayed the same trend, we performed rotating frame 
Overhauser effect spectroscopy (ROESY). The highlighted signals correspond to 
correlations a–c involving the methine proton as shown in figure 2.6. 
In the trans-conformation, the methine proton (quartet) has correlations to the side 
chain CH3 protons (b) as well as the N-acetyl CH3 protons (c). The further downfield 
shifted quartet only has an ROE correlation to the side chain CH3 protons (a). Thus, 
the N-acetyl CH3 group from the conformation with upfield shifted signal is in closer 
proximity to the methine proton, which confirms the assignment of this spin system as 
originating from the trans-conformation.  
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Figure 2.6. ROESY spectrum used for assigning the signals to the cis- and trans-conformations 
respectively. 
 
We also evaluated if using chiral vs. achiral side chains had any effect on the cis–
trans ratio. For this we chose to use a monomer with an spe side chain, as this side 
chain has been shown to determine the handedness of helices in peptoid oligomers.169  
 
 
Figure 2.7. 1H NMR spectra of the racemic mixture 75i (top), and the enantio-pure 75a (bottom). 
! S3!
 
Figure S3. ROESY spectrum of compound 6e. The highlighted signals correspond to correlations a–c involving the methyne proton 
as shown in the scheme above. In the trans-amide conformation, the methine proton (quartet) has correlations to the side chain CH3 
protons (b) as well as the N-acetyl CH3 protons (c). The further down-field shiftet quartet only has an ROE correlation to the side 
chain CH3 protons (a). Thus, the N-acetyl CH3 group from the conformation with up-field shiftet signal is in closer proximity to the 
methine proton, which confirms the assignment of this pin system as originating from the tr ns-amide conformation. 
 
 
Figure S4. ORTEP representation of the solid state structures of compound 5g, 8e, and 15. For crystallographic details, see the CIF 
files. Atom colors: Grey, carbon; white, hydrogen; red, oxygen; blue, nitrogen; green, fluorine; yellow, sulfur. 
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1H NMR of 75a and 75i revealed identical spectra, confirming that the chirality does 
not influence the cis–trans ratio (Kcis/trans) (Figure 2.7).  
To ensure that any observed effects were intramolecular, we recorded a series of 
NMR-spectra at increasing concentrations from 6–200 mM (Figure 2.8). This series 
showed no change in the observed Kcis/trans. 
 
 
Figure 2.8. Concentration dependence on Kcis/trans for compound 75a in CDCl3 at 298 K. 
 
2.5 Conformational investigation of β-peptoid monomers 
As mentioned, sterics play a crucial role in the formation of most secondary 
structures, and as we are installing an additional methylene in the backbone, we are 
also changing the available space for the side chains to occupy. We therefore made a 
series of compounds, inspired by earlier investigations of peptoid monomer behavior. 
For the investigation of our monomer model-systems, we first installed the spe side 
chain (65a). This side chain was chosen as it is one of the most studied side chains, 
with regard to peptoid folding and we thought this as an ideal reference point, as it is 
both α-chiral and contains an aromatic moiety. This side chain gave rise to a slight 
preference for the trans-configuration of the N-terminal amide bond (Table 2.1). Next 
we installed the (S)-1-cyclohexylethyl (sce) side chain (65b) to remove the aromatic 
moiety, but retaining the steric bulk. This substitution resulted in a drop in Kcis/trans, as 
also seen for the peptoid analogues. As the cyclohexyl ring contains five additional 
hydrogen atoms and deviates from planarity, it is thought to be more sterically 
demanding than a phenyl ring. Following the investigations of peptoids, this should 
give rise to an increase in the cis–trans ratio. We interpret the drop as our system 
having enough room to accommodate the additional bulk, and that an interaction 
involving a carbonyl oxygen and the aromatic moiety are present. We next sought to 
decrease the steric congestion of the side chain while retaining the aromaticity, this 
! S2!
 
Figure S1. Comparison of the trans–cis rotamer ratios of enantiomerically pure and racemic versions of compound 5a, which 
expectedly show no difference in equilibria. 
 
Figure S2. Concentration dependence on Kcis/trans for compound 3a. Spectra were recorded in CDCl3 at 298 K.  
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was achieved by introduction of a benzyl (bz) group (65c). This gave comparable cis–
trans ratios to compound 65a.  
 
 
Table 2.1. Rotamer equilibrium constants (Kcis/trans) for acetylated β-peptoid monomers in various 
solvents and their corresponding differences in free energy (ΔG, given in kJ/mol). a Determined by 
integration of 1H NMR spectra of 12 mM solutions at ambient temperature. 
b ΔG = –RT × ln (Kcis/trans). c Not soluble. 
 
This indicates that the α-branching of the side chains is less important than seen for 
peptoids, where the introduction of α-branching gives rise to an approximately 2-fold 
increase in Kcis/trans. Both the aromaticity and the majority of the bulk were removed by 
installation of a sec-butyl side chain (65d). This gave Kcis/trans values comparable to 
65b, which is consistent with peptoid findings. When the bulk of the aromatic moiety 
was increased, by introduction of the (S)-1-(1-naphthyl)ethyl (S1npe) side chain 
(65e), the Kcis/trans showed a preference for the cis-conformation. To assess if the 
increased bulk alone was responsible for the shift in preference, we removed the α-
branching using 1-naphthylmethyl (npm) as side chain (65f). Unlike for the two less 
bulky spe and bn side chains, the removal of the methyl group highly influences 
Kcis/trans. The npm side chain gives comparable values to 65a and 75c, meaning that a 
more bulky aromatic group and additional α-branching is required to induce 
preference for the cis-conformation. In an attempt to determine whether some of the 
bulk can be moved, we installed a benzhydryl (bnz) side chain (65g). Surprisingly, the 
introduction of additional bulk in this position has no effect as compared to the spe 
side chain, which will be elaborated upon in section 2.6. Finally we attached the 
phenyl (ph) moiety directly to the amide nitrogen (65h), which gave rise to a single 
set of NMR signals corresponding to the trans-conformation. This observation is 
consistent with peptoid investigations of a variety of substituted aromatic moieties. 
 Comp.  Side chain  K cis / transa ΔGb  K cis / transa  ΔGb  K cis / transa  ΔGb  K cis / transa  ΔGb  K cis / transa  ΔGb  K cis / transa  ΔGb
 65a spe 0.8 0.5 0.8 0.5 0.7 0.9 0.8 0.5 0.9 0.3 0.8 0.5
 65b sce 0.5 1.7 0.6 1.2 0.4 2.2 0.5 1.7 0.4 2.2 0.5 1.7
 65c bn 1 0 0.9 0.3 0.9 0.3 0.9 0.3 0.7 0.9 0.7 0.9
 65d sbu 0.5 1.7 0.5 1.7 0.4 2.2 0.4 2.2 0.5 1.7 0.4 2.2
 65e s1npe n.s.c - 3.6 –3.1 5.6 -4.2 3.6 –3.1 5.3 –4.1 6.3 –4.5
 65f npm n.s.c - 0.7 0.9 0.9 0.3 0.7 0.9 0.9 0.3 0.9 0.3
 65g bnz n.s.c - 0.9 0.3 0.6 1.2 0.9 0.3 0.7 0.9 0.5 1.7
 65h ph 0.2 3.9 All trans - All trans - All trans - All trans - All trans -
 66a spe 0.7 0.9 0.8 0.5 0.5 1.7 0.8 0.5 0.4 2.2 0.4 2.2
 66b sce 0.3 2.9 0.5 1.7 0.3 2.9 0.4 2.2 0.4 2.2 0.3 2.9
 66c bn 1 0 0.5 0.3 0.7 0.9 0.9 0.3 0.3 2.9 0.3 2.9
 66d sbu 0.2 3.9 0.7 1.7 0.2 3.9 0.4 2.2 0.1 5.6 0.1 5.6
 66e s1npe 2.9 –2.6 3 –2.7 3 –2.7 3.1 –2.8 2.9 –2.6 3.5 –3.1
 66f npm 0.9 0.3 0.6 1.2 0.9 0.3 0.8 0.5 0.4 2.2 0.5 1.7
 66g bnz 0.8 0.5 0.9 0.3 0.5 1.7 0.9 0.3 0.4 2.2 0.5 1.7
 66h ph n.s.c - All trans - All trans - All trans - All trans - All trans -
C-terminal amides
C-terminal esters
D2O DMSO-D6 CD3OD CD3CN CDCl3 C6D6
NR X
O
O
NR X
O
ON OX = OtBu or
Kcis/trans
cis trans
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We also evaluated the same series carrying a C-terminal amide rather than the tert-
butyl ester. The results are shown in the lower panel of table 2.1, and upon inspection 
these compounds show the same trends as the esters. This is interpreted as an 
indication that this terminus does not engage in n → π* interactions. 
Although our reference system (65a) has a slightly different cis–trans ratio than 
observed for the peptoid analogue, the alterations of side chains exhibit the same 
trends as observed for peptoids.  
 
2.5.1 Trifluoroacetylated analogues 
As we found the β-peptoids to display the same behavior as peptoids upon side chain 
substitution, we turned our attention to backbone modifications. We first sought to 
investigate if n → π*amide interactions were a determining factor for the observed 
conformational preferences. Although interactions of this kind would not be expected 
to have a pronounced effect on β-peptoid structure due to unfavorable geometry.218 
First, we reasoned that upon changing the C-terminal capping group from the tert-
butyl ester to the morpholine amide, we also changed the acceptor capabilities of the 
carbonyl carbon. As the oxygen of the ester is electron withdrawing and the amide 
nitrogen is electron-donating, the carbonyl of the ester will be most electrophilic, and 
hence be most prone to engage in an n → π* interaction. We interpreted the lack of 
change in the observed cis–trans ratios upon this change as an absence of an n → π* 
interaction in the N → C-terminal direction. To determine if an interaction in the 
opposite direction was present we installed a trifluoroacetyl group in the N-terminal 
of a selection of compounds. We reasoned that this substitution would significantly 
alter the electronic properties of the carbonyl group due to the inductive electron-
withdrawing effect of the fluorines. This should decrease the electronegativity of the 
N-terminal carbonyl, rendering this position a weaker donor of a lone pair from 
oxygen, while the carbonyl carbon atom would become a stronger acceptor. Upon 
inspection of the Kcis/trans values, we were surprised to find opposing effects in 67a vs. 
65a and 67e vs. 65e which decreased and increased, respectively, while the last 
compound 67f behaved like 65f (Table 2.2).  
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Table 2.2. Rotamer equilibrium constants (Kcis/trans) for trifluoro-acetylated and thioamide containing β-
peptoid monomers in various solvents and their corresponding differences in free energy (ΔG, given in 
kJ/mol). a Determined by integration of 1H NMR spectra of 12 mM solutionsat ambient temperature. b 
ΔG = –RT × ln(Kcis/trans). c Not soluble. 
 
As the effects are opposite or non-existing, another explanation than n → π* 
interactions is most likely causing the changes. The most obvious of the effects is 
seen in 67e, where we have a congested amide to which we add a further bulk. By 
being in the cis-conformation the two sterically demanding groups, the side chain and 
the trifluoroacetyl group, are placed to avoid clashing. On the other hand, in the case 
of 65e, the decrease may be explained by a weakened n → π*aryl interaction. In 
support of this hypothesis, it has been shown that the rotamer equilibrium of a 
trifluoroacetylated proline derivative was governed by sterics, while the mono- and 
difluoroacetylated analogues were affected by the electron-withdrawing inductive 
effect of fluorine.219 Further, it was suggested that fluorine could act as a doner of a 
lone pair to a π* orbital of the adjacent carbonyl carbon, this would give rise to 
stabilization of the opposite of the anticipated conformation. Indeed, this kind of 
interaction is precedented in literature, for example by using molecular torsion 
balances. We also tested the morpholine anlogues, which showed the same Kcis/trans 
values as the tert-butyl esters. This renders it very unlikely that an interaction of the 
C-terminal carbonyl group is involved in conformational stabilization. 
 
2.5.2 Thioamide analogues 
We next investigated the carbonyl donor capabilities by evaluating the thioamide 
analogues. This substitution has been shown to enhance the n → π* interaction in 
proline systems.187 If any carbonyl–carbonyl interactions were to be playing a role in 
the conformational preference of β-peptoids, the enhanced “nucleophilicity” of sulfur 
should give rise to differences in the Kcis/trans as compared to the oxygen-analogues. In 
 Comp.  Side chain  K cis / transa ΔGb  K cis / transa  ΔGb  K cis / transa  ΔGb  K cis / transa  ΔGb  K cis / transa  ΔGb  K cis / transa  ΔGb
67a spe n.s.c - 0.4 2.2 0.3 2.9 0.4 2.2 0.3 2.9 0.3 2.9
67e s1npe n.s.c - 6.8 –4.2 6.3 –4.3 6.6 –4.6 6.3 –4.3 6.3 –4.3
67f npm n.s.c - 0.8 0.5 0.8 0.5 0.8 0.5 0.9 0.3 1.0 0.0
68a spe 0.4 2.2 0.4 2.2 0.3 2.9 0.4 2.2 0.2 3.9 0.2 3.9
68e s1npe n.s.c - 5.6 –4.2 5.0 –3.9 5.5 –4.1 4.8 –3.8 4.5 –3.7
68f npm n.s.c - 0.8 0.5 1.0 0.0 0.8 0.5 0.7 0.9 0.6 1.2
74a spe 0.9 2.2 0.5 1.7 0.5 1.7 0.5 1.7 0.2 3.9 0.2 3.9
74e s1npe n.s.c - 2.0 –1.7 3.4 –3.0 2.8 –2.5 2.2 –1.9 2.6 –2.3
74f npm n.s.c - 0.9 0.3 0.8 0.5 0.9 0.3 0.3 2.9 0.3 2.9
76a spe 0.4 0.9 0.9 0.3 0.4 2.2 0.7 0.9 0.5 1.7 0.5 1.7
76e s1npe n.s.c - 5.4 –4.1 4.7 –3.8 4.5 –3.7 3.3 –2.9 5.2 –4.0
76f npm n.s.c - 1.0 0.0 0.6 1.2 0.9 0.3 0.3 0.3 0.3 2.9
N-terminal thioamides
Trifluoroacetylated C-terminal esters
Trifluoroacetylated C-terminal amides
C-terminal thioamides
C6D6D2O DMSO-D6 CD3OD CD3CN CDCl3
N
O
X = OtBu or
N X
OO
F3C
R
N N
SO
R
N N
OS
RO O
Trifluoroacetylated monomers C-terminal thioamide N-terminal thioamide
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substituting both C- and N-terminal carbonyl oxygens, it is possible to probe if the n 
→ π* interaction is in the C → N or N → C direction. We first installed the thioamide 
in the C-terminal of the compounds 74a, 74e and 74f. We discovered that these 
compounds have the same selectivity as observed in the amide analogues. However, it 
is noticeable that the Kcis/trans for compound 74a is somewhat lower than for the parent 
oxoamide. If an n → π* interaction between the two carbonyl groups in the C → N 
direction were present, it would stabilize the cis-conformation. Therefore the 
interaction might involve the aromatic ring. An interaction from this carbonyl oxygen 
to a side chain moiety has not been described in the peptoid-literature. As the oxygen 
is placed further away in our β-peptoid system, it might be likely that a conformation 
allowing an n → π*aryl interaction is possible. We next synthesized the N-terminal 
thioamides 76a, 76e and 76f, which again followed the same trend as the parent 
oxoamides. In this series the compound containing s1npe (76e) displayed an increased 
Kcis/trans, which is the opposite of the expected if an n → π* interaction is present in the 
N → C direction. This change in the Kcis/trans value would indicate an interaction with 
the aromatic ring rather than the C-terminal carbonyl carbon, as it has been described 
in conventional peptoids and thiopeptoids.176,177,188 
 
2.5.3 Peptoid monomer model systems 
We prepared compounds 77–79 to address if the effects of trifluoroacetylation and 
thioamideintroduction were also present in peptoids. Compound 77 has previously 
been investigated,176 and exhibited the same Kcis/trans values as reported in CD3CN and 
CDCl3 and an intermediate value in DMSO-d6, suggesting the presence of a solvent 
effect. For compound 78, an even higher Kcis/trans was observed, which was much less 
affected by the solvent polarity. Like for the β-peptoid (68e) this equilibrium is most 
likely primarily dictated by sterics. Finally, we saw higher Kcis/trans values for the 
thiopeptoid (79), than for the oxoamide analogue in polar solvents. This again suggest 
the presence of an n → π*aryl interaction between the sulfur and the aromatic side 
chain. 
 
2.6 X-ray crystallography of monomeric model systemsb 
Diffraction quality crystals of 65g and 68e were obtained by slow evaporation from 
chloroform solutions, as well as the peptoid 79 by slow evaporation from ethyl 
acetate. Thus, the solid state crystal structures were solved by X-ray structure 
determination. The structure of 65g revealed a fully extended backbone conformation, 
with trans-amide configuration (Figure 2.9), which is consistent with the observed 
Kcis/trans of 0.7 in CDCl3.  
 
                                                
b X-ray crystal structures were solved by Associate Professor Pernille Harris 
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Figure 2.9. X-ray crystal structure of compound 65g. 
 
It is worth noting the periplanar relationship of the two phenyl groups, which are also 
pointed away from the acetyl CH3 group (Figure 2.9B). This relationship may help 
explain the high trans-amide ratio observed in solution despite a significant steric 
bulk. 
Compound 68e crystallized in the cis-conformation, as would be expected from the 
observed Kcis/trans values (Figure 2.10A). Although we suspected that the electron lone 
pair donating capabilities of the N-terminal carbonyl in the trifluoroacetylated 
compounds would be diminished, it appears to engage in an interaction like those 
described for peptoids by Gorske and co-workers.188 It is also noteworthy that one of 
the naphthyl hydrogens is in close proximity to the carbonyl oxygen, which could also 
be interacting. The X-ray crystal structure revealed a rather dense packing, with two 
monomer molecules aligned with the backbones in an antiparallel manner. As this 
arrangement gives rise to an edge to face aromatic π–π interaction, the presence of 
other interactions in solution involving the aromatic moiety cannot be definitively 
excluded. 
 
 
Figure 2.10. X-ray crystal structure of compound 68e. 
 
The X-ray crystal structure of thiopeptoid 79 also revealed the presence of a cis-amide 
configuration. The distances from the C-terminal carbonyl oxygen to the N-terminal 
carbonyl carbon is fully consistent with the presence of an n → π*amide 
interaction.184,220 As was also the case for compound 68e, the distance to the side chain 
methine-hydrogen is indicative of an indirect interaction.188  
 
 !
 !  ! !
A                               B                                   C 
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Figure 2.11. X-ray crystal structure of compound 79. 
 
Interestingly, the distance between the sulfur and the same naphthyl hydrogen as 
described for 68e is in close proximity, consistent with an overlap of their orbitals, 
which would give rise to a C–H…Samide. This could offer an alternative explanation to 
the stabilization of the cis-conformation upon introduction of a thioamide 
functionality. 
 
2.7 Evidence for aromatic C–H…Samide interactionsc 
In order to explore the identity of the putative non-covalent carbonyl–aryl interaction 
in this system, density functional theory (DFT) calculations were performed. The 
computational study was carried out in order to gain further insight to the molecular 
features responsible for the CH…Samide interaction, and its effect on the observed 
preference for the cis-amide configuration in the presence of the s1npe side chain. 
Initially the molecules 66e and 76e was built in both cis- and trans-conformation, and 
a conformational search was performed. This search showed the cis-amide 
configuration to have the lowest energy for both systems, which is in agreement with 
the experimentally determined Kcis/trans ratios. When visualizing the ensemble of 
conformations within 21 kJ/mol (Figure 2.12), a more homogeneous distribution is 
observed for the thioamide containing system. This difference in distribution indicates 
that there might be a stabilizing interaction between sulfur and the naphthyl group. 
This geometry is also consistent with the X-ray crystal structure for 79, revealing 
close proximity of the naphthyl H-8 and the sulfur.  
 
 
                                                
c The computational investigation of the monomer model systems were preformed by Associate 
Professor Peter Fristrup. 
 
 
 
 
 
 
 
!
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Figure 2.12. Calculated structures of 66e (A and B) and 76e (C and D). B and D shows all structures 
within 21 kJ/mol of the global minimum super imposed. 
 
To further investigate the electronic properties responsible for the observed cis-amide 
preference in the N-terminal thioamide analogues, a natural bond order (NBO) 
analysis was carried out. By including the trifluoroacetylated compounds 68e and 78 
we were able to pinpoint the effect of this substitution in both peptoid and β-peptoid 
backbones. First we compared the cis-conformations of 66e and 76e it is notable that 
although the longer C=S bond compared to the C=O bond (1.7 Å vs. 1.2 Å) caused 
the distance to the hydrogen of the naphthyl to increase from 2.9 Å to 3.2 Å, the NBO 
analysis clearly showed that the interaction was strongest in the thioamide case. We 
found that the natural charge of the naphthyl hydrogen in the thioamide was lower 
than in the oxoamide analogue (0.2436 au or 76e vs. 0.2455 au for 66e), although 
both hydrogens are more electron-deficient than their neighboring hydrogens which 
does not have such intramolecular interactions (0.2503 au for 76e and 0.2487 au for 
66e). In addition, second order perturbation analysis of 76e and 66e revealed a 
calculated stabilizing energy of 0.84 kcal/mol for this interaction in the thioamide, 
while the interaction in the oxoamide gives a stabilization of less than the 0.5 
kcal/mol threshold. 
In the trifluoroacetylated compound 68e, the amide oxygen is less negatively charged 
than its acetylated parent compound 66e (–0.657 au in 68e and –0.716 au in 66e). As 
a consequence, the electrostatic interaction with the naphthyl hydrogen is expected to 
be much smaller than for 66e, and is indeed found to be below the 0.5 kcal/mol 
threshold. This suggest that the increased cis–trans ratio is most likely caused by the 
increased steric congestion upon introduction of a trifluoroacetyl group rather than an 
increase in the electrophilicity of the carbonyl carbon. Finally it should be noted that 
the investigated trans-configured molecules showed a fully extended backbone, with 
neither n → π*aryl nor n → π*amide interactions. 
We next investigated the peptoid series, where the closer proximity of the C-terminal 
carbonyl group may allow for the possibility of n → π* interactions in addition to the 
 
 
 
 
 
 
 
!
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CH…Samide interaction. For all the peptoid compounds an interaction of the carbonyl 
group and the naphthyl hydrogen was present in the second order perturbation of the 
NBO analysis. In the peptoid system the interaction is only slightly stronger for the 
thioamide containing analogue 79 (0.63 kcal/mol) as compared to the oxoamide 77 
(0.58 kcal/mol). Surprisingly the value for the trifluoroacetylated analogue 78 is even 
higher at 0.65 kcal/mol, it should be noted that with the small energies involved, these 
differences are within the accuracy of this method. 
To experimentally probe the existence of an interaction between the sulfur and the 
hydrogen in the eight position of the naphthyl group, we turned our attention back to 
the NMR-spectra. Indeed, a comparison of the chemical shifts assigned to the 
naphthyl hydrogen in the cis-amide conformation of compounds with altered 
electronic properties of the carbonyl support the existence of the proposed interaction 
in solution as well. The decrease in electron density of the carbonyl oxygen by 
introduction of fluorine should render the hydrogen less shielded which should be 
causing an upfield shift of the 1H NMR signal, which was indeed observed (Figure 
2.13, 66e vs. 68e).  
 
 
Figure 2.13. Aromatic region of the 1H-NMR spectra of 66e, 68e and 76e recorded in CD3CN. The 
asterisk denotes the signal assigned to the proton in the eight position in the naphthyl group. 
 
Substitution of oxygen with sulfur (66e vs. 76e) should in principle affect this 
interaction in the same manner. However, the opposite was observed, with a 
downfield shift of the signal, which is consistent with the calculated ensembles and 
the observed Kcis/trans values that indicate a stronger interaction for sulfur. Although 
hydrogen bonds to oxoamides should be stronger than those to thioamides, we 
speculate that the geometric restraint required for formation of the eight membered 
ring in our system does not allow for optimal hydrogen bonding distance, and 
therefore the larger radius of sulfur enables a higher degree of orbital overlap than the 
oxygen. This is also supported by the NBO analysis as mentioned.  
 
2.8 Concluding remarks 
To obtain fundamental knowledge of the amide bond isomerization in β-peptoids, 
several series of monomer model systems including varying steric demand and 
stereoelectronic properties were synthesized. As our results were compared to 
!
66e#
68e#
76e#
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previous studies of α-peptoids we also synthesized two new α-peptoid models 
containing a trifluoroacetyl group and an N-terminal thioamide, respectively. The 
investigation of these model systems show that some of the trends seen in α-peptoids 
translate directly to the β-peptoids. As such, it was shown that a preference for the 
cis-conformation could be induced upon introduction of an s1npe side chain, whereas 
the trans-conformation was exclusively populated when N-aryl type side chains are 
installed. We found that both a bulky substituent and α-branching is required to 
induce a preference for the cis-conformation, as a diphenyl substituted bnz side chain 
did not present a sufficient bulk. To probe if the backbone amides were participating 
in any electronic interactions we altered the stereoelectronic properties. Through an 
NMR investigation of these models evidence of an interaction between an 
amide/thioamide lone pair and an aromatic side chain moiety was found. However, 
we found no evidence of interactions between the carbonyl groups in our monomer 
model systems. Further, we were able to solve the X-ray crystal structure for two 
compounds, both having fully extended backbones, not allowing interactions between 
the termini in either cis- nor trans-conformation. 
We also solved the X-ray crystal structure of a thioamide containing α-peptoid, and 
supported by DFT calculations and chemical shifts from NMR analysis, this structure 
indicated the presence of a stabilizing effect through a thioamide–aromatic interaction 
by a Csp2–H…Samide “hydrogen bond”. 
These observations show that these stereoelectronic alterations of the backbone are 
valuable tools in the investigation and design of peptoid and β-peptoid structure. 
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3  β-Peptoid oligomers 
3.1 Design of Oligomers 
Since high-resolution structures of peptoids have been successfully obtained for 
oligomers of 4–5 residues in length, we envisioned that a hexamer might be sufficient 
to acquire stabilized folding. We chose two different side chains for our investigation, 
first the Nspe, which has been studied for both α- and β-peptoids, and second the 
Ns1npe. The latter was chosen as it has been shown to induce helicity in the crystal 
structure of a peptoid tetramer, and because we have shown that this side chain 
stabilizes the cis-configuration in the monomer (see chapter 2). The last point is 
important as a computational study of the β-peptoid backbone showed a helical 
structure with all amides in a cis-configuration to be the lowest energy 
conformation.218 We reasoned, that the chances of achieving folding of this kind 
would be greater using residues with a predisposition for the desired local 
conformation. 
The Ns1npe side chain has been shown to induce helical conformations in peptoids, 
however, it does not induce significant control of the amide bond rotamer equilibrium 
of β-peptoids. Attempts to determine if this side chain induces any robust secondary 
structures are somewhat ambiguous.206,207 As shown in chapter 2, introduction of a 
trifluoroacetyl group enhanced the preference for the trans-amide in the spe 
containing monomers, we therefore chose to include this substitution in our oligomer 
investigation along with the acetyl control compound. This substitution was also 
included for the second series of Ns1npe oligomers, as it was shown to increase the 
fraction of the cis-amide in the monomer models (Chapter 2). 
 
3.2 Synthesis of β-peptoid oligomers 
When Hamper et al. first presented the β-peptoids, they described the syntheses of 
libraries of di- and trimers.205 These libraries were created by SPS using a 
submonomer strategy, as described for the monomers in chapter 2.205,221 The strategy 
involved acylation of resin-bound amines with acrylic acids followed by conjugate 
aza-Michael addition of the next amine. This strategy was later shown to give rise to 
mixtures and impure products, when extending the oligomer beyond tetramers.207 It 
was further shown that this reaction was highly sensitive to the changes in solvent, as 
it was reported that a THF/H2O (8:2) mixture gave better yields than the originally 
proposed neat dimethylsulfoxid (DMSO).206 A solid-phase strategy using Fmoc 
protected building blocks, was shown to give modest yields of penta- and hexameric 
homo-oligomers of β-peptoids with α-chiral side chains.207 Employing non-chiral side 
chains, Franzyk and co-workers later improved this strategy furnishing a 22’mer in 
good yield.222 
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Figure 3.1. (A) Homooligomer reported by Jaroszewski and co-workers.207 (B) Oligomer reported by 
Franzyk and co-workers.222 
 
We experienced good yields of the aza-Michael addition using MeOH as solvent, as 
described by Taillefumier and co-workers.208 However, this solvent is not optimal for 
SPSs, as it causes most solid-supports to contract leaving the active species 
inaccessible to the reactants. We chose to use a solution-phase strategy used for the 
synthesis of α/β-hybrid peptoids.209 The method of choice resembled that of the 
monomers, starting with an aza-Michael addition of the primary amine to an acrylic 
compound in MeOH (Scheme 3.1). The formed secondary amine could next be 
acylated using acryloyl chloride in the presence of triethyl amine. By performing the 
acylation step in THF, the formed ammonium salts precipitated and could be removed 
by filtration, and the crude product undergo another Michael addition. When the 
desired length of the oligomer was reached it was capped with the desired capping 
group. This strategy calls for only one purification for each residue attached, which 
greatly reduces the time and effort needed to prepare β-peptoid oligomers. 
 
 
Scheme 3.1. Oligomerization and N-terminal functionalization of β-peptoids. a) NEt3, THF, 0 °C. b) 
MeOH, 50. c) AcCl, NEt3, 0 °C. d) (CF3CO)2O, NEt3, CH2Cl2, 0 °C→20 °C . 
 
In this way we prepared oligomer series 82a–86a and 82b–86b containing the Nspe 
side chain, and 87a–91a and 87b–91b containing the N-s1npe side chain (Figure 3.2). 
We also chose to evaluate a non-acylated hexamer of the latter mentioned series 
(91c). 
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Figure 3.2. Synthesized series of β-peptoid oligomers. 
 
3.3 Structure elucidation of β-peptoid oligomers. 
3.3.1 Preliminary NMR study of the solution structure of oligomers 
First we investigated our oligomer series using NMR, to determine how elongation 
affects the cis–trans conformational preference. As expected the spectra revealed 
significant signal overlapping due to the identical side chains of either series. 
However, focusing on the shifts corresponding to the side chain methine protons the 
overall cis–trans ratios could be determined (Table 3.1).  
 
N-(S)-1-Phenylethyl series 
Compound 82a 82b 83a 83b 84a 84b 85a 85b 86a 86b 
CD3CN 0.8 0.3 0.8 0.4 0.8 0.5 0.7 0.5 0.7 0.5 
C6D6 0.6 0.3 0.6 0.3 0.6 0.3 0.5 0.3 0.4 0.3 
N-(S)-1-(1-Naphthyl)ethyl series 
Compound 87a 87b 88a 88b 89a 89b 90a 90b 91a 91b 
CD3CN 5.2 5.4 5.2 6.0 5.9 7.3 –a –a –a –a 
C6D6 4.8 4.0 4.4 4.0 5.6 4.3 6.4 4.9 11.0 10.0 
Table 3.1. Overall Kcis/trans values determined by NMR. aA limited solubility of this compound did not 
allow for analysis in acetonitrile d3. 
 
The NMR data of the Nspe series (82–86) showed no dependency on the length, with 
values close to those reported for their monomers. The data also suggests a rather 
heterogeneous mixture of configurations, consistent with the difficulties to determine 
if stabilized secondary structures are present, as mentioned earlier.206,207  
The N-s1npe series (87–91) on the other hand shows increased Kcis/trans values already 
at the dimer stage, as compared to the monomers. In the acetylated series, the di- and 
trimer (87a–88a) exhibits the same Kcis/trans values, which then increases slightly as the 
oligomer is extended to the tetramer and pentamer. When the sixth residue is attached 
the Kcis/trans value rises more steeply, giving a much more homogenous distribution of 
cis- and trans-conformers. It appears that this trend is not dependent on the solvent, 
but solely on the elongation of the oligomer.  
N
O
OtBuR n
N
O
OtBuR n
n = 2: 82a (R = Ac), 82b (R = COCF3)
n = 3: 83a (R = Ac), 83b (R = COCF3)
n = 4: 84a (R = Ac), 84b (R = COCF3)
n = 5: 85a (R = Ac), 85b (R = COCF3)
n = 6: 86a (R = Ac), 86b (R = COCF3)
n = 2: 87a (R = Ac), 87b (R = COCF3)
n = 3: 88a (R = Ac), 88b (R = COCF3)
n = 4: 89a (R = Ac), 89b (R = COCF3)
n = 5: 90a (R = Ac), 90b (R = COCF3)
n = 6: 91a (R = Ac), 91b (R = COCF3)
          91c (R = H)
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The trifluoroacetylated series (87b–91b) displays the same trend, but for this series 
the conformational distribution appears to be solvent dependent. Going from di- to 
trimer the Kcis/trans rises in acetonitrile, and remains unchanged in benzene. The same 
happens when going from three to four residues. Unfortunately the pentamer and 
hexamer were not sufficiently soluble in acetonitrile to obtain NMR-spectra. In 
benzene the trends continues until the hexamer, at which stage the Kcis/trans rises 
steeply. 
Taken together, these values may indicate a propensity of the Ns1npe oligomers to 
adopt length as well as solvent dependent secondary structures. 
 
3.3.2 Solid state structure elucidationd 
We were able to grow crystals of all three hexamers by slow evaporation from 
MeOH/CHCl3 or benzene solutions. Crystals of a sufficient quality were obtained for 
91a and 91c from MeOH/CHCl3 solution, and their structures were determined by X-
ray crystallography at 1.05 Å and 1.00 Å resolution, respectively. The N-terminally 
non-acylated 91c was the first structure to be solved, and revealed a helical display 
with exactly three residues per turn and a pitch of 9.6 Å (Figure 3.3A).  
 
 
Figure 3.3. X-ray crystal structure of compound 91c. (A) Side view. (B and C) End views from the C-
terminal. Hydrogens are omitted for clarity. 
 
The side chain of the N-terminal residue is twisted away from the core of the helix. 
The remaining naphthyl groups are highly organized along each of the three faces of 
the helix, to give an equilateral triangle when viewed down the helical axis (Figure 
3.3B, C). 
                                                
d X-ray crystal structures were solved by Associate Professor Pernille Harris 
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Based on our monomer study, we envisioned that acetylation of the N-terminal would 
produce another cisoid configuration, aligning the last naphthyl group with the rest. 
The X-ray crystal structure of compound 91a confirmed this (Figure 3.4), with only 
one –CH2CON(1-(1-naphthyl)-ethyl)CH – fragment in the asymmetric unit.  
 
 
Figure 3.4. X-Ray crystal structure of compound 91a. (A) Showing the backbone helical as sticks and 
side chains as lines (hydrogen atoms are omitted for clarity). (B) Space filling representation showing 
the packing of the naphthyl groups along the phases of the triangular prism-shaped conformation. 
 
Thus, the crystal symmetry generates infinitely long, parallel chains, which renders 
the tert-butyl group invisible due to the 1:6 ratio of tert-butyl to naphthyl side chains. 
This results in crystal packing where the helical segments are aligned in a head to tail 
fashion, giving highly regular elongated triangular threads with a helical pitch of 9.8 
Å (Figure 3.4A). This packing was not possible for compound 91c due to the 
positioning of the N-terminal side chain (Figure 3.5A). 
This highly ordered and tight packing of the side chains along the three phases of the 
helical axis (Figure 3.5B), combined with their strong cis-inducing properties, suggest 
that the Ns1npe side chains provide a particularly strong stabilization of this novel 
secondary structure motif. Further, the intramolecular distances indicates interactions 
between the side chain naphthyl groups and backbone methylene groups. This 
interaction may contribute to the stabilization by protecting the helical backbone from 
solvation.  
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Figure 3.5. X-Ray crystal packing. A) Compound 91c. B and C) Compound 91a, viewed from the end 
and perpendicular to the helical axis, respectively. Hydrogen atoms are removed for clarity. 
 
The torsion angles of the two helices show some similarity to one of the helical 
conformations suggested by Hofmann and co-workers, based on DFT-calculations.218 
These helical displays are to our knowledge the first experimental demonstration of 
the existence of this helical type. Most of the previously demonstrated structures of a 
β-peptidic nature have been shown to contain stabilizing hydrogen-bond networks,63 
and investigations of homologated proline-oligomers indicated trans-amide 
conformations.112  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2. Torsion angles of a residue within a helix. aMeasured at residue 5 in the structures to give 
representative values for a residue within the helix. bMeasured by the naphthyl substituent. cMeasured 
by the methyl substituent. d From ref 218. 
 
3.4 Further elucidation of solution structure 
To assess if these molecules exhibited an ordered structure in solution, we evaluated 
the compounds by CD-spectroscopy. This method takes advantage of the fact that 
molecules can absorb right and left polarized light differently, to assign if they display 
an ordered structure. CD is a very sensitive technique, which can be used to monitor 
the folding and unfolding events in globular proteins. CD has also been used to 
elucidate the secondary structures of foldameric compounds. Based on NMR and CD 
 
Compound 91aa 
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investigations of a series of β-hexa- and β-hepta-peptides, Seebach and co-workers 
assigned a distinct CD-pattern to the 14-helix.103 However, further investigations 
showed that this pattern was not unique to the 14-helix, as it was shown that a similar 
sequence containing substituents in axial positions, and thereby unable to display this 
secondary structure, exhibited the same CD-pattern.223 Further, CD-spectra of the 
cyclically constrained β-peptides, shown to fold into 14-helices, differ from the 
assigned pattern.94 On this background a study combining theoretical calculations and 
experimental data was undertaken.224 Since it was possible to reproduce the CD-
spectra by computational methods, factors affecting the spectra could thus be 
evaluated in silico. It was concluded that the exhibited CD-pattern of these oligomeric 
molecules where a combination of the different conformation found in solution, why a 
given pattern can not be exclusively assigned to a given secondary structure. As such, 
no conclusions on the secondary structure of a given foldameric compound can be 
made on the basis of CD-spectra alone.  
 
3.4.1 Circular dichroism of β-peptoid oligomers 
As expected, the CD-spectra of the compounds containing the N-s1npe side chain 
(84a–86a) were similar to those previously reported with this side chain (Figure 
3.6).207 The trifluoroacetylated oligomers (84b–86b) showed tsimilar spectra as the 
acetylated, indicating that this capping group does not provide any structure 
stabilizing effect (Figure 3.6B).  
 
 
Figure 3.6. CD-spectra of oligomers 84a–86a (A) and 84b–86b (B). The spectra were recorded in 
MeCN at a concentration of 60 µM and 298 K. 
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Figure 3.7. CD-spectra of oligomers 87a–91a (A) and 87b–91b (B). The spectra were recorded in 
MeCN at a concentration of 60µM and 298 K. 
 
The oligomers carrying the N-s1npe side chain all revealed a minimum at 224–228 
nm and a maximum at 218–220 nm (Figure 3.7A). The intensity of the signals was 
decreasing with the length of the oligomer, which was unexpected. However, 
inspection of the monomer revealed the same minimum and maximum, which 
disappeared upon removal of the acetyl group, which indicates that these signals are 
not indicative of secondary structure, but rather a signature of the a specific cis- or 
trans-amide motif. Starting at the tetramer length a positive signal appears near 232 
nm, and increases in intensity as the oligomer grows. This trend is indicative of 
length-dependent secondary structure formation. We also obtained CD-spectra for the 
trifluoroacetylated oligomers (87b–91b), which exhibited the same overall spectral 
shape as the acetylated (Figure 3.7B). It is noteworthy that the signal that we assign to 
secondary structure formation only appears for the hexamer. In our monomer study 
the trifluoroacetyl group was stabilizing the cis-configuration, but apparently this 
stabilization does not translate into a stabilizing effect on the secondary structure of 
the oligomers. The lack of stabilization might be explained by the trifluoroacetyl 
group clashing with the first methylene of the backbone. 
 
Finally we wanted to assess whether the positive signal at 232 nm was indicative of 
folding. Therefore we collected a series of CD-spectra at increasing temperatures in 
the range 20–75 °C (Figure 3.8A). We observed a gradual decrease in the signal at 
232 nm upon heating, which is indicative of temperature mediated denaturation.  
A                                                                   B  
20
0
21
0
22
0
23
0
24
0
25
0
26
0
-20
-15
-10
-5
0
5
10
15
20 91a
90a
89a
88a
87a
Wavelength (nm)
M
ea
n 
re
sid
ue
 m
ol
ar
 e
llip
tic
ity
 [θ
]
  (×
10
4  d
eg
 cm
2  d
m
ol
-1
)
20
0
21
0
22
0
23
0
24
0
25
0
26
0
-20
-15
-10
-5
0
5
10
15
20 91b
90b
89b
88b
87b
Wavelength (nm)
M
ea
n 
re
sid
ue
 m
ol
ar
 e
llip
tic
ity
 [θ
]
  (×
10
4  d
eg
 cm
2  d
m
ol
-1
)
 72 
 
Figure 3.8. CD-spectra of 91a at varying temperatures in acetonitrile. 
 
At the same time the remaining spectral shape was not affected, which is in 
accordance with our hypothesis that it is not related to secondary structure. Further 
more, spectra recorded upon cooling of the sample were identical to those obtained 
before heating, indicating that refolding occurs (Figure 3.8B). 
 
3.4.2 Concluding remarks 
By utilizing the data obtained from our monomer study, we designed two series of 
oligomers, one of which should be prone to fold in a specific manner, based on a 
computational study218. In doing so we produced the first high-resolution structure for 
a linear β-peptoid oligomer, which are also the longest of any peptoid oligomer 
determined by X-ray crystallography to date. The novel helical display definitively 
validates the addition of β-peptoids to the ensample of accessible foldamers. The 
crystal structure of two hexameric compounds revealed highly regular equilateral 
triangular prism shaped conformations in the solid state. The hexamers were achieved 
by synthesis in a submonomer fashion using the highly cis-inducing side chain 
Ns1npe. The existence of length- and temperature dependent secondary structure 
formation in organic solution were supported by both 1H-NMR and CD-spectroscopy. 
For the first time control of β-peptoid folding has been demonstrated, enabled by 
backbone composition and stabilized by the tight alignment of the naphthylethyl side 
chains along the three phases of the helical axis. These results open the possibility of 
taking advantage of β-peptoids in designing new well-defined biomimetic materials. 
  
!
! S4!
 
Figure S4. CD spectra of acylated and non-acylated (S)-1-(1-naphthyl)ethyl-containing monomers. 
 
 
 
Figure S5. CD spectra of compound 10a recorded at varying temperatures upon cooling the sample back 
down to room temperature. 
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4 Membrane active α-peptide/β-peptoid-hybrids 
4.1 Introduction 
Since its introduction of penicillin, antibiotics have been a standard part of the 
therapeutic arsenal for treating infectious diseases, and a number of different 
antibiotics are being marketed. However, resistance to conventional antibiotics is an 
increasing concern, which has been increasing over the last decades. This has left the 
selection of antibiotics for treating complicated infections limited.225 It has also been 
noted that the increased amount of multi-resistant bacteria seems to correlate with an 
increase in the consumption of broad spectrum antibiotics.225 To be able to continue 
antibiotic treatment novel antibiotic compounds are needed, which has led to a series 
of modifications to already existing drugs.226 Unfortunately this strategy may 
accelerate the development of resistance, as the mechanism of action is highly similar 
to that of the parent compound.227 The development of resistance to known classes of 
antibiotics has given rise to an intensified search for alternative classes of 
antibacterial compounds. Amongst these the antimicrobial peptides (AMP’s) are a 
promising candidate, being naturally found as part of the antimicrobial defense of 
many forms of life including human.228,229 The AMP’s are especially attractive as they 
target the distinct structure of the bacterial membrane.230 Unfortunately the naturally 
occurring AMP’s suffer from a number of inherent drawbacks in regard to being 
distributed as an antimicrobial drug. Given their natural origin, they are recognized by 
the proteases limiting their bioavailability, which is accompanied by high production 
cost.4 To overcome these issues synthetic modifications and mimics of the natural 
AMP’s have shown great promise in development of effective antimicrobials with 
limited toxicity.  
 
4.2 Natural antimicrobial peptides 
AMP’s are a group of compounds which are ubiquitous in all species of life.231,232 
Such peptides are components of the innate immune response with broad 
antimicrobial activities.231 As the AMP’s are naturally produced in the body and have 
been an effective part of the primary immune defense for millions of years,233 they 
have attracted great interest for their ability to overcome antibiotic resistance.234,235 
This research has led to the discovery of a wide range of AMP’s, of which some have 
proven to be valuable drug candidates.4,236  
 
4.2.1 Structure of antimicrobial peptides 
Within the class of AMP’s more than 2000 compounds have been identified, all 
sharing the common feature of an overall charge.237 Though anionic AMP’s have 
shown to be part of the innate immune defenses,238 the vast majority of AMP’s have 
an overall cationic nature.239  
The cationic AMP’s are defined as peptides of less than 50 residues, a net charge of 
+2 to +9, facilitated by basic residues as lysine and arginine, and a substantial portion 
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(above 30%) of hydrophobic residues.4 Though this may seem that these criteria 
might limit diversity of AMP’s, However, the same peptide is rarely found in two 
different species.230 This diversification enables the host to better cope with the 
microbial challenges of its ecological niche.240 Due to the large sequence diversity 
amongst the AMP’s they are classified based on their secondary structures.241 α-
helical and β-sheet structures are the most frequently encountered, though loops and 
extended structures are known.242 Typically, however, these peptides display 
unordered structures in aqueous solution,243 and frequently fold into an ordered 
arrangement upon contact with  model membranes or membrane mimetics.244,245  
 
 
Figure 4.1. Helical wheel projection of the residue distribution in the 20 N-terminal residues of 150 α-
helical natural AMP's.147 
 
The α-helical AMP’s are the most abundant class, which will fold into an 
amphipathic helix upon contact with membranes, displaying the hydrophobic side 
chains predominantly on the one phase of the helix, and the polar on the other.245 
Though these peptides show little conservatism of the amino acid sequence, there is a 
pronounced trend in the distribution of the type of residue (Figure 4.1).147 
β-sheet peptides are often present as antiparallel β-sheets stabilized by two or more 
disulfide bonds.242 
 
4.3 Cell membranes, the target of antimicrobial peptides 
Despite the discovery of many novel AMP’s during the past few decades, and the 
extensive work in the field, the mechanism of action is still under some debate.246,247 A 
number of studies have pointed to mebrane activity as the reason for AMP-mediated 
cell-death, while others have indicated intracellular activity.248 However, it is 
generally agreed that the cytoplasmic membrane is a target for most cationic AMP’s, 
249,250 and many studies have shown membrane permeabilization as a strong factor in 
the killing of cells.251 In this regard, the cationic nature of AMP’s have proved to be of 
design of short peptides. Given that a random distri-
bution would result in a 5% frequency for each amino
acid, one significantly above or below this can indi-
cate a preference or antipathy of that position for any
given amino acid. Glycine in position 1 is preponder-
ant (Figure 3, bottom). One reason could be that this
is a goo cappi g residue for !-helices (see below),
another that it affords resistance to aminopeptidases.
C-terminal amidation, observed in many peptides of
different origin, could afford a collateral resistance to
carboxypeptidases. Glycine is frequent also at posi-
tion 14, which may correspond to the hinge region
that is often present in natural peptides. Lysine is the
preferred residue at several positions, and is particu-
larly frequent at position 8. Otherwise, the positional
conservation is more tenuous. A clearer picture
emerges if one plots the frequency of residue types on
a helical wheel projection (Figure 3, top). A well-
defined distribution is bserved, with hydrophobic
residues dominating one face of the helix and polar
residues the other. The hydrophobic sector appears to
be particularly well defined, with large aliphatic res-
idues most frequent in the N-terminal stretch and
smaller residues, in particular helix-stabilizing ala-
FIGURE 3 Statistical analysis of residue distribution in the 20-residue N-terminal stretch of
!-helical AMPs from natural sources. This analysis is based on about 150 different peptides present
in the AMSDb database (www.bbcm.univ.trieste.it/!tossi/antimic.html), aligned starting from the
N-terminus. A graphical representation of the frequency of different types of residue at each
position, on a helical wheel projection is shown at the top, followed by a sequence template showing
the most freque t type of residue at each position (h " hydrophobic, p " neutral polar, x
" undefined)#" charged). The single residue % frequency at each position is shown at the bottom.
Amphipathic, !-Helical Antimicrobial Peptides 17
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particular importance for the antimicrobial activity.252 Also the ability to form 
amphipathic structures, providing a structure with separated hydrophobic- and 
hydrophilic regions, has been identified as an important characteristic of the 
AMP’s.253 These characteristics are important for the activity and in some cases also 
the selectivity of the AMP’s due to the structure and lipid composition of the 
membranes on which they act.  
 
Whether the mechanism of action is membrane activity or intracelular activity, 
interactions with the membrane of the cell is inevitable. The cells of bacteria, fungi 
and mammals are composed of different lipids. This composition gives rise to the 
interaction of AMP’s, and their selectivity towards specific cell types. In most 
bacterial membranes the zwitterionic phospholipid phosphatidylethanolamine (PE) is 
the most abundant component.254 In addition to PE, the bacterial membranes contain a 
significant portion of negatively charged phosphatidylglycerol (PG), cardiolipin (CL) 
and phosphatidylserine (PS), which gives the membrane an overall negative charge, at 
physiological pH (Figure 4.2).250 The anionic phospholipids are stabilized by divalent 
cations such as Ca2+ or Mg2+.247 It is this charge that is responsible for the attraction 
and membrane activity of AMP’s.250 In contrast to bacterial cell membranes, 
mammalian cell membranes are composed mainly of zwitterionic phospholipids. The 
outer monolayer of mammalian cells primarily consist of phosphatidylcholine (PC) 
and sphingomyelin (SM), while the inner layer mainly consist of PE.255 Furthemore 
the presence of cholesterole affects the membrane fluidity which stabilizes the lipid 
bilayers, reducing the affinity of AMP’s to these cells.247  
 
 
Figure 4.2. Structures of the most components in bacterial- and mammalian cell membranes. 
 
Bacterial cells are divided into two classes, the Gram-positive and the Gram-negative, 
depending on the cell membrane. The lipid composition of Gram-positive cell 
membranes is not significantly different from that of Gram-negative.  The cell wall of 
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Gram-positive bacteria consist of a thicker peptidoglycan layer (20–40 nm), to which 
acidic polysaccharides (lipoteichoic acids) are bound (Figure 4.3). Membranes of 
Gram-negative bacteria consist of a thin peptidoglycan layer (2–7 nm), in addition to 
this an outer-membrane not seen in Gram-positive cells are present. This outer 
membrane is covered in lipopolysaccharide (LPS) molecules. The polysaccharides 
present on the outer-membrane of both Gram-positive and Gram-negative cell-
membranes contribute to the net negative charge making these bacteria more prone to 
attack from cationic AMP’s.256   
 
 
Figure 4.3. Cell membrane structure of Gram-positive and Gram-negative bacteria. 
 
The AMP’s have been shown to have a higher affinity for the polysaccharides in the 
outer leaflet of the membranes than metal ions such as Mg2+ and Ca2+, which naturally 
counters the negative charge.235 After the initial association with the cells an outer 
layer has to be breached before the peptides can interact with the cytoplasmic 
membrane, for the Gram-positive cells it is the peptidoglycan layer and for the Gram-
negative the outer membrane.237 The cell wall of Gram-positive bacteria is composed 
of peptidoglycan, embedded with polymers of teichoic acids.257 A model that 
describes how the AMP’s traverse this layer is yet to be made, other than the 
attractive ionic forces facilitate peptide accumulation in the cell wall, which 
eventually reaches the plasma membrane.257 The breaching of the outer membrane of 
Gram-negative bacteria, on the other hand, has been more extensively studied and is 
hence much better understood. Upon displacement of the cationic species from the 
surface, the bulkiness of AMP’s relative to the metal ions disrupt the normal barrier 
properties of the membrane.258 This is believed to cause “cracks” in the outer 
membrane, which permits passage of molecules including the AMP itself, this 
mechanism is hence called the self-promoted uptake pathway.234 The ability to disrupt 
the barrier function of the outer membrane also offer an explanation to why some 
studies have shown that AMP’s increase the activity of conventional antibiotics.259 
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permeabilizing the cell membrane [3]. Nevertheless, the
membrane must play some role in targeting of peptides to
different cell types, irrespective of the mechanism of cell killing.
Gram positive and Gram negative bacteria differ fundamentally
in the morphology of their surfaces (Fig. 1). Gram negative
bacteria have an outer membrane that is rich in lipopolysac-
charides in addition to the cytoplasmic membrane. These
bacteria also have a peptidoglycan layer between the two
membranes. In contrast, peptidoglycan makes up the cell wall of
Gram positive bacteria and contains teichoic and lipoteichoic
acids. The peptidoglycan layer of Gram positive bacteria is
much thicker, 20–80 nm, than in Gram negative bacteria where
it is found to be about ten times smaller [4]. Neither the outer
membrane of Gram negative bacteria nor the cell wall of Gram
positive bacteria are generally considered to be a major barrier
to the penetration of peptides into the cell. The major exceptions
to this are peptides that bind to components of the cell wall or
outer membrane, which is not the case for the peptides used in
the present study [5].
We have been studying a pair of oligomers that contains
sequentially alternating α- and β-amino acid residues (“α/β-
peptides”), I and II (Fig. 2). The peptides are shown both as a
linear sequence. There is evidence that this class of peptides
forms i, i+4 C_O–H–N backbone hydrogen bonds, which
occur in alternating 14- and 15-membered rings (“14/15-helix”)
[6]. Although α/β-peptides I and II have identical chemical
composition and identical charge, they have very different
potencies with different cell types (Table 1). α/β-Peptide II is
much more toxic to E. coli than is α/β−peptide I, while α/β-
peptide I is more lytic toward human erythrocytes. The
phospholipid composition of cell membranes can differ
dramatically, even among bacteria (Table 2). Human erythro-
cytes exhibit a large difference in the lipid composition of the
two monolayers of the cell membrane bilayer, with the
cytoplasmic surface having most of the phosphatidylethanol-
amine (PE) and anionic lipid, while the extracellular monolayer
has essentially all of the sphingomyelin (SM) and is devoid of
anionic lipid. In the case of E. coli (Gram negative), the major
lipid in both monolayers is PE, while for B. subtilis (Gram
positive) the major lipids are the anionic phosphatidylglycerol
(PG) and cardiolipin (CL). There are thus major differences in
the phospholipid composition of the exposed membrane surface
among these three cell types (Gram negative bacteria, Gram
positive bacteria, and erythrocytes), and even larger differences
between the two types of bacteria themselves.
There is a phenomenological correlation between the toxicity
of α/β-peptides I and II toward these three cell types and the
rate of aqueous contents leakage induced by these peptides in
liposomes with a lipid composition corresponding to that of a
particular cell type [5]. Thus α/β-peptide I is more hemolytic
(Table 1) and induces greater leakage in liposomes dev id of
anionic lipid, while α/β-peptide II is toxic to E. coli and causes
Fig. 1. Schematic representation of the membrane organization of Gram positive and Gram negative bacteria. Diagrams adapted from the following URL: http://www.
stanford.edu/~amatin/MatinLabHomePage/Student%20Presentation/Zomora/Zamora%20handout.pdf.
1344 R.F. Epand et al. / Biochimica et Biophysica Acta 1758 (2006) 1343–1350
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4.4 Antimicrobial peptides mechanism of action 
Following the initial attachment, several different models have been proposed  
explaining how AMP’s inserts into the cytoplasmic membrane forming trans-
membrane pores (Figure 4.4). In all models the amphipathic nature of the AMP’s is a 
key feature, as a hydrophobic region is necessary to interact with the lipid component 
of the membrane, while the hydrophilic part is responsible for interactions with the 
lipid head groups or face the lumen of the formed pores.260 In general these models 
can explain the ability to form pores of α-helical AMP’s, while the ability of β-sheet 
AMP’s are much less studied, and though these compounds form amphipathic 
displays no experimental evidence exist to tell which model is applicable. 
All models initially propose an interaction of the AMP and the negatively charged 
lipid head groups of the membrane surface, placing the AMP’s parallel to the surface. 
In the first model, known as the aggregate model, the peptides reorient to span the 
membrane as an aggregate with micelle-like complexes of peptides and lipids.261 In 
this model the peptides does not adopt a particular orientation, leading to formation of 
channels that vary in size and structure (Figure 4.4A). This model is used to explain 
how cationic AMP’s can act through both membrane permeabilization an attack 
internal targets.262  
In a similar model, the toroidal pore model, the formed aggregates of peptides insert 
themselves in an orientation perpendicular to the membrane forming more defined 
pores. The insertion of the peptide causes the membrane to bend, with the head-
groups facing the pore, which is lined by the peptides (Figure 4.4B).263  
The barrel-stave model calls for an even higher degree of ordering of the peptides, 
which in this model is oriented as the staves in a barrel, forming a cluster 
perpendicular to the membrane.264 Unlike the toroidal pore model the head-groups of 
the membrane lipids are not part of the pore. The hydrophobic regions of each peptide 
in the cluster are associated with the lipid core, while the hydrophilic regions face the 
lumen of the pore (Figure 4.4C). This model has been used to explain voltage- 
dependant ion-permeable channels in planar lipid membranes, which has a similar 
well defined size and lifetime.265 
A model, the carpet model, proposes that at high enough concentrations the 
cytoplasmic membrane can be saturated by the AMP, causing patches of the 
membrane to break up into micelles.266 These local disturbances causes a decrease in 
membrane stability, which can lead to the formation of holes (Figure 4.4D). 
Even though an exact model explaining all cases of AMP activity has not been 
presented, it is important to recognize that under a given set of conditions all of the 
above models have been validated.260 Also, an examination of a broad range of 
peptides with different size and structure indicated that they interacted quite 
differently with membranes.267 
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Figure 4.4. Different proposed mechanisms of action for AMP’s.260 
 
Not all AMP’s kill bacterial cells by disrupting their membranes, and it has been 
established that several AMP’s do not cause membrane disruption at the minimum 
effective concentrations.260 A growing number of peptides have been shown to 
accumulate intracellularly, where they target a variety of processes leading to cell 
death. Amongst these are inhibition of nucleic acid synthesis, protein synthesis, 
enzymatic activity and cell wall synthesis.237 
The frog derived AMP buforin II has been shown to translocate through the bacterial 
membranes, without causing disruption, and bind to both DNA and RNA within the 
cytoplasm.268 In the same fashion α-helical peptide derivatives of the fish-derived 
FIG. 2. Mechanisms of action of antibacterial peptides. The bacterial membrane is represented as a yellow lipid bilayer with the peptides shown
as cylinders, where the hydrophilic regions are colored red and the hydrophobic regions are blue. Cell wall-associated peptidoglycan molecules are
depicted as purple cylinders. Models to explain mechanisms of membrane permeabilization are indicated (A to D). In the “aggregate” model (A),
peptides reorient to span the membrane as an aggregate with micelle-like complexes of peptides and lipids, but without adopting any particular
orientation. The “toroidal pore” model (B) proposes that peptides insert perpendicular to the plane of the bilayer, with the hydrophilic regions of the
peptides associating with the phospholipid head groups while the hydrophobic regions associate with the lipid core. In this process, the embrane also
curves inward such that the bilayer also lines the pore. In the “barrel-stave” model (C), the peptides insert in a perpendicular orientation to the plane
of the bilay r, form ng the “staves” in a “barrel”-shaped cluster, with the hydrophilic regions of th peptides facing the lumen of the pore and the
hydrophobic regions interacting with the lipid bilayer. The “carpet” model (D) proposes that peptides aggregate parallel to the lipid bilayer, coating local
areas in a “carpet”-like fashion. At a given threshold concentration, this is thought to result in a detergent-like activity, causing formation of micelles and
membrane pores. The mechanisms of action of peptides which do not act by permeabilizing the bacterial membrane are depicted in panels E to I. The
antimicrobial peptides buforin II, pleurocidin, and dermaseptin have all been shown to inhibit DNA and RNA synthesis at their MICs without
destabilizing the membrane (E). Protein synthesis is another macromolecular target for antibacterial peptides such as indolicidin and PR-39, which have
been shown to decrease the rate of protein synthesis in target bacterial cells (F). Several antibacterial peptides have been shown to act on other
intracellular target processes, such as enzymatic activity. The ATPase activity f D aK, an enzyme involved in chaperone-assisted protein folding, is
targeted by pyrrhocidin (G), while inhibition of enzymes involved in the modification of aminoglycosides has also been demonstrated (H). Antimicrobial
peptides can also target th formation of struct ral components, such as the cell wall (I). Lantibiotics such as nisin and mersacidin can bind to and inhibit,
respectively, the transglycosylation of lipid II, which is necessary for the synthesis of peptidoglycan.
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pleuricidin and dermaseptin from frogskin, cause inhibition of DNA- and RNA 
synthesis at their minimal inhibitory concentration (Figure 4.4E).269,270 Different 
structural classes of AMP’s have also been demonstrated to inhibit the synthesis of 
nucleic acids. Amongst these are the human defensins, HNP-1,251 and the extended 
structure of the bovine peptide indolicidin.270 Also some of these peptides have been 
shown to interfere with protein synthesis. Pleuricidin and dermaseptin can block 
tritiated leucine uptake in E. Coli, and indolicidin-treated cells exhibit reduced protein 
synthesis rates (Figure 4.4F).269-271 Pyrrhocidin has been shown to inhibit enzymatic 
activity by binding to DnaK, a heat shock protein, which is involved in chaperone 
assisted protein folding, leading to accumulation of misfolded protein and cell death 
(Figure 4.4G). 272,273 AMP’s can also target the formation of structural components, 
such as the cell wall. Highly cationic peptides have been shown to bind to 
aminoglycoside modifying enzymes, which contain an anionic binding site, causing 
inhibition of the enzyme (Figure 4.4H).274 The bacterially produced peptide 
mersacidin interferes with the transglycocylation of lipid II, a necessary step in the 
synthesis of peptidoglycan (Figure 4.4I).275 
It is likely that the action of the individual AMP’s vary according to the particular 
target, the concentration at which the assay is performed and the physical properties 
of the membrane.260 It is also likely that that the AMP’s utilize more than one specific 
mode of action, such as destabilization of the membrane in combination with the 
targeting of one or more intracellular targets.242 This high degree of complexity in 
mechanism of action is a very likely reason why it is extremely difficult to select a 
mutant that is resistant to cationic-peptides.276,277 
 
4.5 Unnatural antimicrobial compounds  
As described in the previous sections, the AMP’s are an important part of the immune 
defense, but as eluted to in chapter 1, they suffer from an intrinsic instability towards 
proteases. This makes them unfit for treating infectious deceases in humans. For this 
reason an extensive amount of compounds aimed at mimicking the function of the 
AMP’s has been proposed.  
 
4.5.1 Unnatural Antimicrobial peptide-mimics 
In 1999 DeGrado and co-workers reported the first antibacterial foldamer, which was 
based on a 14-helical β-peptide scaffold, consisting purely of β3-residues.113 From this 
study compounds with an efficiency matching that of the natural AMP’s where found. 
However, these compounds turned out to cause hemolysis near the active 
concentration. In another study, Gellman and co-workers used a β-peptide based on a 
12-helix which showed significant selectivity for bacterial cells over mammalian red 
blood cells, and still retained a high antibacterial activity (92).278 In a later study 
Seebach and co-workers showed that the 14-helical scaffold can also be used to 
produce selective antimicrobials, e.g. compound 28 which was also used to 
demonstrate inhibition of lipid uptake.114 In this study it was also demonstrated that 
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the exact structure of the side chains, and not just the overall amphiphilicity, is 
important in determining both activity and selectivity of antimicrobial β-peptides. 
Investigations of this class of AMP-mimics have shown them to act in a similar 
manner to the natural AMP’s.148,279,280 
Unnatural AMP-mimics have also been constructed from heterogeneous backbones, 
consisting of mixed α- and β-peptides (92) as it was shown that these hybrids formed 
stable helices.281-283 Further studies of this hybrid system was aimed at mechanistic 
studies284,285 and the relationship between the choice of side chain and the 
activity.286,287 Surprisingly, it was revealed that the overall amphiphilicity is not a 
requirement for antimicrobial activity, as some scrambled control sequences without 
an overall amphiphilic motif in the folded state turned out to be potent 
antimicrobials.283 
 
 
Figure 4.5. Example of unnatural AMP-mimics. 
 
Pure- and hybrid-peptoids have also been used to furnish rather potent and selective 
antimicrobial compounds.9,288 Using the polyproline-type-1-like peptoid helix, Barron 
and co-workers produced a series of very active mimics of the AMP magainin-2-
amide.194 This helix was designed to be amphipathic, with 1/3 hydrophilic side chains, 
and 2/3 of hydrophobic side chains (93). As for other classes of backbones it was 
shown that the identity of the sequence and side chain composition had a great 
importance on the activity and selectivity of the compounds.162 Analogues of natural 
AMP’s containing single or a few peptoid substitutions have also been shown to 
furnish potent compounds. A cyclized mimic of the hairpin-structured protegrin-1, 
which upon substitution of a lysine to N-lysine (94) showed a slightly increased 
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activity, and a much lower hemolytic activity than the natural compound.289 The 
membrane-active and non-selective bee-venom derived melittin also showed 
increased selectivity for bacterial cells upon peptoid substitutions.290 
 
4.5.2 Peptide mimics with α-peptide/β-peptoid hybrid backbones 
Sequences consisting exclusively of β-peptoids have proved difficult to synthesize in 
lengths exceeding pentamers. However, it has been found that by synthesizing di- and 
trimer building blocks, longer sequences (9 to19 mers) can be formed by solid-phase 
coupling of these building blocks.291 At best these compounds exhibited an 
antimicrobial activity which was about an order of magnitude lower than natural 
AMP’s such as magainin.  
In an approach to circumvent the difficulties of synthesis, the β-peptoids were 
coupled to α-amino acids, furnishing hybrid dimer building blocks. These building 
blocks were efficiently coupled using Fmoc SPS (see section 1.2.1), giving an 
alternating sequences of α-amino acids and β-peptoids (Figure 4.5).11 Gram-scale 
synthesis of a series of such dimeric building blocks,292 and an efficient solid-phase 
strategy giving good yields have furnished hybrid-α-peptide/β-peptoid compounds up 
to the hexadecamer length.11,293  
 
 
Figure 4.6. α-peptide/β-peptoid hybrids designed to extend the structural space of peptidomimetic. 
 
The compounds in figure 4.6 were initially designed to resemble the heteromeric 
backbone of α/β-peptides, and due to the different side chain positioning extend the 
structural space.11 Also the incorporation of α-amino acids introduce the possibility of 
hydrogen bonding, which should increase the stability of potential secondary 
structures. Like the observed non-amphipathic antimicrobial α/β-peptide sequences, 
reported by Gellman and co-workers,283 these oligomers are not expected to display a 
global amphipathic secondary structure. CD-spectroscopy was initially performed on 
dodecamers of the two series with α-chiral side chains (956 and 966), which in various 
solvents showed indications of secondary structure formation, which disappeared as 
the chirality was lost in the third series (976).11 It was further shown that the formation 
of secondary structure became stronger as the oligomers were elongated to the 
tetradeca- and hexadecamers. In the initial study it was also shown that all of these 
hybrid oligomers exhibited good antimicrobial activity towards both Gram-positive 
and Gram-negative bacteria whilst being non-hemolytic and proteolytically stable.11 
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These data also indicated that secondary structure was not essential for the 
antimicrobial activity, as the achiral series was twice as active as the chiral. In a 
following study these oligomers were shown to also posses antiplasmoidal activity, 
for which α-chiral side chains increased the potency.13 
The oligomers from figure 4.6, including 5(6)-carboxyfluorescein (CF) labeled 
analogues of the hexamers (99–101) were further tested against a broader spectrum of 
bacteria (Table 4.1).12  
 
 
Table 4.1. Antimicrobial activity of hybrid α-peptide/β-peptoids and antimicrobial peptides. MRSA = 
methicillin-resistant Staphylococcus aureus (ATCC 33591), VRE = vancomycin-resistant Enterococus 
facium (ATCC 700221, E. coli = Eschericia coli (ATCC 25922), P. aureg = Pseudomonas aureginosa 
(ATCC 27853), C. albic = Candida albicans (ATCC 200955), HC10 = concentration that causes 10% 
hemolysis. hRBCs = human red blood cells. MIC values from ref. 12. 
 
From this investigation it is apparent that elongation of the compounds enhance their 
activity towards most pathogens.12 However, this trend was diminished or even 
reversed for the two series containing guanidino- rather than amino functionalities, 
when tested against E. coli. It was also shown that the guanidino versions were 
generally more efficient against all pathogens except P. aereginosa, where the 
hexadecamer of the amino series was more active than both guanidino containing 
hexadecamer analogues.12 A hexamer with cyclohexyl ethyl side chains (98) instead 
of phenyl ethyl, showed high activity, however, the activity was accompanied by a 
large increase in hemolytic activity as well. It is also noteworthy that most of the 
compounds exhibit comparable or even better MIC values than the natural AMP’s 
melittin, magainin-2 and the synthetically derived pexiganan (from magainin). This 
activity is accompanied by higher HC10 values than seen for the natural AMP’s, 
making the hybrid structures attractive as lead drug candidates. Unlike the 
 Comp. Sequence MIC measurements for various pathogens (ug/mL) !!
HC10 
(ug/mL) 
!! !! MRSA VRE E. coli P. aureg. C. albic. !! hRBCs 
Amino!a(
chiral!
! !     !  955 Ac-(Lys-βNspe)5-NH2 >500 500 >500 125 >500 
!
>500!
956 Ac-(Lys-βNspe)6-NH2 500 250 63 63 125 
!
>500!
957 Ac-(Lys-βNspe)7-NH2 250 125 63 31 63 
!
>500!
958 Ac-(Lys-βNspe)8-NH2 125 63 31 16 63 
!
>500!
Guanidino, a-chiral      
!
 965 Ac-(hArg-βNspe)5-NH2 16 32 8 125 250 
!
>500!
966 Ac-(hArg-βNspe)6-NH2 16 16 16 63 125 
!
>500!
967 Ac-(hArg-βNspe)7-NH2 9 9 16 37 148 
!
>500!
968! Ac-(hArg-βNspe)8-NH2 16 8 16 31 31 
!
>500!
Guanidino,!non(chiral! ! ! ! ! !
!
!
975$ Ac-(hArg-βNphe)5-NH2 143 71 9 143 71 
!
>500!
976! Ac-(hArg-βNphe)6-NH2 67 17 4 67 33 
!
>500!
977! Ac-(hArg-βNphe)7-NH2 64 16 16 64 32 
!
>500!
978! Ac-(hArg-βNphe)8-NH2 34 9 34 34 34 
!
>500!
Guanidino,!α(chiral!lipophilic! ! ! ! ! !
!
!
98$ Ac-(hArg-βNsce)6-NH2 8 4 8 64 16 
!
25!
5(6)(Carboxyfluorescein(labeled! ! ! ! ! !
!
!
99$ CF-(Lys-βNspe)6-NH2 >256! 128 256 >256! 256 
!
ND!
100$ CF-(hArg-βNspe)6-NH2 256! 64! 128! 256! 256!
!
ND!
101$ CF-(hArg-βNphe)6-NH2 128! 64 64 256! 128 
!
ND!
Antimicrobial!peptides! ! ! ! ! !
!
!
Melittin! H-GIGAVLKVLTTGLPALISWIKRKRQQ-NH2 8! 8 64 256! 32 
!
2!
Magainin(2! GIGKFLHSAKKFGKAFVGEIMNS-NH2 500! 250! 125! 250! 500!
!
>500!
Pexiganan! GIGFLKKAKKFGKAFVKILKK-NH2 63! 16 16 16! 63 
!
40!
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preliminary study, it was shown that the compounds containing chiral β-peptoids and 
a guanidino functionality was more potent than those with achiral β-peptoids and 
guanidino groups.12,294 The opposite only seems to be the case when  the dodecamers 
are tested against E. coli, which were the case in the preliminary study.11 Also C. 
albic, the only fungus in the panel, showed more sensitivity towards the achiral 
oligomers.12 Finally it was shown that for the oligomers containing an amino 
functionality, the CF-tag increased the activity against MRSA and VRE, whereas a 
decrease was observed for other pathogens and when having a guanidine 
functionalized oligomer.12 
 
 
Figure 4.7. NBD tagged hybrid a-peptide/β-peptoid compounds. 
 
For the studies described in the following sections of this chapter, we wanted to 
evaluate the importance of the cationic group further. For this purpose we synthesized 
compounds 956 and 966, along with a nitrobenzoxadiazole (NBD) labeled analogues 
(102 and 103). To assure that our compounds were active they were tested against 
five selected pathogens, for which the results described above was confirmed, 
however, we found that when labeling the compounds with NBD the compounds 
retained their activity. To validate that the fluorophore did not cause this increase 
itself, we decided to test it (104) alone, in which case we saw no activity. 
 
 
Table 4.2. Antimicrobial activity of two hexameric hybrid oligomers and their NBD labeled analogues. 
E. coli = Escherichia coli (ATCC 25922), K. pneumoniae = Klebsiella pneumonia (ATCC 13883), V. 
vulnificus = Vibrio vulnificus (ATCC 27562), S. aureus = Staphyllococcus aureus (8325-4). a Extended 
Spectrum Beta-Lactamase (ESBL)-producing clinical strain isolated from a Danish patient in 2007 
(AAS-EC-009).  
 
Such labeled compounds are of great value in studying the interactions with live 
bacteria using confocal fluorescence microscopy. In fact, such an investigation led to 
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 Comp. Sequence MIC measurements for selected pathogens (ug/mL / uM) 
!! !! Gram-negative !!
Gram-
positive 
!! !! E.#coli# E. coli K. pneumoniae V. vulnificus S. aureus 
956 Ac-(Lys-βNspe)6-NH2 128/50 128/50 256–512 64/25 
!
64–128/25–
50 
102 NBD-(Lys-βNspe)6-NH2 32/11 32/11 128/44 64/22 
!
32/11 
966 Ac-(hArg-βNspe)6-NH2 3-Aug 16/3 16–32/3–6 3-Aug 
!
4/1.5 
103 NBD-(hArg-βNspe)6-NH2 16/5 32/10 64/20 16/5 
!
16/5 
104 ε-N-NBD-6-aminohexanamide >128/>436 >128/>436 >128/>436 >128/>436 !! >128/>436 
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the observation that the hybrid compounds internalize into HeLa cells.13 Further 
studies of this property led to the conclusion that the alternating α-peptide/β-peptoids 
have good cell penetrating abilities.292 In this regard, the application of a fluorophore 
that does not affect the activity of the hybrid-oligomes could be of great value.  
4.5.3 Backbone composition 
To improve on the stability of peptidic lead compounds, replacement of single 
residues, fragments or entire sequences with peptidomimetic residues described in this 
thesis, amongst others, have been carried out. Still focusing on the ability to inhibit 
bacterial cell growth, a study aimed at comparing the efficiency of these mimics, and 
their hybrids has recently been performed.222 To obtain knowledge concerning the 
importance of the composition of the backbone, a library consisting of alternating 
lysine and phenylalanine residues and combinations of their mimics was synthesized 
(Figure 4.8). 
 
Figure 4.8. Library consisting of different combinations of various mimics and amino acids. 
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The activity of this library was tested against a series of multidrug resistant E. coli 
and K. pneumoniae strains. It was shown that all mimics had lower MIC values than 
the parent peptide sequence (Table 4.3).222 The data also show that hybrid compounds 
seem to have improved antimicrobial activity compared to the pure mimic sequences. 
 
 
Table 4.3. Antimicrobial activity of various combinations of mimics and amino acids.MIC values from 
ref. 222. 
 
These results clearly indicate that by choosing the right backbone composition a gain 
in activity can be obtained. This also shows that factors other than the amount of 
hydrophobic or hydrophilic residues are important for the activity, and that these 
systems can be optimized in different ways, also depending on the particular system 
on which they are thought to act. 
 
4.6 Synthesis of hybrid oligomers 
Synthesis of the hybrid oligomers were achieved by the creation of dimeric building 
blocks, formed by coupling of Nε-Boc-protected lysine with an N-terminal Fmoc 
proteting group and the C-terminally tert-butyl protected spe β-peptoid monomer 
(63A) to form compound 105. As opposed to the literature procedure, we used 
prolonged reaction times rather than microwave heating,293 as we found this to give 
satisfying yields. Selective and simultaneous removal of the tert-butyl and the Boc-
groups, in the presence of Fmoc, could be achieved upon treatment with 50% TFA in 
CH2Cl2 furnishing 106. The resulting compound with free acid and amino 
functionalities was then selectively re-protected at the Nε-amine. Aiming to use an 
Fmoc based solid support strategy we chose to synthesize two series of oligomers 
incorporating either protecting groups allowing for simultaneous cleavage and 
deprotection, or which could be removed without cleaving the compound from the 
resin. For the first scenario we chose to reinstall the Boc-group (107), which is a 
classic solution for the Fmoc strategy. In order to establish an on-resin 
functionalization we incorporated an orthogonal 1-(4,4-dimethyl-2,6-
dioxacyclohexylidene)ethyl (Dde) group (108).295,296          
 
Sequence E. coli   K. pneumoniae !!   
!! ATCC 25922 ESBL AmpC NDM-1 !! KPC-2 NDM%1! !! MRSA 
All L-aa peptide >256 >256! >256! 128!
!
>256! >256!
!
16!
All D-aa peptide 128 256! 256! 128!
!
256! 256!
!
16!
Peptoid 32 64! 32! 32!
!
256! 256!
!
256!
Peptoid/peptide 16 16! 32! 32!
!
256! 256!
!
>256!
Peptide/peptoid 4! 8! 8! 2!
!
128! 128!
!
256!
β-peptoid 16 8! 16! 4!
!
256! 256!
!
256!
β-Peptoid/peptide 8 16! 16! 2!
!
64! 256!
!
256!
Peptide/β-peptoid 8 4! 8! 4!
!
128! 256!
!
>256!
β3-peptide 16 32! 32! 32!
!
32! 32!
!
16!
β3peptide/peptide 8 8! 16! 4!
!
128! 256!
!
256!
Peptide/β3%peptide! 64 32! 32! 64! ! 128! 128! ! 32!
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Scheme 4.1. Synthesis of hybrid dimer building blocks. . a) Fmoc-Lys(Boc)-OH (1.7 equiv), HBTU 
(1.7 equiv), iPr2NEt (4 equiv), DMF, 18 h. b) TFA–CH2Cl2 (4:6), 2 h. c) Boc2O (1.5 equiv), iPr2NEt (2 
equiv), DMF, 0 °C for 1 h then rt 2 h, d) Acetyl dimedone (1.7 equiv), iPr2NEt (2.7 equiv), DMF, 18 h. 
 
Oligomerization of these building blocks was performed on a ChemMatrix resin using 
a rink linker, as a C-terminal amide was desired. After six rounds of 
coupling/deprotection of 108, the resin bound dodecamer was achieved (109), the N-
terminal was then capped with an acetyl group and the Dde groups removed to give 
110. At this point the compound could either be cleaved to give 956, or undergo a 
functionalization using 111 to give the corresponding guanidinylated compound, 
which upon simultaneous cleavage and deprotection gave 966.297  
 
 
Scheme 4.2. Oligomerization of hybrid dimer building blocks. a) 108 (4.5 equiv), HBTU (4.5 equiv), 
iPr2NEt (9 equiv), DMF, 18 h. b) Piperidine–DMF (1:4), 2 × 10 min. c) DBU–piperidine–DMF 
(2:2:96), 20 min. d) Ac2O–iPr2NEt–DMF (1:2:3), 2 h. (e) Hydrazine–DMF (2:98), 2 × 45 min. f) 50% 
TFA–CH2Cl2, 2 × 1 h. (g) N,N’-Bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine (111, 36 
equiv), iPr2NEt (72 equiv), DMF, 18 h. HBTU = O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate. 
                         
We also tried to incorporate the NBD fluorophore building block 113 following this 
procedure. This, however, did not give the desired products (102 and 102) upon 
cleavage from the solid support. Due to a change in the resin color from bright yellow 
to a pale orange upon undergoing Dde deprotection, we believe that the chosen 
fluorophore is sensitive to hydrazine, used in the deprotection step. For the formation 
of 102 and 103 we therefore decided to oligomerize 107, and luckily the fluorophore 
was stable to the cleavage/deprotection conditions required. Unfortunately this meant 
that the guanidino groups had to be installed in solution. As the crude product from 
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the cleavage of 112 (102) was fairly pure, the guanidino-functionalization was 
performed without purification of the crude 102, eliminating an additional purification 
steps. 
 
 
Scheme 4.3. NBD-labeling of dodecamers on solid support. 107 (4.5 equiv), HBTU (4.5 equiv), 
iPr2NEt (9 equiv), DMF, 18 h. (b) piperidine–DMF (1:4), 2 × 10 min. (c) DBU–piperidine–DMF 
(2:2:96), 20 min. (d) 113 (6.5 equiv), PyBOP (7.5 equiv), iPr2NEt (13 equiv), DMF, 18 h. (e) TFA–
CH2Cl2 (1:1), 2 × 1 h. (f) N,N’-Bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine (111, 36 equiv), 
iPr2NEt (72 equiv), DMF, 18 h. 
 
Finally 113 was attached directly to the resin, and then cleaved to give an amide as 
the C-terminal functionality (103). 
 
4.7 Membrane study 
Whether the mechanism of action involves disruption of the membrane or 
perturbation of intracellular targets, an initial interaction of the antimicrobial 
compound and the cell surface is inevitable. A better fundamental understanding of 
these interactions is therefore important for further optimization of future antibiotics. 
The structure of cell membranes is rather complex and are currently not applicable for 
highly sensitive surface X-ray scattering methods.298-300 Previous studies of the 
membrane-destabilizing effect of α-peptide/β-peptoid hybrids have been performed in 
model liposomes prepared from PC, which is predominantly found in eukaryotic 
cells.292 For this reason PC-containing systems do not represent the bacterial envelope 
sufficiently. Furthermore, the interactions of this class of compounds with model 
membranes have never been investigated using sensitive X-ray methods. To create a 
better model for the investigation of the interactions between the hybrids and the outer 
surface of Gram-positive and Gram-negative bacteria, monolayers of 1,2-dipalmitoyl-
H2N
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sn-glycero-3-phosphatidylglycerol (DPPG) and truncated LPS Kdo-2-lipid A, 
respectively, were prepared (Figure 4.9). As the hydrophobic core of the LPS 
envelope of most Gram-negative bacteria consist of Kdo-2 lipid A, while PG are a 
predominant phospholipid species in the cytoplasmic membrane of Gram-positive 
bacteria, we believe these to more closely resemble the actual cell surfaces.  
 
 
Figure 4.9. Lipids used to study the membrane interactions of the hybrid oligomers. 
 
This approach has been used to study the lysis of bacterial membranes by human 
AMP LL-37,300 protegrin-1298,301 and gramicidin302 by liquid surface X-ray scattering. 
 
4.7.1 Epifluorescence microscopye 
First it was tested whether the hybrid oligomers would disrupt the model monolayers, 
which was done by exposing monolayers doped with Texas red dye to the oligomers. 
The first frame in figure 4.10 Show the monolayers prior to the exposure, using an 
epifluorescence microscope. The image shows the DPPG monolayer as branched dark 
domains, separated by brightly colored fluid areas. After injection of 956 (Figure 
4.10A) and 966 (Figure 4.10B) it is apparent that after 4 min. the morphology of the 
surface is changed to contain less of the condensed lipid phase. In the next two frames 
the ordered phase is eliminated and the majority of the film is found in the liquid-
disordered phase after 15-20 min. At the end of the experiment, ordered regions are 
either destroyed or too small for the microscope to see (<1 µm). This shows that both 
                                                
e  Epifluorescence microscopy was performed by Konstantin Andreev, Christopher Bianchi and 
Professor David Gidalevitz, at Illinois Institute of Technology, Chicago, USA. 
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types of cations display crystallinity-disruptive behavior, at least on the micrometer 
scale. 
 
Figure 4.10. Epifluorescence images of DPPG monolayers after injection of compound 956 (A) and 966 
(B) at concentrations corresponding to 20% of their MIC values against S. aureus. 
 
4.7.2 Specular X-ray reflectivityf 
X-ray reflectivity (XR) is a technique that gives information on the electron density 
along a plane perpendicular to the surface of a monolayer and the thickness of that 
layer. A slab-model, or box model, can be used to fit the data giving information 
about the thickness and electron densities of the individual slabs.303 
 
Figure 4.11 shows the profile of the electron density along the surface normal 
obtained by model-independent stochastic fitting, of data extracted from reflectivity 
measurements. The lipid film shows no electron density at the air–water interface, 
then through the hydrocarbon-tail region the electron density rises sharply reaching 
the maximum density in the head group region at a distance of ~20-25 Å from the air–
water interface. The pure DPPG monolayers were modeled as two slabs, one 
corresponding to the hydrocarbon region and the next to the head group region. 
Analysis of the obtained XR-data revealed the acyl chain slab to have a thickness of 
16.5 Å and an electron density of 0.312 e−/Å3.  The thickness of the head group slab 
was found to be 8.3 Å and have an electron density of 0.477 e−/Å3. The data for the 
Kdo-2 Lipid A revealed a 12.0 Å thick hydrocarbon layer with an electron density of 
0.31 e−/Å3. The second slab corresponding to the layer of the carbohydrate 3-deoxy-D-
mannooctulosonic acid (known as Kdo) had a thickness of 12.8 Å and an electron 
density of 0.485 e−/Å3. Insertion of the antimicrobials into the monolayer results in 
extra electrons per lipid molecule in each slab, which can be calculated using equation 
1. Here, l slab and ρ slab are thickness and electron density of the slab, respectively; Alipid 
+ ΔAlipid is the area per lipid molecule upon insertion and Ninitial e-slab is the number of 
electrons in the slab of the original untreated monolayer. 
                                                
f Specular X-ray reflectivity measurements and interpretation was performed by Konstantin Andreev, 
Christopher Bianchi and Professor David Gidalevitz, at Illinois Institute of Technology, Chicago, USA. 
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Nextra e-slab = l slab × ρ slab × (Alipid + ΔAlipid) – Ninitial e-slab     (eq. 1) 
Upon insertion of 956 the minimum of the reflectivity curve were shifted from a qz ≈ 
0.24 Å−1 to a higher qz value moving the peak of electron density towards the air–
water interface. This indicates a decrease in thickness of the film as a result of the 
insertion. However, injection of compound 966 did not result in a thinning of the 
DPPG monolayer, but led to appearance of two distinct minima on the reflectivity 
profile at qz ≈ 0.21 Å−1 and 0.35 Å−1 giving a notable bump in the electron density 
curve within the range of 20–40 Å away from air-water interface. This might be due 
to an additional layer of distinct electron density higher than the electron density of 
subphase present underneath the head group region.  
 
 
Figure 4.11. Electron density profiles and reflectivity curves for DPPG (A) and Kdo2-Lipid A (B) 
monolayers at 30 mN x m–1.  
 
The data were treated using a model dependent analysis which are summarized in 
table 4.4. As mentioned this system is best fitted using a two-slab model, however, 
the occurrence of the second minimum in the reflectivity upon insertion of 966 was 
best modeled using a third slab. The lower increase in area per lipid molecule upon 
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addition of 966 compared to 956 can be explained by dimerization or aggregation of 
966 on the outer surface of the DPPG monolayer (Table 4.4). 
 
 
Table 4.4. Parameters of DPPG and Kdo-2-Lipid A monolayers before and after introduction of 
oligomers. a Subscripts: T, tails; H, heads; and OL, outer layer. b Extra electrons calculated using Eq. 1. 
c Area per lipid molecule (Alipid) = Nlipid molecules / Atotal. 
 
From the number of extra electrons it is seen that both 956 and 966 readily inserts into 
the polar domain of both DPPG and Kdo-2 Lipid A, resulting in a reduced electron 
density in the bottom slab. It is also seen that neither of the compounds are able to 
penetrate into the overlaying hydrophobic region. A more substantial decrease in 
electron density of the DPPG head group region, along with three times more 
additional electrons being present upon introduction of 966 points to a higher Gram-
positive membrane disruptive potential of guanidino-containing oligomer compared 
to the amino-containing analogue. The same general trend was observed for the 
labeled analogues 102 and 103. However, the guanidino containing analogue was 
shown to penetrate the entire depth of the monolayer including the hydrophobic tail 
region. Furthermore, the addition of 103 led to a greater number of added electrons in 
total, as well as a four-fold increase in area per lipid molecule, which is indicative of a 
favorable effect of the guanidine groups on the insertion. 
Contrary to the observations from DPPG monolayers, the reflectivity curves for the 
Kdo-2 Lipid A monolayer after insertion of 956 and 966 looks nearly identical (Figure 
4.11B). For the model-dependent analysis revealed very similar mechanisms of action 
for the two compounds against the Gram-negative membrane mimic. The similarity in 
mode of action between 956 and 966, as well as between 102 and 103 was confirmed 
by similar changes in thickness of respective slabs within the monolayer and by 
similar number of contributed extra electrons. The increase in area per lipid molecule 
in both pairs of compounds was also similar. 
 
Samplea' ''
lT 
(Å) 
ρT 
(e-/Å3) 
Extra 
e-Tb 
lH 
(Å) 
ρH 
(e-/Å3) 
Extra 
e-H 
lOL 
(Å) 
ρOL 
(e-/Å3)'
Extra 
e-OL 
Area per lipid 
molecule (Å2)c 
' ' '     '  ' ' 'DPPG 16,5 0,312' -' 8,3' 0,477' -'
' ' '
45,5'
DPPG/956 11,0 0,320' 0' 7,1' 0,450' 53'
' ' '
66'
DPPG/102 12,0 0,314' 0' 11,6' 0,410' 112'
' ' '
57'
DPPG/966 12,3' 0,314' 0' 12,1' 0,430' 167' 9,6 0,405 43' 63'
DPPG/103 12,1 0,317' 89' 9,7' 0,408' 197'
' ' '
90'
  
' ' ' ' ' ' ' ' 'Kdo 2 Lipid A 12,0 0,310 - 12,8 0,485 -
' ' '
125'
Kdo 2 Lipid A/956 8,9 0,293' 0' 14,0' 0,451' 234'
' ' '
158'
Kdo 2 Lipid A/102 8,4 0,283' 5' 14,1' 0,420' 389'
' ' '
195'
Kdo 2 Lipid A/966 8,9 0,300' 0' 13,7' 0,445' 256'
' ' '
168'
Kdo 2 Lipid A/103 9,2 0,255' 0' 14,9' 0,441' 489' ' ' ' 191'!
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4.7.3 Grazing incidence X-ray diffractiong                                                                                                       
Grazing incidence X-ray diffraction (GIXD) data obtained for the DPPG monolayer 
before and after injection of the four compounds are shown in figure 4.12. It is seen 
that the pure DPPG monolayer display two distinct Bragg peaks at Qxy = 1.39 Å-1 and 
Qxy = 1.47 Å-1, which is indicative of an ordered structure being present. From the 
peaks the unit cell has the dimensions 5.32 x 8.54 Å, giving a total area per DPPG 
molecule of 45.5 Å2. Insertion of 966 and 103 fully disrupted the crystallinity of the 
monolayer, seen by the total absence of the Bragg peaks. Surprisingly, insertion of 956 
and 102 only caused one of the Bragg peaks to disappear, indicative of a 
rearrangement of the monolayer. Further, the labeled compound 102 was shown to 
decrease the size of the crystallized domains as well as the order of crystallinity to a 
greater extent than the non-labeled compound.  
 
 
Figure 4.12. Bragg peaks plot of scattering vector as a function of intensity. 
 
4.8 Concluding remarks 
The data presented provide solid evidence of a higher membrane activity against 
Gram-positive bacteria of guanidine containing α-peptide/β-peptoid hybrids than their 
amino analogues. Guanidino containing compounds were found to possess improved 
membrane disruptive capabilities against DPPG monolayers, mimicking the outer 
leaflet of Gram-positive bacteria cell membranes. Somewhat surprisingly, this 
guanidine effect was not present when tested against a LPS (Kdo-2 Lipid A), 
mimicking the external leaflet of Gram-negative bacteria membranes. The obtained 
XR data are hence in good agreement with the previously published results from 
biological assays, especially as the length of the hybrid oligomers are increased.12,294 
                                                
g Grazing incidence X-ray diffraction measurements and interpretation was performed by Konstantin 
Andreev, Christopher Bianchi and Professor David Gidalevitz, at Illinois Institute of Technology, 
Chicago, USA. 
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Figure 4.13 shows a cartoon representation of the proposed mode of interaction 
between the hybrid oligomers and the monolayers. 
 
 
Figure 4.13. Cartoon representation of possible interaction of compound 956 and 966with DPPG (A) 
and Kdo2-Lipid A (B). 
 
Since both types of cation are fully protonated at physiological pH we believe that the 
ability of the guanidino group to engage in more stable bidentate electrostatic 
interaction with the negatively charged phosphodiester moieties affects the DPPG 
lipids to a greater extent than Kdo-2 Lipid A due to the more rigid structure of the 
latter. These findings thus provide fundamental insights that should be useful in the 
future design of optimized synthetic peptidomimetics with selective antibiotic effects. 
Finally, labeling with the NBD fluorophore did not reduce the observed activity of the 
tested hybrids, which correlate with the observed retained antimicrobial potency 
against bacteria in vitro. In addition the NBD-labeled compounds demonstrated an 
even greater ability to destroy both DPPG, than their non-tagged analogues.  
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5 Conclusion 
Mimetic compounds of natural oligomers may well serve as a valuable addition to the 
existing arsenal of existing drugs, as they deal with some of the inherent problems of 
using therapeutics based on natural compounds such as cost of production and 
proteolytic stability. Furthermore, even by introducing minimal perturbations to the 
natural design, a vast amount of modifications are made possible. Common for these 
modified compounds are the goal of mimicking the folding patterns of the natural 
proteins, to achieve protein-like functions.  
 
Inspired by earlier work for similar foldameric compounds, we sought to obtain a 
better understanding of the folding propensities of β-peptoids, by synthesizing and 
evaluating series of monomeric model systems. Through this evaluation we saw that 
the identity of the side chains could be used to gain control over the rotation of the 
amide bond, in a similar way to that observed for α-peptoids. We also introduced 
alterations to the stereoelectronic properties of the backbone, which revealed a novel 
aromatic–thioamide interaction. It was shown that the introduction of an increased 
steric bulk in the backbone, rather than the side chains, could be used to impact the 
cis-trans equilibrium. These findings provide two new ways to affect the 
conformations of peptoidic residues, enabling a more rational design using these 
residues. 
 
We next synthesized a homo-oligomer consisting of residues we found most prone to 
fit a helical display proposed based on DFT-calculations. A preliminary NMR-study 
revealed an increasing homogeneity as the oligomer was elongated. We were able to 
solve the X-ray crystal structure for two hexameric compounds with a free N-terminal 
amine and with an N-terminal acetyl group, respectively. These are the first examples 
of high-resolution structures of linear β-peptoid oligomers, and clearly show that 
these compounds form unique helical arrangements. These helices thus definitively 
validate the addition of β-peptoids to the already existing ensemble of foldamer 
designs. 
 
The type of helix displayed by β-peptoids is unique to other peptidomimetic helices as 
one turn consists of exactly three residues, leaving the side chains perfectly aligned, 
while stretched to give a pitch of almost 10 Å. This display allows for the separation 
of three types of functionalities, e.g. the separation of apolar and charged side chains 
on two phases, and another functionality along the third. Given the excellent cell-
penetrating properties of amphipathic peptoids, this setup might be highly useful for 
transport across membranes. However, oligomers of the same backbone carrying a 
different side chain did not exhibit the same homogeneity, expressing the need to 
investigate what substitutions are tolerated in this helical display. Given the obtained 
results on β-peptoid amide bond rotational behavior we have enabled the possibility 
of a more rational design of this and other motifs.  
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During the course of the Ph.D. project we also engaged in a collaboration with the 
laboratory of Prof. David Gidalevitz, to further elucidate the membrane interaction of 
cationic antimicrobial α-peptide/β-peptoid hybrid compounds. Using X-ray surface 
scattering techniques the interaction of two oligomers, containing different cationic 
moieties, and model lipid membranes mimicking Gram-positive and Gram-negative 
bacterial membranes, respectively, were investigated. Through these measurements 
we were able to obtain data on the binding interactions of the membrane mimics and 
our oligomeric compounds useful for future design of antimicrobial agents. 
Furthermore, we identified a fluorophore that allows labeling of the compound 
without diminishing antimicrobial activity. Such fluorophores are valuable tools for 
future studies of the mechanism and distribution of these compounds. 
 
Applications of peptidomimetic compounds have been developed through the 
understanding of folding propensities. The investigations made throughout this 
project, provides fundamental knowledge on some of the important factors governing 
the conformational preferences of β-peptoids. Providing the first high-resolution data, 
we have presented the first example of a unique secondary structure available to this 
class of peptidomimetics. These structures validate the addition of β-peptoids to the 
existing peptidomimetic foldamers, expanding the structural space available to this 
class of compounds. The bioactivity of β-peptoids are already established, and I 
believe that our findings constitute an important step toward a structure based design, 
with  novel bioactivity or enhancement of the activity towards existing targets.  
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ABSTRACT: Non-natural peptide analogs have signiﬁcant potential for
the development of new materials and pharmacologically active ligands.
One such architecture, the β-peptoids (N-alkyl-β-alanines), has found use in
a variety of biologically active compounds but has been sparsely studied
with respect to folding propensity. Thus, we here report an investigation of
the eﬀect of structural variations on the cis−trans amide bond rotamer
equilibria in a selection of monomer model systems. In addition to various
side chain eﬀects, which correlated well with previous studies of α-peptoids,
we present the synthesis and investigation of cis−trans isomerism in the ﬁrst
examples of peptoids and β-peptoids containing thioamide bonds as well as
triﬂuoroacetylated peptoids and β-peptoids. These systems revealed an
increase in the preference for cis-amides as compared to their parent
compounds and thus provide novel strategies for aﬀecting the folding of peptoid constructs. By using NMR spectroscopy, X-ray
crystallographic analysis, and density functional theory calculations, we present evidence for the presence of thioamide−aromatic
interactions through Csp2−H···Samide hydrogen bonding, which stabilize certain peptoid conformations.
■ INTRODUCTION
The 20 canonical α-amino acids constitute the fundamental set
of building blocks necessary for human ribosomal synthesis of
the major class of biopolymers comprised of proteins and
peptides. In traditional medicinal chemistry, this class of
compounds has not been considered suitable for drug
development, due to susceptibility to proteolytic degradation
in cellular environments and often poor cell permeability
properties. Nevertheless, recent tendencies in the pharmaceut-
ical industry have revealed an increased interest in the
development of so-called biologics. This may, at least in part,
be due to the successful approval and marketing of several
monoclonal antibodies as therapeutics during the past decade.
In order to circumvent the inherent stability problems,
however, extensive research in the ﬁeld of peptidomimetic
designs has been undertaken. In addition to the nature of the
functional groups themselves, bioactive α-peptides realize their
high potency and selectivity due to stabilized secondary
structure formation, which displays these functionalities
accurately in three-dimensional space. Non-natural compounds
that are capable of adopting stabilized three-dimensional
structures mimicking or complementing those found in nature
are therefore of great interest, and as a class of compounds,
these various chemotypes have been coined “foldamers”.1 A
wide variety of foldamers have been developed and extensively
studied,2 with some of the prominent peptidomimetic examples
being β-peptides3 and peptoids (N-alkylglycines)4 (Figure 1A).
The tertiary amide backbone architecture in peptoids renders
them unable to stabilize putative folded structures by forming
intramolecular hydrogen-bond networks. Furthermore, the
presence of tertiary backbone amide bonds gives rise to
increased ﬂexibility due to a low-energy barrier between cis and
trans conﬁgurations. Thus, a high degree of cis-amide bonds
may occur in peptoids, which is almost exclusively observed at
proline in natural peptides and proteins (Figure 1B)5 and have
been enhanced by introduction of synthetic proline derivatives.6
The eﬀect of various N-alkyl side chain functionalities on this
cis−trans equilibrium in peptoids has been studied by NMR
spectroscopy.7−10 Despite the inherent ﬂexibility of peptoids,
secondary structures of oligomeric and cyclic peptoids have
been studied in some detail in solution by NMR spectrosco-
py11−13 and in the solid state by X-ray crystallography, and
some requirements for the formation of secondary peptoid
structure have been identiﬁed.13−16 For instance, the handed-
ness of a helical conformation depends on the enantiomeric
nature of α-chiral N-alkyl side chains, and the helix formation is
favored by the presence of bulky and aromatic substitu-
ents.11,16−18 Electronic n → pi* interactions19 have also been
proposed to take part in the stabilization of secondary
structures of peptoids.8,9 These interactions involve donation
of a lone pair from a carbonyl oxygen atom into an empty pi*
orbital of carbon atom of another carbonyl or an aromatic ring
(Figure 1C)20 and are optimal when mimicking the Bürgi−
Dunitz trajectory for nucleophilic attack.21 The β-peptides
(Figure 1A), on the other hand, retain the capability to form
intramolecular hydrogen-bond networks to stabilize secondary
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structures, while the geometry of known helices is unlikely to
be stabilized by n → pi* interactions.2,3
By combining the features of β-peptides and peptoids, the
ensembles of available foldameric scaﬀolds may be expanded
with β-peptoids, and several examples of biologically active
compounds containing this motif have been reported.22 The
structural properties of compounds with a β-peptoid backbone
architecture, however, have been studied to a far lesser extent
than its parent compounds since the ﬁrst examples were
reported by Hamper et al. in 1998.23 The ﬁrst three-
dimensional structure of a β-peptoid, which was achieved for
a cyclic tetramer, was thus reported by Taillefumier and co-
workers in 2008.24 Computational studies of linear oligomeric
β-peptoids have predicted several possible helical conforma-
tions,25 containing both the cis- and trans-amides, but studies
based on circular dichroism (CD) spectroscopy have been
inconclusive.26 To obtain experimental data regarding the
folding propensity of these molecules, we decided to prepare a
series of β-peptoid monomers and evaluate the structural
inﬂuence on cis−trans amide bond isomerization by NMR
spectroscopy under various conditions. Our collection of model
compounds was designed to investigate how stereoelectronic
eﬀects and substituent bulk aﬀect the conformational
preferences of β-peptoid monomers.
■ RESULTS AND DISCUSSION
Design and Synthesis. All our model compounds were
based on acylated β-peptoid monomers. This minimal design
was chosen to mimic the local interactions of a residue within
an oligomer structure. In this way the eﬀect of side chains may
be investigated with respect to steric and stereoelectronic
interactions. Furthermore, it was the scope of this work to
assess whether changes in the electronic properties of the
backbone would alter the conformational preferences of the
residues.
The ﬁrst array of monomers was designed to include a
structurally diverse set of N-alkyl side chains accommodating
variations in steric bulk, α-branching, aromatic vs saturated
substituents and ﬁnally including an N-aryl substituent
(phenyl). The chosen set of eight diﬀerent side chains (a−h)
was installed in two diﬀerent monomer series: (1) 3a−h
containing a C-terminal ester functionality and (2) 4a−h
containing a C-terminal tertiary amide functionality thought to
better mimic the local environment of a single residue within an
oligomeric structure (Scheme 1A). The tert-butylester series
was prepared since these can be readily deprotected, which
allows for further coupling reactions as well as installation of
additional C-teminal functionalities. To probe the eﬀects of the
various side chains on the rotameric preference of the β-peptoid
amide bond (the cis−trans equilibrium), acetyl groups were
installed to give N-terminal tertiary amides, as also investigated
in α-peptoid model systems.8−10 Analogous to those studies,
the trans−cis isomerism in our compounds could then be
determined by integration of the 1H NMR peaks assigned to
each rotamer.
Syntheses of the β-peptoid monomers were achieved by aza
Michael addition of a primary amine to acrylester (1) or
acrylamide (2) in MeOH,24 which has turned out to be an ideal
solvent for this tranformation as opposed to the originally
reported reactions in DMSO (Scheme 1A).23 This was
followed by acetylation to give the two series of monomer
model compounds (5a−h and 6a−h) for evaluation by NMR
spectroscopy.
In addition to the various N-alkyl side chains and diﬀerences
in C-terminal functionality, we were also interested in probing
the possibility of local n → pi* interactions by altering the
electronic properties of amide carbonyls. The N-terminal
amides were therefore modiﬁed by introduction of triﬂuor-
oacetyl groups in place of the acetyl groups in selected
compounds (Scheme 1B). These were readily prepared from
3a,e,f and 4a,e,f by treatment with triﬂuoroacetic anhydride
(Scheme 1B).
Finally, we substituted carbonyl oxygen atoms with sulfur in a
selection of compounds to achieve introduction of minimal
peptide bond surrogates with altered electronic properties.27
Both amides in compounds 6a,e,f were individually mutated to
thioamides to give 10a,e,f and 12a,e,f, respectively (Scheme
1C,D). For their preparation, we utilized Lawesson’s reagent,28
which selectively converts amides to thioamides in the presence
of esters. Preparation of the C-terminal thioamides 10a,e,f,
were achieved by treating precursors 4a,e,f with Lawesson’s
reagent to give 9a,e,f, which were then acetylated to give the
target compounds (Scheme 1C). The N-terminal thioamides
12a,e, f, on the other hand, were synthesized by treating 5a,e,f
with Lawesson’s reagent to give 11a,e,f, followed by tert-
butylester cleavage and coupling to morpholine to yield the
target compounds (Scheme 1D). These changes were thus
quite eﬃciently introduced from common precursors to alter
the donor and acceptor capabilities of the two carbonyl groups.
NMR Spectroscopy of Acetylated Monomers. In order
to take possible solvent eﬀects into consideration in our
evaluation of the monomers, we recorded NMR spectra in six
Figure 1. (A) Generic structures of the backbone architectures of
peptides (i.e., α-peptides), peptoids (i.e., α-peptoids), β3-peptides (β2-
and disubstituted β-peptides are not shown), and β-peptoids. (B)
Depiction of the equilibrium of trans- and cis-amide conformations in
proline and peptoid residues. (C) Examples of n → pi* interactions
previously reported to exist in peptoids.8
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diﬀerent deuterated solvents of varying polarities (Table 1).
First, we looked at compound 5a containing the (S)-1-
phenylethyl side chain, which is one of the most well-studied
functionalities with respect to folding propensity of α-
Scheme 1. Synthesis of β-Peptoid Model Compoundsa
a(A) Acetylated monomers 5a−h and 6a−h. Reagents and conditions: (a) MeOH, 50 °C, 16 h; (b) (i) for esters Ac2O (2 equiv), pyridine (2 equiv),
DMF, 0 °C→ rt, 4 h or (ii) for amides AcCl (2 equiv), pyridine (2 equiv), DMF, CH2Cl2, 0 °C, 1 h. (B) Synthesis of triﬂuoroacetylated monomers
7a,e,f and 8a,e,f. Reagents and conditions: (c) Triﬂuoroacetic anhydride (2 equiv), pyridine (2 equiv), CH2Cl2, 0 °C, 4 h. (C and D) Synthesis of
thioamide-containing β-peptoid monomeric model compounds. Reagents and conditions: (d) Lawesson’s reagent (1.5 equiv), toluene, 110 °C, 3 h;
(e) AcCl (2 equiv), i-Pr2NEt (2 equiv), CH2Cl2, 0 °C, 3 h; (f) Lawesson’s reagent (0.6 equiv), toluene, 110 °C, 1 h; (g) 1 M LiOHaq−DMF 1:1, rt,
16 h; (h) morpholine (2 equiv), HBTU (2 equiv), i-Pr2NEt (2 equiv) CH2Cl2, rt, 16 h. (E) Abbreviations for N-alkyl side chains used are as follows:
spe = (S)-1-phenylethyl, sce = (S)-1-cyclohexylethyl, bn = benzyl, sbu = sec-butyl, s1npe = (S)-1-(1-naphthyl)ethyl, npm = 1-naphthylmethyl, bnz =
benzhydryl, ph = phenyl.
Table 1. Rotamer Equilibrium Constants (Kcis/trans) for Acetylated β-Peptoid Monomers in Various Solvents
a and Their
Corresponding Diﬀerences in Free Energy (ΔG values given in kJ × mol−1)b
D2O DMSO-d6 CD3OD CD3CN CDCl3 C6D6
compd side chain Kcis/trans ΔG Kcis/trans ΔG Kcis/trans ΔG Kcis/trans ΔG Kcis/trans ΔG Kcis/trans ΔG
C-terminal esters
5a spe 0.8 0.5 0.8 0.5 0.7 0.9 0.8 0.5 0.9 0.3 0.8 0.5
5b sce 0.5 1.7 0.6 1.2 0.4 2.2 0.5 1.7 0.4 2.2 0.5 1.7
5c bn 1.0 0 0.9 0.3 0.9 0.3 0.9 0.3 0.7 0.9 0.7 0.9
5d sbu 0.5 1.7 0.5 1.7 0.4 2.2 0.4 2.2 0.5 1.7 0.4 2.2
5e s1npe n.s.c − 3.6 −3.1 5.6 −4.2 3.6 −3.1 5.3 −4.1 6.3 −4.5
5f npm n.s.c − 0.7 0.9 0.9 0.3 0.7 0.9 0.9 0.3 0.9 0.3
5g bnz n.s.c − 0.9 0.3 0.6 1.2 0.9 0.3 0.7 0.9 0.5 1.7
5h ph 0.2 3.9 all trans − all trans − all trans − all trans − all trans −
C-terminal amides
6a spe 0.7 0.9 0.8 0.5 0.5 1.7 0.8 0.5 0.4 2.2 0.4 2.2
6b sce 0.3 2.9 0.5 1.7 0.3 2.9 0.4 2.2 0.4 2.2 0.3 2.9
6c bn 1.0 0 0.9 0.3 0.7 0.9 0.9 0.3 0.3 2.9 0.3 2.9
6d sbu 0.2 3.9 0.5 1.7 0.2 3.9 0.4 2.2 0.1 5.6 0.1 5.6
6e s1npe 2.9 −2.6 3.0 −2.7 3.0 −2.7 3.1 −2.8 2.9 −2.6 3.5 −3.1
6f npm 0.9 0.3 0.6 1.2 0.9 0.3 0.8 0.5 0.4 2.2 0.5 1.7
6g bnz 0.8 0.5 0.9 0.3 0.5 1.7 0.9 0.3 0.4 2.2 0.5 1.7
6h ph n.s.c − all trans − all trans − all trans − all trans − all trans −
aDetermined by integration of 1H NMR spectra of 12 mM compound solutions at ambient temperature. bΔG = −RT × ln(Kcis/trans). cNot soluble.
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peptoids17 and has been studied brieﬂy by CD spectroscopy in
β-peptoids.26 This model β-peptoid exhibited a slight
preference for the trans-amide conﬁguration without any
notable solvent eﬀect, and expectedly, we further showed that
the chiral identity had no inﬂuence on the conformational
distribution, by synthesizing the corresponding racemate and
the (R)-enantiomer (see Figure S1Supporting Information). As
no signiﬁcant eﬀects of the concentration on the Kcis/trans had
previously been reported for peptoids,9 we gratifyingly found
that to be true for β-peptoid solutions in CDCl3 between 6−
200 mM as well (Figure S2). Finally, we performed rotating
frame Overhauser eﬀect spectroscopy (ROESY) experiments
on selected compounds (e.g., see Figure S3) in order to show
that the methyne group exhibiting the most downﬁeld chemical
shift arises from the cis-amide conformation, which is in
agreement with previously published peptoid studies.8−10
Next, we compared the Kcis/trans data for 5a with those
obtained for 5b, which is a nonaromatic, fully saturated version
of 5a. The loss of aromaticity with only a slight increase in
steric bulk gave rise to an increase in the preference for the
trans conformation. This, in turn, indicates that the aromatic
moiety may cause a slight shift toward the cis-amide, which is
consistent with previous ﬁndings reported by Blackwell and co-
workers for peptoids.9 Likewise, this was also the case when we
decreased the steric congestion of the side chain by introducing
a benzyl group (5c), as the recorded Kcis/trans values were
comparable to those of 5a in all the tested solvents. We then
evaluated a combination of decrease in steric bulk further and
removal of aromaticity using the sec-butyl side chain (5d).
Similar equilibrium constants were observed for 5b and 5d,
which was in accordance with α-peptoid ﬁndings,9 as was the
signiﬁcant preference for cis-amide conﬁguration induced by the
(S)-1-(1-naphthyl)ethyl side chain (5e).15
Interestingly, introduction of a 1-naphtylmethyl side chain
(5f) resulted in approximately a 1:1 mixture of rotamers as
observed for 5a and 5b, showing that the naphthyl group itself
is not suﬃcient to induce a predominant amount of the cis-
amide. Thus, it would seem that the lack of α-branching enables
the naphthyl group to avoid structure inducing steric
interactions. Furthermore, we altered the bulk of the side
chain by introducing the disubstituted benzhydryl group (5g),
which, perhaps somewhat suprisingly, also gave rise to similar
Kcis/trans values as found for compound 5a. This shows that α-
branching only in combination with a very bulky group will
promote induction of the cis-conformation, which apparently is
uniquely well represented in the (S)-1-(1-naphthyl)-ethyl side
chain. However, alternative constructs, taking advantage of a
putative n → pi*aryl interaction (Figure 1C) by introducing
electron-deﬁcient aromatic substituents instead of increasing
the steric bulk, have been reported for peptoids as well.9,29
Finally, peptoid studies have also shown that direct
attachment of a phenyl group to the nitrogen atom (i.e.,
prepared from aniline subunits) leads to a very strong
preference for trans-amides.13 A single β-peptoid model system
of this type (5h) was evaluated and exhibited the expected
selectivity, by virtually giving rise to single sets of signals in all
tested solvents when analyzed by 1H NMR. As mentioned, we
also evaluated the entire series of side chains a−h in model
systems having C-terminal amides (6a−6h) instead of esters, to
mimic the environment of a β-peptoid residue within an
oligomer more appropriately. The data are shown in the lower
panel of Table 1, and inspection of the results reveals the same
trends as discussed for the C-terminal tert-butylesters.
Taken together, our side chain investigations indicate that
there may be a slight intrinsic preference for the trans-amide
rotamer in β-peptoid model systems (5d and 6d), which is in
agreement with results from peptoids containing methyl or
ethyl side chains.9 The equilibrium then shifts toward the cis-
amide rotamer to approximately 1:1 mixtures when adding
aromatic functionalities as substituents in the α-position of the
side chains. Based on the results of 5a vs 5b as well as 6a vs 6b
(in the polar solvents), it seems plausible that an n → pi*aryl
interaction could play a role. Though, this interaction, in the
case of a phenyl or naphthyl group, is too weak to induce the
cis-amide as the preferred conformation. However, it is not
possible to unambiguously attribute this eﬀect of the
aromaticity on Kcis/trans to an n → pi*aryl interaction based on
our side chain experiments alone. Furthermore, the only
examples of a strong preference for the cis-amide required quite
speciﬁc steric properties of the side chain (5e and 6e). In an
attempt to gain further insight regarding possible stereo-
electronic eﬀects on Kcis/trans in β-peptoids, we turned our
attention to model systems containing carbonyls with altered
electronic properties.
NMR Spectroscopy of Triﬂuoroacetylated Analogs. As
we found that the β-peptoid model systems display the same
behavior as peptoids upon side chain substitutions, we turned
our attention to backbone modiﬁcations. Examples of such
investigations have been reported for proline but have not, to
the best of our knowledge, been utilized for interrogation of
peptoid structure and conformational preference.
Noncovalent n→ pi*amide (Figure 1C) interactions contribute
to stabilization of protein secondary structures30 and have been
studied extensively in relation to collagen polyproline type-II
helical conformations.31 The presence of this type of interaction
has also been suggested in certain peptoid model systems.8
Table 2. Rotamer Equilibrium Constants (Kcis/trans) for Triﬂuoroacetylated β-Peptoid Monomers in Various Solvents
a and Their
Corresponding Diﬀerences in Free Energy (ΔG values given in kJ × mol−1)b
D2O DMSO-d6 CD3OD CD3CN CDCl3 C6D6
compd side chain Kcis/trans ΔG Kcis/trans ΔG Kcis/trans ΔG Kcis/trans ΔG Kcis/trans ΔG Kcis/trans ΔG
C-terminal esters
7a spe n.s.c − 0.4 2.2 0.3 2.9 0.4 2.2 0.3 2.9 0.3 2.9
7e s1npe n.s.c − 6.8 −4.7 6.3 −4.3 6.6 −4.6 6.3 −4.3 6.3 −4.3
7f npm n.s.c − 0.8 0.5 0.8 0.5 0.8 0.5 0.9 0.3 1.0 0
C-terminal amides
8a spe 0.4 2.2 0.4 2.2 0.3 2.9 0.4 2.2 0.2 3.9 0.2 3.9
8e s1npe n.s.c − 5.6 −4.2 5.0 −3.9 5.5 −4.1 4.8 −3.8 4.5 −3.7
8f npm n.s.c − 0.8 0.5 1.0 0 0.8 0.5 0.7 0.9 0.6 1.2
aDetermined by integration of 1H NMR spectra of 12 mM compound solutions at ambient temperature. bΔG = −RT × ln(Kcis/trans). cNot soluble.
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Although such interactions would not be expected to have a
stabilizing eﬀect on β-peptoid secondary structure due to
unfavorable geometry,25 we were interested in testing whether
the Kcis/trans values in our model systems were sensitive to this
type of interaction.
First we reasoned that substitution of the N-terminal acetyl
group for a triﬂuoroacetyl group would signiﬁcantly alter the
electronic properties of the carbonyl through the strong
inductive electron-withdrawing eﬀect of ﬂuorine. This should
thus decrease the electronegativity of the N-terminal carbonyl,
which would render this position weaker as donor of a lone pair
from oxygen, whereas the carbonyl carbon atom would become
a better acceptor. Since the alkyl side chains exhibited
disfavoring of the cis-conformer, we chose to investigate
triﬂuoroacetylated analogs containing aromatic side chains
exclusively. We thus evaluated model compounds containing
(S)-1-phenylethyl (7a), (S)-1-(1-napthyl)-ethyl (7e), and
naphtylmethyl (7f) side chains (Table 2).
Surprisingly, at ﬁrst glance, opposite eﬀects were observed for
7a vs 5a and 7e vs 5e with a decrease and an increase in
Kcis/trans, respectively, while compounds 7f and 5f behaved alike
each other. Retrospectively, however, we hypothesize that a
decrease of the cis-amide fraction in the (S)-1-phenylethyl
system may in fact be explained by a weakened n → pi*aryl
interaction, whereas the opposite trend in the (S)-1-(1-
napthyl)ethyl system is most likely of entirely steric nature.
The triﬂuoromethyl group is more sterically demanding than
the methyl, which may indeed be of particular signiﬁcance in
the already congested amide bond of 7e. In support of this
hypothesis, we recently became aware of a study by Raines and
co-workers, in which it was shown that the rotamer equilibrium
of a triﬂuoroacetylated proline derivative was governed by
sterics, while the corresponding mono- and diﬂuorinated
analogs were aﬀected by the electron-withdrawing inductive
eﬀect of ﬂuorine.29 It was also suggested by Raines and co-
workers that ﬂuorine may act as donor of an electron pair to an
antibonding pi* orbital of the adjacent carbonyl, which would
then results in the opposite of the anticipated inductive eﬀect.
Such interactions are indeed precedented in the literature, for
example, by using molecular torsion balance double mutant
systems.32
We also tested the morpholine analogs (8a,e,f), and again
these exhibited trends that were similar to the tert-butylesters.
Thus, it seems unlikely that the C-terminal carbonyl should be
involved in the stabilization of monomer conformations.
Although we are not able to propose unequivocal guidelines
for the eﬀects of introducing ﬂuorine atoms in peptoid or
peptide backbones, we believe that this could prove to be a
useful addition to the arsenal of strategies for future design of
peptide mimics.
NMR Spectroscopy of Thioamide Analogs. Inspired by
another study of prolines by Raines and co-workers,27 we next
altered the carbonyl-donor capabilities by individually sub-
stituting the oxygen atoms with sulfur to increase the
“nucleophilicity”. If any carbonyl−carbonyl interactions (in
the N → C or C → N directionality) were to be playing a
signiﬁcant role on the β-peptoid conforms, these sulfur
substitutions should give rise to diﬀerences in the Kcis/trans
values as compared to the corresponding oxygen-containing
compounds. Evaluating ﬁrst the thioacetylated compounds
(12a,e,f), we found that they behaved similar to the acetylated
compounds. The only diﬀerence was observed in the (S)-1-(1-
napthyl)ethyl system (12e), which showed increased fractions
of the cis-amide. This would indicate that the sulfur is
interacting with the aromatic ring rather than the C-terminal
carbonyl. On the other hand, substitution of the C-terminal
oxygen atom with sulfur (10a,e,f) resulted in Kcis/trans values
very similar to those recorded for their acetylated parent
monomers (6a,e,f) in all cases (Table 3). This indicates that an
n → pi*amide interaction in the C → N directionality, which in
theory should stabilize the cis conﬁguration, is highly unlikely.
These are the ﬁrst examples of thioamides in peptoids, and our
results show that this minimal amide bond surrogate may be
valuable for interrogation of higher oligomers and possibly also
in N-alkylglycine-based peptoids.
Peptoids. To address the eﬀects of ﬂuorination or
thioamide introduction in peptoids as well, we ﬁnally prepared
compounds 13−15 (Chart 1). These syntheses were achieved
by applying published methods for solution-phase peptoid
Table 3. Rotamer Equilibrium Constants (Kcis/trans) for Thioamide-Containing β-Peptoid Monomers in Various Solvents
a and
Their Corresponding Diﬀerences in Free Energy (ΔG values given in kJ × mol−1)b
D2O DMSO-d6 CD3OD CD3CN CDCl3 C6D6
compd side chain Kcis/trans ΔG Kcis/trans ΔG Kcis/trans ΔG Kcis/trans ΔG Kcis/trans ΔG Kcis/trans ΔG
10a spe 0.4 2.2 0.5 1.7 0.5 1.7 0.5 1.7 0.2 3.9 0.2 3.9
10e s1npe n.s.c − 2.0 −1.7 3.4 −3.0 2.8 −2.5 2.2 −1.9 2.6 −2.3
10f npm n.s.c − 0.9 0.3 0.8 0.5 0.9 0.3 0.3 2.9 0.3 2.9
12a spe 0.7 0.9 0.9 0.3 0.4 2.2 0.7 0.9 0.5 1.7 0.5 1.7
12e s1npe n.s.c − 5.4 −4.1 4.7 −3.8 4.5 −3.7 3.3 −2.9 5.2 −4.0
12f npm n.s.c − 1.0 0 0.6 1.2 0.9 0.3 0.3 2.9 0.3 2.9
aDetermined by integration of 1H NMR spectra of 12 mM compound solutions at ambient temperature. bΔG = −RT × ln(Kcis/trans). cNot soluble.
Chart 1. Structures and Kcis/trans Values for the Investigated
N-Alkylglycine Peptoids
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synthesis33 in combination with the protocols described for β-
peptoid functionalization vide supra (Scheme S1).
Compound 13, which has been investigated previously,
exhibited the same Kcis/trans values as reported in CD3CN and
CDCl3
9 and an intermediate value in DMSO-d6, suggesting the
presence of a solvent eﬀect in this system. Comparing these
values to the ones obtained for β-peptoid 8e revealed a similarly
lowered Kcis/trans value in CD3CN as compared to the other
tested solvents (Table 1). For compound 14, an even higher
preference for the cis-amide conformation was observed, and
this was aﬀected to a much lesser extent by a change in the
solvent polarity. In analogy to the arguments presented for the
triﬂuoroacetylated β-peptoids, we hypothesize that this
equilibrium is primarily dictated by sterics, but also note that
the additional stabilization of the cis-amide conformation in the
peptoid (e.g., DMSOKcis/trans for 14 vs 8e = 7.1 and 5.6,
respectively) may involve the aforementioned possibility of an
interaction between ﬂuorine and the C-terminal carbonyl.
However, compelling evidence for the latter point would
require further experimentation.
Finally, the thioamide analog 15, like β-peptoid 12e,
exhibited higher Kcis/trans values than its oxoamide analog
(13) in polar solvents, and a signiﬁcant decrease in the cis-
amide fraction in CDCl3 (Chart 1). This again indicates that
there is an interaction between the sulfur and the aromatic
residue, which results in favoring of the cis-amide conformation.
X-ray Crystallography. We were able to obtain diﬀraction
quality crystals for two β-peptoids, 5g and 8e, by slow
evaporation of chloroform solutions as well as the peptoid 15
by slow evaporation from an AcOEt solution. Thus, the solid-
state crystal structures of these model compounds were solved
by X-ray structure determination. The structure of 5g revealed
an extended backbone conformation (Figure 2A) with trans-
amide conﬁguration, which is consistent with the obtained
Kcis/trans = 0.7 in CDCl3. Notably, the two phenyl groups adopt
a periplanar relationship and are both pointed away from the
acetyl CH3 group (Figure 2B), which may also explain the
relatively high trans-amide ratio observed in solution despite its
signiﬁcant steric bulk.
Compound 8e adopted the cis-amide conformation in the
solid state (Figure 2C), as would also be expected judging from
its Kcis/trans values. We had suspected that the attenuated
electron lone-pair donor capabilities of the N-terminal carbonyl
in the triﬂuoroacetylated compounds compared to acetylated
analogs would result in a decreased n → pi*aryl eﬀect. The
crystal structure of 8e shows no such interaction, and there are
no signs of ﬂuorine−carbonyl interactions either. However, due
to the very dense crystal packing with antiparallel β-peptoid
backbones (Figure 2D) and edge to face aromatic pi−pi
interactions (Figure 2E), the presence of n→ pi*aryl interactions
in solution cannot be deﬁnitively excluded.
The X-ray crystal structure of the N-terminal thioamide
peptoid analog 15 also revealed the presence of a cis-amide
conﬁguration, as would be expected from the NMR data
(Figure 3). The distance between the C-terminal carbonyl and
the carbon of the thioamide is consistent with the presence of
an n → pi*amide interaction (Figure 3A),
19,30 which may explain
the higher Kcis/trans values recorded for the glycine-based
peptoids compared to the β-alanine-based peptoids. As was also
the case for compound 8e, the solid-state structure did not
provide any evidence of an n→ pi*aryl interaction. Interestingly,
however, the distance between one of the naphthyl hydrogen
atoms and the sulfur shown in Figure 3B (2.9 Å) is consistent
with an overlap of their orbitals to give rise to an aromatic C−
H···Samide interaction. This could oﬀer an alternative explan-
ation of the stabilizing eﬀect on the cis-amide conformation
obtained by introduction of the N-terminal thioamide
functionality. In order to shed more light on the identity of
the putative noncovalent carbonyl−aryl interaction in this
system, we performed density functional theory (DFT)
calculations on selected compounds (vide inf ra). We also
Figure 2. Solid-state structures of compound 5g (A and B) and compound 8e (C−E) determined by X-ray crystallography. Atom coloring: gray,
carbon; white, hydrogen; red, oxygen; blue, nitrogen; and turquoise, ﬂuorine. Green arrows indicate N → C directionality (D), and the dashed
magenta colored line indicates an edge to face aromatic interaction (E). The hydrogen atoms have been removed for clarity in D and E.
Figure 3. Solid-state structure of compound 15 determined by X-ray
crystallography. Stick representations showing the COi+1···CiS
distance in green (A) and the distances between sulfur and its two
closest hydrogen atoms in magenta (B). Space-ﬁlling representations
showing hydrophobic packing of the naphthyl and the piperidine
groups (C) and (D). The hydrogen atoms have been removed for
clarity in A and B (except for the two hydrogens in close proximity to
sulfur).
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note that the proximity of the side chain methyne hydrogen,
and the carbonyl in this crystal structure (2.5 Å) as well as in
the structure of 8e described above are consistent with the
downﬁeld shift observed in 1H NMR for this proton in the cis-
amide conformations.
Evidence for Aromatic C−H···Samide Interactions. To
gain further insight into the molecular features responsible for a
C−H···Samide interaction and its eﬀect on the observed
preference for the cis-amide conﬁguration in the presence of
the (S)-1-(1-napthyl)ethyl side chain, a computational study
was carried out. Initially, the peptoids (6e, 8e, 12e, 13−15)
were built in either the cis or the trans conﬁguration and
subjected to a conformational search running 1000 steps using
the OPLS-2005 force-ﬁeld34 and a GB/SA solvation model35
for water as incorporated in Macromodel version 9.6.36 The cis-
or trans-amide conformations were retained by applying a
constraint of 100 kJ × mol−1 × radian−2 to those particular
dihedral angles. Furthermore, to prevent irrelevant rotamers of
the morpholine headgroup to appear in the conformational
search, additional dihedral constraints were applied to the N-
terminal part of the molecules. The conformational search was
carried out using a combination of Monte Carlo multiple
minimum (MCMM) algorithm37,38 and the “Low-Mode”
search algorithm,39 with an energy window of 21 kJ × mol−1.
After this initial conformational search all of the generated
conformations were submitted to a further optimization with
DFT using the B3LYP functional.40 We used the 6-31G* basis
set41 along with the polarized continuum solvent model (PCM-
SCRF)42 with parameters suitable for water.
The lowest energy conformations of both 6e and 12e
contained the cis-amide conﬁguration in agreement with our
Kcis/trans data from NMR as well as the X-ray diﬀraction data
(Figure 4). Notably, when visualizing the ensemble of
conformations with energies within 21 kJ × mol−1 (Figure
4B,D), the more homogeneous positioning of the N-alkyl side
chain in the thioamide analog indicates that there may be a
stabilizing interaction between the sulfur and the naphthyl
group. This is again consistent with the trends of Kcis/trans
observed by NMR, and the preferred geometry is the same as
we found in the solid-state for compound 15 revealing close
proximity of the proton in position eight of the naphthyl
functionality with the carbonyl (Figure 4A,C).
To further investigate the electronic properties responsible
for the observed cis-amide preference in the thioamide series,
we carried out natural bond order (NBO) analyses.43 By
inclusion of the triﬂuoroacetylated compounds 8e and 14 we
would be able to pinpoint the eﬀect of this substitution in both
peptoid and β-peptoid backbones. For this purpose, super-
imposable, low-energy conformations of both cis- and trans-
isomers of 6e, 8e, 12e, 13−15 were selected. When comparing
the two cis-conformations of 6e and 12e, it is notable that while
the longer CS compared to CO (1.7 vs 1.2 Å) caused the
distance to the hydrogen of the naphtyl group to increase from
2.9 to 3.2 Å, the NBO analysis clearly showed that the
interaction is stronger in the thioamide case.
First of all, the natural charge on the aromatic hydrogen in
the thioamide (12e) is lower than in the amide compound
(0.2436 au for 12e vs 0.2455 au for 6e), although both
hydrogens are more electron deﬁcient than their neighboring
hydrogen, which does not have such intramolecular interactions
(0.2503 au for 12e and 0.2487 au for 6e). In addition, second-
order perturbation analyses of 12e and 6e revealed calculated
stabilizing energies of this interaction to be 0.86 kcal × mol−1
and below the 0.5 kcal × mol−1 threshold, respectively.
In the triﬂuoroacetylated compound 8e, the amide oxygen is
less negatively charged as expected (−0.657 au in 8e vs −0.716
au in 6e). As a consequence, the electrostatic interaction with
the naphthyl hydrogen is expected to be even smaller than for
6e, however, in this case it is also below the threshold of 0.5
kcal × mol−1. This suggests that the increased cis−trans ratio
upon change of methyl to triﬂuoromethyl likely is caused by the
increased steric congestion of the larger ﬂuorine atoms rather
than arising from an increased electrophilicity of the amide
carbonyl carbon. Finally, the three trans conﬁgured structures
featured a fully extended backbone with neither n → pi*amide
nor electrostatic C−H···Samide interactions.
Next, we turned our attention to the peptoid series (13−15)
where the closer proximity of the other carbonyl group may
allow for the possibility of n → pi*amide interactions in addition
to the electrostatic C−H···Samide interaction. For all of these
compounds, the C−H···Samide interaction shows up in the
second-order perturbation analysis part of the NBO analysis,
and it is only slightly stronger for the thioamide 15 (0.63 kcal ×
mol−1) compared to the amide 13 (0.58 kcal × mol−1). For the
triﬂuoroacetylated peptoid 14, the value is even higher at 0.65
kcal × mol−1, but the small energies considered, these
diﬀerences may well be within the inaccuracy of the method.
These eﬀects on peptoid structure are currently under further
investigation in our laboratories.
A comparison of the chemical shifts assigned to the naphthyl
H-8 hydrogen in the cis-amide conformations of compounds
with altered electronic properties of the carbonyl support the
presence of the proposed interaction in solution as well (Figure
5). Thus, attenuation of the electron density of the oxygen by
introduction of ﬂuorine atoms should render the hydrogen less
shielded and cause an upﬁeld shift of the signal, which was
indeed what the spectra showed (6e vs 8e). Substitution of
oxygen with sulfur (6e vs 12e) should in principle aﬀect this
putative interaction in the same manner. However, the opposite
Figure 4. Calculated structures of compounds 6e (A and B) and 12e
(C and D). All structures within 21 kJ × mol−1 of the global minimum
were superimposed.
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eﬀect was observed with a downﬁeld shift of the signal (Figure
5), which gratifyingly is consistent with the calculated
ensembles and the Kcis/trans values that indicate a stronger
interaction for sulfur. Although hydrogen bonds to oxoamides
should be stronger than thioamides, we speculate that the
geometric restraint required for formation of the eight-
membered ring in our system does not allow for an optimal
hydrogen-bond distance, and therefore the larger radius of the
sulfur enables a higher degree of orbital overlap than the
oxygen. This is supported by the NBO analysis on the β-
peptoids 6e and 12e (see above). Additionally, the diﬀerence in
polarizability of thioamides as compared to oxoamides may play
a role44 and could also provide arguments to help explain the
solvent eﬀects observed on Kcis/trans for some thioamide
compounds (vide supra).44a
■ CONCLUSIONS
To get a better understanding of the amide bond isomerization
in peptoids, we have synthesized and evaluated several series of
monomer β-peptoid model systems with varying electronic and
steric properties as well as two novel N-alkylglycine (peptoid)
model compounds containing a triﬂuoroacetyl group or an N-
terminal thioamide, respectively. Our studies show that some of
the trends found in peptoids are directly applicable to β-
peptoids. As such, the (S)-1-(1-napthyl)ethyl side chain
strongly induces the cis-amide conformation, while N-aryl
gives rise to trans. We thus found that a bulky substituent like
naphthyl in combination with α-branching is required for a cis-
amide preference, as a diphenyl-substituted benzhydryl side
chain was not suﬃciently sterically demanding. In addition to
the investigation of various side chain eﬀects, we prepared
model systems containing triﬂuoroacetyl groups as well as
thioamides to probe the electronic eﬀects of the carbonyl
donor−acceptor capabilities. The NMR-based studies of these
compounds provided evidence for an interaction of the N-
terminal carbonyl/thiocarbonyl lone pair with the aromatic side
chain, but we saw no evidence for conformational stabilization
through noncovalent carbonyl−carbonyl interactions. The X-
ray crystal structures of two β-peptoid model compounds were
solved, which revealed one trans- and one cis-amide,
respectively. Those rotamer conformations were both in
agreement with the NMR experiments.
Furthermore, the X-ray crystal structure of a thioamide-
containing peptoid model compound was solved, and
supported by DFT calculations and NMR chemical shift
analysis, this structure indicated the presence of a stabilizing
eﬀect through thioamide−aromatic interactions by Csp2−
H···Samide “hydrogen bonds”. Whereas aromatic−sulfur inter-
actions have been described for proteins as well as in other
systems,45 the present work, to the best of our knowledge,
provides evidence for the ﬁrst examples of intramolecular
conformation-stabilizing eﬀects by introduction of thioamides,
which is in contrast to the destabilizing eﬀect of thioamide
introduction in α-helical peptides.46
Importantly, this work shows that minimal peptide bond
surrogates like thioamides as well as ﬂuorinated backbone
analogs are useful for investigation of peptoid and β-peptoid
structure. These modiﬁcations should therefore be considered
valuable for other types of peptidomimetics as well.
Thioamides, in particular, have recently found use in peptide
ligands and have been site-speciﬁcally introduced into proteins
to probe folding.47 We envision that the straight forward
methodology presented herein may encourage further studies
of thioamide-containing peptoid and β-peptoid oligomeric
systems.
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Figure S1. Comparison of the trans–cis rotamer ratios of enantiomerically pure and racemic versions of compound 5a, which 
expectedly show no difference in equilibria. 
 
Figure S2. Concentration dependence on Kcis/trans for compound 3a. Spectra were recorded in CDCl3 at 298 K.  
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Figure S3. ROESY spectrum of compound 6e. The highlighted signals correspond to correlations a–c involving the methyne proton 
as shown in the scheme above. In the trans-amide conformation, the methine proton (quartet) has correlations to the side chain CH3 
protons (b) as well as the N-acetyl CH3 protons (c). The further down-field shiftet quartet only has an ROE correlation to the side 
chain CH3 protons (a). Thus, the N-acetyl CH3 group from the conformation with up-field shiftet signal is in closer proximity to the 
methine proton, which confirms the assignment of this spin system as originating from the trans-amide conformation. 
 
 
Figure S4. ORTEP representation of the solid state structures of compound 5g, 8e, and 15. For crystallographic details, see the CIF 
files. Atom colors: Grey, carbon; white, hydrogen; red, oxygen; blue, nitrogen; green, fluorine; yellow, sulfur. 
 
! S4!
Figure S5. Assignment of the aromatic signals of compound 6e. For full 2D spectra of this β-peptoid as well as 8e and 12e, see pages 
S55–S63. 
Scheme S1. Synthesis of peptoid compounds 13–15. Reagents and conditions: (A) (a) i) piperidine (0.9 equiv), i-Pr2NEt (1 equiv), 
THF, 0 °C, 1 h. ii) (S)-1-(1-naphthyl)ethylamine (2 equiv), NEt3 (2 equiv), THF, 0 °C → rt, 16 h, 58%; (b) (RCO)2O (3 equiv), 
pyridine, DMF, 0 °C → rt, 16 h, [13 (63%) and 14 (46%)]. (B) (c) (S)-1-(1-naphthyl)ethylamine (2 equiv), NEt3 (2 equiv), THF, 0 °C 
→ rt, 16 h; (d) Ac2O (3 equiv), pyridine, DMF, 0 °C → rt, 16 h, 70% two steps; (e) Lawesson’s reagent (0.6 equiv), toluene, reflux, 
1h, 71%; (f) LiOH (2 equiv), DMF/H2O, rt, 2h; (g) piperidine (2 equiv), HBTU (2 equiv), i-Pr2NEt (2 equiv), CH2Cl2, rt, 16 h, 44% 
two steps.   
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Materials and Methods 
General. All chemicals and solvents were analytical grade 
and used without further purification. Vacuum liquid 
chromatography (VLC) was performed on silica gel 60 
(particle size 0.015−0.040 mm). UPLC−MS analyses were 
performed on a Waters Acquity ultra high-performance liquid 
chromatography system. A gradient with eluent I (0.1% 
HCOOH in water) and eluent II (0.1% HCOOH in 
acetonitrile) rising linearly from 0% to 95% of II during t = 
0.00–2.50 min was applied at a flow rate of 1 mL/min 
(gradient A) or during t = 0.00–5.20 min (gradient B). 
Compounds, for which purity could not be assessed by 
UPLC-MS, were analyzed using HPLC performed on a [250 
mm × 20 mm, C18 Phenomenex Luna column (5 μm, 100 
Å)] using an Agilent 1260 LC system equipped with a diode 
array UV detector and an evaporative light scattering detector 
(ELSD). A gradient C with eluent III (95:5:0.1, 
water−MeCN−TFA) and eluent IV (0.1% TFA in 
acetonitrile) rising linearly from 0% to 95% of IV during t = 
5−45 min was applied at a flow rate of 20 mL/min. 1D NMR 
spectra were recorded on a Varian Mercury 300 instrument. 
1H NMR, 13C NMR, were recorded at 300 and 75 MHz, 
respectively. 2D NMR spectra were recorded on a varian 
INOVA 500 MHz instrument at 500 MHz for 1H and 125 
MHz for 13C. All spectra were recorded at 298 K. Correlation 
spectroscopy (COSY) spectra was recorded with a relaxation 
delay of 1.5 sec before each scan, a spectral width of 6k × 6k, 
collecting 8 FIDs and 1k × 512 data points. Heteronuclear 
single quantum coherence (HSQC) spectra were recorded 
with a relaxation delay of 1.5 sec before each scan, a spectral 
width of 6k × 25k, collecting 16 FIDs and 1k × 128 
datapoints. Heteronuclear 2-bond correlation (H2BC) spectra 
were recorded with a relaxation delay of 1.5 sec before each 
scan, a spectral width of 4k × 35k, collecting 16 FIDs at 295 
K and 1k × 256 datapoints. Heteronuclear multiple-bond 
correlation (HMBC) spectra were recorded with a relaxation 
delay of 1.5 sec before each scan, a spectral width of 6k × 35 
k, collecting 32 FIDs and 1k × 256 datapoints. Rotating 
frame Overhauser effect (ROESY) spectra were recorded 
with a relaxation delay of 2 sec before each scan, a spectral 
width of 4k × 4k, collecting 8 FIDs at 295 K, 1k × 256 
datapoints, and a mixing time of 100 ms. Chemical shifts are 
reported in ppm relative to deuterated solvent peaks as 
internal standards (δH, DMSO-d6 2.50 ppm; δC, DMSO-d6 
39.52 ppm, δH, CDCl3 7.26 ppm; δC, CDCl3 77.16 ppm. 
Coupling constants (J) are given in hertz (Hz). Multiplicities 
of 1H NMR signals are reported as follows: s, singlet; d, 
doublet; t, triplet; q, quartet; m, multiplet. Signals marked 
with an asterisk (*) correspond to peaks assigned to the minor 
rotamer conformation. 
General procedure for aza-Michael addition to give tert-
butylester containing monomers.  
tert-Butyl acrylate (1 equiv) was dissolved in MeOH and 
heated to 50 °C on an oil bath. The desired primary amine 
(1.2 equiv) was added and the reaction was stirred overnight. 
The solvent was removed in vacuo and the crude product was 
purified by vacuum liquid chromatography (VLC) (<1 gram 
3 × 6 cm column CH2Cl2–MeOH 0.2 % gradient from 
0→5%; from 1–5 grams 6 × 6 cm column CH2Cl2–MeOH 0.2 
% gradient from 0→5%).  
(S)-tert-Butyl 3-((1-phenylethyl)amino)propanoate (3a). 
Yield 17.3 g (85%) as a clear oil. 1H NMR (300 MHz, 
CDCl3)! δ = 1.34 (d, 3H, J = 6.8 
Hz, H-6), 1.44 (s, 9H, H-1), 1.70 
(s, 1H, H-4), 2.38 (t, 2H, J = 6.3 
Hz), 2.60–2.75 (m, 2H, H-3), 
3.77 (q, 1H, J = 6.6 Hz, H-2), 
7.20–7.27(m, 1H, H-p), 7.20–
7.35 (m, 4H, H-o, H-m). 13C NMR (75 MHz, CDCl3)!
δ = 24.7, 28.3, 36.1, 43.4, 58.4, 80.7, 126.8, 127.1, 128.6, 
145.8, 172.52. UPLC-MS gradient a, tR = 0.96 min (>95%), 
MS (m/z) 250.3 ([M + H]+ C15H24NO2+ calcd 250.4). [α]589.2: 
–29° (c = 2.2 , 293 K, CHCl3 ). 
(S)-tert-Butyl 3-((1-cyclohexylethyl)amino)propanoate 
(3b). Yield: 5.68 g (85%) as a clear oil. 1H NMR (300 MHz, 
CDCl3)! δ!=! 0.95 (d, 3H, J = 6.5 
Hz, H-6), 0,93–1.30 (broad m, 
7H, c-Hex, H-4), 1.42 (s, 9H, H-
1), 1.63–1.74 (broad m, 5H, c-
Hex), 2.35–2.42 (m, 3H, H-2, H-
5), 2.69–2.88 (m, 2H, H-3). 13C 
NMR (75 MHz, CDCl3)!δ!=!17.0, 26.7, 26.9, 27.0, 28.2, 28.3, 
30.10 36.4, 43.0, 43.1, 57.7, 80.6, 172.6. UPLC-MS gradient 
A, tR = 1.07 min, m/z 256.4 ([M + H]+, C15H30NO2+ calcd 
256.4), gradient C: >95%. [α]589.2: +8° (c = 1.6 , 293 K, 
CHCl3). 
tert-Butyl 3-(benzylamino)propanoate (3c). Yield: 5.24 g 
(40%) as a clear oil. 1H NMR (300 
MHz, CDCl3)!δ =1.44 (s, 9H, H-1), 
1.73 (s, 1H, H-4), 2.45 (t, 2H, J = 
6.6 Hz, H-2), 2.85 (t, 2H, J = 6.6 
Hz, H-3), 3.79 (s, 2H, H-5), 7.20–
7.30 (m, 1H, H-p), 7.31–7.32 (m, 4H, H-o, H-m). 13C NMR 
(75 MHz, CDCl3)! δ = 28.4, 36.1, 45.0, 54.1, 80.7, 127.1, 
128.3, 128.6, 140.5, 172.4. UPLC-MS gradient A, tR = 0.92 
min (>95%), m/z 236.3 ([M + H]+, C14H22NO2+ calcd 236.3). 
tert-Butyl 3-(sec-butylamino)propanoate (3d). Yield: 3.82 
g (56%) as a clear oil. 1H NMR  
(300 MHz, CDCl3)! δ = 0.79 (t, 
3H, J = 7.4 Hz, H-8), 0.93 (d, 3H, 
J = 6.3 Hz, H-5), 1.15–1.29 (m, 
1H, H-4), 1.36 (s, 9H, H-1), 2.32 (t, 2H, J = 5.9 Hz, H-2), 
2.41–2.51 (m, 1H, H-6), 2.65–2.80 (m, 2H, H-3). 13C NMR 
(75 MHz, CDCl3)!δ = 10.4, 19.9, 28.2, 29.7, 36.2, 42.7, 54.4, 
80.5, 172.4, UPLC-MS gradient A, tR = 1.28 min, m/z 202.3 
([M + H]+, C11H24NO2+ calcd 202.3). HPLC gradient C: 
ELSD >95%. 
(S)-tert-Butyl 3-((1-(naphthalen-1-yl)ethyl)amino)propan-
oate (3e). Yield 1.38 g (78%) as 
a yellow oil. 1H NMR (300 MHz, 
CDCl3)! δ = 1.45 (s, 9H, H-1), 
1.49 (d, 3H, J = 6.6 Hz, H-6), 
1.82 (s, 1H, H-4), 2.43 (t, 2H, J = 
6.4 Hz, H-2), 2.76–2.81 (m, 2H, 
H-3), 4.65 (q, 1H, J = 6.6, H-5), 
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7.44– 8.21 (5 × m, 7H, H-a, H-b, H-c, H-d, H-e, H-f, H-g). 
13C NMR (75 MHz, CDCl3)!δ =!24.0, 28.4, 36.4, 43.6, 53.8, 
80.8, 122.9, 123.2, 125.5, 127.3, 129.2, 131.5, 134.2, 141.3, 
172.5. UPLC-MS gradient A, tR = 1.20 min (>95%), m/z 
300.3 ([M + H]+, C19H26NO2+ calcd 300.4). [α]589.2: –36° (c = 
2.2 , 293 K, CHCl3). 
tert-Butyl 3-((naphthalen-1-ylmethyl)amino)propanoate 
(3f). Yield: 1.35 g (74%) as a clear oil. 1H NMR (300 MHz, 
CDCl3)!δ = 1.4 ( s, 9H, H-1), 1.72 (s, 
1H, H-4), 2.51 (t, 2H, J = 6.5 Hz, H-
2), 3.00 ( t, 2H, J = 6.5 Hz), 4.25 ( s, 
2H, H-5), 7.41–8.16 ( 4 × m, 7H, H-
a, H-b, H-c, H-d, H-e, H-f, H-g). 13C 
NMR (75 MHz, CDCl3)! δ = 28.4, 
36.3, 45.7, 51.8, 80.7, 124.00, 125.6, 
125.8, 126.2, 126.3, 128.0, 128.9, 132.1, 134.1, 136.1, 172.4. 
UPLC-MS gradient A, m/z ([M + H]+, C18H23NO2+ calcd 
285.4). 
tert-Butyl 3-(benzhydrylamino)propanoate (3g). Yield: 
5.44 g (64%) as a white solid. 1H 
NMR (300 MHz, CDCl3)!
δ = 1.44 ( s, 9H, H-1), 1.94 (s, 1H, 
H-4), 2.45 (t, 2H, J = 6.4 Hz, H-
2), 2.80 (t, 2H, J = 6.4 Hz, H-3), 
4.83 (s, 1H, H-5), 7.17–7.41 (3 × 
m, 10H, H-o, H-m, H-p). 13C NMR (75 MHz, CDCl3)!
δ = 28.4, 36.3, 43.9, 67.5, 80.7, 127.2, 127.5, 128.7, 144.2, 
172.4. UPLC-MS gradient A, tR = 1.32 min (>95%), m/z 
312.4 ([M + H]+, C20H26NO2+ calcd 312.4). 
tert-Butyl 3-(phenylamino)propanoate (3h). Yield: 2.51 g 
(21%) as an orange oil. 1H NMR (300 
MHz, CDCl3)! δ = 1.48 (s, 9H, H-1), 
2.54 (t, 2H, J = 6.4 Hz, H-2), 3.41 (m, 
2H, H-3), 4.06 (s, 1H, H4), 6.63–7.23 
(3 × m, 5H, H-o, H-m, H-p). 13C 
NMR (75 MHz, CDCl3)! δ = 28.4, 
35.3, 39.9, 81.1, 113.3, 117.8, 129.5, 148.1, 172.0. UPLC-
MS gradient A, tR = 1.94 min (>95%), m/z 222.3 ([M + H]+, 
C13H20NO2+ calcd 222.3). 
tert-Butyl 3-((1-phenylethyl)amino)propanoate (rac-3a). 
Yield: 0.71 g (80%) as a clear oil. 
1H NMR (300 MHz, CDCl3)!
δ = 1.34 (d, 3H, J = 6.7 Hz, H-6), 
1.44 (s, 9H, H-1), 1.69 (s, 1H, H-
4), 2.38(t, 2H, J = 6.3 Hz, H-2), 
2.66 (m, 2H, H-3), 3.76(q, 1H, J = 
6.6 H-5), 7.20–7.31 (3 × m, 1H, H-p), 7.31 (d, 4H, J = 4.38, 
H-o, H-m). 
(R)-tert-Butyl 3-((1-phenylethyl)amino)propanoate [(R)-
3a]. 7.58 g (82%) as a clear oil. 1H NMR (300 MHz, CDCl3)!
δ = 1.33 (d, 3H, J = 6.6 Hz, H-6), 
1.43 (s, 9H, H-1), 1.72 (s, 1H, H-
4), 2.37 (t, 2H, J = 6.4 Hz, H-2), 
2.68 (m, 2H, H-3), 3.8 (q, 1H, J = 
6.6 Hz, H-5), 7.18–7.25 (m, 1H, 
H-p), 7.30–7.31 (d, 4H, H-o, H-m). 13C NMR (75 MHz, 
CDCl3)! δ =! 24.7, 28.3, 36.2, 43.4, 58.4, 80.6, 126.8, 127.1, 
128.6, 154.8, 172.5. UPLC-MS gradient A, tR = 1.00 min 
(>95%), m/z 250.3 ([M + H]+, C15H24NO2+ calcd 250.4). 
[α]589.2: +29° (c = 1.3 , 293 K, CHCl3). 
General procedure for aza-Michael addition to give 
morpholine containing monomers.  
N-Acryloyl morpholine (1 equiv) was dissolved in MeOH 
and heated to 50 °C. The primary amine (1.2 equiv) was 
added and the reaction was stirred overnight. The solvent was 
removed in vacuo. The crude product was purified by VLC 
(3 × 6 cm column, CH2Cl2–MeOH, 0.2% gradient from 0–
>5%). 
(S)-1-morpholino-3-((1-phenylethyl)amino)propan-1-one 
(4a). Yield 613 mg (56%) as a clear oil, 
UPLC-MS gradient B, tR = 0.67 min 
(>95%), m/z 263.2 ([M + H]+, 
C15H23N2O2+ calcd 263.4). 
 
(S)-1-morpholino-3-((1-(naphthalen-1-yl)ethyl)amino)-
propan-1-one (4e). Yield: 821 mg (77%) as a yellow oil, 
UPLC-MS gradient B, tR = 0.88min 
(85%), m/z 313.3 ( [M + H]+, C19H25N2O2+ 
calcd 313.4). 
 
 
1-morpholino-3-((naphthalen-1-ylmethyl)amino)propan-
1-one (4f). Yield: 561 mg (59%) as a clear oil, UPLC-MS 
gradient B, tR = 0.84min (94%), m/z 299.4 
([M + H]+, C18H23N2O2+ calcd 299.4).!
!
!
General procedure for acetylation of monomers.  
The monomer and pyridine (2 equiv) were dissolved in DMF 
(1 mL/mmol) and cooled to 0 °C. Acetic anhydride (2 equiv) 
was added dropwise and the temperature was allowed to rise 
to room temperature (r.t.). After stirring for 4h, the reaction 
mixture was taken up in saturated aqueous ammonium 
chloride (50 mL) and extracted with ethyl acetate (3 × 50 
mL). The combined organic phases were dried (Na2SO4), 
filtered, and evaporated to dryness. The crude product was 
purified by VLC (3 × 6 cm column, hexane–EtOAc 5% 
gradient). 
(S)-tert-Butyl 3-(N-(1-phenylethyl)acetamido)propanoate 
(5a). Yield: 548 mg (94%) as a 
clear oil. 1H NMR (300 MHz, 
CDCl3)! δ = 1.31 (s, 9H, H-1), 
1.45*/1.56 (2 × d, 3H, J = 7.1 
Hz, H-6), 1.98*/2.32 (2 × m, 
2H, H-2), 2.16/2.21* (2 × s, 3H, 
H-4), 3.10–3.47 (3H, H-3), 5.00/5.95 (2 × q, 1H, J = 7.1 Hz), 
7.17–7.31 (m, 5H, H-o, H-m, H-p). 13C NMR (75 MHz, 
CDCl3)! δ= 16.8, 18.2, 18.43, 22.17, 22.5, 28.2, 28.3 (3C), 
34.7, 36.7, 39.0, 40.2, 51.1, 56.6, 126.8 (2C), 127.7, 127.8 
(2C), 127.9, 128.7 (2C), 129.0 (2C), 140.4 140.8, 170.4, 
170.7, 170.8, 171.4. UPLC-MS gradient A, tR = 1.92 min 
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(>95%), m/z 292.3 ([M + H]+, C17H25NO3+ calcd 292.4). 
[α]589.2: –59° (c = 2.7 , 293 K, CHCl3 ). 
(S)-tert-Butyl 3-(N-(1-cyclohexylethyl)acetamido)propan-
oate (5b). Yield: 120 mg (52%) 
as a clear oil. 1H NMR (300 
MHz, CDCl3)!δ = 0.73–0.93 (m, 
2H, c-Hex), 1.11–1.24 (m, 3H, 
c-Hex), 1.16*/1.18 (2 × d, 3H, J 
= 7.0*/6.8 Hz, H-6), 1.35–1.53 
(m, 1H, c-Hex), 1.43/1.46* (2 × s, 9H, H-1), 1.64–1.78 (m, 
5H, c-Hex), 2.06/2.11* (2 × s, 3H, H-4), 2.35–2.77 (2 × m, 
2H, H-2), 3.15–3.60 (3 × m, 3H, H-3, H-5). 13C NMR (75 
MHz, CDCl3)!δ = 16.9*, 17.5, 22.1*, 22.4, 25.9, 26.0*, 26.1, 
26.2, 28.1* (3C), 28.1 (3C) 30.0*, 30.4*, 30.5, 30.5, 34.4, 
36.6*, 37.5, 40.7*, 41.4, 59.6, 80.5, 81.3*, 170.4*, 170.6, 
170.7, 171.5 . UPLC-MS gradient B, tR = 2.22 min, m/z 298.3 
([M + H]+, C17H32NO3+ calcd 298.4). HPLC gradient C: 
ELSD >95%. [α]589.2: +3° (c = 1.2, 293 K, CHCl3).  
tert-Butyl 3-(N-benzylacetamido)propanoate (5c). Yield: 
355 mg (80%) as a white solid. 
1H NMR (300 MHz, CDCl3)!
δ =!1.42/1.43* (2 × s, 9H, H-1), 
2.11/2.23* ( 2 × s, 3H, H-4), 
2.44*/2.54 (2 × t, 2H, J = 7.1 
Hz, H-2), 3.52*/3.59 (2 × t, 2H, 
J = 7.0 Hz, H-3), 4.59/4.60* (2 × s, 2H, H-5), 7.15–7.39 (m, 
5H, H-o, H-m, H-p). 13C NMR (75 MHz, CDCl3)! δ = 22.9, 
28.1, 34.1, 45.1, 80.8, 128.2, 128.3, 129.9, 142.8, 170.4, 
170.8. UPLC-MS gradient A, tR = 1.75 min (>95%), m/z 
278.3([M + H]+, C16H24NO3+ calcd 278.4). 
tert-Butyl 3-(N-(sec-butyl)acetamido)propanoate (5d). 
Yield: 208 mg (85%) as a clear 
oil, 1H NMR (300 MHz, CDCl3)!
δ = 0.68–0.76 (m, 3H, H-8), 
1.00*/1.04 (2 × d, 3H, J = 6.8 
Hz, H-5), 1.29/1.31* (2 × s, 9H, H-1), 1.36–1.45 (m, 2H, H-
6), 1.95/1.98* (2 × s, 3H, H-4), 2.33/2.47* (2 × d, 2H, H-2), 
3.16*/3.32 (2 × m, 2H, H-3), 3.56/4.22* (2 × m, 1H, H-6). 
13C NMR (75 MHz, CDCl3)! δ = 11.3, 18.6*, 19.6, 22.3*, 
22.4, 27.4*, 28.0*, 28.2, 34.8, 36.7, 36.9*, 40.2*, 51.7*, 55.7, 
80.5, 81.3*, 170.4*, 170.6, 170.8*, 171.5. UPLC-MS 
gradient A, tR = 1.68 min (>95%), m/z 244.2 ([M + H]+, 
C13H26NO3 calcd 244.3). 
(S)-tert-butyl 3-(N-(1-(naphthalen-1-yl)ethyl)acetamido)-
propanoate (5e). Yield: 205 mg (91%) as a yellow oil. 1H 
NMR (300 MHz, CDCl3)!
δ= 1.16*/1.85 (2 × m, 2H, H-
2), 1.23 (s, 9H, H-1), 
1.56/1.67* (2 × d, 3H, J = 6.9 
Hz, H-6), 2.09/2.31* (2 × s, 
3H, H-4), 3.17/3.35* (2 × m, 
2H, H-3), 5.59*/6.56 (2 × q, 
1H, J = 6.9 HZ, H-5), 7.38–7.93 (7H, H-a, H-b, H-c, H-d, H-
e, H-f, H-g). 13C NMR (75 MHz, CDCl3)! δ = 17.0, 19.1*, 
22.2, 22.2*, 28.1 (3C), 34.5*, 36.0, 38.7*, 39.8, 47.8, 53.7*, 
80.4*, 81.0, 122.6*, 123.8, 124.8*, 125.0, 125.2, 125.5*, 
126.1*, 126.2, 127.0*, 127.1, 128.9, 129.1, 129.2*, 129.4*, 
131.5*, 132.3, 133.8, 133.9*, 135.4*, 135.8, 170.3, 170.3, 
170.7*, 171.2*. UPLC-MS gradient A, tR = 2.10 min (>95%), 
m/z 342.3 ( [M + H]+, C21H28NO3+ calcd 342.4). [α]589.2: –63° 
(c = 1.3, 293 K, CHCl3 ). 
tert-Butyl 3-(N-(naphthalen-1-ylmethyl)acetamido)-
propanoate (5f). Yield: 308 mg (59%). 1H NMR (300 MHz, 
CDCl3) δ = 1.41 (s, 9H, H-1), 
2.07/2.25* (2 × s, 3H, H-4), 
2.37*/2.62 (2 × t, 2H, J = 
7.5*/7.0 Hz, H-2), 
3.46*/3.71(2 × t, 2H, J = 7.0 
Hz, H-3), 5.06*/5.10 (2 × s, 
2H, H-5), 7.15–8.06 (7H, H-
a, H-b, H-c, H-d, H-e, H-f, H-g). 13C NMR (75 MHz, CDCl3)!
δ = 21.8, 21.9*, 28.2*, 28.3, 34.4, 34.7*, 43.7*, 63.6, 45.9*, 
51.0, 80.93, 81.6*, 122.3, 122.5, 124.0*, 125.5*, 125.8, 
126.2*, 126.3, 126.7, 126.8*, 126.9*, 128.2, 128.7*, 128.8*, 
129.8, 130.8*, 131.8*, 132.0, 132.4, 134.0, 134.1*, 170.6*, 
170.7, 171.5, 172.0. UPLC-MS gradient A, tR = 2.03 min 
(>95%), m/z 328.4 ([M + H]+, C20H26NO3+ calcd 328.4).!
tert-Butyl 3-(N-benzhydrylacetamido)propanoate (5g). 
Yield: 623 mg (93%) as a white 
solid. 1H NMR (300 MHz, 
CDCl3) δ =! 1.25/1.27* (2 × s, 
9H, H-1), 1.65*/1.81 ( 2 × t, 
2H, J = 8.2 Hz, H-2), 
2.13/2.20* (2 × s, 3H, H-4), 
3.50–3.55 (m, 2H, H-4), 6.15/7.05* (2 × s, 1H, H-5), 7.11–
7.30 (2 × m, 10H, H-o, H-m, H-p).  13C NMR (75 MHz)!
δ = 22.1*, 22.5, 28.2 (3C), 33.8, 35.6*, 40.7, 42.2*, 60.8*, 
66.2, 80,3, 81.1*, 127.8*, 128.2, 128.8* (2C), 128.8 (2C), 
129.9 (2C), 129.0*(2C), 139.0, 139.5*, 170.3*, 171.0*, 
171.1, 171.2. UPLC-MS gradient A, tR = 2.16 min (>95%), 
m/z 354.4 ([M + H]+, C22H28NO3+ calcd 354.5).!
tert-Butyl 3-(N-phenylacetamido)propanoate (5h). Yield: 
110 mg (46%) as an orange 
oil. 1H-NMR (300 MHz) 
δ = 1.29 (s, 9H, H-1), 1.73 (s, 
3H, H-4), 2.40 (t, 2H J = 7.4 
Hz, H-2), 3.88 (t, 2H J = 7.4, 
H-3), 7.09–7.30 (2 × m, 5H, 
H-o-H-m, H-p). 13C NMR (75 MHz, CDCl3)! δ: 22.9, 28.1, 
34.1, 45.1, 80.8, 128.2, 128.3, 128.9, 142.8, 170.4, 170.8. 
UPLC-MS gradient A, tR = 1.74 min (>95%), m/z 286.3 ([M 
+ Na]+, C15H21NO3Na+ calcd 286.3) 
General procedure for preparation of morpholine 
containing monomers. 4-Acryloyl morpholine (1 equiv) 
were dissolved in MeOH and heated to 50 °C. The primary 
amine (1.2 equiv) were added and the reaction was stirred 
overnight. The solvent was removed in vacuo. The crude 
monomer (1 equiv) and pyridine (2 equiv) were dissolved in 
DMF (1–3 mL/mmol) and cooled to 0 °C. Acetyl chloride (2 
equiv) was added dropwise. After  being stirred for 1 hour at 
0°C the reaction mixture was taken up in 1M HCl (aq) (50 
mL) and extracted with ethyl acetate (2 × 50 mL). The 
organic phase was dried (Na2SO4), filtered, and evaporated to 
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dryness. The crude product was purified by VLC (3 × 6 cm 
column, CH2Cl2–MeOH, 0.2% gradient from 0→5%). 
(S)-N-(3-morpholino-3-oxopropyl)-N-(1-phenylethyl)-
acetamide (6a). Yield: 157 mg 
(17%) as a clear oil. 1H NMR 
(300 MHz, CDCl3)!
δ =!1.43*/1.58 (2 × d, 3H, J = 
7.0 Hz, H-8), 1.68*/2.36 (2 × m, 
2H, H-5), 2.10*/2.18(2 × s, 3H, 
H-7), 3.23/2.92* (2 × m, 2H, H-6), 3.38–3.57 (m, 8H, H-1, 
H-2, H-3, H-4), 5.02/6.02* (2 × q, 1H, J = 7.0* Hz, H-9), 
7.18–7.32 (m, 5H, H-o, H-m, H-p). 13C NMR (75 MHz, 
CDCl3)! δ = 16.4*, 18.3, 22.2*, 22.5, 32.59, 33.3*, 39.8, 
40.4*, 41.9, 45.6*, 46.1, 50.7*, 66.6*, 66.9*, 67.0, 127.0, 
127.8*, 128.1, 128.2*, 128.8*, 129.0, 140.2, 141.2*, 168.9*, 
170.0, 170.8*, 171.0. UPLC-MS gradient A, tR = 1.20 min 
(>95%), m/z 305.4 ([M + H]+, C17H25N2O3+ calcd 305.4). 
[α]589.2: –61° (c = 1.6, 293 K, CHCl3). 
(S)-N-(1-cyclohexylethyl)-N-(3-morpholino-3-
oxopropyl)acetamide (6b). Yield: 35 mg (38%) as a clear 
oil. 1H NMR (300 MHz, CDCl3)!
δ = 0.70–0.88 (m, 2H, c-Hex), 
1.06–1.16 (m, 2H, c-Hex), 
1.07*/1.15 (m, d, 3H, J = 6.8 Hz, 
H-9), 1.35–1.41 (m, 2H, c-Hex), 
1.58–1.74 (m, 5H, c-Hex), 2.02/2.04* (2 × s, 3H, H-7), 
2.38/2.46 (m, 1H, H-5), 2.74–2.83 (m, 1H, H-5), 3.17–3.40 
(2 × m, 2H, H-6), 3.42–3.62 (m, 9H, H-1, H-2, H-3, H-4, H-
8). 13C NMR (75 MHz, CDCl3)! δ = 17.3*, 17.6, 22.5, 26.0, 
26.2, 26.3, 26.3*, 28.2*, 28.5*, 30.2*, 30.5*, 30.6, 30.7, 
33.7*, 38.8, 40.9*, 41.5, 42.0, 45.8*, 46.2, 60.0, 67.0, 67.0, 
169.0*, 170.2, 170.9*, 171.2, UPLC-MS gradient A: tR = 
1.52 min, m/z 311.4 ([M + H]+, C17H31N2O3+ calcd 311.4), 
Gradient C: >95%, [α]589.2: –2° (c = 1.4, 293 K, CHCl3). 
N-benzyl-N-(3-morpholino-3-oxopropyl)acetamide (6c). 
Yield: 56 mg (7%) as a clear oil. 
1H NMR (300 MHz, CDCl3)!
δ =!2.08/2.19* (2 × s, 3H, H-7), 
2.32*/2.61 (2 × t, 2H, J = 7.4 Hz, 
H-5), 3.18*/3.43 (2 × t, 2H, J = 
5.5 Hz, H-6), 3.49–3.63 (m, 8H, H-1, H-2, H-3, H-4), 
4.56*/4.60 (2 × s, 2H, H-8), 7.11–7.33 (5H, H-o, H-m, H-p). 
13C NMR (75 MHz, CDCl3)! δ = 21.8*, 22.04, 31.9, 31.9*, 
42.1, 43.8, 44.6*, 45.8*, 46.2, 48.9*, 53.5, 66.6*, 66.9, 67.0*, 
126.5, 127.6*, 127.8, 128.2*, 128.8*, 129.1, 137.1, 138.0*, 
168.9*, 170.0, 171.0*, 171.6, UPLC-MS gradient A, tR = 
1.13 min (>95%), m/z 291.3 ([M + H]+, C16H23N2O3+ calcd 
291.4). 
 N-(sec-butyl)-N-(3-morpholino-3-oxopropyl)acetamide 
(6d). Yield: 136 mg (20%) as a 
clear oil. 1H NMR (300 MHz, 
CDCl3)!δ =!0.82 (t, 3H, J = 7.8 
Hz, H-11), 1.06*/1.14 (2 × d, 
3H, J = 6.9 Hz, H-8), 1.49 (m, 2H, H-10), 2.04/2.05* (2 × s, 
2H, H-7), 2.45–2.72 (2 × m, 2H, H-5), 3.24–3.47 (2H, H-6), 
3.55–3.68 (m, 9H, H-1, H-2, H-3, H-4, H-9). 13C NMR (75 
MHz, CDCl3)!δ = 11.4, 18.8*, 19.6, 22.3*, 22.4, 27.6*, 27.9, 
32.9, 34.0*, 37.9, 40.2*, 42.0, 45.8*, 46.2, 52.5*, 56.0, 66.6*, 
66.9*, 67.0, 67.1, 169.0*, 170.2, 170.9*, 171.1. UPLC-MS 
gradient A, tR = 1.02 min (>95%), m/z 257.3 ([M + H]+, 
C13H25N2O3+ calcd 257.3) 
(S)-N-(3-morpholino-3-oxopropyl)-N-(1-(naphthalen-1-
yl)ethyl)acetamide (6e). Yield: 
230 mg (24%) as a yellow oil. 
1H NMR (300 MHz, CDCl3)!
δ = 0.82/1.36*/1.64 (3 × m, 3H, 
H-5), 1.34/1.70* (2 × d, 3H, J = 
6.8 Hz, H-8), 2.10/2.36 (2 × s, 
3H, H-7), 2.23/2.41/2.93 (3 × 
m, 2H, H-6), 2.90–3.51 (2 × m, 8H, H-1, H-2, H-3, H-4), 
5.61*/6.60 (2 × q, 1H, J = 6.6 Hz, H-9), 7.38–7.97 (3 × m, 
7H, H-a, H-b, H-c, H-d, H-e, H-f, H-g). 13C NMR (75 MHz, 
CDCl3)!δ= 16.6, 19.0*, 22.2, 22.2*, 32.1* 32.6, 39.6*, 40.2, 
41.7, 45.2, 45.8*, 47.8, 53.8, 66.3, 66.8, 66.9*, 122.7*, 124.1, 
125.2, 125.3*, 125.5, 125.8*, 126.1*, 126.4, 127.0*, 127.4, 
128.7, 128.9, 129.3*, 129.5*, 131.6*, 132.5, 133.9, 133.9*, 
135.0*, 136.3, 168.8, 169.7*, 170.3, 170.9*. UPLC-MS 
gradient A, tR = 1.45 min (>95%), m/z 355.6 ([M + H]+, 
C21H27N2O3+ calcd 355.4). [α]589.2: –49° (c = 2.3, 293 K, 
CHCl3). 
N-(3-morpholino-3-oxopropyl)-N-(naphthalen-1-
ylmethyl)acetamide (6f). Yield: 308 mg (15%) as a clear oil. 
1H NMR (300 MHz, CDCl3)!
δ =!2.09/2.25* (2 × s, 3H, H-7), 
2.17*/2.74 (2 × t, 2H, J = 7.3 
Hz, H-5), 2.98* (t, 1H, J = 5.0 
Hz, H-6*), 3.43–3.74 (broad m, 
9H, H-1, H-2, H-3, H-4, H-6), 
5.09*/5.14 (2 × s, 2H, H-8), 
7.19–8.07 (broad m, 7H, H-a, 
H-b, H-c, H-d, H-e, H-f, H-g). 13C NMR (75 MHz)!δ = 21.7, 
21.9*, 31.8*, 31.9, 41.9*, 42.0, 44.0*, 44.3, 45.6*, 46.1, 
46.9*, 51.4, 66.4*, 66.6*, 66.8, 66.9, 122.3, 122.5, 123.9*, 
125.4*, 125.6, 126.2, 126.6, 126.8* 127.1* 128.2, 128.7*, 
128.8*, 129.1, 130.7, 131.8*, 132.0, 133.0*, 133.9, 133.9*, 
168.7*, 169.9, 170.7*, 172.3. UPLC-MS gradient A: tR = 
1.43 min (>95%), m/z 341.4 ([M + H]+, C20H25N2O3+ calcd 
341.2). !
N-benzhydryl-N-(3-morpholino-3-oxopropyl)acetamide 
(6g). Yield: 181 mg (18%) as a white solid. 1H NMR (300 
MHz, CDCl3)!δ  =!1.58*/1.91 (2 × 
m, 2H, H-5), 2.22/2.28* (2 × s, 
3H, H-7), 2.85*/3.23 (2 × t, 2H, J 
= 4.9 Hz, H-6), 3.45–3.75 (4 × m, 
8H, H-1, H-2, H-3, H-4), 
6.24*/7.18 (2 × s, 1H, H-8), 7.19–7.40 (2 × m, H-o, H-m, H-
p). .13C NMR (75 MHz, CDCl3)!δ = 21.8*, 22.3, 31.1, 32.2* 
41.3, 41.5, 42.4*, 45.3*, 45.6, 60.2*, 65.9, 66.2*, 66.5, 66.6*, 
66.7, 127.5*, 128.0, 128.5* (2C), 128.6, (2C), 128.8 (2C), 
128.9* (2C), 138.6, 139.4*, 168.6*, 169.4, 170.8*, 171.3. 
UPLC-MS gradient A, tR = 1.51 min (>95%), m/z 367.4 ([M 
+ H]+, C22H27N2O3+ calcd 367.5). 
N-(3-morpholino-3-oxopropyl)-N-phenylacetamide (6h). 
Yield: 154 mg (20%) as a red oil. 1H-NMR (300 MHz, 
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CDCl3)!δ =!1.79 (s, 3H, H-7), 2.53 (t, 2H, J = 6.4 Hz, H-5), 
2.93–4.17 (4 × t, 4 × 2H J = 4.8 
Hz, H-1, H-2, H-3, H-4), 4.15 (t, 
2H, J = 7.5 Hz, H-6), 6.95–7.12 (2 
× m, 5H, H-o, H-m, H-p). 13C 
NMR (75 MHz, CDCl3)!δ = 22.7,  
31.4,  41.7,  46.0,  46.4,  66.6, 
66.7,  127.8 (2C), 128.0, 129.7 (2C), 142.9, 169.2, 170.5. 
UPLC-MS gradient A, tR = 1.06 min (>95%), m/z 277.3 ([M 
+ H]+, C15H21N2O3+ calcd 277.3).!
General procedure for trifluoroacetylation.  
The monomer (3a, 3e, 3f, 4a, 4e, and 4f) was dissolved in 
CH2Cl2 (3mL/mmol) and cooled to 0 °C. Then triethylamine 
(3 equiv) and trifluoroacetic anhydride ( 2 equiv) were added. 
After stirring for 4 h, the reaction was taken up in saturated 
aqueous sodiumhydrogen carbonate (50 mL), and extracted 
with ethyl acetate (3 × 100 mL). The combined organic 
phases were dried (Na2SO4), filtered and evaporated. The 
crude product was purified by VLC (3 × 6 cm column, 
hexane–EtOAc, 5% gradient). 
(S)-tert-Butyl 3-(2,2,2-trifluoro-N-(1-phenylethyl)-
acetamido)propanoate (7a). Yield: 383 mg (69%), as a clear 
oil. 1H NMR (300 MHz, CDCl3)!
δ = 1.37/1.39* (2 × s, 9H, H-1), 
1.63*/ 1.67 (2 × s, 3H, J = 7.0Hz, 
H-4), 2.04/2.42 (2H, H-2), 
3.35/3.55* (2H, H-3), 2.30/2.75* 
(2 × q, 1H, J = 6.9 Hz, H-5), 7.38 
(m, 5H, H-o, H-m, H-p). 13C NMR (75 MHz)! δ= 
16.5*, 17.6, 28.1 (3C), 33.4, 36.4*, 39.8, 54.8* 55.4, 81.0, 
81.4*, 116.9 (q, JC-F = 287.0 Hz), 127.4 (2C), 127.9* (2C) 
128.5*, 128.6, 129.0 (2C), 129.1 (2C), 137.9, 138.7*, 156.7 
(q, JC-O = 35.9 Hz), 169.9*, 170.5. UPLC-MS gradient A, tR = 
2.36 min (>95%), m/z 368.2 ([M + Na]+, C17H22F3NO3Na+ 
calcd 368.4), [α]589.2: –43° (c = 2.3, 293 K, CHCl3)!
(S)-tert-Butyl-3-(2,2,2-trifluoro-N-(1-(naphthalen-1-yl)-
ethyl)acetamido) propanoate (7e). Yield 252 mg (80%) as a 
clear oil. 1H NMR (300 MHz, 
CDCl3)! δ = 1.18/2.00/2.25* (3 
× m, 2H, H-2), 1.28 (s, 9H, H-
1), 1.72/1.84* (2 × d, 3H, J = 
6.9 Hz, H-4), 3.35 (m, 2H, H-
3), 5.93*/6.53 (2 × q, 1H, J = 
7.0 Hz, H-5), 7.48–7.91 (4 × m, 
5H, H-o, H-m, H-p). 13C NMR (75 MHz, CDCl3) 
δ = 16.5, 19.8, 28.1 (3C), 33.4*, 35.6, 38.9, 40.5*, 50.7, 
53.2*, 81.2, 116.8 ( q, JC-F = 291.7 Hz), 122.5*, 122.9, 125.3, 
125.6, 125.8*, 126.3*, 126.5, 127.3*, 127.7, 129.2, 129.5*, 
129.9, 132.2, 133.4, 133.8, 157.3 (q, JC-O = 36.1 Hz), 169.7. 
UPLC-MS gradient A, tR = 2.55 min (>95%), m/z 418.2 ([M 
+ Na]+, C21H24F3NO3Na+ calcd 418.4). [α]589.2: –41° (c = 1.7, 
293 K, CHCl3).!
tert-Butyl 3-(2,2,2-trifluoro-N-(naphthalen-1-ylmethyl)-
acetamido)propanoate (7f). Yield: 352 mg (77%) as a clear 
oil. 1H NMR (300 MHz, CDCl3)! δ = 1.39*/1.42 (2 × s, 
9H, H-1),  2.48*/2.61 (2 × t, 2H, J = 7.1 Hz, H-2), 3.63 (m, 
2H, H-3), 5.16/5.23* (2 × s, 2H, H-4), 7.21–7.93 (7H, H-a, 
H-b, H-c, H-d, H-e, H-f, H-g). 13C NMR (75 MHz, CDCl3)!
δ = 27.9, 28.0*, 32.8, 34.6*, 
42.1*, 44.1, 47.4, 49.4*, 81.2*, 
81.5, 116.5*/116.7 (q, JC-F = 
288.4 / 288.2 Hz), 121.9*, 
122.9, 123.5*, 125.2, 125.4*, 
126.2*, 126.2, 126.4, 126.7*, 
129.9, 128.5*, 128.9, 129.1*, 
129.1, 130.0, 130.5, 130.6*, 131.3*, 133.7* 133.9. UPLC-
MS gradient A, tR = 2.51 min (>95%), m/z 404.3 ([M + Na]+, 
C20H22F3NO3Na+ calcd 404.4). 
(S)-2,2,2-trifluoro-N-(3-morpholino-3-oxopropyl)-N-(1-
phenylethyl)acetamide (8a). Yield: 242 mg (42%). 1H NMR 
(300 MHz, CDCl3)!
δ = 1.59*/1.72 (2 × d, 3H, J = 
7.0*/7.0 Hz, H-9), 2.22*/2.46 (2 × 
m, 2H, H-5), 2.66/2.98* (2 × m, 
2H, H6), 2.73*/2.85 (2 × s, 3H, H-
7), 3.38–4.04* (2 × broad m, 8H, 
H-1, H-2, H-3, H-4), 5.57* (q, 1H, J = 6.9 Hz, H-8), 7.25–
7.45 (broad m, 6H, H-8, H-o, H-m, H-p). 13C NMR (75 MHz, 
CDCl3) δ = 15.9*, 17.3*, 30.7, 33.2*, 39.8*, 40.5, 41.8, 
45.3*, 54.7, 54.1*, 55.4, 66.3*, 66.5, 66.7*, 116.6 (q , JC-F = 
288.9 Hz ), 127.4, 128.1*, 128.3*, 128.5, 128.9*, 129.0, 
137.7, 138.9*, 156.7 (q, JC-O = 35.2 Hz), 168.2*, 168.8. 
UPLC-MS gradient B, tR = 1.95 min (>95%), m/z 359.2 ([M 
+ H]+, C17H22F3N2O3+ calcd 359.4), [α]589.2: –42° (c = 1.0, 293 
K, CHCl3).!
(S)-2,2,2-trifluoro-N-(3-morpholino-3-oxopropyl)-N-(1-
(naphthalen-1-yl)ethyl) acetamide (8e). Yield 212 mg 
(43%) as a clear oil that can be 
crystallized from chloroform and 
hexane. 1H NMR (300 MHz, 
CDCl3)! δ = 0.71/1.09*/1.72 (3 × 
m, 2H, H-5), 1.65/1.79 (2 × d, 3H, 
J = 6.8 Hz, H-7), 
2.25/2.47/2.69*/2.88* (2H, H-6), 
3.07–3.67 (broad m, 8H, H-1, H-2, H-3, H-4), 5.87*/6.52 (2 
× q, 1H, J = 6.8 Hz, H-8), 7.41–7.97 (7H, H-a, H-b, H-c, H-
d, H-e, H-f, H-g). 13C NMR (75 MHz, CDCl3) δ = 16.3, 
19.7*, 30.7*, 32.7, 39.2, 41.3*, 41.7, 41.8*, 45.0. 45.5*, 50.4, 
53.2*, 66.2, 66.5*, 66.8, 66.9*, 116.8 (q, JC-F = 287.2 Hz ), 
123.2, 125.6, 125.7*, 125.9, 126.3*, 126.7, 127.2*, 127.8, 
128.9, 129.4*, 129.6, 130.0*, 132.4, 133.0*, 133.6, 133.9, 
157.3/158.2 (2 × q, JC-O = 35.0 Hz), 168.2. UPLC-MS 
gradient B, tR = 2.17 min (>95%), m/z 409.2 ([M + H]+, 
C21H24F3N2O3+ calcd 409.4). [α]589.2: –49° (c = 11 , 293 K, 
CHCl3). 
2,2,2-trifluoro-N-(3-morpholino-3-oxopropyl)-N-
(naphthalen-1-ylmethyl) acetamide (8f). Yield: 195 mg 
(31%) as a clear oil. 1H NMR 
(300 MHz, CDCl3) 
δ = 2.33*/2.69 (m*/t, 2H, J = 
6.9, H-5), 3.10*/ 3.42 (2 × t, 2H, 
J = 4.8*/4.6 Hz, H-6), 3.47–3.80 
(broad m, 8 H, H-1, H-2, H-3, 
H-4), 5.18*/5.29 (2 × s, 2H, H-
7), 7.22–7.95 (7H, H-a, H-b, H-c, H-d, H-e, H-f, H-g). 13C 
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NMR (75 MHz, CDCl3)!δ = 30.5, 32.1*, 41.9*, 42.2, 43.0*, 
44.8, 45.6*, 46.1, 48.4*, 49.8, 66.3* 66.6, 66.7*, 66.7, 116.5 / 
116.7*(2 × q, JC-F = 288.0 / 288.0 Hz), 122.1, 123.1*, 123.8, 
125.4*, 125.5, 126.3, 126.4*, 126.8*, 126.9, 127.1*, 128.7, 
129.0*, 129.1, 129.3*, 130.4*/130.5, 130.8, 131.4*, 
157.3/158.2 (2 × q, JC-O = 36.7/36.7 Hz), 168.2*, 169.3. 
UPLC-MS gradient A, tR = 2.07 min (>95%), m/z 417.3 ([M 
+ Na]+, C20H21F3N2O3Na+ calcd 417.4). 
General procedure for C-terminal thioamide formation.  
Lawesson’s reagent (1.5 equiv) was dissolved in toluene 
5mL/mmol) and heated to 110 °C under reflux. After the 
reagent was dissolved, the morpholine-containing monomer 
(4a, e, and f) was added and the reaction was heated at reflux 
for 3 hours. The solvent was removed in vacuo, and the crude 
product was purified by VLC (3 × 6 cm, CH2Cl2–MeOH, 
0.2% gradient from 0→5%). 
 
(S)-1-morpholino-3-((1-phenylethyl)amino)propane-1-
thione (9a). Yield: 275 mg (45%) 
as a brown oil, UPLC-MS gradient 
B, tR = 0.87min (50%), m/z 279.2 
([M + H]+, C15H23N2OS+ calcd 
279.4). 
 
(S)-1-morpholino-3-((1-(naphthalen-1-yl)ethyl)amino)-
propane-1-thione (9e). Yield: 453 
mg (58%) as a brown oil, UPLC-MS 
gradient B, tR = 1.10 min (83%), m/z 
329.3 ([M + H]+, C19H25N2OS+ calcd 
329.5). 
 
1-morpholino-3-((naphthalen-1-ylmethyl)amino)propane-
1-thione (9f). Yield: 127 mg (21%) 
as a brown oil, UPLC-MS gradient 
B, tR = 1.30min, m/z 315.2 ([M + 
H]+, C18H23N2OS+ calcd 315.4). !
General procedure for acetylation of C-terminal 
thioamides. 
The thioamide (1 equiv) was dissolved in CH2Cl2 (5 
mL/mmol) and cooled to 0 °C. Then i-Pr2NEt (2 equiv) and 
acetylchloride (2 equiv) were added and the reaction was 
stirred for 3 h at 0 °C. The solvent was evaporated, and the 
crude product purified by VLC (3 × 6 cm column, hexane–
EtOAc, 5% gradient). 
(S)-N-(3-morpholino-3-thioxopropyl)-N-(1-phenylethyl)-
acetate (10a). Yield: 0.42 g (59 %) as a brown oil. 1H NMR 
(300 MHz, CDCl3) 
δ = 1.43*/1.65 (2 × d, 3H, J = 7.1 
Hz, H-9), 2.24/2.24* (2 × s, 3H, 
H-7), 2.96–4.28 (7 × m, 12 H, H-
1, H-2, H-3, H-4, H-5, H-6), 
5.09/6.06* (2 × q, 1H, J = 7.0 Hz, H-8), 7.24–7.40 (m, 5H, 
H-o, H-m, H-p). 13C NMR (75 MHz, CDCl3) δ = 16.2*, 18.5, 
22.2, 42.3*, 42.5, 43.0, 43.7*, 49.5*, 49.5, 50.9, 50.8*, 56.8, 
66.4*, 66.9, 67.1, 126.7, 127.8*, 128.0, 128.4*, 128.7*, 
129.0, 139.9, 171.2, 199.7. UPLC-MS gradient B, tR = 1.71 
min (>95%), m/z 321.2 ([M + H]+, C17H25N2O2S+ calcd 
321.4), [α]589.2: –33° (c = 1.6 , 293 K, CHCl3). 
(S)-N-(3-morpholino-3-thioxopropyl)-N-(1-(naphthalen-1-
yl)ethyl)acetamide (10e). Yield: 0.228 g (44%), as a clear 
oil. 1H0NMR! (300! MHz, 
CDCl3)! δ = 1.31/2.20* (m, 2H, 
H-5), 1.62/1.81* (2 × d, 2H, J = 
6.8 Hz, H-7), 2.45/2.84* (2 × 
m, 2H, H-6), 2.28/2.40* (2 × s, 
3H, H-7), 3.09–4.18 (broad m, 
8H, H-1, H-2, H-3, H-4), 
5.70*/6.65 (2 × q, 1H, J = 6.9 Hz, H-8), 7.54–7.89 (2 × broad 
m, 8H, H-a, H-b, H-c, H-d, H-e, H-f, H-g). 13C NMR (75 
MHz, CDCl3) δ = 16.8, 23.3, 42.0, 43.7, 48.1, 49.3, 49.5, 
66.3, 66.5, 124.2, 125.1, 125.3, 126.7, 127.0, 127.7, 128.7, 
129.0, 129.5, 129.6, 170.9, 199.1. UPLC-MS gradient B: tR = 
2.00 min (>95%), m/z 371.2 ([M + H]+, C21H26N2O2S+ calcd 
371.5). [α]589.2: –87° (c = 0.3 , 293 K, CHCl3).!
N-(3-morpholino-3-thioxopropyl)-N-(naphthalen-1-
ylmethyl)acetamide (10f). Yield: 0.061 g (42%) as a clear 
oil. 1H-NMR (300 MHz, 
DMSO-d6) δ = 2.01*/2.19 (2 × 
s, 3H, H-7), 
2.62*/3.51/3.63/3.85*/4.14 (m, 
8H, H-1, H-2, H-3, H-4), 3.05 
(m, 2H, H-5), 3.57 (m, 2H, H-
6), 5.02/5.11* (2 × s, 2H, H-8), 
7.22–8.05 (m, 7H, H-a, H-b, H-c, H-d, H-e, H-f, H-g). 13C 
NMR (75 MHz, CDCl3)!δ = 21.6, 41.9, 46.7, 50.1, 50.7, 50.9, 
66.6, 67.0, 122.1, 122.6, 125.6, 126.3, 126.8, 127.8, 128.4, 
129.2, 130.7, 131.3, 169.4, 187.9. UPLC-MS gradient B: tR = 
1.95 min (>95%), m/z 357.2 ([M + H]+, C20H25N2O2S+ calcd 
357.5).!
General procedure for N-terminal thioacetyl formation. 
Lawesson’s reagent (0.6 equiv) was dissolved in toluene 
5mL/mmol) and heated to 110°C under reflux. After the solid 
was dissolved, the acetylated monomer (5a, e, and f) was 
added and the reaction was refluxed for 1 hour. The solvent 
was removed in vacuo. The crude product was purified by 
VLC (3 × 6 cm, hexane–EtOAc, 5% gradient). 
(S)-tert-butyl 3-(N-(1-phenylethyl)ethanethioamido)-
propanoate (11a). Yield: 145 
mg (69%) as a yellow oil, 
UPLC-MS gradient B, tR = 2.52 
min (>95%), m/z 308.2 ([M + 
H]+, C17H26NO2S+ calcd 308.4). 
(S)-tert-butyl 3-(N-(1-(naphthalen-1-yl)ethyl)ethane-
thioamido)propanoate (11e). 
Yield: 289 mg (74%) as a 
yellow oil, UPLC-MS gradient 
B, tR = 2.47min (>95%), m/z 
358.3 ([M + H]+, C21H28NO2S+ 
calcd 358.5). 
tert-butyl 3-(N-(naphthalen-1-ylmethyl)ethane-
thioamido)propanoate (11f): Yield: 618 mg (70%) as a 
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yellow oil, UPLC-MS gradient B, tR = 2.17min (>95%), m/z 
344.3 ([M + H]+, C21H28NO2S+ 
calcd 344.5). 
 
 
 
 
General procedure for morpholine amide formation in N-
terminal thioamides.  
The thioacetylated monomers (11a, e, and f) were dissolved 
in DMF (2mL/mmol) and hydrolyzed using 1M LiOH (4 
eqiuv). After 2 hours the reaction mixture was taken up in 
1M HCl and extracted with EtOAc (3 × 100 mL). The 
combined organic phases were dried (Na2SO4), filtered, and 
evaporated to dryness. The crude product, HBTU (2 equiv) 
and i-Pr2NEt (2 equiv) were dissolved in CH2Cl2 (2 
mL/mmol). After stirring for 10 min at room temperature, 
morpholine (2 equiv) was added. After stirring overnight, the 
solvent was evaporated and the crude product was purified by 
VLC (3 × 6 cm, CH2Cl2–MeOH, 0.2% gradient from 
0→5%). 
(S)-N-(3-morpholino-3-oxopropyl)-N-(1-phenylethyl)-
ethanethioamide (12a). Yield: 91 mg (62%) as a clear oil. 
1H NMR (300 MHz, CDCl3) δ 
= 1.59*/1.72 (2 × d, 3H, J = 7.0 
Hz, H-9), 2.22*/2.46 (2 × m, 2H, 
H-5), 2.66/2.98* (2 × m, 2H, H6), 
2.73*/2.85 (2 × s, 3H, H-7), 3.38–
4.04 (2 × broad m, 8H, H-1, H-2, H-3, H-4), 5.57* (q, 1H, J = 
6.9 Hz, H-8), 7.25–7.45 (broad m, 6H, H-8, H-o, H-m, H-p). 
13C NMR (75 MHz, CDCl3) δ = 30.2, 31.1* 32.7*, 32.9, 38.7, 
41.8*, 42.0, 45.5*, 46.2, 47.2*, 51.3, 55.0, 66.2*, 66.6*, 66.7, 
66.8, 122.1, 122.3, 123.6, 125.4*, 125.6, 126.3*, 126.3, 
126.7*, 126.8, 127.0*, 128.4, 128.8*, 129.1, 130.0, 130.4, 
131.0*, 131.6*, 133.8, 167.9*, 169.4, 201.2*, 201.9. UPLC-
MS gradient A: tR = 1.62 min (>95%), m/z 311.2 ([M + H]+, 
C17H25N2O2S+ calcd 321.4). [α]589.2: –133° (c = 0.8, 293 K, 
CHCl3). 
(S)-N-(3-morpholino-3-oxopropyl)-N-(1-(naphthalen-1-
yl)ethyl)ethanethioamide (12e). Yield: 172 mg (57%) as a 
yellow oil. 1H-NMR (300 MHz, 
CDCl3)! δ = 0.80/1.75 (2 × m, 
2H, H-5), 1.68/1.80* (2 × d, 2H, 
J = 6.7 Hz, H-9), 2.20/2.42 (2 × 
m, 2H, H-6), 2.68/3.03* (2 × s, 
3H, H-7), 3.07–4.30 (8H, H-1, 
H-2, H-3, H-4), 6.00* (q, 1H, J 
= 6.7 Hz, H-8), 7.46–8.08 (broad m, 8H, H-8, H-a, H-b, H-c, 
H-d, H-e, H-f, H-g). 13C NMR (75 MHz, CDCl3)!
δ = 14.6, 17.2*, 17.6*, 18.6*, 29.6*, 31.4, 32.7, 32.82*, 41.6, 
43.4, 44.9, 45.5*, 46.1*, 55.5*, 56.4, 57.6*, 66.0, 66.4*, 66.5, 
66.6*, 122.1, 124.4, 125.5, 125.7, 126.2*, 126.4, 127.3*, 
127.6, 128.5, 129.1, 129.3*, 129.7*, 131.7*, 132.8, 133.2, 
133.2*, 133.5*, 135,2, 167.7, 168.9*, 199.3. UPLC-MS 
gradient B: tR = 1.81 min (>95%), m/z 371.3 ([M + H]+, 
C21H26N2O2S+ calcd 371.5). [α]589.2: –309° (c = 2.8, 293 K, 
CHCl3).!
N-(3-morpholino-3-oxopropyl)-N-(naphthalen-1-
ylmethyl)ethanethioamide (12f). Yield: 186 mg (56%) as a 
clear oil. 1H NMR (300 MHz, 
CDCl3) δ = 2.25*/3.01 (2 × t, 
2H, J = 6.9 Hz, H-5), 
2.65/2.84* (2 × s, 3H, H-7), 
3.45–3.70 (8H, H-1, H-2, H-3, 
H-4), 3.87*/4.30 (2 × s, 2H, J = 
6.8 Hz, H-6), 5.46/5.78* (2 × s, 
2H, H-8), 7.10–8.03 (m, 7H, H-a, H-b, H-c, H-d, H-e, H-f, H-
g). 13C NMR (75 MHz, CDCl3) δ = 30.2, 31.1* 32.7*, 32.9, 
38.7, 41.8*, 42.0, 45.5*, 46.2, 47.2*, 51.3, 55.0, 66.2*, 66.6*, 
66.7, 66.8, 122.1, 122.3, 123.6, 125.4*, 125.6, 126.26*, 
126.3, 126.7*, 126.8, 127.0*, 128.4, 128.8*, 129.1, 130.0, 
130.4, 131.0*, 131.6*, 133.8, 167.9*, 169.4, 201.2*, 201.9, 
UPLC-MS gradient B: tR = 1.97min (>95%), m/z 357.1 ([M + 
H]+, C21H26N2O2S+ calcd 357.5). 
(S)-N-(1-(naphthalen-1-yl)ethyl)-N-(2-oxo-2-(piperidin-1-
yl)ethyl)acetamide (13). Yield: 53 mg as a pale yellow oil. 
1H NMR (300 MHz, CDCl3)!
δ = 1.29-166 (broad m, 6H, H-2, H-
3, H-4), 1.57/1.78* (2 × d, J = 7.0 
Hz, 2H, H-9), 2.03/2.30* (2 × s, 
3H, H-7), 2.86-3.79 (m, 6H, H-1, 
H-5, H-6), 5.79*/6.69 (2 × q, J = 
7.1 Hz), 7.40-8.10 (m, 7H, H-a, H-
b, H-c, H-d, H-e, H-f, H-g). 13C 
NMR (75 MHz, CDCl3) δ = 16.7, 19.9*, 21.8*, 22.3, 24.4, 
24.6*, 25.6, 26.3*, 26.4, 43.5, 44.0*, 44.8, 45.4*, 45.8, 46.2*, 
48.3, 49.8*, 54.0*, 54.5*, 122.6*, 124.1*, 124.4, 124.8, 
124.9, 125.4*, 126.1*, 126.2, 126.9, 127.0*, 128.5, 128.8*, 
128.9, 129.2*, 131.0*, 132.1, 133.9, 134.0*, 136.5, 137.2*, 
166.1, 166.7*, 171.4*, 171.5. UPLC-MS gradient B: tR = 
1.92 (>95%). [α]589.2: –25° (c = 0.6, 293 K, CH2Cl2). 
(S)-2,2,2-trifluoro-N-(1-(naphthalen-1-yl)ethyl)-N-(2-oxo-
2-(piperidin-1-yl)ethyl)acetamide (14). Yield: 45 mg as a 
pale yellow oil. 1H NMR (300 MHz, 
CDCl3)! δ = 1.26-1.66 (broad m, 6H, 
H-2, H-3, H-4), 1.72/1.89 (2 × d, J = 
6.8 Hz, 3H, H-8), 2.87-3.10/3.26-
3.40/3.47-3.70 (4H, H-1, H-5), 
3.52/3.90/4.24* (3 × d, J = 18.4 Hz, 
2H, H-6), 6.04*/6.52 (2 × q, J = 6.9 
Hz), 7.45-7.91 (7H, H-a, H-b, H-c, H-
d, H-e, H-f, H-g). 13C NMR (75 MHz, CDCl3) δ = 15.1, 
18.4*, 23.1, 24.2 (broad), 24.8 (broad), 29.7*, 36.0*, 36.8*, 
37.3*, 37.4*, 42.5 (broad), 43.4 (broad), 43.5 (broad), 43.9*, 
44.5 (broad), 49.5*, 50.4, 52.4*, 115.4 (q, JC-F = 288.3 Hz), 
122.0, 123.6, 123.8*, 124.3, 125.0*, 125.1, 125.9*, 126.0, 
127.6, 127.9*, 128.4, 130.6, 132.7, 132.9, 157.3 (q, JC-O = 
35.0 Hz), 163.1*, 164.0. UPLC-MS gradient B: tR = 2.36 
(>95%). [α]589.2: –13° (c = 0.6, 293 K, CH2Cl2). 
(S)-N-(1-(naphthalen-1-yl)ethyl)-N-(2-oxo-2-(piperidin-1-
yl)ethyl)ethanethioamide (15). Yield: 52 mg as a white 
solid. 1H NMR (300 MHz, CDCl3)!δ = 1.23-1.80 (m, 6H, H-
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2, H-3, H-4), 1.70/1.91* (2 × d, J 
= 6.9 Hz, H-9), 2.60/2.94* (2 × s, 
H-7), 2.90-3.75 (m, 4H, H-1, H-
5), 3.79*/3.80/3.93/5.24* (4 × d, 
J = 17.2 Hz, 2H, H-6), 6.13* (q, 
J = 7.0 Hz, H-8), 7.48-8.11 (m, 
8H, H-8, H-a, H-b, H-c, H-d, H-
e, H-f, H-g). 13C NMR (75 MHz, 
CDCl3) δ = 14.9, 19.1*, 22.5*, 22.7*, 24.4, 24.7*, 25.6, 
25.7*, 26.2*, 26.4, 32.4*, 33.3, 43.5, 44.7*, 45.9, 46.6*, 48.0, 
51.0*, 57.3, 58.5*, 122.4*, 124.4*, 124.9, 125.0, 125.5, 
125.6*, 126.3*, 126.5, 127.3, 127.5*, 128.6, 129.3*, 129.4*, 
129.5, 131.0*, 132.5, 133.9, 134.1*, 135.8*, 135.9, 164.0, 
164.8*, 201.4*, 202.0. UPLC-MS gradient B: tR = 2.24 
(>95%). [α]589.2: –55° (c = 0.6, 293 K, CH2Cl2). 
 
 
 
Table S1. High-resolution mass spectrometry (HRMS) Data.a 
compd. [M+H]+ calcd. found 
(m/z) 
ΔM 
(ppm) 
3a C15H23NO2 250.1802 250.1805 1.2 
3b C15H29NO2 256.2271 256.2275 1.6 
3c C14H21NO2 236.1645 236.1645 0.0 
3e C19H25NO2 300.1958 300.1958 0.0 
3f C18H23NO2 286.1802 286.1802 0.0 
3h C13H19NO2 222.1489 222.1491 0.9 
5a C17H25NO3 292.1907 292.1907 0.0 
5b C17H31NO3 298.2377 298.2378 0.3 
5c C16H23NO3 278.1751 278.175 0.4 
5d C13H25NO3 244.1907 244.1905 0.8 
5e C21H27NO3 342.2064 342.2068 1.2 
5f C20H25NO3 328.1904 328.1908 1.2 
5g C22H27NO3 354.2064 354.2069 1.4 
5h C15H21NO3 264.1594 264.1596 0.6 
6a C17H24N2O3 305.1860 305.1859 0.3 
6b C17H30N2O3 311.2329 311.2331 0.6 
6c C16H22N2O3 291.1703 291.1706 1.0 
6d C13H24N2O3 257.1860 257.1861 0.4 
6e C21H26N2O3 355.2016 355.2017 0.3 
6f C20H24N2O3 341.1860 341.1862 0.6 
6g C22H26N2O3 367.2016 367.2021 1.4 
6h C15H20N2O3 277.1547 277.1551 1.4 
7a C17H22F3NO3 346.1625 346.1623 0.6 
7e C21H24F3NO3 396.1781 396.1779 0.5 
7f C20H22F3NO3 382.1625 382.1623 0.5 
8a C17H21F3N2O3 359.1577 359.1579 0.6 
8e C21H23F3N2O3 409.1734 409.1739 1.2 
8f C20H21F3N2O3 395.1577 395.1583 1.5 
10a C17H24N2O2S 321.1631 321.1634 0.9 
10e C21H26N2O2S 371.1788 371.1790 0.5 
10f C20H24N2O2S 357.1631 357.1635 1.1 
12a C17H24N2O2S 321.1631 321.1641 3.1 
12e C21H26N2O2S 371.1788 371.1790 0.5 
12f C20H24N2O2S 357.1631 357.1640 2.5 
14 C21H23F3N2O2 393.1784 393.1788 1.1 
15 C21H26N2OS 355.1839 355.1840 0.3 
aDetermined by ESI-TOF HRMS on a maXis G3 quadrupole 
time-of-flight (TOF) mass spectrometer (Bruker Daltonics, 
Bremen, Germany) equipped with an electrospray (ESI) 
source. 
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Trianguler Prism-Shaped Helices—Synthesis and Structural 
Determination of β-Peptoid Oligomers** 
Jonas S. Laursen, Pernille Harris, and Christian A. Olsen* 
Abstract: “β-Peptoids” are N-alkylated β-aminopropionic acid 
residues (or N-alkyl-β-alanines). Here, we present the first examples 
of high-resolution structures of linear oligomeric constructs of this 
type of peptide mimic. We describe synthesis and characterization of 
oligomers up to the hexamer length containing two different types of 
N-alkyl side chains, and furthermore investigation of the effect of N-
terminal trifluoroacetylation. Our X-ray crystallographic data 
reveal right-handed helical conformations with exactly three 
residues per turn and a helical pitch of 9.6–9.8 Å between turns in 
the solid state. These are the longest helical peptoid structures 
solved by X-ray crystallography to date. 
The ability to mimic or complement native protein and peptide 
folds using nonnatural oligomers endowed with resistance towards 
proteolysis holds promise for the design of chemotypes with 
valuable applications in medical and materials sciences. Oligomeric 
architectures able to adopt well-defined folding patterns have been 
coined “foldamers”,[1] and several peptidomimetic designs have 
demonstrated this type of behavior,[2] including β-peptides[3, 4] 
and ”peptoids” (N-alkylglycines).[5] The β-peptoids, first described 
as dimers and trimers by Hamper and coworkers,[6] combine the 
structural features of the two latter mentioned foldamers (Figure 1A), 
and have been suggested by theoretical methods to be able to adopt 
helical conformations.[7] However, CD-spectroscopical evaluation of 
oligomers containing β-peptoid units with α-chiral side chains have 
proven inconclusive,[8] and high-resolution structures have been 
lacking, except for head-to-tail cyclized species.[9] Nevertheless, β-
peptoid units have been incorporated in oligomers showing non-
hemolytic antimicrobial,[10, 11] antiplasmodial,[12] and cell-
penetrating[13] activities as well as excellent stability towards 
proteolytic enzymes.[11] Inspired by studies performed with α-
peptoid model systems,[14, 15] we and others have recently reported 
on tunability of the cis–trans-amide bond equilibria of the tertiary 
amide bonds in β-peptoids (Figure 1B).[16, 17] Building on these 
insights, we here report the first high-resolution structures of helical 
β-peptoid oligomers, which should enable a more informed and 
structure-based design of foldameric materials of this type in the 
future. 
We planned to investigate oligomers up to the hexamer length. 
Since high-resolution structures of α-peptoids have been 
successfully obtained for oligomers of just 4–5 residues in length, 
we envisioned that a hexamer might be sufficient to acquire 
stabilized folding. Two different α-chiral side chains were chosen 
(Figure 1C), the N-(S)-1-phenylethyl (1–5), which has been studied 
in both α- and β-peptoids, and the N-(S)-1-(1-naphthyl)ethyl (6–10), 
which was applied in an α-peptoid tetramer structure solved by X-
ray crystallography.[18]  
Figure 1. (A) Generic structures of the backbone architectures of peptoids (i.e., 
α-peptoids), β3-peptides (β2- and disubstituted β-peptides are not shown), and 
β-peptoids. (B) Depiction of the equilibrium of transoid and cisoid amide 
conformations in peptoid residues. (C) β-Peptoid oligomers prepared for 
structural and spectroscopic evaluation in this study. 
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Table 1. Overall Cis–Trans-Amide Bond Ratios (Kcis–trans) Determined by NMR Spectroscopy. 
N-(S)-1-Phenylethyl series 
Compound 1a 1b 2a 2b 3a 3b 4a 4b 5a 5b 
CD3CN 0.8 0.3 0.8 0.4 0.8 0.5 0.7 0.5 0.7 0.5 
C6D6 0.6 0.3 0.6 0.3 0.6 0.3 0.5 0.3 0.4 0.3 
N-(S)-1-(1-Naphthyl)ethyl series 
Compound 6a 6b 7a 7b 8a 8b 9a 9b 10a 10b 
CD3CN 5.2 5.4 5.2 6.0 5.9 7.3 –[a] –[a] –[a] –[a] 
C6D6 4.8 4.0 4.4 4.0 5.6 4.3 6.4 4.9 11.0 10.0 
[a] Limited solubility of this compound did not allow for NMR analysis in acetonitrile-d6. 
The N-(S)-1-phenylethyl side chain, although shown to 
successfully induce helical conformations in α-peptoids,[19] does not 
induce significant control of the amide bond cis–trans equilibrium. 
It is therefore not entirely surprising that β-peptoid oligomers of this 
type have not previously been unambiguously shown to establish 
robust secondary structures. In recent monomer-based model 
systems, however, we found that the trans-amide conformation was 
preferred upon trifluoroacetylation of N-(S)-1-phenylethyl 
monomers.[17] The effect of this substitution was therefore included 
in the present investigation (1b–5b) along with the acetylated 
control compound series 1a–5a. The second series contained the N-
(S)-1-(1-naphthyl)ethyl side chain (6a–10d), which was first 
introduced in β-peptoids,[20] and later found to strongly induce cis-
amide conformations in model systems[15, 17] as well as in helical[18] 
and ribbon-shaped[21] α-peptoids. All compounds were prepared by 
a subunit approach in solution, essentially as previously described[22] 
(see, the Supporting Information for details). For the considerably 
sterically congested naphthyl-containing compounds, in particular, 
we found the necessary reaction times to increase with the growing 
length of the oligomer. For future preparation of longer chains we 
therefore envision that a fragment-based strategy may be necessary.  
1H NMR spectra of the oligomers exhibited significant signal 
overlapping due to the identical side chains throughout each series 
as would be expected. We therefore focused on the shifts 
corresponding to the side chain methine protons to determine overall 
cis–trans-amide bond ratios (Table 1). NMR data showed no 
significant trend on the overall cis–trans ratios for the compounds in 
the N-(S)-1-phenylethyl series (1–5). In the N-(S)-1-(1-
naphthyl)ethyl series (6–10), however, increases in Kcis–trans values 
could be observed upon elongation of the oligomers, as particularly 
evident for the constants determined for the hexamers in benzene 
(Table 1). Unfortunately, the two highest oligomers were not 
sufficiently soluble in acetonitrile to obtain NMR spectra of 
sufficient quality, but especially for the trifluoroacetylated series, 
there appears to be a slight increase in Kcis–trans from dimer to 
tetramer. Taken together, these values may indicate propensity for 
the oligomers to adopt length- as well as solvent-dependent 
secondary structures, although high-resolution measurements are 
required to determine whether this is the case.  
Gratifyingly, we were able to crystallize compounds 10a, 10b, 
and 10c by slow evaporation of MeOH–CHCl3 or benzene solutions 
of the compounds. Diffraction quality crystals were obtained for 10a 
and 10c from MeOH–CHCl3, and their structures were solved by X-
ray crystallography at 1.05 Å and 1.00 Å resolution, respectively. 
The N-terminally non-acylated compound 10c was solved first, and 
revealed a helical conformation of precisely three residues per turn 
and a pitch of ∼9.6 Ångström with only the N-terminal naphthyl side 
chain twisted away from the helix (Figure 2A). The remaining 
naphthyl groups were highly organized along each of the three faces 
of the helix to give an equilateral triangle when viewed down the 
helical axis (Figure 2B,C). The main helix thus adopts a triangular 
prism shape, not taking the N-terminal side chain into consideration.  
Figure 2. X-Ray crystal structure of compound 10c. (A) Side view. (B and C) 
End views from the C-terminal. The backbone is shown in orange and hydrogen 
atoms are omitted for clarity. Representations of X-ray crystal structures were 
prepared using the PyMOL Molecular Graphics System, Schrödinger, LLC. 
We envisioned, based on our monomer studies, that acetylation 
of the N-terminal would also force this amide into a cisoid 
configuration, and hoped that this would direct the final side chain 
to alignment along the third phase of the molecule. The X-ray 
crystal structure of compound 10a indeed confirmed this (Figure 3), 
as this compound turned out to crystallize in the highly symmetric 
R3 space group with only one -CH2CON(1-(1-naphthyl)ethyl)CH2- 
fragment in the asymmetric unit (see the CIF file in the Supporting 
Information for details). Thus, the crystal symmetry generates 
infinitely long, parallel chains, and this renders the t-butyl group 
  
3 
invisible, due to the 1:6 ratio of t-butyl to 1-(1-naphthyl)ethyl. This 
results in crystal packing where the helical segments are arranged in 
a head-to-tail manner to give highly regular elongated triangular 
threads (Figure 4) with a helical pitch of 9.8 Å (Figure 3A). To 
reveal the complete molecule, including the N-terminal-acetamido 
and C-terminal t-butyl ester groups, data sets were collected on 
several crystals and unsuccessful attempts were made to solve the 
structure in P1. This packing issue was not observed for compound 
10c due to the positioning of N-terminal side chain, and therefore 
enabled visualization of the full structure including the C-terminal t-
butyl (Figure 4A). 
Figure 3. X-Ray crystal structure of compound 10a. (A) Showing the backbone 
helical as sticks and side chains as lines (hydrogen atoms are omitted for 
clarity). (B) Spacefilling representation showing the packing of the naphthyl 
groups along the phases of the triangular prism-shaped conformation. 
Figure 4. X-Ray crystal packing. (A) Compound 10c viewed perpendicular to 
the helical axis with the N-terminal side chain pointing out of the plane. 
Additional representations of the packing are shown in Supplementary Figures 
S3 and S4. (B and C) Compound 10a, viewed from the end and perpendicular 
to the helical axis, respectively. Hydrogen atoms are removed for clarity. 
The torsion angles in the two helices are very similar (Table 2), 
and the extended structures compare reasonably well with one of the 
helical conformations previously suggested by density functional 
theory (DFT) calculations, albeit with a ∼20 degree difference in the 
ω and θ angles (Supplementary Table S1).[7] To the best of our 
knowledge, however, the present work provides the first 
experimental demonstration of the existence of this helical type. 
Most previously determined helical conformations of a β-peptidic 
nature have been shown to contain stabilizing hydrogen bond 
networks,[4] and investigation of oligomers of homologated proline 
residues indicated trans-amide-containing conformations.[23] Our 
structures are thus unique to the field of foldamers. The highly 
ordered, tight packing of the side chains along the three phases of 
the helical axis (Figure 3B) combined with their strong cis-amide 
inducing properties,[17] it appears that this type of side chain 
provides a particularly strong stabilization of this novel secondary 
structure motif. Furthermore, intramolecular distances indicate CH–
π interactions between backbone methylene group and side chain 
naphthyl groups, which may also contribute to stabilization and 
protection of the helical backbone from solvation (Supplementary 
Figure S4 and Table S2). This is quite different from the X-ray 
crystal structure reported for an α-peptoid tetramer containing the 
same side chains.[18] In agreement with that structure, however, as 
well as the findings from our previous monomer investigations, we 
did not see evidence for stabilizing n→π*Ar interactions in our 
crystal structure. On the other hand, our cis-amide conformations 
were in agreement with the recently described “bridged” effect.[24] 
In future work it will now be interesting to investigate the ratio of N-
(S)-1-(1-naphthyl)ethyl side chains to other functionalities, which 
are required to adopt stable secondary structure.  
Table 2. Torsion Angles in the Helical Structures. 
 
Compound 10a[a] 
ϕ θ ψ ω χ1[b] χ2[c] 
96.3 172.5 –175.3 –13.8 53.6 –80.4 
Compound 10c[a] 
ϕ θ ψ ω χ1b χ2c 
97.4 166.0 –173.9 –13.4 56.3 –73.8 
[a] Measured at residue 5 in the structure to give representative values for a 
residue within the helix. See Table S1 in the Supporting Information for dihedral 
angles of additional residues.  [b] Measured by the naphthyl substituent.  [b] 
Measured by the methyl substituent. 
Finally, we evaluated the compounds by CD spectroscopy. The 
CD spectra of the acetylated N-(S)-1-phenylethyl series (Figure 5A–
B) were similar to those previously reported for β-peptoids 
containing this side chain, whereas the N-(S)-1-(1-naphthyl)ethyl 
series (6a–10a) revealed a minimum at 224–228 nm and a 
maximum at 215–218 nm (Figure 5C). At first glance, we were 
surprised that these Cotton effects decreased with increasing length 
of the oligomer. However, both the minimum and the maximum 
were present in the CD spectrum of an acetyled monomer and not of 
a non-acetylated monomer (Supplementary Figure S5), which 
indicates that these signals are not indicative of secondary structure 
formation but rather a signature of the amide motif itself. Starting at 
the tetramer length (8a), on the other hand, a positive signal started 
to appear near 232 nm. This signal intensified with growing length 
of the oligomers, suggesting that this peak may be indicative of 
length-dependent secondary structure formation. 
We also obtained CD spectra of the trifluoroacetylated 
oligomers, which exhibited the same overall spectral shapes (Figure 
5D). Notably, six residues were necessary to obtain a positive signal 
N
O O
1-Naph
θω ψϕ
χ
H3C H
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at 232 nm in this series, suggesting that trifluoroacetylation has a 
negative effect on secondary structure formation in acetonitrile. In 
our monomer study, we observed stabilization of the cis-amide 
conformation upon trifluoroacetylation compared to acetylation, but 
this apparently does not translate into a stabilizing effect on 
oligomer secondary structure. This may be explained by a steric 
clash between the bulkier trifluoroacetyl group and the first 
backbone methylene group at the N-terminal. 
Figure 5. CD spectra of compounds 3a–5a (A), 3b–5b (B), 6a–10a (C), and 
6b–10b (D) in acetonitrile (∼60 µM). 
Figure 6. CD spectra of compound 10a at varying temperatures in acetonitrile 
(∼60 µM). 
To assess whether the positive signal at 232 nm is indicative of 
folding, we also collected CD spectra at temperatures in the range 
20–75 °C (Figure 6). The gradual decrease in signal intensity at 232 
nm upon heating is indeed indicative of temperature-mediated 
denaturation. Importantly, the remaining spectral shape was not 
affected significantly, which is in accordance with our hypothesis 
that this is not related to secondary structure. Furthermore, spectra 
recorded upon cooling were identical to those obtained before 
heating, indicating refolding of the structure (Supplementary Figure 
S6). However, CD spectroscopy of peptide analogues is not 
sufficient to derive specific secondary structures,[25] and although 
we find it likely that our oligomers may adopt some degree of 
helical conformation in solution based on our collective results, we 
stress that this is be no means proven by our current level of NMR 
and CD data. 
In summary, we report the first examples of high-resolution 
structures of linear oligomeric β-peptoids, which are also the longest 
structures of any peptoid oligomer determined by X-ray 
crystallography to date. These novel helical structures definitively 
show that the β-peptoids qualify as a valid addition to the already 
rich ensemble of foldamer designs. Our crystal structures revealed 
highly regular equilateral triangular prism-shaped conformations in 
the solid state, which was achieved by synthesis of homomeric 
hexamers containing the highly cis-amide-inducing side chain, (S)-
1-(1-naphthyl)ethylamine. Furthermore, 1H NMR- and CD 
spectroscopic data supported the existence of length-and 
temperature-dependent secondary structures in solution in organic 
solvents, although the determination of high-resolution solution 
structures will be an important future challenge. Taken together we 
demonstrate control of β-peptoid folding for the first time, which 
now opens the possibility of taking advantage of β-peptoids in 
design of novel structurally well-defined biomimetic materials. We 
are therefore currently investigating various strategies to introduce 
alternative functionalities while retaining the structural integrity of 
these novel scaffolds. 
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Figures and Schemes 
 
Scheme S1. Oligomerization and N-terminal functionalization of β-peptoids. a) NEt3, THF, 0 °C. b) MeOH, 
50. c) AcCl, NEt3, 0 °C. d) (CF3CO)2O, NEt3, CH2Cl2, 0 °C→20 °C . 
 
 
 
  
Figure S1. The asymmetric unit in crystal 10c. Left: seen perpendicular to the helix axis. Right: Seen along 
the helix axis. The figure was prepared using the Mercury software.2 
 
 
 
 
 
Figure S2. The asymmetric unit in crystal 10a. The figure was prepared using the Mercury software.2 
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 A 
B 
Figure S3:  Crystal packing of 10c. (A) Viewed along the helical axis. The helices arrange in a pseudo-
trigonal manner. (B) Perpendicular to the helical axis. The figure was prepared using the Mercury software.2 
 
               
   A       B 
Figure S4. (A) Naphthyl-backbone interactions in cpd 10a. (B) Naphthyl-backbone interactions in cpd 10c. 
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Figure S5. CD spectra of acylated and non-acylated (S)-1-(1-naphthyl)ethyl-containing monomers. 
 
 
 
Figure S6. CD spectra of compound 10a recorded at varying temperatures upon cooling the sample back 
down to room temperature. 
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Table S1. Torsion Angles for Additional Residues 
Compound 10a 	  	   ϕ θ ψ ω χ1 χ2 	  	   96.2 172.5 –175.3 –13.7 53.6 –80.5 
Compound 10c 
Residue ϕ θ ψ ω χ1 χ2 
3 96.9 166.4 –179.9 –19.4 66.7 –61.5 
4 94.3 168 –178.8 –9.5 54.4 –74.2 
5 97.4 166 –173.9 –13.4 56.3 –73.8 
From DFT calculations previously published (Hofmann et al.)3 
 95.8 –179.6 –178.2 8.6 n.a. n.a. 
 
 
Table S2. Examples of Naphthyl-Backbone Interactions (shown in green in Figure S4) 
Compound 10a Distance (Å) Compound 10c Distance (Å) 
C1–C6 3.31(2) C22–C62 3.35(2) 
C3–C15 3.44(2) C14–C152 3.40(2) 
O1–C15 3.54(1) C152–O14 3.53(2) 
 
 
Table S3. Characterization Data for Compounds 1a–10b 
Comp. Formula 
Yielda 
(%) 
MS: m/z for [M+H]+ 
(calcd./obs.) 
HRMS: m/z for [M+H]+ 
[calcd./obs. (ΔM)] 
HPLC    
(tR/min) 
HPLC      
(% Purity)b 
1a C28H38N2O4 21 467.3/467.3 467.2904/467.2920 (3.4) 12.50 96 
1b C28H35N2O4 30 521.3/521.2 521.2622/521.2630 (1.6) 14.11 95 
2a C39H51N3O5 35 642.4/642.5 642.3901/642.3901 (0.0) 13.32 95 
2b C39H48F3N3O5 25 696.4/696.4 696.3619/696.3625 (0.9) 15.10 98 
3a C50H64N4O6 34 817.5/817.5 839.4718/839.4737c (2.3) 14.24 93 
3b C50H61F3N4O6 45 871.5/871.5 871.4616/871.4658 (4.8) 16.06 95 
4a C61H77N5O7 22 992.6/992.8 992.5896/992.5935 (4.0) 15.00 97 
4b C61H74F3N5O7 34 1046.6/1046.7 1046.5613/1046.5646 (3.1) 16.83 95 
5a C72H90N6O8 44 1167.9/1167.8 1189.6712/1189.6737c (2.1) 16.23 98 
5b C72H87F3N6O8 43 1221.7/1221.7 1243.6430/1243.6429c (0.1) 18.42 97 
6a C36H42N2O4 38 567.3/567.4 567.3218/567.3242 (4.3) 14.05 96 
6b C36H39F3N2O4 36 621.3/621.2 621.2935/621.2959 (3.8) 16.14 99 
7a C51H57N3O5 39 792.4/792.4 792.4371/792.4396 (3.1) 18.40 95 
7b C51H54F3N3O5 16 846.4/846.3 846.4089/846.4114 (3.3) 19.41 98 
8a C66H72N4O6 30 1017.6/1017.5 1017.5526/1017.5566 (3.9) 20.34 99 
8b C66H69F3N4O6 32 1071.5/1071.5 1071.5242/1071.5287 (4.2) 23.17 97 
9a C81H87N5O7 34 1242.7/1242.6 1264.6498/1264.6537c (3.2) 24.31 96 
9b C81H84F3N5O7 6 1296.6/1296.4 n.a. 22.14 97 
10a C96H102N6O8 53 1468.9/1468.7 734.8969/734.8985d (2.1) 28.66 96 
10b C96H99F3N6O8 54 1522.9/1522.4 761.8828/761.8832d (0.5) 30.06 95 
aIsolated yields for addition of one residue and subsequent acylation (3 steps). bThe HPLC purities are reported at 230 
nm. cThe values correspond to [M+Na]+. dThe values correspond to [M+2H]2+  
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Materials and Methods 
General. All chemicals and solvents were analytical grade and used without further purification. 
Vacuum liquid chromatography (VLC) was performed on silica gel 60 (particle size 0.015−0.040 
mm). UPLC−MS analyses were performed on a Phenomenex Kinetex column (1.7 µm, 50 × 2.10 
mm) using a Waters Acquity ultra high-performance liquid chromatography system. A gradient 
with eluent I (0.1% HCOOH in water) and eluent II (0.1% HCOOH in acetonitrile) rising linearly 
from 0% to 95% of II during t = 0.00–5.20 min was applied at a flow rate of 1 mL/min. Preparative 
HPLC purification was performed on a C18 Phenomenex Luna column (5 μm, 100 Å, 250 mm × 20 
mm) using an Agilent 1260 LC system equipped with a diode array UV detector and an evaporative 
light scattering detector (ELSD). A gradient with eluent III (water−MeCN−TFA, 95:5:0.1) and 
eluent IV (0.1% TFA in acetonitrile) rising linearly from 45% to 95% of IV during t = 5−35 min, 
and isocratically at 95% from t = 35–55 min was applied at a flow rate of 20 mL/min. Analytical 
HPLC was performed on a C18 phenomenex Luna column (3 µm, 100 Å, 150 mm × 4.60 mm) 
using an Agilent 1100 series system equipped with a diode array UV detector. A gradient using 
eluent III and eluent IV rising linearly from 0% to 80% of IV during t = 2−10 min, then from 80% 
to 95% during t = 10–27 min, and finally isocratically at 95% IV from t = 27–33 min was applied at 
a flow rate of 1 mL/min. High-resolution LC-DAD-MS was performed on an Agilent 1100 system 
equipped with a photodiode array detector (DAD) and coupled to a LCT orthogonal time-of-flight 
mass spectrometer (Waters-Micromass, Manchester, UK) with Z-spray electrospray ionisation 
(ESI). 2D NMR spectra were recorded on a Bruker Ascend 400 MHz at 400 MHz for 1H and 100 
MHz for 13C. All spectra were recorded at 298 K. Heteronuclear single quantum coherence (HSQC) 
spectra were recorded with a relaxation delay of 1.5 sec before each scan, a spectral width of 4800 
× 16600, collecting 4 FIDs and 1k × 256 datapoints. All spectra were recorded at 298 K. Chemical 
shifts are reported in ppm relative to deuterated solvent peaks as internal standards (δH, C6D6 7.16 
ppm; δC, C6D6 128.06 ppm, δH, CD3CN 1.94 ppm; δC, CD3CN 1.32 ppm).  
Oligomerization of β-peptoids. The β-peptoids were oligomerized using a procedure closely 
resembling that of Taillefumier and co-workers.1 Briefly, the β-peptoid (1.0 equiv) and NEt3 (1.2 
equiv) were dissolved in THF (0.05 M) and cooled to 0 °C. Then acryloyl chloride (1.4 equiv) was 
added and the reaction was stirred for 1 h. The reaction mixture was filtered and the solids were 
washed with EtOAc. The combined filtrates were concentrated in vacuo yielding crude acrylamide. 
The crude acrylamide was dissolved in MeOH (0.1 M), the desired primary amine (2.0 eqiuv) was 
added, and the reaction was stirred for 18 h at room temperature. In case of the penta- and hexamer 
of compounds containing N-(S)-1-(1-naphthyl)ethyl side chains, additional amine (2.0 equiv) and 
stirring for 72 h were needed for the reaction to go to completion. Furthermore, the acrylamide of 
the N-(S)-1-(1-naphthyl)ethyl-containing pentamer was poorly soluble in MeOH, therefore MeOH–
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CH2Cl2 (1:3, 0.015 M) was used for the final aza-Michael step. Purification was performed using 
Vacuum liquid silica gel chromatography, applying a gradient of MeOH in CH2Cl2 from 0→5%.  
N-terminal functionalization of β-peptoid oligomers. Acetylation of β-peptoid oligomers was 
achieved by dissolving the β-peptoid oligomer (1.0 eqiuv) in CH2Cl2 (0.02 M) at 0 °C, then adding 
NEt3 (1.4 equiv) and acetyl chloride (1.2 equiv) under stirring for 1h. Trifluoroacetylation of β-
peptoid oligomers required addition of NEt3 (4.0 equiv) and trifluoroacetic anhydride (5.0 equiv) to 
the β-peptoid solution, which was stirred for 1 h at 0 °C, followed by ambient temperature for 18h. 
For both acetylated and trifluoroacetylated compounds, purification could be achieved by 
evaporation of the solvent in vacuo followed by preparative reversed-phase HPLC. 
Vacuum liquid silica gel chromatographic (VLC) purification of compounds 6a–10b applying a 
gradient of 0.2% MeOH in CH2Cl2 from 0→5% was unsuccessful. However, crude 10a and 10b 
could be redisolved in DMF, and precipitated upon addition of water. The solid product contained 
only minor impurities, which could be removed using VLC with the mentioned gradient. 
CD spectroscopy. Spectra were acquired with an Olis DSM 10 CD spectrophotometer (Olis Inc., 
Bogart, GA, USA), equipped with a Quantum Systems temperature control module, using 1 mm 
quartz cuvettes at 25 °C. Samples (60 µM) were prepared in CH3CN. Compound concentrations (60 
µM) were determined using dry weight of the lyophilized material. The data are averages of 3 
successive accumulations. Spectra were recorded in millidegree units, corrected for solvent 
contributions, and normalized to mean residue ellipticity [θ] = 100ψ/lcn, where ψ is the signal in 
millidegrees, l is the path length (0.1 cm), c is the concentration in mM, and n is the number of 
peptoid amide bonds. 
Crystallization. Selected peptoid hexamers (∼30 mg) were dissolved in a minimum amount of 
CHCl3 and MeOH was added until precipitation could be observed, then sufficint CHCl3 was added 
to give clear solutions. The solutions were left slow evaporation at room temperature, and crystrals 
were generally formed within a week. The crystals could be removed from the solvent and washed 
using MeOH. The hexamers (30 mg) also crystalized upon slow evaporation from benzene, 
however, these specimens were of insufficient quality for X-ray diffraction. 
X-ray crystallography. 
Data collection. Several crystals of each compound were tested before suitable crystals were found. 
Measurements were performed at room temperature as cryo cooling turned out to destroy the 
crystals. Data collection was performed on an Agilent Supernova Diffractometer using CuKα 
radiation. For crystal 10a data was included to 1.00 Å resolution and for crystal 10c data to 1.05 Å 
resolution were included. Data were processed and scaled using the CrysAlisPro software (Agilent 
Technologies). Details of the data collection are found in the supplementay cif-files.  
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Structural determination and refinement. Compound 10c crystallized in space group P1 with 
one molecule in the asymmetric unit. The structure was solved using SHELXS and refined using 
SHELXL (Sheldrick, 2008).3 Due to the rather low resolution, it turned out, however, that 
geometric restraints had to be included in the refinement. All naphthyl groups were imposed with 
FLAT and DELU restraints. The N-terminal naphthyl group had rather large thermal parameters 
and was restrained further using RIGU and ISOR restraints. Furthermore, the tert-butyl group was 
restrained using DELU, and all 6 residues were restrained to be similar using a SAME command. In 
the rather large voids between the helices we observed disordered electron density. The three largest 
peaks were modeled as oxygen with occupancy of 0.5. Compound 10a, on the other hand, 
crystallized in space group R3 with one peptoid residue in the asymmetric unit. The structure was 
solved using SHELXS and refined in SHELXL (Sheldrick, 2008).4 Also here geometric restraints 
had to be included in the refinement and the naphthyl group was imposed with FLAT and DELU 
restraints. The peptoid oligomer reveals when crystallographic symmetry is imposed. However, the 
crystal structure generates infinitely long chains and the tert-butyl group was invisible, although for 
every sixth naphthyl group a tert-butyl group must be present. Hydrogen atoms were included on 
ideal positions using riding coordinates for both crystals. The data quality did not allow for 
determination of the absolute configurations, which were imposed in accordance with the 
stereochemistry of the building blocks used in the synthesis. 
 
Supporting References. 
(1) T. Hjelmgaard, S. Faure, C. Caumes, E. De Santis, A. A. Edwards, C. Taillefumier, C. Org. 
Lett. 2009, 11, 4100. 
 
(2) C. F. Macrae, I. J. Bruno, J. A. Chisholm, P. R. Edgington, P. McCabe, E. Pidcock, L. 
Rodriguez-Monge, R. Taylor, J. van de Streek, P. A. Wood J. Appl. Crystallogr. 2008, 41, 466. 
 
(3) C. Baldauf, R. Guenther, H.-J. Hofmann, Phys. Biol. 2006, 3, S1. 
 
(4) G. M. Sheldrick Acta Crystallogr. 2008, A64, 112. 
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Parts of the HSQC 2D NMR spectra showing the side chain methyne cross peaks. 
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Abstract:  
A promising class of potential new antibiotics are the antimicrobial peptides or their 
synthetic mimics. Herein we assess the effect of the type of cationic side chain (i.e., guanidino 
vs. amino groups) on the membrane perturbing mechanism of antimicrobial α-peptide–β-peptoid 
chimeras. Two separate Langmuir monolayers composed of 1,2-dipalmitoyl-sn-glycero-3-
phosphatidylglycerol (DPPG) and lipopolysaccharide Kdo2-lipid A were applied to model the 
outer membranes of Gram-positive and Gram-negative bacteria, respectively. We report the 
results of the measurements using an array of techniques, including high-resolution synchrotron 
surface X-ray scattering, epifluorescence microscopy, and in vitro antimicrobial activity to study 
the molecular mechanisms of peptidomimetic interaction with bacterial membranes. We found 
guanidino group-containing chimeras to exhibit greater disruptive activity on DPPG monolayers 
than the amino group-containing analogues. However, this effect was not observed for 
lipopolysaccharide monolayers where the difference was negligible. Furthermore, the addition of 
the nitrobenzoxadiazole fluorophore did not reduce the activity of these antimicrobials, which 
may be useful for future cellular localization studies. 
Keywords: antimicrobial peptidomimetics; peptide–peptoid chimeras; guanidino cation; 
bacterial membrane; X-Ray scattering 
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1. Introduction 
Antimicrobial peptides (AMPs) are ubiquitous in Nature; present in virtually all 
organisms they serve as endogenous antibiotics through the innate immune response.[1, 2] 
Members of this class of compounds have been studied extensively due to their potential as 
promising alternative antibiotics to treat disease caused by the growing number of resistant 
pathogenic microbes.[1-4] It is generally believed that AMPs exert their direct killing of 
invading pathogens by selectively interacting with the negatively charged bacterial surfaces over 
the globally neutral (zwitterionic) eukaryotic cell membranes. The mechanism by which the 
membranes are permeated is not completely understood, and several models have been proposed 
based on studies conducted with various peptidic structures.[1] Moreover, recent studies have 
shown that some of these chemotypes are endowed with additional intracellular modes of action 
such as interference with cell wall biosynthesis or immunomodulatory effects.[5-9] These 
findings complicate the understanding of this class of compounds even further and have called 
for the use of a perhaps more appropriate class designation, host-defense peptides (HDPs).[3]  
Despite their diversity in amino acid sequence, lipophilicity and secondary structure,[10] 
most HDPs share common features includig positive net charge and generally amphipathic 
nature, separating hydrophilic and hydrophobic residues to the opposite faces of the 
molecule.[11-13] Typically,  positive net charge of naturally occurring peptides is contributed by 
the guanidino groups of the arginine (Arg)[14, 15] and/or amino groups of the lysine (Lys) 
residues.[16-18] Both Arg and Lys side chains are generally thought to promote the initial long 
range electrostatic attractive forces that guide antimicrobials towards the negatively charged 
bacterial membranes.[19] However, guanidino groups have higher acid dissociation constant 
(pKa) due to efficient resonance stabilization of the charged protonated state together with 
efficient solvation in water, which makes them stronger bases and, thus, better suited for stable 
electrostatic interactions with the negatively charged phosphodiester and phosphomonoester 
groups of phospholipids.[20-24] Examples of naturally occuring AMPs containing arginine 
rather than lysine residues include several members of the cathelicidin family, such as indolicidin 
and tritrpticin.[25, 26] Also, Muhle and Tam[28] found that Arg-to-Lys substitution in a cyclic 
disulfide-stabilized peptide decreased activity against Gram-negative bacteria. Nakase et al. 
demonstrated improved membrane permeability of antimicrobial peptide (RLA) with lysine 
substituted by arginine.[29] Other studies have shown that for lactoferricin B and bactenecin 5, 
which have no hemolytic activity, the replacement of arginine for lysine reduced antibacterial 
activity.[30] So, the incorporation of guanidino groups into the peptide side chains may have its 
appeal in drug design.[31-33]  
However, there are concerns related to the use of α-peptides in a clinical setting due to 
their high cost of manufacturing[34] and inherent susceptibility to proteases,[35] which has led 
to numerous studies aimed at mimicry of peptides using non-natural compounds. Thus, a variety 
of classes such as β-peptides,[36-38] oligoureas,[39] arylamides,[40, 41] N-substituted 
oligoglycines (peptoids),[42-44] cyclic D,L-α-peptides,[45-47] hybrid peptidomimetics,[33, 48-
50] and polymers[51-53] have been designed to mimic the function of AMPs.  
α-peptide–β-peptoid chimeras represent a distinct class of peptidomimetics with 
backbone composed of alternating peptide and β-peptoid residues. In the present, study we 
elucidate the role of the cation type on the antimicrobial properties of this type of synthetic AMP 
mimics using two α-peptide–β-peptoid chimeras (1 and 2),[33, 50, 60-62] which differ from each 
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other solely in the identity of cationic functionality [amine (lysine) vs. guanidino group 
(homoarginine)]. In addition, because fluorophore-labeled analogues of AMPs, which retain 
antimicrobial activity, constitute powerful tools for studying mechanisms of action and cellular 
localization, we also prepared and evaluated nitrobenzoxadiazole (NBD)-labeled oligomers 1a 
and 2a (Fig. 1A). 
Regardless of whether the primary mode of action is of a membrane-disrupting nature or 
entails perturbation of intracellular targets, the initial interaction between antimicrobial and 
bacteria involves the cell surface. A fundamental understanding of these lipid–antimicrobial 
interactions is therefore important for the future design of improved antibiotics for potential 
clinical use. Since cell membranes have a complex structure and are currently not applicable for 
highly sensitive surface X-ray scattering methods, the model systems are generally employed to 
undertake detailed mechanistic studies of membrane-associated processes.[63-67] Previously, the 
membrane-destabilizing effects of the α-peptide–β-peptoid chimeras have only been investigated 
in model liposomes prepared from phosphatidylcholine (PC), a phospholipid found 
predominantly in eukaryotic cells.[61] However, PC-containing systems do not adequately 
represent bacterial envelope, and furthermore, these compounds have not been investigated using 
sensitive X-ray methods before. 
In order to model the outer surface of Gram-positive and Gram-negative bacteria we have 
employed insertion assay experiments on two separate Langmuir monolayers composed of 1,2-
dipalmitoyl-sn-glycero-3-phosphatidylglycerol (DPPG) and truncated lipopolysaccharide (LPS) 
Kdo2-Lipid A, respectively (Fig. 1B). The reason behind this choice of lipids is that Kdo-2 lipid 
A constitutes the hydrophobic core of LPS envelope in most Gram-negative bacteria, while PGs 
are predominat phospholipid species within cytoplasmic membranes of Gram-positive strains. 
This approach has been successfully used in conjunction with liquid surface X-ray scattering to 
study bacterial membrane lysis by human antimicrobial peptide LL-37,[66] protegrin-1,[63, 68] 
gramicidin,[69] and SMAP-29[67] antimicrobial peptides as well as by peptide mimics.[44, 65, 
70, 71] 
2. Experimental Section 
2.1  Monolayer construction 
Both DPPG and Kdo2-Lipid A were purchased from Avanti Polar Lipids (Alabaster, AL) 
and were used without further purification.  To form the monolayer systems both DPPG and 
Kdo2-Lipid A were first dissolved in chloroform–methanol (65:25) at a concentration of 0.2 
mg/mL. Using a microliter syringe (Hamilton) the solutions were then spread on the surface of a 
Dulbecco's phosphate buffered saline (DPBS) (Invitrogen, Carlsbad, Ca) void of calcium and 
magnesium ions contained in a single barrier Langmuir trough.  Over 15 minutes the organic 
solvents evaporated to form a self-assembled monolayer.  The monolayer was then compressed 
to a biologically relevant packing density of 30 mN × m–1, which was monitored by a Wilhelmy 
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plate.  This surface pressure and a temperature of 22 ± 0.5 oC were maintained throughout the 
experiment.  As a result, if changes in the surface pressure occur, the barrier will have to move in 
order to maintain the set surface pressure.  Such change in barrier position then allows for 
change in area/lipid molecule or area/LPS molecule ΔA to be calculated.  Once the monolayer 
was compressed the chamber containing the Langmuir trough was sealed and purged with 
helium to lower the oxygen levels in the chamber, which minimizes background X-ray scattering 
during the X-ray experiments[64, 72]. 
2.2 X-ray reflectivity (XR) 
XR gives the information about electron density gradient along the plane perpendicular to 
the surface of monolayer as well as about the film thickness. [73-75]  A slab-model, also known 
as a box model, was used to analyze XR data.  This model is based on the Parratt recursive 
method[76] that describes the interface as a stack of slabs with distinct electron densities (ρ), and 
thicknesses (l).[77-81] The final fit was achieved by minimizing the χ2-square value while 
ensuring that parameters obtained were physically relevant. The software used to fit 
experimental XR data was RFit2000.[82-84]  In addition to model-dependent fits, model-
independent fits where the electron density profile of the film versus the vertical position along 
film perpendicular was generated using the software StochFit.[85]   
2.3 Grazing-incidence X-ray diffraction (GIXD) 
Grazing incidence X-ray diffraction measurements were performed to monitor the effect 
of compound insertion on the molecular packing of the lipid monolayers.[86]  Lipid films spread 
at the air-water interface may be described by a large number of two-dimensional crystalline 
domains of ordered hydrocarbon chains randomly oriented around the surface normal.[87] In a 
GIXD experiment, the momentum transfer has a horizontal and vertical component, Qxy and 
Qz.[88] The Qxy positions of the observed Bragg peaks yield the repeat distances, dhk = 2π/qhk for 
the 2D lattice, from which specific parameters (a, b, γ) of the crystal system can be extracted. 
From the full-width half-maximum (FWHM) values of Bragg peaks, the in-plane coherence 
length, Lxy was calculated using the Scherrer formula, Lxy = 0.9 × 2π/FWHM. The intensity 
distribution along the Bragg rod was measured at Bragg peak positions to evaluate the tilt of acyl 
chains. 
All X-ray measurements were done at sector 9-ID at the Advanced Photon Source (APS) 
of Argonne National Labs (Chicago IL) with an X-ray wavelength of 0.9202 Å.  After XR and 
GIXD were performed on a given monolayer system α-peptide–β-peptoid hybrids were 
introduced into the system using a bent needle syringe (Hamilton).  The needle is placed 
underneath the barrier and the compounds were injected underneath the monolayer to mimic the 
approach of the compound from the extracellular fluid to the outer leaflet of the membrane.  
After injection both XR and GIXD measurements were taken for comparison.  
2.4 Real-time epifluorescence microscopy (EFM) imaging 
Morphological changes of DPPG films were studied on a microscopic level before and 
after the introduction of α-peptide–β-peptoid chimeras according to protocols previously 
described.[89, 90] Briefly, the Langmuir trough setup and procedures used in the formation of 
the lipid monolayers were essentially the same, except that a 0.1 mol % of lipid-linked Texas 
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Red dye [TR-DHPE (Molecular Probes, Eugene, OR)] was premixed with stock DPPG solution. 
A heated glass-plate was placed over the trough to reduce contamination and evaporation of the 
subphase during the experiment.  
2.5 Chemical synthesis 
Fmoc-Lys(Dde)-βNspe-OH (8). Fmoc-Lys-βNspe-OH (7) (1.61 g, 2.96 mmol) and iPr2NEt 
(1.4 mL, 8.0 mmol) were dissolved in DMF (30 mL), and added acetyl dimedone (913 mg, 5.0 
mmol). After stirring for 18 h, the solvent was 
evaporated in vacuo and the crude product redissolved 
in EtOAc (100 mL). The solution was washed with 1 
M HCl (aq) (2 × 100 mL) and water (2 × 100 mL), 
dried (Na2SO4), filtered, and evaporated in vacuo to 
give 1.22 g (82%) of the desired product as a white 
solid. 1H NMR (300 MHz, CD3OD) δ 1.48 (m, 2H, H-
7), 1.66/1.56* (2 × d, 3H, J = 7.0 Hz, H-4), 1.68–1.82 
(broad m, 4H, H-6, H-8), 2.17/2.51 (3 × m, 2H, H-1), 
2.27*/2.28/2.51*/2.52 (4 × m, 6H, H-11, H-12) 3.19/3.38 (2 × m, 2H, H-2), 3.48 (m, 5H, H-9, H-
10), 4.17 (m, 1H, H-15), 4.27–4.43 (broad m, 2H, H-14), 4.52*/4.81 (2 × m, 2H, H-5) 5.42/5.81* 
(2 × q, 1H, J = 7.0 Hz, H-3), 7.23–7.41 (broad m, 9H, Ph, Fmoc ArH), 7.66 (m, 2H, Fmoc ArH) 
7.79 (d, 2H, J = 7.5 Hz, Fmoc Ar). [α]589.2: –46° (c = 1.0, 293 K, CHCl3). UPLC-MS gradient 
A, tR = 2.20 min (>95), MS: (m/z) [M + H]+ calcd. for C32H38N3O5+: 708.9, found: 708.6. 
HRMS: (m/z) [M + H]+ calcd. for C32H38N3O5+: 708.3643, found: 708.3649 (ΔM = 0.8 ppm). 
Solid-phase synthesis of 9. Fmoc-protected Rink amide resin (590 mg, 0.25 mmol) was 
treated with piperidine–DMF (1:4, 5 mL, 2 × 20 min), and washed with DMF, MeOH, and 
CH2Cl2 (3 × 5 mL). Oligomerization was performed with a mixture of Fmoc-Lys(Dde)-βNspe-
OH (8) (750 mg, 1.1 mmol, 4.5 equiv), HBTU (417 mg, 1.1 mmol, 4.5 equiv), and iPr2NEt (0.38 
mL, 2.2 mmol, 9 equiv) in DMF (5 mL), which were preincubated for 10 min before being added 
to the Rink amide resin and shaken for 18 h. After each coupling the resin was washed with 
MeOH, DMF and CH2Cl2 (3 × 5 mL). Fmoc deprotection was achieved with piperidine–DMF 
(1:4, 5 mL, 2 × 20 min) followed by DBU–piperidine–DMF (2:2:96, 5 mL, 2 × 20 min), after 
each deprotection step the resin was washed using the same procedure as above. This three-step 
coupling/deprotection sequence was performed 6 times to give the resin-bound oligomer.  
Ac-(Lys-βNspe)6-NH2 (1). The terminal amino groups of (9) (100 mg, 0.024 mmol) were 
capped with a mixture of Ac2O–iPr2NEt–DMF (1:2:3, 2 mL, 2 h) and the resin was washed with 
DMF, MeOH, and CH2Cl2 (3 × 2 mL). The side chains were deprotected using 2% hydrazine in 
DMF (2 × 2 mL, 45 min). The crude product was cleaved from the support with 50% TFA–
CH2Cl2 (2 mL, 2 × 1 h). The TFA was co-evaporated with toluene (3 × 30 mL), toluene–CH2Cl2 
(3 × 30 mL), and CH2Cl2 (3 × 3 mL). The residue was purified by preparative RP-HPLC 
(gradient C) and fractions were lyophilized to give compound 1 as white fluffy material [12.3 
mg, 15% (90% per step)]. HPLC gradient D, tR = 10.47 (>95%). HRMS: m/z [M+3H]3+ calcd for 
C104H158N19O133+: 627.07567, found: 627.07553 (ΔM: 0.22 ppm).[50]  
N OH
O
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Ac-(hArg-βNspe)6-NH2 (2). The terminal amino group of (9) (75 mg, 0.024 mmol) was 
capped with a mixture of Ac2O–iPr2NEt–DMF (1:2:3, 2 mL, 2 h) and the resin was washed with 
DMF, MeOH, and CH2Cl2 (3 × 2 mL). The side chains were deprotected using 2% hydrazine in 
DMF (2 × 2 mL, 2 × 45 min), and washed as above. Boc-protected guanidino groups were 
introduced by addition of a mixture of N,N’-bis(tert-butoxycarbonyl)-1H-pyrazole-1-
carboxamidine (11) (285 mg, 0.92 mmol) and iPr2NEt (0.32 mL, 1.84 mmol) in DMF for 18 h, 
followed by the above washing procedure. The crude guanidinium-containing product was 
simultaneously deprotected and cleaved from the support with TFA–CH2Cl2 (1:1, 2 mL, 2 × 1 h). 
The TFA was co-evaporated with toluene (3 × 30 mL), toluene–CH2Cl2 (3 × 30 mL) and CH2Cl2 
(3 × 30 mL). The residue was purified by preparative RP-HPLC (gradient C) and fractions were 
lyophilized to give compound 2 as white fluffy material [12.9 mg, 20% (90% per step)]. HPLC 
gradient D, tR = 10.39 (>95%). HRMS: m/z [M+3H]3+ calcd for C110H170N31O133+: 711.1193, 
found: 711.1190 (ΔM: 0.35 ppm).[50] 
NBD-(Lys-βNspe)6-NH2 (1a). A Rink amide resin-bound oligomer with Boc protected lysine 
side chains (150 mg, 0.039 mmol) was prepared as described for 9 using the Fmoc-Lys(Boc)-
bNspe-OH[59] building block. The N-terminal was then functionalized with a mixture of N-
NBD-6-aminohexanoic acid (73 mg, 0.25 mmol), iPr2NEt (87 µL, 0.5 mmol), and PyBOP (156 
mg, 0.3 mmol) in DMF (2 mL). After shaking for 18 h, the resin was washed with DMF, MeOH, 
and CH2Cl2 (3 × 2 mL), and the compound was cleaved from the support using TFA–CH2Cl2 
(1:1, 2 mL, 2 × 1 h). Trifluoroacetic acid was co-evaporated with toluene (3 × 30 mL), toluene–
CH2Cl2 (3 × 30 mL), CH2Cl2 (3 × 3 mL), and the residue was purified by preparative RP-HPLC 
(gradient C). Lyophilization of the fractions containing the titel compound furnished a yellow 
fluffy material [12.5 mg, 15% (88% per step)]. HPLC gradient D, tR = 10.29 (>95%). HRMS: 
m/z [M+3H]3+ calcd. for C114H168N23O163+: 705.4352, found: 705.4361 (ΔM: 1.3 ppm), and m/z 
[M+4H]4+ calcd. for C114H169N23O164+: 529.3252, found: 529.3261 (ΔM: 1.7 ppm). 
NBD-(hArg-βNspe)6-NH2 (2a). Crude NBD-(Lys-βNspe)6-NH2 (1a) (30 mg, 0.014 mmol) and 
iPr2NEt (29 µL, 0.16 mmol) were dissolved in DMF (2 mL), followed by addition of N,N’-
bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine (40 mg, 0.13 mmol). After stirring for 3 
h, the solvent was evaporated in vacuo, and excess reagent removed by vacuum silica gel 
chromatography [2 × 6 cm, CH2Cl2–MeOH 0.5% gradient 0→10% (containing 1% concentrated 
aqueous NH3)]. The product was then deprotected with TFA–CH2Cl2 (1:1, 2 mL, 2 × 1 h) and 
TFA was removed by co-evaporation with toluene (3 × 30 mL), toluene–CH2Cl2 (3 × 30 mL), 
and CH2Cl2 (3 × 3 mL). The compound was purified by preparative RP-HPLC (gradient C) to 
give 2a as a yellow fluffy material (5 mg, 15%). HPLC gradient D, tR = 11.05 (>95%). HRMS: 
m/z [M+4H]4+ calcd. for C120H181N35O164+: 592.5609, found: 592.5603 (ΔM: 1 ppm). 
Details of synthetic procedures, charaterization data, as well as 1H and 13C NMR spectra 
for all new compounds are presented in Supporting  Information. 
2.6 Bacterial strains and culture conditions 
Activity experiments were carried out with five bacterial species representing common 
laboratory strains and clinical strains derived from both food-borne and nosocomial infections. 
Stock cultures were stored at –80 oC in 4% (w/v) glycerol, 0.5% (w/v) glucose, 2% (w/v) 
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skimmed milk powder, and 3% (w/v) tryptone soy powder. All experiments were carried out 
with bacteria incubated for one night (approximately 18 hours) at 37 oC. Experiments were 
performed in cation-adjusted Mueller Hinton II broth [MHB (Becton Dickinson 212322)] 
adjusted to pH 7.4. Brain Heart Infusion (CM1135) with 1.5% agar (VWR 20768.292) as gelling 
agent was used throughout for colony plating. 
2.7 Antimicrobial activity assay 
MIC was determined using the micro-dilution method according to guidelines of the 
Clinical and Laboratory Standards Institute (CLSI). Two-fold serial dilutions of the 
peptidomimetic hybrids were prepared from 1024 µg/mL stock solutions in Milli-Q water to give 
a final range of 512–0.5 µg/mL in the wells; compound 3 containing only the fluorophore and 
the spacer was included but due to solubility issues this stock was 258 µg/mL, thus giving a final 
range of 128–0.125 µg/mL in the wells. Colonies grown on BHI agar for approximately 18 hours 
were suspended in 0.9% saline to give a turbidity of 0.13 at OD546 (approximately 1 × 108 
CFU/mL), and then diluted in MHB pH 7.4 to a final concentration of 5 × 105 CFU/mL in each 
well. Polypropylene plates (Nunc 442587) were used to minimize peptide binding, and the 
incubation time was 18–20 hours at 37 oC. MIC values, i.e., the lowest concentration of the 
peptide analogue at which no visible growth was observed, were determined in duplicate. 
Activity is expressed in µg/mL and µM.  
3. Results 
3.1 Synthesis 
The syntheses of 1–2a were achieved by preparation of dimeric building blocks followed 
by oligomerization on solid support using variations of previously described methods.[50, 59, 
91] In order to enable an on-resin functionalization of the lysine ε-amino groups we installed an 
orthogonal 1-(4,4-dimethyl-2,6-dioxacyclohexylidene)ethyl (Dde) group[92, 93] on the lysine 
side chain functionality to give building block 8 (Scheme 1).  
For the standard Fmoc solid-phase peptide synthesis (SPPS) oligomerization, a Chem-
Matrix® resin was chosen due to its excellent swelling properties in a variety of solvents. After 
six rounds of coupling/deprotection (9), the N-terminal was acetylated and the Dde group was 
removed to give 10, which upon cleavage afforded compound 1 (Scheme 2). Functionalization of 
the free amines in 10 by guanidinylation,[94] followed by simultaneous deprotection and 
cleavage furnished compound 2. Unfortunately, introduction of the fluorophore proved 
incompatible with our new protecting group strategy, most likely due to sensitivity towards 
hydrazine during the Dde deprotection step. For the syntheses of labeled analogues 1a and 2a, a 
different strategy involving guanidinylation in solution was therefore adopted as shown in 
Supplementary Scheme S1 and Scheme S2.  
3.2 Antimicrobial activities 
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Previously, fluorescein-labelled versions of these α-peptide–β-peptoid oligomers have 
been prepared to investigate their potential as cell-penetrating peptides,[60, 61] and subsequent 
antimicrobial testing of these showed a severe decrease in potency when introducing the 
fluorescein label.[33] The compounds were therefore tested for their antimicrobial activity 
against a selection of pathogens to determine if the novel fluorescent-labeled analogues could 
inhibit bacterial growth. The NBD-labeled compounds exhibited minimum inhibitory 
concentrations (MICs) that were comparable to the parent compounds with a maximum 
difference of 4-fold in MIC values (Table 1).  
Interestingly, however, the labeled compound gave rise to lower MIC values than the 
parent in about half of the cases in the amino series, while this trend was opposite in the 
guanidino series. To determine whether the fluorophore itself was responsible for any 
antimicrobial activity, compound 3 containing the fluorophore and the spacer was synthesized 
and evaluated as well, and no effect was recorded against the tested strains. Since the 
fluorescent-labeled compounds retained activity within acceptable range of the parent 
compounds, we decided to include the NDB-labeled compounds in the model study along with 1 
and 2. 
3.3 Epifluorescence microscopy 
EFM images of the DPPG monolayer at 30 mN × m–1 displays an array of branched dark 
domains of condensed phase ~25–50 µm in diameter separated from each other by brightly 
colored “fluid” (disordered) areas. Fig. 2 shows the dynamics of surface morphology changes in 
lipid film after injection of 1 and 2 into the subphase. Both compounds caused a decrease in the 
size of condensed-phase domains starting from 4th min and followed by their complete 
elimination with transition of the majority of the film to a liquid-disordered phase after 15–20 
min. Structurally ordered regions in this case might be either fully destroyed or reduced in size to 
become smaller than the microscope resolution (<1 µm). This points out to a crystallinity-
disruptive behavior of the studied α-peptide–β-peptoid chimeras against DPPG monolayers 
regardless of the identity of the cations they contain, at least on micrometer scale. 
3.4 Specular X-ray reflectivity 
Fig. 3 shows electron density profiles along the surface normal extracted from reflectivity 
data by model-independent stochastic fitting. The graphs are combined in such a way as to allow 
visual comparison of amino- and guanidino-containing compounds. For the lipid monomolecular 
films, the electron density is zero at the air-water interface, then rises sharply through the 
hydrocarbon tail region, and comes to a plateau reaching its maximum values for the head groups 
(at a distance of ∼20–25 Å from the air side of the film) before slightly decaying to the subphase 
electron density. In addition, model-dependent analyses were performed on XR data.  Pure 
DPPG monolayers were modeled as two slabs, with the first slab corresponding to the 
phospholipid acyl chains, and the second reperesenting the lipid head groups. XR analysis 
yielded the thickness of the slab related to acyl chains to be 16.5 Å with an electron density of 
0.312 e−/Å3.  The thickness of the slab used to model the head groups was found to be 8.3 Å with 
an electron density of 0.477 e−/Å3. Two-slab model-dependent fitting of Kdo-2 Lipid A data 
yielded 12.0 Å long upper hydrocarbon chain region with electron density of 0.31 e−/Å3. The 
second slab corresponding to the complex of head moieties and the outer layer of carbohydrate 
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3-deoxy-D-mannooctulosonic acid known as Kdo has the thickness of 12.8 Å and an electron 
density of 0.485 e−/Å3. Insertion of antimicrobials into the membrane mimic results in extra 
electrons per lipid molecule in each slab and is calculated using formula (1). Here, l slab and ρ slab 
are thickness and electron density of the slab, respectively; Alipid + ΔAlipid is the area per lipid 
molecule upon insertion and Ninitial e-slab minus the number of electrons in the slab in the original 
untreated monolayer. 
Nextra e-slab = l slab × ρ slab × (Alipid + ΔAlipid) – Ninitial e-slab     (eq. 1) 
Preliminary information about the mode of antimicrobial interaction with membane 
mimics can be obtained directly from the electron density profiles (Fig.3A). Compounds 1 and 2 
displayed a drastic difference in their mode of action against DPPG monolayers. Following 
injection of 1 the first minimum of reflectivity curve shifted from qz ≈ 0.24 Å−1 to a 
higher qz value with the peak of electron density moved towards the air–water interface. This 
indicates a decrease in thickness of the film as a result of its insertion. However, compound 2 
instead of thinning DPPG monolayer, led to appearance of two minima on the reflectivity profile 
at qz ≈ 0.21 Å−1 and 0.35 Å−1 and a notable bump of the electron density curve within the range 
of 20–40 Å away from air-water interface.  This might be due to an additional layer of distinct 
electron density higher than the electron density of subphase present underneath the head group 
region. These data are corroborated by the model-dependent analysis and are summarized in 
Supplementary Table S1. Injection of 1 into DPPG resulted in an experimental XR curve, which 
was again best fit with two layers. However, an additional box was required to fit XR data upon 
introduction of compound 2. The lower increase in area per lipid molecule observed upon 
insertion of compound 2 as compared with 1 could possibly be explained by partial dimerization 
or aggregation of 2 on the outer surface of lipid monolayer. According to the number of extra 
electrons contributed by incorporated antimicrobials, both 1 and 2 readily insert into the polar 
moieties of DPPG and Kdo-2 Lipid A resulting in reduced electron density of bottom slab, but 
they are both unable to penetrate deeply into overlying hydrophobic core of lipid monolayers. 
The more substantial decrease in electron density of the DPPG head group region, along with 
three times more additional electrons present upon introduction of 2 points to a higher Gram-
positive membrane disruptive potential of guanidino-containing oligomer versus its amino-
containing counterpart. The same trend was observed for the NBD-tagged hybrids. Here 
compound 2a permeated the entire depth of DPPG film including hydrophobic acyl chains, 
whereas 1a was found only in the hydrophilic outer shell of the lipid monolayer. Furthermore, 
the introduction of 2a led to a greater contribution of additional electrons in toto, as well as to a 
four-fold larger increase in area per single DPPG molecule (ΔAlipid) indicating a favorable effect 
of arginine residues on the antimicrobial insertion. 
In contrast to DPPG, the reflectivity curves of Kdo-2 Lipid A monolayer after 
introduction of 1 and 2 look nearly identical (Fig. 3B). For model-dependent analysis two boxes 
were sufficient to fit experimental XR data and revealed very similar mechanism of action 
utilized by guanidino- and amino-containing hybrid oligomers against Gram-negative bacteria 
LPS. This consistency in mode of action between 1 and 2, as well as between 1a and 2a was 
confirmed by similar changes in thickness of respective slabs within Kdo-2 Lipid A monolayer 
and by similar number of contributed extra electrons.The area increase per lipid molecule in both 
pairs of compounds was also about the same. 
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Additionally, the effect of NBD-fluorophore was investigated by comparing 1 and 2 to 
their NBD-tagged fluorescent analogues 1a and 2a respectively. According to the results of XR 
analysis, functionalization of α-peptide–β-peptoid chimeras by NBD does not reduce their 
capability to interact with bacterial membranes. Moreover, fluorophore-carrying chimeras have 
provided even greater contribution of additional electrons to the lipid head-groups. This implies a 
higher number of chimeras to be inserted into the lipid films. 
3.5 Grazing-incidence X-ray diffraction. 
GIXD data for DPPG monolayer before and after injection of antimicrobials are 
presented in Fig. 4. The corresponding values of unit cell dimensions, d-spacings and sizes of 
crystallized domains are presented in Table 2. At the surface pressure of 30 mN × m−1 pure 
DPPG yields two distinct Bragg peaks at Qxy = 1.39 Å-1 and Qxy = 1.47 Å-1 corresponding to d-
spacings of 4.51 and 4.26 Å, respectively. This indicates the presence of ordered structure with 
the centered rectangular packing (a ≠ b, γ = 90o) having unit cell dimensions a = 5.32 Å and b = 
8.54 Å and an area of 45.5 Å2 per single DPPG molecule. For Kdo2-Lipid A, on the other hand, 
no Bragg peak was observed. This means that there were no diffractable 2D crystalline regions 
within the monolayer, which does not allow a detailed analysis of the surface morphology. 
According to GIXD data, guanidino group-containing compounds 2 and 2a fully destroy the 
lateral crystallinity of DPPG monolayers evidenced by complete disappearance of Bragg peaks. 
Conversely, both 1 and 1a, instead of disordering, caused structural rearrangement of the crystal 
lattice from a centered rectangular crystal packing to a hexagonal (a = b, γ = 120o) resulting in 
appearance of a single Bragg peak. The coherence length was also reduced, which might explain 
the disappearance of ordered regions upon introduction of compound 1 observed by EFM. 
Furthermore, fluorophore-labelled 1a was shown to decrease the size of crystallized domains as 
well as the order of their crystallinity to a greater extent than its non-labelled counterpart, even 
though the main parameters of crystal lattice didn’t change much. This supports the hypothesis 
that labelling of antimicrobials with NBD may enhance their membrane-disruptive potential 
without drastically changing the primary mechanism of action. 
4. Discussion 
Overall, our data provide solid mechanistic evidence of higher membrane activity against 
Gram-positive strains displayed by guanidino-containing α-peptide–β-peptoid chimeras as 
compared to their amino-substituted counterparts. Guanidino groups were shown to considerably 
improve the capability of these antimicrobial peptidomimetics to compromise the integrity of 
DPPG monolayers mimicking the external leaflet of Gram-positive bacteria cell membranes. 
Surprisingly, this favorable effect of guanidinium cations on their insertion properties was not 
observed for lipopolysaccharide (Kdo-2 Lipid A) monolayers, which model the outer membrane 
of Gram-negative bacteria. These XR data are in excellent agreement with the previously 
published results obtained from biological assays on a larger array of α-peptide–β-peptoid 
oligomers, especially at higher oligomer lengths.[33, 62] The increased potency of guanidino-
containing chimera 2 over its amino-containing counterpart 1 on Gram-negative strains in vitro 
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(Table 1) might thus arise from other mechanisms of action in addition to direct membrane 
permeabilization. A full explanation of this finding, however, would require extensive 
experiments beyond the scope of this work. A schematic cartoon illustrating the proposed 
mechanism of membrane interaction of the antimicrobials is represented in Fig. 5.  
As both types of cation are fully protonated at physiological pH we hypothesize that the 
ability of the guanidino group to form a more stable bidentate electrostatic interaction with 
negatively charged phosphodiester moieties affects the DPPG lipids to a greater extent than the 
more structurally rigid Kdo-2 Lipid A. These findings thus provide fundamental insights that 
should be useful in the future design of optimized synthetic peptidomimetics with selective 
antibiotic effects. 
Finally, addition of the NBD fluorophore did not reduce the insertion activity of the 
tested chimeras that also correlate with their retained antimicrobial potency against bacteria in 
vitro. Moreover, the NBD-labeled compounds demonstrated even greater ability to destroy both 
DPPG and Kdo-2 Lipid A monolayers, than their non-tagged analogues. It is assumed that this is 
a result of increased lipophilicity of modified molecules due to incorporation of the hydrophobic 
benzofurazan ring of NBD. The resulting amphiphilic properties may reduce the energy penalties 
associated with penetration of antimicrobials into hydrophobic core and, thus, favor the 
disruption of membrane structure. The use of fluorescently tagged AMP mimics might facilitate 
future cellular localization studies aimed at the elucidation of the mechanism of action of 
oligomeric AMPs in general. 
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Figure legends 
Figure 1. Molecular structures of the tested compounds (A) and lipids used for modeling 
bacterial cell membranes (B). 
Figure 2. Epifluorescence images of DPPG monolayers after injection of compound 1 (A) and 2 
(B) at concentrations corresponding to 20% of their MIC values observed against S. aureus 
respectively. Lipid-linked Texas Red-DHPE fluorescence probe (1 mol %) was added to the 
phospholipid solutions for EFM experiments. Because of steric hindrance, the dye is located in 
the liquid-disordered phase, rendering it bright whereas the liquid-ordered phase remains dark. 
Figure 3. Electron density profiles and corresponding Fresnel-divided reflectivity curves against 
the scattering vector (q) in the z direction (qz) for DPPG (A) and Kdo2-Lipid A (B) monolayers 
at 30 mN × m–1. Electron density profiles were normalized to the electron density of the 
subphase buffer. On the XR graphs, the scatter plots are experimental values and solid lines are 
the best fits of the models to the experimental data. Fresnel reflectivity is the reflectivity from 
ideal smooth surface. 
Figure 4. Bragg peaks plot of scattering vector Qxy as a function of intensity. 
Figure 5. Cartoon schematic of possible interactions of compounds 1 and 2 with (A) DPPG and 
(B) Kdo-2 Lipid A monolayers at 30 mN × m–1. Chimeras carrying amino groups are solely 
located in the polar head-moieties of DPPG accompanied with considerable thinning of the entire 
monolayer, whereas their guanidino-substituted analogues form an extra layer on the surface of 
lipid film resulting in more compact distribution of inserted molecules within the model 
membrane. Unlike DPPG, the mechanisms of antimicrobial insertion into Kdo-2 Lipid A model 
look nearly identical. 
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Scheme 1. Synthesis of Dimeric Building Block 8. Reagents and conditions: (a) Fmoc-Lys(Boc)-
OH (1.7 equiv), HBTU (1.7 equiv), iPr2NEt (4 equiv), DMF, 18 h. (b) TFA–CH2Cl2 (4:6), 2 h. 
(c) Acetyl dimedone (1.7 equiv), iPr2NEt (2.7 equiv), DMF, 18 h. 
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Scheme 2. Solid Supported Oligomerization of Building Block 8. Reagents and conditions: (a) 8 
(4.5 equiv), HBTU (4.5 equiv), iPr2NEt (9 equiv), DMF, 18 h. (b) Piperidine–DMF (1:4), 2 × 10 
min. (c) DBU–piperidine–DMF (2:2:96), 20 min. (d) Ac2O–iPr2NEt–DMF (1:2:3), 2 h. (e) 
Hydrazine–DMF (2:98), 2 × 45 min. (f) 50% TFA–CH2Cl2, 2 × 1 h. (g) N,N’-Bis(tert-
butoxycarbonyl)-1H-pyrazole-1-carboxamidine (11, 36 equiv), iPr2NEt (72 equiv), DMF, 18 h. 
HBTU = O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate. 
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Table 1. Antimicrobial Activities of α-Peptide–β-Peptoid Chimeras 
 
[a] MIC = Minimum Inhibitory Concentration: lowest concentration without visible growth. The 
values are based on two individual experiments conducted in duplicate. bEscherichia coli ATCC 
25922. cEscherichia coli AAS-EC-009 [Extended Spectrum Beta-Lactamase (ESBL)-producing 
clinical sample isolated from a Danish patient in 2007]. dK. pneumoniae = Klebsiella 
pneumoniae ATCC 13883. eV. vulnificus = Vibrio vulnificus ATCC 27562.  fS. aureus = 
Staphylococcus aureus 8325-4. 
  
 MIC measurements for selected pathogens (µg × mL–1 / µM)[a] 
 Gram-negative Gram-positive 
 E. colib E. colic K. pneumoniaed V. vulnificuse S. aureusf 
1 128/50 128/50 256-512/100-200 64/25 64-128/25-50 
1a 32/11 32/11 128/44 64/22 32/11 
2 8/3 16/3 16-32/3-6 8/3 4/1.5 
2a 16/5 32/10 64/20 16/5 16/5 
3 >128/>436 >128/>436 >128/>436 >128/>436 >128/>436 
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Table 2. Structural Parameters of Crystal Monolayer Lattice 
 
Sample Peak position (Å
-1) D-spacing (Å) Unit cell 
parameters Lxy [a]  (Å) Area unit cell (Å2) 
DPPG 
Qxy 1=1.39,	  
Qxy 2=1.47 
d11=4.51,	  
d02=4.26[ b] 
a = 5.32 Å	  
b = 8.54 Å	  
γ = 90o	  
θ =27o	  
L11=93	  
L02=196 
44.51 
DPPG-1 1.48 4.25 
a = 6.93 Å	  
γ = 120o	  
θ =0o	  
156 41.62 
DPPG-1a 1.48 4.25 
a = 6.94 Å	  
γ = 120o,	  
θ =0o	  
85 41.69 
DPPG–2 and DPPG–2a displayed no visible GIXD peaks 
 24 
 
Fig. 1
 25 
Fig. 2
 
 
  
 26 
Fig. 3 
  
 27 
Fig. 4 
  
 28 
Fig. 5 
 S1 
SUPPORTING INFORMATION 
 
 
Guanidino Groups Greatly Enhance the Action of Antimicrobial 
Peptidomimetics Against Gram-positive Bacteria Membranes. 
 
Konstantin Andreev,
†,#
 Christopher Bianchi,
†,# 
 Jonas S. Laursen,
‡
 Line Hein-Kristensen,
∆
 Lone Gram,
∆
 Ivan 
Kuzmenko,
○
 Christian A. Olsen,
‡
 and David Gidalevitz*
,†
 
 
†Department of Physics, Center for Molecular Study of Condensed Soft Matter, Pritzker Institute of 
Biomedical Science and Engineering, Illinois Institute of Technology, 3440 S. Dearborn St., Chicago, 
Illinois 60616, United States. 
‡Department of Chemistry, Technical University of Denmark, Kemitorvet 207, DK-2800, Denmark. 
∆Division of Industrial Food Research, National Food Institute, Technical University of Denmark, Søltofts 
Plads 221, DK-2800, Kongens Lyngby, Denmark. 
○Advanced Photon Source, Argonne National Laboratory, 9700 S. Cass Ave., Lemont, Illinois. 
 
 
 
 
 
 
Table of Contents 
Supplementary Schemes 1 and 2        S2 
Materials and Methods         S3–S6 
Supplementary References         S6 
NMR Spectra           S7 
  
 S2 
Supplementary Figures and Schemes 
 
Scheme S1. Building block syntheses. (A) (a) Fmoc-Lys(Boc)-OH (1.7 equiv), HBTU (1.7 equiv), 
iPr2NEt (4 equiv), DMF, 18 h. (b) TFA–CH2Cl (4:6), 2 h. (c) Boc2O (1.5 equiv), iPr2NEt (2 equiv), 
DMF, 0 °C for 1 h then rt 2 h. (B) (d) NBD-Cl (1 equiv), Methyl 6-aminohexanoate (1 equiv), NEt3 
(1.1 equiv), DMF, 18h. (e) 1 M LiOH (aq) (28 equiv, MeOH, 3h. (f) 14 (4 equiv), Rink amide 
Chem-Matrix
®
 (1 equiv), PyBOP (4 equiv), iPr2NEt (4 equiv), DMF, 18h. (g) TFA–CH2Cl2 (1:1), 2 
 1 h. 
 
Scheme S2. Solid supported oligomerization of building block 12. (a) 12 (4.5 equiv), HBTU (4.5 
equiv), iPr2NEt (9 equiv), DMF, 18 h. (b) piperidine–DMF (1:4), 2 × 10 min. (c) DBU–piperidine–
DMF (2:2:96), 20 min. (d) 14 (6.5 equiv), PyBOP (7.5 equiv), iPr2NEt (13 equiv), DMF, 18 h. (e) 
TFA–CH2Cl2 (1:1), 2  1 h. (f) N,N’-Bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine (11, 
36 equiv), iPr2NEt (72 equiv), DMF, 18 h. 
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Materials and Methods 
General. All chemicals and solvents were analytical grade and used without further purification. 
Vacuum liquid chromatography (VLC) was performed on silica gel 60 (particle size 0.015−0.040 
mm). UPLC−MS analyses were performed on a Phenomenex Kinetex column (1.7 µm, 50 × 2.10 
mm) using a Waters Acquity ultra high-performance liquid chromatography system. A gradient 
with eluent I (0.1% HCOOH in water) and eluent II (0.1% HCOOH in acetonitrile) rising linearly 
from 0% to 95% of II during t = 0.00–2.50 min was applied at a flow rate of 1 mL/min (gradient A) 
or during t = 0.00–5.20 min (gradient B). Preparative HPLC purification was performed on a C18 
Phenomenex Luna column (5 μm, 100 Å, 250 mm × 20 mm) using an Agilent 1260 LC system 
equipped with a diode array UV detector and an evaporative light scattering detector (ELSD). A 
gradient with eluent III (water−MeCN−TFA, 95:5:0.1) and eluent IV (0.1% TFA in acetonitrile) 
rising linearly from 0% to 95% of IV during t = 5−45 min was applied at a flow rate of 20 mL/min 
(gradient C). High-resolution LC-DAD-MS was performed on an Agilent 1100 system equipped 
with a photodiode array detector (DAD) and coupled to a LCT orthogonal time-of-flight mass 
spectrometer (Waters-Micromass, Manchester, UK) with Z-spray electrospray ionisation (ESI). 
Analytic HPLC was performed on a C18 phenomenex Luna column (3 μm, 100Å, 150mm  
4.60mm) using an Agilent 1100 series system equipped with a diode array UV detector. A gradient 
with eluent V (0.1% TFA in water) and eluent IV (0.1% TFA in acetonitrile) rising linearly from 
0% to 95% of IV during t = 5−26 min was applied at a flow rate of 1 mL/min (gradient D). 1H 
NMR and 
13
C NMR spectra were recorded on a Varian Mercury 300 instrument at 300 and 75 
MHz, respectively. 2D NMR spectra were recorded on a Bruker Ascend 400 MHz instrument. All 
spectra were recorded at 298 K. Correlation spectroscopy (COSY) spectra was recorded with a 
relaxation delay of 1.5 sec before each scan, a spectral width of 6k  6k, collecting 8 FIDs and 1k  
512 data points. Chemical shifts are reported in ppm relative to deuterated solvent peaks as internal 
standards (δH, CD3OD 3.31 ppm; δC, CD3OD 49.00 ppm, δH, CDCl3 7.26 ppm; δC, CDCl3 77.16 
ppm. Coupling constants (J) are given in hertz (Hz). Multiplicities of 1H NMR signals are reported 
as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Signals marked with an asterisk 
(*) correspond to peaks assigned to the minor rotamer conformation. 
(S)-tert-Butyl 3-((1-phenylethyl)amino)propanoate (5).
1
 t-Butyl acrylate (6.0 mL, 41 mmol) was 
dissolved in MeOH and heated to 50 °C on an oil bath, followed by addition of 
(S)-1-phenylethylamine (6.25 mL, 48 mmol). After stirring for 18 h, the solvent 
was evaporated in vacuo and the crude product was purified by vacuum liquid 
chromatography (6  6 cm, heptane–EtOAc 0→12%) to give 8.78 g (86%) as a 
colorless oil. 
1
H NMR (300 MHz, CDCl3)  1.34 (d, 3H, J = 6.6 Hz, H-6), 1.44 (s, 9H, H-1), 1.70 
(s, 1H, H-4), 2.38 (t, 2H, J = 6.3 Hz, H-2), 2.60–2.75 (m, 2H, H-3), 3.77 (q, 1H, J = 6.6 Hz, H-5), 
 S4 
7.20–7.27 (m, 1H, H-p), 7.20–7.35 (m, 4H, H-o, H-m). 13C NMR (75 MHz, CDCl3)  24.7, 28.3, 
36.1, 43.4, 58.4, 80.7, 126.8, 127.1, 128.6, 145.8, 172.52. UPLC-MS gradient A, tR = 0.96 min 
(>95%), MS: (m/z) [M + H]
+
 calcd. for C15H24NO2
+
: 250.4, found 250.3. [α]589.2: –29° (c = 2.2 , 293 
K, CHCl3). 
Fmoc-Lys(Boc)-Nspe-OtBu (6).2 Fmoc-Lys(Boc)-OH (3.75 g, 7.95 mmol), HBTU (3.02 g, 8.0 
mmol) and iPr2NEt (3.45 ml, 19.8 mmol) were dissolved in 
DMF (50 mL), and preincubated for 10 min at room 
temperature, followed by addition of the Nspe peptoid (15) 
(1.70 g, 4.8 mmol). The reaction mixture was stirred at room 
temperature for 18 h. The reaction mixture was diluted with 
EtOAc (300 mL), and washed with water (3  100 mL), 1 M 
HCl (aq.) (2  100 ml), sat aq. NaHCO3 (2  100 mL) and brine (2  100 mL). The organic phase 
was dried (Na2SO4), filtered and evaporated in vacuo to give the crude product, which was purified 
by VLC (6  6 cm, heptane–EtOAc 0→16%) to give 2.65 g (78%) as colorless solid. UPLC-MS 
gradient B, tR = 2.79 min (>90%), MS: (m/z) [M + H]
+
 calcd. for C32H38N3O5
+
: 700.9, found: 700.5. 
Fmoc-Lys-Nspe-OH (7).2 Fmoc-Lys(Boc)-Nspe-OtBu (6) (2.90 g, 4.3 mmol) was dissolved in 
40% solution of trifluoroacedic acid in CH2Cl2 (30 mL). After 
stirring for 2 h at room temperature, the solvent was evaporated in 
vacuo. The residual trifluoroacetic acid was co-evaporated with 
toluene (3  100 mL), toluene–CH2Cl2 (3  100 mL, 1:1, v/v) and 
CH2Cl2 (3  100 mL) to give 2.33 g (82%) of the desired product 
as a colorless oil. UPLC-MS gradient B, tR = 1.61 min, MS: (m/z) [M + H]
+
 calcd. for C41H54N3O7
+
: 
544.7, found: 544.3. 
Fmoc-Lys(Boc)-Nspe-OH (12).2 Fmoc-Lys-Nspe-OH (7) (3.65 g, 5.2 mmol) and iPr2NEt (2.04 
mL, 11.7 mmol) were dissolved in DMF (25 mL) and cooled to 0 
°C, followed by addition of Boc2O (1.70 g, 7.8 mmol). After 
stirring for 1 h the reaction was allowed to warm to ambient 
temperature and was stirred for 2 h. The reaction mixture was 
poured into EtOAc (200 mL) and extracted with 1 M HCl (aq) (3  
100 mL), water (2  100 mL) and brine (2  100 mL). The organic 
phase was dried (Na2SO4), filtered, and evaporated. The crude product was purified by VLC (6  6 
cm, CH2Cl2–MeOH, 0.5% grad from 0→5%), to give 2.44 g (72%) of the product as a white solid. 
1
H NMR (300 MHz, CD3OD)  1.41 (s, 9H, H-10), 1.53*/1.67 (2  d, 3H, J = 6.9 Hz, H-4), 1.61–
1.80 (broad m, 2H, H-6), 2.17/2.62 (3  m, 2H, H-1), 3.04/3.47* (2  m, 2H, H-9), 3.10–4.42 (3  
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m, 2H, H-2), 4.18 (m, 1H, H-12), 4.27–4.35 (m, 2H, H-11), 4.52*/4.81 (2  m, H, H-5) 5.42/5.81* 
(2  q, 1H, J = 6.9 Hz, H-3), 7.22–7.42 (broad m, 9H, Ph, Fmoc ArH), 7.67 (m, 2H, Fmoc ArH) 
7.80 (d, 2H, J = 7.5 Hz, Fmoc Ar).  
13
C NMR (100 MHz, CD3OD)  17.1*, 18.1, 23.0*, 23.7, 24.0, 
24.2*, 28.8,  30.5*, 30.6, 33.1, 40.8*, 40.9, 41.0, 41.1*, 45.7, 48.4, 52.9, 53.3*, 53.5*, 56.1, 68.0, 
79.5, 79.8*, 120.9, 126.3, 128.2, 128.2*, 128.4, 128.8, 129.7, 141.0, 141.9*, 142.6, 145.2*, 145.3, 
158.5, 158,5, 174.2, 175,1. UPLC-MS gradient B, tR = 2.53 min (>95), MS: m/z [M + H]
+
 calcd. for 
C32H38N3O5
+
: 644.8, found: 644.4. []589.2: -49° (c = 3.2, 293 K, CHCl3)  
Methyl 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanoate (13).
3
 Methyl 6-
aminohexanoate (460 mg, 2.5 mmol) and NEt3 (38 μL, 2.75 mmol) 
were dissolved in DMF (5 mL). 4-Chloro-7-nitrobenzofurazan (0.5 g, 
2.5 mmol) was dissolved in DMF (4 mL) and added dropwise to the 
methyl 6-aminohexanoate solution. After stirring for 18 h, the 
reaction mixture was poured into water (100 mL) and extracted with CH2Cl2 (3  100 mL). The 
combined organic phases were dried (MgSO4), filtered and evaporated in vacuo. The crude product 
was purified by VLC (2  6 cm, hexane–EtOAc, 5% gradient) to give 315 mg (41%) of the desired 
product as a red solid.
 1
H NMR (300 MHz, CDCl3)  1.52 (m, 2H, H-4), 1.73 (m, 2H, H-3), 1.84 
(m, 2H, H-5), 2.37 (t, 2H, J = 7.3 Hz, H-2), 3.51 ( q, 2H, J = 6.9 Hz, H-6), 3.60 (s, 3H, H-1), 6.17 
(d, 1H, J = 8.8 Hz, H-8) 6.23 (broad s, 2H, H-7) 8.50 (d, 1H, J = 8.8 Hz, H-9). 
13
C NMR (100 MHz, 
DMSO-d6)  24.1, 25.9, 27.3, 33.2, 43.2, 51.2, 99.1, 120.5, 138.0, 144.2, 144.4, 145.2, 173.3. 
UPLC-MS gradient A, tR = 1.62 min (>95%), MS: m/z [M+H]
+
 calcd. for C13H17N4O5
+
: 309.3, 
found: 309.3. 
6-((7-Nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanoic acid (14).
3
 Methyl 6-((7 
nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanoate (16) (110 mg, 
0.35 mmol) was dissolved in MeOH (20 mL) and 1 M LiOH (aq) (10 
mL, 10 mmol) was added. After stirring for 3 h at room temperature, 
the reaction was taken up in 1 M HCl (aq.) (100 mL) and extracted 
with CH2Cl2 (3  100 mL). The organic phase was dried (Na2SO4), filtered, and evaporated in 
vacuo to give the desired product as a red solid. UPLC-MS gradient A, tR = 1.31 min, MS: m/z 
[M+H]
+
 calcd. for C12H16N5O4
+
: 295.3, found: 295.2. 
6-((7-Nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanamide (3). 
6-((7-Nitrobenzo[c] [1,2,5]oxadiazol-4-yl)amino)hexanoic acid (14) 
(205 mg, 0.66 mmol), HBTU (250 mg, 0.66 mmol) and iPr2NEt (115 
μL, 0.66 mmol) in DMF (2 mL) were preincubated for 10 min at 
room temperature. The activated acid was then added to a Rink amide resin (370 mg, 16.6 mmol) 
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and shaken for 18 h. The compound was cleaved from the solid support using 50% TFA in CH2Cl2 
(2  2 mL) for 30 min. The resin was washed with MeOH and CH2Cl2 (2  2 mL each), the 
washings were collected and evaporated in vacuo. The crude was purified by preparative HPLC to 
give the desired product as a red solid (56 mg, 29% two steps). 
1
H NMR (300 MHz, CD3OD)  1.49 
(m, 2H, H-4), 1.69 (m, 2H, H-3), 1.80 (m, 2H, H-5), 2.23 (t, 2H, J = 7.6 Hz, H-2), 3.54 (m, 2H, H-
6), 6.34 (d, 1H, J = 8.7 Hz, H-8) , 8.52 (d, 1H, J = 8.7 Hz, H-9). 
13
C NMR (100 MHz, DMSO-d6)  
24.7, 26.1, 27.7, 35.0, 43.3, 99.1, 120.5, 138.0, 144.2, 144.5, 145.2, 174.2. UPLC-MS gradient B, tR 
= 1.17 min (>95%), MS: m/z [M+H]
+
 calcd. for C12H16N5O4
+
: 294.1, found: 294.1. HRMS: (m/z) 
[M + H]
+
 calcd. for C12H16N5O4
+
: 294.1197 found: 294.1206 (M = 3.0 ppm). 
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